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Abstract
The purpose of the work described in this thesis was to investigate the effects of 
upregulation of c-erbB-2 by cDNA transfection and the downregulation by ribozyme 
transfection on chemotherapeutic drug sensitivity, in vitro invasion, and expression of a 
range of mRNA and proteins.
Four novel multidrug resistant variants of the human breast carcinoma cell line, MDA- 
MB-435S-F, were established by pulse selection with taxol or adriamycin. In vitro 
toxicity tests revealed that the taxol resistant variants, MDA-MB-435S-F/Taxol-10p and 
MDA-MB-435S-F/Taxol-10p4p were significantly more resistant to taxol, with cross­
resistance to vincristine and taxotere, but not to adriamycin, carboplatin, etoposide or 5- 
fluorouracil. Adriamycin accumulation studies revealed that both variants displayed 
increased adriamycin efflux. P-glycoprotein and possibly topoisomerases, but not 
mrpl, mrp2, mrp4, mrp5, DHFR, thymidylate synthase or GST n, were found to play a 
role in taxol resistance.
MDA-MB-435S-F cells were resistant to adriamycin selection. MDA-MB-435S-F/Adr- 
lOp gained no significant increase in resistance to adriamycin following 10 rounds of 
exposure to adriamycin, although it did become resistant to VP-16 and was sensitised to 
vincristine and 5-fluorouracil. MDA-MB-435S-F/Adr-10pl0p was slightly resistant to 
adriamycin, VP-16, taxotere and vincristine. It was sensitised to taxol, 5-fluorouracil 
and carboplatin. P-glycoprotein, mrpl, mrp2, mrp4 and mrp5 were not altered at the 
mRNA level in the adriamycin selected variants. Reduced adriamycin accumulation 
appears to be the mechanism by which MDA-MB-435S-F/Adr-10pl0p became slightly 
resistant to adriamycin.
Drug selection induced c-erbB-1 expression at protein but not mRNA level in MDA- 
MB-435S-F. C-erbB-3 protein levels fell dramatically after drug selection. Drug 
selection of MDA-MB-435S-F induced more aggressively invasive cell lines, as defined 
by the gain of an ability to invade and relocate. This is a novel discovery for this thesis. 
The aggressive two-staged invasive phenotype appears to be linked to decreased 
adhesion and motility and perhaps c-erbB-1 induction and c-erbB-3 repression, but not 
to increased secretion of a range of proteases. C-erbB-2 was not found to play a role.
C-erbB-2 levels as altered by cDNA and ribozyme transfection were found to be 
positively associated with invasiveness, and accompanied by decreased adhesion to 
ECM components and protease secretion in the BT474A ribozyme transfected model. 
An increase in invasion was observed in two of these MCF-7 H3 c-erbB-2 cDNA 
transfectants but not the third. This was accompanied by reduction in expression of a 
serine protease, but not by MMP secretion or changes in adhesive properties.
Alteration of c-erbB-2 expression in BT474A and MCF-7 H3 by cDNA and ribozyme 
transfection resulted in changes in chemotherapeutic drug resistance. These changes 
correlated between the two models only for adriamycin and 5-fluorouracil. Changes in 
drug sensitivity to taxol and carboplatin appeared to be cell line specific. C-erbB-2 
upregulation in MCF-7 H3 cDNA transfected cell lines resulted in increased c-erbB-3 
protein expression and decreased c-erbB-4 mRNA and protein expression. C-erbB-1 
was increased at mRNA level, but not protein. Other ErbB receptors were not found to 
be affected by c-erbB-2 levels in BT474A except for c-erbB-3 protein, which decreased 
with decreasing c-erbB-2.
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1.0 Introduction
1.1 Incidence of Breast Cancer and Risk Assessment
Breast cancer remains the most common cancer among women (31% of all cancers) and 
the second highest cause of cancer deaths (15%, second only to lung cancer). Women 
are considered to have a high risk of cancer if their risk is greater than that of an average 
60-year-old woman. Woman under the age of 39 have a 1 in 225 risk of developing 
breast cancer, this rises to 1 in 24 between the ages of 40 and 59, 1 in 14 between 60 
and 79. A woman’s overall risk in their lifetime of developing breast cancer is 1 in 8. 
These figures can be further broken down into three categories as described in table 1.1.
Age interval 
(years)
Risk of developing 
breast cancer (%)
Risk of developing 
invasive breast 
cancer (%)
Risk of dying from 
breast cancer (%)
Birth-110 10.2 9.8 3.6
20-30 0.04 0.04 0.00
20-40 0.49 0.42 0.09
20-110 10.34 9.94 3.05
35-45 0.88 0.83 0.14
35-55 2.53 2.37 0.56
35-110 10.27 9.82 3.56
50-60 1.95 1.86 0.33
50-70 4.67 4.48 1.04
50-110 8.96 8.68 2.75
65-75 3.17 3.08 0.43
65-80 5.48 5.29 1.01
65-110 6.53 6.29 1.53
Table 1.1 Risk of developing and dying from breast cancer (white woman, USA).
Risk of developing breast cancer increases with age, the longer a woman lives without 
breast cancer, the lower her risk over the rest of her life. Other risks are early menarche 
and late menopause, which are associated with a 30-50% increased risk. This appears to 
be related to the number of ovulatory menstrual cycles a woman experiences during a 
life time. Pregnancy at a young age, especially before the age of 20 reduces the risk,
whereas a woman having her first pregnancy after the age of 30 doubles her risk. Non 
proliferative benign breast lesions do not carry an increased risk of developing into 
cancer. Benign lesions characterised by epithelial proliferative changes, especially if 
associated with atypia, is associated with a 4-5 fold increase in risk of breast cancer, 
which further rises to 11-fold if accompanied by a first-degree relative with breast 
cancer. Premalignant lesions such as lobular or ductal carcinoma in situ are associated 
with increased risk of subsequent invasive carcinoma. A patient with a prior history of 
breast cancer is at increased risk for developing cancer in the contralateral breast. This 
risk is estimated to be at about 1% per year. Development of breast cancer at a young 
age may be indicative of an underlying predisposition of breast parenchyma to 
malignant transformation.
A distinction exists between familial and hereditary breast cancer. Familial breast 
cancer refers to patients having one or more first- or second- degree relatives with breast 
cancer. Hereditary breast cancer is a subset of familial breast cancer, in which the 
incidence of breast cancer is related to autosomal dominant highly penetrant cancer 
susceptibility such as in the hereditary breast-ovarian cancer syndrome. The cumulative 
probability of a 30-year-old woman, with a sister or a mother with breast cancer, 
developing breast cancer by the age of 70 is between 7% and 18%. This increases 
with number of relative having breast cancer, to a maximum of 30%. A woman with a 
mother and sister with breast cancer has a 25% risk of developing the disease. Several 
specific gene loci have been identified that play a role in hereditary breast cancer, 
including BRCA1, BRCA2, p53, PTEN and ataxia-telangiectasia gene. BRCA1 and 
BRCA2 are the most common in hereditary disease. Among women who carry germ- 
line mutations the cumulative risk of breast cancer is thought to range between 40% to 
85%, and for ovarian cancer 5% to 60% depending on the population from which the 
figures are derived (Sakorafas et ah, 2002).
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1.2 Growth Factor Families and Their Receptors
Growth factors and their receptors have been shown to play a major role in cancer 
development. Most, if not all, cancer cells contain genetic damage that appears to lie at 
the heart of tumourigenesis. Malignant cells arise as a result of a stepwise progression 
of genetic events that include the unregulated expression of growth factors or 
components of their signalling pathways. Cells of most, if not all, major tissue types are 
targets of growth factors that mediate their activity by means of receptors with intrinsic 
tyrosine kinase activity. Signalling pathways that mediate the normal function of 
growth factors are commonly subverted in cancer, leading to uncontrolled proliferation 
(Aaronson, 1991).
In multicellular organisms communication between individual cells is essential for their 
regulation and co-ordination of complex cellular processes such as growth, 
differentiation, migration and apoptosis. The signal transduction pathways mediating 
these processes are regulated in part by polypeptide growth factors that generate signals 
by activating cell surface receptors. The primary mediators of such physiological cell 
responses are receptor tyrosine kinases (RTKs). RTKs can be divided into 20 
subfamilies on the basis of their structural characteristics. All RTKs consist of a single 
transmembrane domain that separates the intracellular tyrosine kinase domain from the 
extracellular binding domain. The latter exhibit a variety of conserved elements such as 
immunoglobulin (Ig)-like or epidermal growth factor (EGF)-like domains, fibronectin 
type III repeats or cysteine-rich regions that are characteristic for each subfamily. The 
catalytic domain that displays the highest level of conservation includes the ATP- 
binding site that catalyses receptor autophosphorylation and tyrosine phosphorylation of 
RTK substrates. Ligand binding to the extracellular domain leads to conformational 
changes that induce and stabilise receptor dimérisation leading to increased kinase 
activity and autophosphorylation of tyrosine residues (Zwich et al., 2001).
Aberrant RTK signalling is a major factor in cancer and other hyperproliferative 
diseases. Constitutive activation of RTKs can occur by several mechanisms, such as 
gene amplification, overexpression or mutation. Somatic and germline mutations have 
been observed in at least 10 different RTK families. These alterations include deletion
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or mutation within the extracellular domain or alterations in the catalytic domain, 
resulting in a constitutively active RTK.
RTK families involved in cancer development include the epidermal growth factor 
receptor (EGFR/ErbB) family (described further in section 1.3), insulin growth factor 
receptor (IGFR) family, vascular endothelial growth factor receptor (VEGFR) family, 
fibroblast growth factor receptor (FGFR) family, hepatocyte growth factor receptor 
(HGFR) family and platelet-derived growth factor receptor (PDGFR) family.
The IGFR family consists of the insulin receptor (IR) and the insulin-like growth factor 
(IGF) receptor (IGF-IR). Both receptors consist of two extracellular a  subunits, which 
are responsible for ligand binding and two membrane spanning (3 subunits bearing the 
tyrosine kinase domain and autophosphorylation sites. Ligands for these receptors 
include insulin, IGF-I and IGF-II. While insulin is mostly a metabolic hormone, IGF-I 
and IGF-II are crucial for normal development and carcinogenesis. IGF-IR and its 
ligands have been found to play a major role in breast and prostate cancer. In primary 
breast cancer IGF-I and IGF-II are primarily expressed by the stromal fibroblasts 
surrounding the normal and malignant tissue, whereas IGF-IR is overexpressed in breast 
cancer with enhanced tyrosine kinase activity.
VEGF is one of the main inducers of endothelial cell proliferation and permeability of 
blood vessels. The VEGFR family consists of two receptors VEGFR-1 and VEGFR-2, 
which are expressed on endothelial cells during embryonic development and are the key 
regulators of angiogenesis. Expansion of tumours beyond l-2mm requires de novo 
formation of vascular network to provide the tumour with oxygen and nutrients. Many 
studies have shown a role for the VEGF-VEHGFR ligand-receptor system in tumour 
vascularisation and metastasis. Tumours secrete VEGF activating VEGFR-2 and thus 
inducing proliferation of stromal endothelial cells and sprouting of new blood vessels.
The FGFs represents the largest family of growth factors, with over 20 members 
identified to date. Two classes of FGFRs have been discovered. The first class 
comprises the four high affinity FGFRs, whereas the second class is defined by low 
affinity FGF binding sites. Evidence suggests that the by low affinity FGF binding sites 
represent heparan sulphate proteoglycan molecules (HSPG) located on the cell surface, 
which may support the fine tuning of cell responses to FGFs. The family of high
affinity FGFRs is composed of FGFR1 (fig), FGFR2 (bck), FGFR3 and FGFR4. 
Ligand binding of FGF to FGFRs results in dimerisation and phosphorylation of the 
cytoplasmic tyrosine residues, but full activation is only achieved in the presence of 
heparan. A remarkable number of FGFs were discovered as genes isolated from 
tumours due to their ability to induce proliferation or transformation of fibroblasts. This 
points to the major role these growth factors play in tumourigensis. Changes in the 
levels of FGFRs, such as point mutations, elevated expression or different splicing, 
result in disregulated FGFR signalling, and has been observed in breast, prostate, 
melanoma, thyroid and salivary gland tumours. Somatic mutations in FGFR-3 similar to 
the activating mutations in skeletal dysplasias have been identified in bladder cancer 
and in multiple myeloma.
HGFR is encoded by the proto-oncogene met, and was identified as a regulator of a 
variety of morphogenic processes like cell migration, cell scattering and invasion of 
extracellular matrices. It is a disulphide-linked heterodimer with a glycosylated 
extracellular a-chain and a (3-chain, which consists of the transmembrane domain and 
cytoplasmic tyrosine kinase domain. The ligands for HGFR are HGF and scattering 
factor (SF), which are expressed by mesenchymal-derived cells. HGR overexpression 
has been described in a variety of tumours, such as thyroid and colorectal carcinomas, 
and appears to be prognostically significant for non-small cell lung and breast cancer.
Kit, PDGFR-a and PDGFR-P are members of the PDGFR family. These proteins are 
characterised by an extracellular domain with five Ig-like domains and an intracellular 
tyrosine kinase domain split by 1000 amino acids. Two genes have been identified 
encoding PDGFR-a and PDGFR-P and both receptors are activated by a ligand dimer 
consisting of PDGF-A and/or PDGF-B. This in turn leads to receptor dimerisation with 
three possible configurations; a a , pp, ap. Co-expression of PDGFR and its ligands has 
been reported in glioblastoma and other astrocytic brain tumours, whereas normal brain 
tumours do not express these proteins.
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1.3 ErbB Receptor Family of Tyrosine Kinase Receptors
The ErbB receptor family consists of type I growth factor receptors, and is made up of 
four members, c-erbB-1 (EGFR), c-erbB-2 (HER-2/neu), c-erbB-3 (HER-3) and c-erbB- 
4 (HER-4). These proteins share a similar structure, with an extracellular domain having 
two elements contributing to ligand binding and two cysteine-rich regions, followed by 
a transmembrane region. The cytoplasmic domain consists of a tyrosine kinase domain 
and a carboxy-terminal domain that contains mapped autophosphorylation sites (Graus- 
Porta et al., 1997). The receptors share 40-50% sequence identity in their extracellular 
domains, 60-80% identity in their kinase domains and 10-30% identity in their tails. 
Although the extracellular domain of c-erbB-3 is homologous to those of the other 
family members its intracellular domain has diverged significantly (Carraway III and 
Burden, 1995).
1.3.1 ErbB Receptor Ligands
ErbB ligands can be classified into four groups depending on their receptor affinities 
and specificities. (1) epidermal growth factor (EGF), amphiregulin (AR) and 
transforming growth factor a  (TGFa) which bind to ErbB-1; (2) betacellulin (BTC), 
epiregulin and heparin binding EGF-like growth factor (HB-EGF) which bind to c- 
erbB-1 and c-erbB-4; (3) Neuregulins/heregulins NRG1 and NRG2 which are ligands of 
c-erbB-3 and c-erbB-4, low and high affinity receptors respectively; NRG3 and NRG4 
ligands of c-erbB-4. Common to all these growth factors is the EGF domain with six 
conserved cysteine residues characteristically spaced to form three intramolecular 
disulphide bridges (Prenzel et al., 2001). After binding to their receptors, EGF-related 
peptides induce receptor homodimerisation and heterodimerisation, allowing the 
receptors to signal. Although none of these ligands bind directly to c-erbB-2, they all 
induce its tyrosine phosphorylation by triggering heterodimerisation and cross­
phosphorylation. ErbB receptors have been shown to compete for dimérisation with c- 
erbB-2. C-erbB-2 has been shown to enhance EGF-induced tyrosine phosphorylation of 
c-erbB-1 and NRG-induced tyrosine phosphorylation of c-erbB-3 and c-erbB-4. It also 
potentiates and prolongs the signal transduction pathways elicited by EGF and NRG. 
C-erbB-2 also increases the affinity of both EGF and NRG for their receptors. These
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results suggest that e-erbB-2 acts as a common receptor sub-unit for all the other ErbB 
receptors (Graus-Porta et al., 1997).
1.3.2 C-erbB-1
C-erbB-1 is a 170kDa glycoprotein translated from mRNA transcripts encoded by a 
gene on chromosome 7q21. C-erbB-1 is present at fairly low levels in normal breast 
epithelial cells. It has been found to be overexpressed in 40% of breast cancers, but 
rarely due to gene amplification (2%). The overexpression of c-erbB-1 is inversely 
correlated with the presence of estrogen receptors. Overexpression of c-erbB-1 is 
associated with short relapse-free interval and survival in multivariate analyses. It is 
also associated with a lack of response to endocrine therapy (Rajkumar and Gullick,
1994). C-erbB-1 is expressed throughout development and in a variety of cell types 
(Hung and Lau, 1999). The c-erbB-1 signal transduction occurs through two distinct 
pathways. One is the phosphatidylinositol pathway, which leads to the activation of 
protein kinase C and increased intracellular calcium concentration. The other is through 
the ras protein leading to the activation of the MAP kinase cascade. Both these 
pathways can trigger a mitogenic response (Suo et al., 1998). C-erbB-1 is frequently 
overexpressed in non-small cell lung, bladder, cervical, ovarian, kidney and pancreatic 
cancer, and occurs with very high incidence in squamous cell carcinomas of the head 
and neck (Zwick et al., 2001). A number of c-erbB-1 deletions have been identified in 
human cancer and most of these mutations alter the extracellular binding domain of the 
receptor and result in truncated c-erbB-1 with constitutively active kinase function.
1.3.3 C-erbB-2
C-erbB-2 has been mapped to chromosome 17q21. No ligand for c-erbB-2 has been 
found. Overexpression due to gene amplification has been found in 10-40% of breast 
cancers, although some carcinomas overexpress c-erbB-2 in the absence of gene 
amplification (Suo et al., 1998). Transcription of the c-erbB-2 gene generates two 
mRNAs, a 4.6 kb transcript encoding the full length 185 kDA transmembrane protein 
and a truncated 2.3 kb transcript encoding only the extracellular domain of the c-erbB-2 
protein. Overexpression of c-erbB-2 has been reported in approximately 35% of
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ovarian, 30% of prostate, 20% of gastric and 2% of colorectal cancers (Markogiannakis 
et al., 1997).
High levels of c-erbB-2 expression have been shown to correlate strongly with poor 
prognosis in breast cancer (Verbeek et al., 1998). Oncogenic activation of c-erbB-2 can 
occur by deletion of the extracellular domain or by overexpression as previously 
mentioned. In rats, but not humans, overexpression can occur through a point mutation 
in the transmembrane domain (Guy et al., 1992). C-erbB-2 receptor activation 
stimulates signal transduction leading to increased intracellular calcium and increased 
plasma membrane potential, rapidly inducing c-fos and c-jun, leading to a mitogenic 
response (Suo et al., 1998).
C-erbB-2 has intrinsic tyrosine kinase activity. To date, no ligands have been found 
capable of binding directly to c-erbB-2. However it can be activated by all the erbB 
ligands through heterodimerisation with other ErbB receptors. C-erbB-2 when activated 
can interact with various cellular proteins, such as She, PLC-y and GAP, which play 
significant roles in signal transduction. C-erbB-2 is also capable of dimerising with c- 
erbB-1, c-erbB-3 and c-erbB-4 (Hung and Lau, 1999).
1.3.4 C-erbB-3
C-erbB-3 is located at chromosome 12ql3 and is transcribed as a 6.2 kb mRNA, which
translates as a 160-180kDa glycoprotein. The higher weight protein is found in breast
tumour cells, while the lower is found in human kidney cells. The size difference is
thought to be due to levels of glycosylation. In breast tumour cell lines, variable levels
of expression are seen, with the highest levels observed in BT-483, MDA-MB-453 and
T47-D, intermediate levels seen in ZR75-1, SKBR-3, MDA-MB-175 and MDA-MB-
361. It is absent or present in very low levels in MDA-MB-157 and MCF-7. Non-
malignant breast cell lines MTSV-1.7, MRSV-2.1 and HBL100 are negative. Most
breast cell lines that overexpress c-erbB-2 also overexpress c-erbB-3. It is also
interesting to note that the promoter of c-erbB-2 is very similar to c-erbB-3. In primary
tumours overexpression of c-erbB-3 is probably due to up-regulation of gene
transcription rather than gene amplification. C-erbB-3 overexpression is associated with
the presence of nodal metastasis in breast tumours. The gastric cancer cell line MKN45
has been shown to produce a 1.4kb c-erbB-3 transcript at similar levels to the full length
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6.2kb transcript. This transcript corresponds to a secreted receptor extracellular domain. 
83% of gastrointestinal tumours overexpress c-erbB-3. Squamous cell carcinoma shows 
96% overexpression, while adenocarcinomas and adenomas are at 76%. In the normal 
pancreas, only the islets of Langerham stain for c-erbB-3. The c-erbB-3 kinase domain 
has two non-conservative amino acid replacements, Histidine 740 and Asparagine 815, 
at sites completely conserved as glutamic acid and aspartic acid in all other known 
tyrosine and serine/threonine kinases. C-erbB-3 is a defective tyrosine kinase and lacks 
stimulatible tyrosine kinase activity (Rajkumar and Gullick, 1994).
It has been shown that c-erbB-3 can be transphosphorylated by c-erbB-1, resulting in 
phosphatidylinositide-3’-OH kinase recruitment. However, this heterodimer is 
incapable of coupling with PLC-y or GAP, thereby making the c-erbB-3 signalling 
pathway different to those of the other ErbB family members (Hung and Lau, 1999).
1.3.5 C-erbB-4
The c-erbB-4 protein has a molecular weight of 180kDa and its mRNA is expressed at 
high levels in normal skeletal muscle, heart, pituitary, parathyroid, spleen, breast, testis, 
brain and kidney. T47-D, MDA-MB-453, BT-474 and H3396 express high levels of c- 
erbB-4 mRNA. MCF-7, MDA-MB-330 and MDA-MB-361 express intermediate 
levels, while MDA-MB-231, MDA-MB-157, MDA-MB-468 and SKBR-3 express low 
or no levels of c-erbB-4 (Rajkumar and Gullick, 1994). Signal transduction of c-erbB-4 
may play an important role in cell growth and differentiation, and its expression may be 
linked to cell differentiation and favourable prognosis in breast cancer (Suo et al., 
1998).
C-erbB-4 is localised to chromosome 2q33.3-34. It encodes a 1283 amino acid protein.
The extracellular domain of c-erbB-4 is most similar to c-erbB-3, whereas its
cytoplasmic domain exhibits a 79% and 77% identity with EGFR and c-erbB-2,
respectively. The NRGs, betacellulin and heparin-binding EGF have been shown to
function as ligands for c-erbB-4. Downstream, the c-erbB-4 cytoplasmic domain
interacts with SH-2-domain containing proteins such as pl20-ras GTPase activating
protein, SHC, and the p85 subunit of phophatidylinositol-3’-kinase, which activate the
mitogen-activated protein kinase pathway (Srinivasan et al., 1998). The study by
Srinivasan et al. (1998) investigated the distribution of c-erbB-4 in normal human adult
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and fetal tissues and in a sample of common human cancers. There was a widespread 
distribution in both adult and fetal tissues. In cancers there was a loss of expression in 
most tumours. Loss of expression was noted in 40-80 per cent of adenocarcinomas and 
up to 100 per cent of squamous cell carcinomas, whereas overexpression was observed 
in about 10-20 per cent of adenocarcinomas and astrocytomas. In general, the pattern of 
c-erbB-4 expression in normal tissues and cancers suggests that it tends to be associated 
with the differentiated compartment.
1.3.6 ErbB Dimérisation and Signalling
C-erbB-2 is a receptor with high transforming activity, which can be 
transphosphorylated through heterodimerisation with other ErbB receptors. The orphan 
c-erbB-2 receptor is the preferred heterodimerisation partner for the ErbB receptor 
family as it decreases ligand dissociation from the receptor heterodimer thus enhancing 
and prolonging the activation of signal transduction.
Figure 1,3.6a Receptor dimérisation.
Receptor Dimérisation
Figure 1.3.6a shows the variety of signals activated by the ErbB receptors depending on 
their dimérisation partners and the ligand occupying their extracellular domains. C- 
erbB-2 is the preferred heterodimerisation partner for all other ErbB receptors. By the 
binding of EGF-like ligands to the extracellular domain of their respective receptors, 
these peptides can induce both homo- and heterodimerisation. Although none of these 
ligands bind directly to c-erbB-2, all of them induce its tyrosine phosphorylation by 
triggering heterodimerisation and cross-phosphorylation. C-erbB-1, c-erbB-3 and c- 
erbB-4 receptors have been shown to compete for dimérisation with c-erbB-2. C-erbB-2
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has been shown to enhance EGF-induced tyrosine phosphorylation of c-erbB-1 and 
NRG-induced tyrosine phosphorylation of c-erbB-3 and c-erbB-4. It also potentiates 
and prolongs the signal transduction pathways elicited by EGF and NRG. C-erbB-2 
also increases the affinity of both EGF and NRG for their receptors.
Figure 1.3.6b represents the signalling combinations inducible by the ErbB receptor 
family members.
PI£K PI3K PI3K PI3K PI3K PI3K
Src Src
c-Yes
Src Src •Src Src Src
c-Yes
Src
c-Yes
ras-GAP ras-GAP ras-GAP ras-GAP ras-GAP ras-GAP ras-GAP
PLCy PLCy PLCy PLCy PLCy PLCy PLCy PLCy
She She She She She She She She She She
Grb-2 Grb-2 Grb-2 Grb-2 Grb-2 Gib-2 Gib-2 Grb-2
Gib-7 Gib-7 Gib-7 Gib-7 GA-7 Gib-7 Gib-7 Gib-7
Nek Nek Ndk Nek Nek Nek
Crk Cric Cik Cik Cik Cik Cik
c-Cbl c-Cbl c-Cbl c-Cbl
c-Abl c-Abl c-Abl c-Abl
KPS.8 FP8-8
FTP1D
EPS-8 EPS-8 RPS-8 RPS-8 RPS-8
PTP1D
UPS-«
PTP1D
+ ++ ++ +++ +++ +-H-+ ++-H- - ++ -
NRG activates c-erbB-3 and c-erbB-4 heterodimerisation with EGFR only when there is 
no available c-erbB-2. EGF and BTC induced activation of c-erbB-3 is impaired in the 
absence of c-erbB-2. C-erbB-2 also enhances c-erbB-3 phosphorylation and association 
with p85, a subunit of phosphatidylinositol-3-kinase. These results suggest that c-erbB- 
2 acts as a common receptor subunit of all the other ErbB receptors (Graus-Porta et al., 
1997).
Gamett et al. (1997) provided evidence for a new mechanism of growth factor 
stimulated receptor dimer formation. They stated that the growth factor induced 
dimérisation and ensuing receptor trans-phosphorylation results in the disassociation of 
the original receptor dimer. Each phosphorylated receptor monomer then interacts with 
a new unphosphorylated receptor to form a secondary dimer. EGF was found to induce 
c-erbB-2/c-erbB-3 secondary receptors and NRG was found to induce c-erbB-2/EGFR
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secondary dimers. This is backed up by the fact that following c-erbB-2/c-erbB-3 
heterodimerisation induced by NRG, c-erbB-3 disassociates from c-erbB-2 and forms a 
complex withp85, the regulatory subunit of phosphatidylinositol-3-kinase.
Olayioye et al (1998) constructed NIH3T3 cell lines expressing c-erbB-1 and c-erbB-2 
singularly and in pairwise combinations with each of the erbB family members. They 
found that when c-erbB-1 was activated by EGF it was capable of coupling to both She 
and Grb2, but when activated by NRG (i.e. through heterodimerisation) it was only 
capable of interacting with She. EGF-activated c-erbB-1 was rapidly internalised, 
whereas NRG -activated c-erbB-1 showed delayed internalisation characteristics. The 
p85 subunit of phosphatidylinositol-3-kinase associated with EGF-activated c-erbB-1 in 
a biphasic manner and with NRG -activated c-erbB-1 in a monophasic manner. C-erbB- 
2 binding to peptides containing the Src homology 2 domain of Grb2 or p85 and the 
phosphotyrosine binding domain of She varied according to the mode of receptor 
activation. Tryptic phosphopeptide mapping of both c-erbB-1 and c-erbB-2 revealed 
that receptor phosphorylation is dependent on dimérisation partner. Differential 
receptor phosphorylation may therefore be the basis for the differences in signalling 
properties observed. The biological responses triggered by c-erbB-2 are varied. C- 
erbB-2 can trigger transformation, monoclonal antibody-induced growth inhibition, 
ligand induced growth stimulation, and apoptosis. Coupling of a given receptor to 
specific intracellular signalling proteins is modulated by the dimérisation partner and 
indeed originates from differential receptor phosphorylation. Internalisation of an ErbB 
receptor is influenced by its ligand and dimérisation partner. The subsets of signalling 
molecules that couple to an activated receptor undergo time-dependant changes, 
suggesting that ErbB receptor phosphorylation is not static.
Cohen et al (1996) created a collection of NIH3T3 cell lines expressing each member of 
the ErbB family singularly or in pairs. Transformation (measured by growth in soft 
agar) occurred only in those clones that expressed two different family members, and 
the presence of the appropriate ligand. None of the cell lines expressing single erbB 
members were able to form tumours in mice. C-erbB-2 was tumourigenic when 
expressed with c-erbB-1 or c-erbB-3, but not with c-erbB-4. They also found that the 
activation of c-erbB-1 was necessary for the induction of a calcium flux and the 
phosphorylation of phospholipase Cyl. In the absence of an added ligand, the steady 
state level of a c-erbB receptor phosphorylation is affected by the co-expression of other
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c-erbB family members. C-erbB-1 phosphorylation is elevated when expressed alone or 
in combination with c-erbB-3. When it is co-expressed with either c-erbB-2 or c-erbB-4 
levels of phosphorylation drop. C-erbB-2 phosphorylation is elevated, except when 
expressed with c-erbB-3. C-erbB-3 phosphorylation is stimulated when co-expressed 
with c-erbB-1 or c-erbB-2 but not c-erbB-4. C-erbB-4 is high when expressed alone or 
with c-erbB-1 but not with c-erbB-2 or c-erbB-3. This would suggest that receptor 
complexes can form in the absence of the necessary ligands, and the phosphorylation of 
these complexes is differentially regulated. C-erbB-3, while a defective kinase, does 
show a weak response to NRG.
Figure 1.3.6c demonstrates the diversity of signalling pathways initiating from c-erbB-
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T47D, a breast tumour cell line, expresses all of the ErbB members at moderate levels. 
Beerli et al. (1996) used this cell line to study which of the receptors were activated by 
the following ligands - EGF, transforming growth factor a  (TGFa), amphiregulin (AR), 
heparin binding EGF (HB-EGF), betacellulin (BTC) and neu differentiation factor 
(NRG). All except NRG stimulated phosphorylation of c-erbB-1. All except AR were 
able to stimulate the phosphorylation of c-erbB-2. EGF, TGFa, and AR only had a 
moderate effect on c-erbB-3. NRG, HB-EGF and BTC significantly stimulated
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association of phosphotidylinositol with c-erbB-3. HB-EGF induced low levels of c- 
erbB-4 tyrosine phosphorylation, while BTC was as efficient as NRG.
Tzahar et al. (1997) investigated the mechanism of ligand induced erbB receptor 
dimerisation. Two molecular mechanisms were compared. (1) Binding of the 
monomeric ligand induces a conformational change similar to the alteration noted in 
soluble EGFR after EGF binding, which exposes a cryptic receptor dimerisation site. 
(2) The second mechanism assumes that EGF-like ligands are bivalent, like in the case 
of the growth hormone and its receptor. The growth hormone uses two different sites to 
bind two receptor molecules sequentially. The first binding is diffusion controlled and 
the second is enhanced by the formation of direct receptor contact areas. Analysis of 
NRG induced c-erbB-2/c-erbB-3 heterodimerisation shows the use of the second, 
bivalence model. The ligand simultaneously binds both receptors, but due to its 
extremely low affinity for c-erbB-2, it only succeeds when the receptors are membrane 
bound. The full length NRG (32 binds the extracellular domain of c-erbB-3 with a 
dissociation constant of 26±9nM, while it shows a 1000-fold weaker binding for c- 
erbB-2 (Horan et al., 1995).
Combinatorial ligand/receptor/effector interactions allow large potential for signal 
diversification of the ErbB receptor family. Waterman et al. (1998) addressed the 
possibility that turn-off mechanisms enhance the diversification potential. Signalling 
patterns stimulated by all erbB receptors are all directed through the same MAPK 
pathway. However unlike the shared rapid MAPK coupling, the kinetics of MAPK 
inactivation depends on the identity of the stimulating receptor. Concentrating on c- 
erbB-1 and two of its ligands, EGF and TGF-a, and NRG and one of its receptors, c- 
erbB-3, they showed that ligand binding variably accelerates endocytosis of the 
respective ligand-receptor complex. However, unlike the EGF-activated c-erbB-1, 
which is destined primarily to degradation in lysosomes, NRG and TGF-a direct their 
receptors to recycling, probably because these ligands dissociate from their receptors 
earlier along the endocytic pathway. In the case of NRG, structural, as well as 
biochemical, analyses imply that ligand degradation occurs at a relatively late 
endosomal stage. Attenuation of receptor down-regulation by this mechanism 
apparently confers to both NRG and TGF-a more potent and prolonged signalling 
activity. Alternative endocytic trafficking of ligand-ErbB complexes may tune and 
diversify signal transduction by EGF family ligands.
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1.4 The Role of the ErbB Receptor Family in Cancer
1.4.1.The Role of c-erbB-1 in Human Cancers
Elevated levels of c-erbB-1 and/or its cognate ligands has been identified as a common 
component of multiple cancer types and appears to promote solid tumour growth. More 
than 200 studies were identified by Nicholson et al. (2001) that analysed relapse-free- 
interval or survival data directly in relation to c-erbB-1 levels in over 20000 patients. 
Analysis of the data showed that 10 cancer types both express elevated levels of c-erbB-
1 relative to normal tissues and have been studied in sufficient depth to allow sound 
judgements to be made concerning the association between c-erbB-1 and patient 
outlook. C-erbB-1 was found to act as a strong prognostic indicator in head and neck, 
ovarian, cervical, bladder and oesophageal cancers. In these cancers, increased c-erbB-1 
expression was associated with reduced recurrence-free or overall survival rates in 70% 
of studies. In gastric, breast, endometrial and colorectal cancers, c-erbB-1 provided 
more modest prognostic information, correlating to poor survival rates in 52% of 
studies, while in non-small cell lung cancer (NSCLC), c-erbB-1 expression only rarely 
related to patient outlook.
Overexpression and/or amplification of c-erbB-lwas observed in 22.00% of infiltrating 
ductal carcinoma breast tumours (n=315). 16% were grade I, 61% grade II and 23% 
grade III tumours. Axillary lymph node metastasis had significant correlation with 
intensified positivity of c-erbB-1 (p < 0.05). A significant number of c-erbB-1 positive 
patients developed local recurrence and distant metastases to brain, liver and bone (p < 
0.05). c-erbB-1 positivity showed significant correlation with the disease-free and 
overall survival (p < 0.05). At a median follow-up of 48 (4 years) months in c-erbB-1 
positive patients, the overall survival was 3.39 years and disease-free survival was 2.86 
years. C-erbB-1 negative tumour patients showed a better survival (Aziz et al., 2000). 
Suo et al. (2001) also detected c-erbB-1 expression in 43.9% of primary breast 
carcinomas (n=107). In contrast they detected no significant associations between the 
expressions of c-erbB-1 and overall survival.
Immunohistochemical staining for c-erbB-1 was performed on frozen sections of 
primary breast cancer from 1029 patients with a mean follow-up duration of 46 months.
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C-erbB-1 was positive in 26.9% of cases which inversely correlated with the estrogen 
receptor (ER) status. A univariated analysis indicated that c-erbB-1 had a significant 
prognostic value in both the disease free survival (DFS) and the overall survival (OS), 
in both node negative and node positive breast cancer. A multivariate analysis indicated 
that c-erbB-1 was an independently significant prognostic factor for DFS (p = 0.0174) 
and OS (p = 0.0105) in all patients, but that c-erbB-1 demonstrated a prognostic 
significance only for DFS (p = 0.0241) in node negative and only for OS (p = 0.0333) in 
node positive breast cancer. Multivariate analysis indicated that the combination of c- 
erbB-l(+)/ER(-) was an independently significant factor for both DFS and OS in node 
negative as well as node positive breast cancer (Tsutsui et al., 2002).
100 breast carcinoma patients with a follow up of 7-11 years were included in a study of 
ErbB family members, using immunohistochemistry and RT-PCR (Suo et al., 2002). By 
immunohistochemistry, 36%, 27%, 26%, and 82% of the tumours were positive for c- 
erbB-1, c-erbB-2, c-erbB-3, and c-erbB-4. All the immunoreactive tumours were 
confirmed positive by RT-PCR. Statistical analysis of ErbB family members in these 
tumours showed a significant association between c-erbB-2 expression and reduced 
disease-free and cancer-specific survival. C-erbB-4 expression was associated with a 
more favourable outcome. Co-expression of c-erbB-2 and c-erbB-1 was associated with 
a worse prognosis. C-erbB-4 expression, however, showed an antagonistic effect on the 
clinical influence of c-erbB-2 expression.
Tumour c-erbB-1 levels were determined by a specific ligand binding assay in 780 
consecutive breast cancer patients between 1980 and 1993. All patients had undergone 
tumour resection with axillary lymph node dissection: 373 patients (47.8%) underwent 
mastectomy, 37 (5%) subcutaneous mastectomy and 370 (47.2%) tumorectomy. Only a 
small proportion of patients exhibited a relatively marked c-erbB-1 expression. There 
was no link between tumour size, grade, node status and c-erbB-1 tumoural levels. 
There was a constant and significant decrease in c-erbB-1 tumoural levels according to 
patient age. A significant inverse relationship was found between ER and c-erbB-1 
(Ferrero et al., 2001).
Approximately 65% to 70% of human colon carcinomas have been shown to express c- 
erbB-1. Several investigators have reported that c-erbB-1 expression correlates with 
more aggressive disease and a poorer prognosis (O'Dwyer et al., 2002). Lee et al.
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(2002) examined the role of the ErbB family in the neoplastic transformation of the 
human colon by immunohistochemical analysis in paraffin-embedded specimens from 
125 resected colorectal cancers. Data showed that for c-erbB-1 expression, 50% were 
scored as 2% as '++'. For c-erbB-2 expression, 31% were classified as '+', and 4% as 
'++'. For c-erbB-3 expression, 34% were scored as and 2% as '++'. A significantly 
higher percentage of overexpressed c-erbB-3 was observed in early stage carcinomas 
(Dukes' stage A or B) (50%) than in advanced stage cancers (Dukes' stage C or D) 
(15%) (PO.OOOl). For c-erbB-4 expression, 18% were scored as '+', and 4% as '++'. 
Early stage patients had a lower percentage of c-erbB-4 overexpression than the late 
stage ones (18% versus 28%). Concomitant overexpression of c-erbB-2 and c-erbB-3 
occurred in 21% of the early stage carcinomas, whereas it occurred in only 2% of the 
late stage ones (P=0.003). Conversely, simultaneous overexpression of c-erbB-2 and c- 
erbB-4 occurred in 17% of the late stage carcinomas but in only 4% of the early stage 
ones (P=0.02). Overexpression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 alone was 
not significantly associated with a shortened survival. However, patients with a 
simultaneous overexpression of c-erbB-2 and c-erbB-4 had a shorter OS time than 
others in the univariate analysis (P=0.01). This significance disappeared after 
adjustment for Dukes' staging in the Cox model.
76 paraffin-embedded sections from consecutive stage IIIC-IV ovarian cancer patients 
with measurable disease after first surgery were examined for expression of COX-2, c- 
erbB-1, and c-erbB-2. No association was found among COX-2, c-erbB-1, and c-erbB-
2. COX-2 positivity was found in a statistically significant higher percentage of 
unresponsive cases (80.0%) than in patients responding to chemotherapy (35.7%) (P =
0.0008) (Ferrandina et al., 2002).
Vered et al. (2002) performed a study of 34 samples of formalin-fixed, paraffin- 
embedded specimens of salivary gland adenoid cystic carcinoma (ACC) and their 
expression of c-erbB-1. Overlying oral mucosa and adjacent normal salivary ducts 
served as internal controls. Both membrane and cytoplasmic staining were evaluated. In 
the final analysis 27 of the 34 specimens were included; 7 were excluded, because the 
internal control did not reveal any staining. Of these 27 specimens, 85% stained 
positively for c-erbB-1.
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Storkel et al. (1993) investigated 100 cases of oral squamous cell carcinomas (SCC) 
immunohistologically with respect to the expression of c-erbB-1 and the proliferating 
cell nuclear antigen (PCNA). In conclusion, the amount of antigen expression of both 
antigens increased with the increasing grade of malignancy of the SCC. Furthermore, 
there was a statistically significant correlation between the amount of antigen 
expression and the patient's prognosis. An overexpression of c-erbB-1 and PCNA was 
associated with a short survival of the patient. Oppositely, c-erbB-1 positivity was 
protective against locoregional relapse of oral and oropharyngael SCC (Smith et al, 
2001).
Brabender et al. (2001) studied the association between the mRNA expression of c- 
erbB-1 and c-erbB-2, and survival in primary tumour and matching nonmalignant 
tissues from 83 patients with NSCLC. Analysis was performed using a quantitative real­
time PCR system. C-erbB-1 and c-erbB-2 mRNA expression was detectable in all 
specimens analysed. 34.9% of patients had high c-erbB-2 expression, and 33.7% of 
patients had high c-erbB-1 expression. A high c-erbB-1 and c-erbB-2 coexpression was 
detectable in 16.9% of patients. High c-erbB-2 expression was associated with inferior 
survival (P = 0.004), whereas high c-erbB-1 expression showed a trend toward inferior 
survival (P = 0.176). The impact of c-erbB-1 and c-erbB-2 coexpression on patients' 
survival was additive (P = 0.003). Multivariate analysis determined high c-erbB-1 and 
c-erbB-2 coexpression (P = 0.030) as significant and independent unfavourable 
prognostic factors.
1.4.2 The Role of c-erbB-2 in Human Cancers
Pfeiffer et al. (1996) examined 186 unselected and systemically untreated patients with 
non-sm all cell lung cancer (NSCLC) for c-erbB-2 and c-erbB-1 status. C-erbB-1 was 
found to be highly expressed in 55% of tumours while c-erbB-2 was highly expressed in 
26% of tumours. The expression of c-erbB-1 was higher in squamous cell carcinoma, 
while c-erbB-2 was highest in adenocarcinomas. Overexpression of these receptors was 
found to have no correlation with prognosis. In contrast, Tsai et al. (1996) reported 
that the intrinsic chemosensitivity of NSCLC cells correlated well with the expression 
of c-erbB-2, and transfection of c-erbB-2 cDNA into low c-erbB-2 expressing NSCLC 
significantly enhanced chemoresistance to adriamycin, cisplatin, mitomycin C and VP- 
16 (Tsai et al, 1996).
18
The majority of normal ovarian tissues express low levels of c-erbB-2. Therefore only 
tumours that express greater levels of c-erbB-2 can be considered overexpressers. A 
noted consistency of expression between primary tumours and metastatic sites has been 
found. No change in expression is seen over time. C-erbB-2 is overexpressed in 
approximately 30% of ovarian cancers. Some researchers have shown a positive 
correlation between overexpression and poor prognosis. On the other hand, other 
reports have shown no adverse prognostic significance for c-erbB-2 overexpression. No 
correlation was found between c-erbB-2 overexpression and clinicopathological factors 
such as age, stage, cell type, histological grade, residual tumour after primary 
cytoreduction or the likelihood of a negative re-exploration after chemotherapy. 
However, the uniformly poor prognosis for ovarian cancer may effect these results. 
Clear cell tumours have been found to have an increase in overexpression, with 68% 
showing overexpression, as opposed to 9% of other cells (Cirisano and Karlan, 1996).
Overexpression of c-erbB-2 has been found in 27% of patients with metastatic disease, 
as opposed to 4% of patients with disease confined to the uterus. Overexpression 
correlated with established prognostic variables of grade, stage, depth of invasion, more 
aggressive disease and disease-related mortality. Heavy staining of cell membrane 
correlated with 56% 5-year survival, intermediate staining correlated with 83% 5-year 
survival and negative staining correlated with 95% 5-year survival (Cirisano and 
Karlan, 1996).
Of 396 adenocarcinomas of the stomach, 10.1% overexpressed c-erbB-2. This 
overexpression broke down as 15.2% of well differentiated tumours and 3.0% of 
undifferentiated tumours, showing that c-erbB-2 overexpression is more prevalent in 
well differentiated gastric tumours. Gene amplification was detected in all the 
overexpressing tumours (Ooi et ah, 1997).
1.4.3 The Role of c-erbB-3 in Human Cancers
C-erbB-3 protein expression was investigated immunohistochemically in a series of 97
malignant breast tumours. 28.8% of cases displayed overexpression, 32% displayed
normal levels and 39.2% of cases were c-erbB-3 negative. C-erbB-3 overexpression was
positively but not significantly related to negative lymph node status. 21% of lymph
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node positive patients as opposed to 41% of lymph node negative patients showed c- 
erbB-3 overexpression, accompanied by a positive association between c-erbB-3 
overexpression and improved survival over a 10-year follow-up period, but it did not 
achieve statistical significance (Quinn et al., 1994).
Bobrow et al. (1997) studied 57 cases of ductal carcinoma in situ of the breast (DCIS) 
by immunocytochemical methods. Staining was either absent (29.8%), present at levels 
equivalent to that found in adjacent normal tissue (35%) or greater than in normal tissue 
(35%). In most cases the pattern of staining was cytoplasmic, but in 4 cases with the 
most intense reaction there was also focal membrane staining. Each of these 4 cases 
were poorly differentiated. Positive staining was present in 24 poorly differentiated, 8 
intermediately differentiated and 8 well differentiated tumours. In the same series of 
cases, c-erbB-2 protein had previously been shown to be overexpressed in 49% of cases, 
c-erbB-2 overexpression was correlated with normal level of c-erbB-3, and lack of c- 
erbB-2 expression was correlated with c-erbB-3 overexpression.
Maurer et al. (1998) determined whether c-erbB-3 is found in normal human colon and 
whether its expression is altered in colorectal cancer in 35 colorectal cancer patients. 
They also included c-erbB-2 and c-erbB-1 in their analysis to determine their 
coexpression with c-erbB-3. Normal human colon showed weak c-erbB-3 and c-erbB-2 
immunostaining, predominantly in surface epithelial cells. C-erbB-1 immunoreactivity 
in normal colon varied from weak to strong. In contrast, in 89% and in 83% of colonic 
cancers, moderate to strong immunoreactivity for c-erbB-3 and c-erbB-2, respectively, 
was present in most epithelial cancer cells. A concomitant c-erbB-3 and c-erbB-2 
immunostaining advantage could be found in 77% of cancerous tissues in comparison 
with the normal colon. No difference in c-erbB-1 immunostaining was evident between 
normal colon and cancer. mRNA levels of c-erbB-3 and c-erbB-2 were found to be 
increased in 64% of cancers in comparison with normal colon samples. 85% of cancers 
with c-erbB-3 mRNA overexpression showed an increase in c-erbB-2 mRNA. C-erbB-
1, however, was decreased in cancer on mRNA level. These findings indicate that c- 
erbB-2 and c-erbB-3, but not c-erbB-1, may contribute to tumour growth and disease 
progression in colon cancer.
Funayama et al. (1998) studied the overexpression of c-erbB-3 in human SCC. They 
analysed human SCC cells (A431, SAS and Ca-9-22) for c-erbB-3 gene amplification,
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but found no difference between them and normal cells (HFF and TIG-7). Using two 
sets of primers, one corresponding to the transmembrane form of c-erbB-3 and the 
other, the secreted form of c-erbB-3, which yields bands of 564bp and 520bp, they 
found that both types of c-erbB-3 mRNA were overexpressed in oral SCC cell lines and 
their expression varied in SCC cell lines. Both c-erbB-1 and c-erbB-3 were found to be 
overexpressed in SCC. C-erbB-3 mRNA was found to be overexpressed at levels 3-5- 
fold greater in metastatic tumours of nude mice as compared to the primary transplanted 
tumour.
C-erbB-3 and c-erbB-4 protein expression was analysed using immunohistochemistry in
138 fresh-frozen thyroid tissue samples from 106 patients, including 56 cases of 
papillary thyroid carcinoma. Increased expression of c-erbB-3 and c-erbB-4 proteins 
was observed in papillary carcinomas compared to non-neoplastic thyroid tissue. No c- 
erbB-3 expression was found in any of the normal thyroid tissue samples. Coexisting 
overexpression of c-erbB-1, c-erbB-2, c-erbB-3, and c-erbB-4 was demonstrated in 64% 
of papillary thyroid carcinomas. These findings suggest a common regulatory 
mechanism for the ErbB family of receptors in papillary thyroid carcinomas and provide 
numerous possibilities for functional receptor interactions (Haugen et a l, 1996).
Rajkumar et al. (1993) examined the expression of the c-erbB-3 protein in a wide range 
of tumours of the gastrointestinal (GI) tract using immunocytochemical staining. C- 
erbB-3 protein was found in normal epithelial cells throughout the GI tract, in squamous 
epithelium of the oropharanyx and oesophagus, in the parietal cells of the stomach, and 
in the surface enterocytes of the small and large bowel. 76 tumours arising at these sites 
were examined for c-erbB-3 protein expression. Widely varying levels of expression 
were seen, from absent to intense staining with cell membrane accentuation.
1.4.4 The Role of C-erbB-4 in Human Cancers
Merimsky et al. (2002) assessed the possible role of c-erbB-4 as a tissue marker for
soft-tissue sarcomas (STS) and its correlation with the response to chemotherapy. The
histological specimen of 29 patients with STS of a limb who had received pre-operative
adriamycin-based chemotherapy were studied for the degree of necrosis and the
expression of c-erbB-4. C-erbB-4 expression in the pre-operative tissue samples was
compared with the expression in the postchemotherapy resected tumour. The true
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objective response rate to pre-operative chemotherapy was 34%. The tumour necrosis 
was above 90% in 9 patients, 60-90% in 12, and less than 60% in 7 patients. An 
increase in c-erbB-4 expression was more common in cases with no response to 
chemotherapy, while no change or a decrease in c-erbB-4 was more common in 
responsive tumours (P=0.004). No correlation could be found between the degree of 
necrosis or the chemotherapeutic regimen and the change in expression of c-erbB-4. 
The median DFS was longer for patients with a decrease or no change in expression of 
c-erbB-4. It is believed that postchemotherapy new expression or lack of 
downregulation of the c-erbB-4 molecule represents tumour aggressiveness and 
increased capability of growth and spread.
Gilmour et al. (2001) reported that immunohistochemical expression of c-erbB-4 
protein was identified in 93% of ovarian cancers (n=53) using the HFR-1 antibody 
(targeted to the cytoplasmic domain of the erbB4 receptor) and in 89% of ovarian 
cancers using the H4.77.16 antibody (targeted to the extracellular domain). Tumours of 
serous histology were more likely to express a higher level of c-erbB-4 than 
endometrioid tumours, and for stage III serous tumours, long-term survival was 
associated with moderate to high coexpression of c-erbB-4 and c-erbB-2. Within 
ovarian cancer cell lines, high c-erbB-4 expression was associated with cisplatin 
resistance. Using RT-PCR, the presence of multiple isoforms of c-erbB-4 mRNA was 
identified in both ovarian primary tumours and cell lines. Splice variants in the 
juxtamembrane (JM-a and JM-d) and cytoplasmic (CT-a and CT-b) regions were 
identified in mRNA of both cell lines and primary tumours. Scoccia et al. (1998) 
detected expression of c-erbB-1, c-erbB-2 and c-erbB-3, but failed to detect c-erbB-4 in 
ovarian carcinomas (17 serous cystadenocarcinomas).
Granulosa cell (GC) tumours represent approximately 7% of all malignant ovarian 
neoplasms. Ten out of 12 granulosa tumours expressed c-erbB-4 at moderate to high 
levels in >50% of cancer cells, whereas c-erbB-2 (6 out of 12) and c-erbB-3 (2 out of 
12) were expressed less frequently (Furger et al., 1998).
Al Moustafa et al. (1999) reported on the differential expression of c-erbB-2, c-erbB-3 
and c-erbB-4, and their ligand NRGa, in normal bronchial epithelial, and NSCLC cell 
lines. Expression of c-erbB-2 and c-erbB-3 vary from very low to a high level in 
NSCLC cell lines and a low level in normal bronchial cells. In contrast, c-erbB-4 was
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detected only in NSCLC cell lines but not in normal bronchial cells. NRGa is expressed 
at intermediate levels in the normal and cancer cell lines studied. Immunoprécipitation, 
using antibodies to c-erbB-2, c-erbB-3 or c-erbB-4 receptors, coupled to 
phosphotyrosine Western blot analysis indicates that these three receptors are 
constitutively tyrosine phosphorylated in lung cancer cell lines, but only c-erbB-2 and c- 
erbB-3 are autophosphorylated in normal cells. These data suggest that constitutive 
activation of c-erbB-2, c-erbB-3 and c-erbB-4 receptors could be induced by NRGa via 
an autocrine loop mechanism, and that the active forms of c-erbB-4 may cooperate with 
the other members of the EGF-receptor family in human lung carcinogenesis.
Graber el al. (1999) reported that c-erbB-4 mRNA expression decreased 6-fold in the 
non-metastatic stages of pancreatic cancer when compared to tumours with lymph node 
or distant métastasés or to the normal pancreas. In addition, immunohistochemistry 
demonstrated that in the normal pancreas, the c-erbB-4 antigen was predominantly 
present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much 
lower level, in islet cells. In pancreatic cancer, 61 out of 75 samples exhibited weak to 
moderate immunoreactivity for c-erbB-4 in the tumour cells. Moreover, in the peri- 
tumorous region with chronic pancreatitis-like morphological changes, there was weak- 
to-moderate c-erbB-4 immunostaining in small ductules and degenerating acinar cells.
Co-overexpression of c-erbB-2 and c-erbB-4 was found to be associated with a shorter 
overall survival time in colorectal cancer patients (Lee et al., 2002).
Bei et al. (2001) compared the expression of all four ErbB receptors by 
immunohistochemistry, using receptor-specific polyclonal antisera, in 32 invasive, 11 in 
situ carcinomas, 6 benign lesions, and 22 samples of histologically normal mucosa 
adjacent to specimens of carcinoma originating from oral cavity epithelium. Among 
invasive and in situ carcinoma, c-erbB-1 expression was the most prevalent (in 29/32 
and 8/11 cases, respectively) followed by c-erbB-2 (17/32 and 2/11) and c-erbB-4 (9/32 
and 1/10), while c-erbB-3 was only detected in invasive tumours (12/32). Specific 
patterns included invasive tumours with expression of c-erbB-1 (8/32) or c-erbB-4 
(1/32) alone, as well as different receptor combinations (c-erbB-1+c-erbB-2, c-erbB- 
l+c-erbB-4, c-erbB-l+c-erbB-2+c-erbB-3, c-erbB-l+c-erbB-2+c-erbB-4, and all four 
receptors). Simultaneous expression of three or four ErbB receptors correlated with 
tumour invasion. Some benign lesions and histologically normal mucosa adjacent to
23
carcinomas showed weak immunostaining of c-erbB-1 (10/28), c-erbB-2 (4/28) or c- 
erbB-4 (3/28). By comparison, overexpression, as indicated by increased staining 
intensity, was observed in invasive tumours for c-erbB-1 (18/32), c-erbB-2 (8/32), c- 
erbB-3 (3/32), and c-erbB-4 (3/32). Statistical evaluation demonstrated a significant 
association of c-erbB-1 or c-erbB-2 overexpression with invasive carcinoma when 
compared with benign lesions and apparently normal epithelium.
The expression patterns of ErbB receptors was determined by immunohistochemistry in 
primary human bladder cancer (n = 245) and compared with conventional biological 
indicators for their prognostic significance. Expression of c-erbB-1, c-erbB-2, c-erbB-3, 
or c-erbB-4 receptors was detected in 72.2, 44.5, 56.3, and 29.8% of bladder cancer 
cases, respectively. Important indicators in association with patient survival were 
tumour staging (P = 0.017), c-erbB-2 (P = 0.018), c-erbB-1-c-erbB-2 (P = 0.023), and c- 
erbB-2-c-erbB-3 (P = 0.042) (Chow et al., 2001).
There is a significant relationship between tumour cell expression of c-erbB-4, and 
aggressive tumour phenotype in childhood medulloblastoma. Two alternative 
juxtamembrane (JM) isoforms of the c-erbB-4 receptor have been described. Termed 
JMa and JMb, these variants possess different receptor processing and ligand-binding 
characteristics. The pattern of c-erbB-4 JM isoform expression in 78 pediatric 
medulloblastomas was studied. JMa and JMb transcript expression was detected in 53% 
and 28% of tumour samples, respectively. In addition, two novel c-erbB-4 JM isoforms, 
subsequently termed JMc and JMd, were isolated from 10% and 36% of tumours, 
respectively. Sequence analysis revealed the JMc transcript to contain a deletion of the 
entire JM region. In contrast, JMd includes an extended coding region, retaining both 
the JMa and JMb sequences. Neither of these novel isoforms was detected in normal 
human adult cerebellum, but expression of JMd was observed in developing fetal 
cerebellum, suggesting that this later isoform may represent an c-erbB-4 transcript 
restricted to primitive neuroectoderm-derived tissue. To confirm that the four c-erbB-4 
JM isoforms arise by alternative RNA splicing, the intron-exon junctions of the human 
c-erbB-4 gene were sequenced within the JM region. This demonstrated the four c- 
erbB-4 JM variants to be encoded by two short exons containing the JMb and JMa 
sequences positioned in the order 5' to 3' and separated by a 121 bp intron (Gilbertson et 
al., 2001).
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Knowlden et al. (1998) examined c-erbB3 and c-erbB4 mRNA expression in 47 
primary breast cancer samples and investigated correlations between these parameters 
and the expression of both ER and c-erbB-1 and with Ki67 immunostaining. A direct 
association was found between c-erbB-3 and c-erbB-4, and ER marker status. Inverse 
associations were seen between c-erbB-3 and c-erbB-4, and c-erbB-1. A significant 
relationship was seen between Ki67 and c-erbB-4. Measurements of c-erbB-3 protein 
levels in tumour samples removed from a further 89 patients of known response to 
endocrine therapy: (i) confirmed the relationship between c-erbB-3 and ER and (ii) 
identified that patients whose ER positive tumours expressed high levels of c-erbB-3 
were most likely to benefit from endocrine measures. These results clearly demonstrate 
that increased c-erbB-3 and c-erbB-4 expression appears to be associated with the 
prognostically-favourable ER phenotype.
C-erbB-4 expression was investigated in a range of human tumour cell lines and in 
normal and malignant breast tissue. Using primers which amplified a 658 base pair (bp) 
region corresponding to part of the cytoplasmic domain of c-erbB-4, the receptor was 
found to be expressed in some but not all breast and ovarian tumour cell lines and also 
in a glioma cell line. The highest level of c-erbB-4 expression was found in the ovarian 
carcinoma OVCAR-3 and the breast carcinoma T-47D. In all cell lines where the 'full- 
length' c-erbB-4 was detected, a second previously undescribed c-erbB-4 sequence was 
also found as a 610 bp PCR product. The alternative PCR product was identical in 
sequence to c-erbB-4 except for a deletion of 48 bp which encodes a consensus 
phosphatidylinositol 3-kinase (PI3K) binding site. This suggested that the two forms of 
c-erbB-4 might interact with different intracellular signalling pathways and therefore 
influence a wider variety of cellular responses to NRG than previously thought. 
Expression of both c-erbB-4 variants was found in 7/7 normal breast tissues but only in 
9/12 breast tumours analysed. In line with the terminology of Elenius et al. (1997b) the 
two isoforms of the C-terminal transcripts were designated as CT-a (full-length) and 
CT-b which lacks the P13K binding motif (Sawyer et al., 1998).
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Table 1.4 Summary of Effects of ErbB Receptor Expression in Cancer
A uthor ErbB
Type
Cancer Type Findings
Nicholson et al., 2001 1 Multiple Prognostic indicator of poor outcome
Aziz et al., 2000 1 Breast Prognostic indicator of poor outcome
Tsutsui et al., 2002 1 Breast Prognostic indicator of poor outcome
Suo et al., 2002 1,2,3,4 Breast Poor out come for 1,2,3. Favourable 
outcome for 4
Ferrero etal., 2001 1 Breast No effect on prognosis
O-Dwyer et al., 2002 1 Colon Prognostic indicator of poor outcome
Ferrandina et al., 2002 1,2 Ovarian No effect on prognosis
Vered et al., 2002 1 Salivary gland 85% Positive for overexpression of c- 
erbB-1
Storkel et al., 1993 1 Oral Prognostic indicator of poor outcome
Brabender et al., 2001 1,2 NSCLC Prognostic indicator of poor outcome
Pfeiffer et al., 1996 1,2 NSCLC No effect on prognosis
Cirisano and Karlan., 
1996
2 Ovarian Prognostic indicator of poor outcome
Ooi etal., 1997 2 Stomach Overexpressed
Quinn et al., 1994 3 Breast Prognostic indicator of favourable 
outcome
Maurer et al, 1998 3 Colon Increased expression of c-erbB-2 in 
tumours
Funayama etal., 1998 3 s e e Overexpression
Haugen et al., 1996 3,4 Thyroid Overexpression
Rajkumar etal., 1993 3 Gastrointestinal Inconclusive
Merimsky et al., 2002 4 Soft tissue Prognostic indicator of poor response to 
chemotherapy
Gilmouretal., 2001 4 Ovarian Overexpression
Furger el al., 1998 2,3,4 Ovarian Overexpression of 2 and 4
Al Moustafa et al., 
1999
2,3,4 NSCLC Overexpression of 4
Graber et al., 1999 4 Pancreatic Overexpression in metastatic and 
decreased expression in non-metastatic 
tumours
Lee et al., 2002 2,4 Colorectal Prognostic indicator of poor outcome
Bei et al., 2001 1,2,3,4 Oral C-erbB-1 overexpression most prevalent
Chow et al., 2001 1,2,3,4 Bladder C-erbB-1 overexpression most prevalent
Gilbertson et al, 2001 4 Medullablastoma Overexpression
Knowlden et al., 1998 3,4 Breast Prognostic indicator of favourable 
outcome
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1.5 The Role of C-erbB-2 in Breast Cancer
1.5.1 C-erbB-2 Overexpression as a Prognostic Factor in Breast Cancer
In a study of 166 primary breast cancers by Dittadi et al. (1996), 21.6% showed c-erbB- 
2 overexpression, while 27.1% and 85 51.3% showed intermediate and low level 
expression. A good correlation was found between DNA content and c-erbB-2 
positivity. Overexpressers were associated with DNA aneuploidy. Cirisano and Karlan 
(1996) reported that the frequency of amplification averages 20-25% of breast cancer 
cases. The majority of studies have found that overexpression is most common in 
cancers with positive axillary lymph nodes and is correlated with worse prognosis for 
both node-negative and node positive tumours. In a study of 122 primary breast tumours 
and 62 metastases, the frequency of amplification of c-erbB-2 was less in metastases, 
although not enough to be statistically significant (Driouch et al., 1997).
A study of 163 tumours from patients with different stages of breast cancer were 
analysed by Marx et al. (1990) in order to evaluate the distribution of c-erbB-2. 33% of 
cases were found to be c-erbB-2 positive. Only 5% of infiltrating lobular carcinomas 
(small cell carcinomas) showed positivity. Invasive ductal carcinomas show 33% 
positivity. Non-invasive and early invasive ductal carcinomas, both of the large cell 
comedo typ,e also showed positivity. C-erbB-2 protein expression was slightly more 
common in lymph-node positive (37%) than lymph-node negative cancer (30%). 50% 
of patients with three or more positive lymph-nodes were c-erbB-2 positive. C-erbB-2 
overexpression correlated negatively with steroid receptor status and positively with c- 
erbB-1 expression.
A study by Quenel et al. (1995) of 942 invasive ductal carcinomas found 24% with 
positive membrane staining. They found a significant association between c-erbB-2 and 
tumour grade. Grading was performed according to Scarff-Bloom-Richardson criteria, 
with 11.2% of Grade 1, 21.5% of Grade 2 and 35.2% of grade III expressing c-erbB-2. 
Negative correlation with estrogen and progesterone receptor status was found. No 
association was found between c-erbB-2 and tumour size, nodal status or patient age. C- 
erbB-2 positivity correlated with the least differentiated tumours, higher mitotic rate and 
with the most marked polymorphism. Multivariate analysis showed that c-erbB-2 was
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an independent prognostic factor, associated with earlier relapse or metastasis in node­
negative patients.
In a study of 33 patients treated for advanced breast cancer, plasma c-erbB-2 levels were 
determined (this refers to the extracellular domain shed from the cell surface). 30.3% of 
the metastatic breast cancer were found to be c-erbB-2 positive. 20 of the patients 
received standard FEC regimen (5-fluorouracil, epirubicin and cyclophosphamide), 8 
received a modified FEC regimen, 2 patients received CMF (5-fluorouracil, 
methotrexate and cyclophosphamide) and 3 patients received vinorelbine. No 
statistically significant difference was noted in response to chemotherapy between c- 
erbB-2+ and c-erbB-2- patients. In the 10 c-erbB-2+ patients, two increases and eight 
decreases were seen in plasma concentrations. Remarkably 5 of 23 c-erbB-2- patients 
had an increase in plasma c-erbB-2 during treatment. One observation made was that 
plasma c-erbB-2 positivity is associated with advanced breast cancer. Between 34.6- 
51% of patients with metastatic breast cancer and 33% of patients with locally recurrent 
breast cancer show plasma c-erbB-2 positivity, while no patients with locoregional non­
inflammatory breast cancer showed positivity (Revillion et al., 1996).
C-erbB-2 gene amplification is associated with poor prognosis in non-inflammatory 
breast carcinoma, mainly where axillary nodes are invaded and are associated with 
increased risk of multiple metastases developing simultaneously. In patients with 
inflammatory breast carcinoma, c-erbB-2 overexpression was not found to be associated 
with a higher risk of death, suggesting that c-erbB-2 plays different roles in these two 
cancers (Prost et al., 1994).
123 breast tumour biopsies were examined for c-erbB-2 and c-erbB-1 expression. C- 
erbB-1 was found to be expressed at lower levels in 975 of tumours. C-erbB-2 was 
overexpressed in 91% of tumours. Of the c-erbB-2 overexpressing cells, two 
populations emerged with one having levels of c-erbB-2 from 0.33 to 19 and 45 to 480 
times normal. Within the lower group c-erbB-1 expression was inversely related to c- 
erbB-2 expression. The second population was found to have c-erbB-2 gene 
amplifications. No inverse correlation was found in this group between c-erbB-2 and c- 
erbB-1. C-erbB-1 expression was found to correlate indirectly with potential doubling 
time, but not with the duration of the S-phase. C-erbB-2 showed no correlation with 
doubling time (Robertson et al., 1996).
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Breast carcinoma in situ (CIS) is considered to be the earliest form of breast cancer. 
Although 90% of patients with CIS are cured by surgery, the hypothesis that CIS lesions 
are precursors of invasive breast cancer is supported by the reports of a significant rate 
of local reoccurrence in patients who are not treated with mastectomy. Liu et al. (1992) 
assessed the amplification and overexpression of c-erbB-2 in paraffin-embedded 
specimens from 27 in situ carcinomas of the breast and 122 stage II breast cancers. 
Gene amplification was detected in 48% of in situ carcinomas and in 21% of stage II 
lesions. C-erbB-2 protein levels corresponded with amplification levels. These results 
suggest that the amplification of c-erbB-2 is an early event in human breast cancer.
Parkes et al. (1990) investigated the expression of c-erbB-2 in 70 human primary breast 
cancers. They found gene amplification in 17.5% of cases. Analysis of c-erbB-2 
mRNA levels found overexpression in 30% of tumours associated with those of ductal 
origin. They demonstrated that enhanced c-erbB-2 expression could occur in the 
presence or absence of c-erbB-2 gene amplification. In situ hybridisation showed that 
elevated levels of mRNA expression were specific to malignant cells within the breast 
tumour. A significant correlation was made with poor tumour grade.
C-erbB-2 is overexpressed in 80% of large cell comedo carcinoma in situ. It has been 
postulated that the receptor may be an early event in the genesis of certain types of 
breast carcinomas, and subsequently may be lost once the tumour becomes invasive. 
57.1% of cases of apocrine adenosis were found to be positive for c-erbB-2 
overexpression. The staining intensities were classed as strong in 4 cases and weak in 8. 
Three cases were associated with ductal carcinoma, two with negative staining of both 
the apocrine adenosis and the carcinoma, while the third showed staining in both. The 
proliferation rate was increased in some of the lesions and all of the lesions showed 
some of the cells to be in the cell cycle. The expression of abnormal oncogenes and 
increased proliferation suggests that there may be an association between these lesions 
and large cell ductal carcinoma in situ and hence invasive carcinoma (Wells et al.,
1995).
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1.5.2 C-erbB-2 as a Predictor of Response to Chemotherapy in Cell Line Models
Transfection of MDA-MB435 human breast cancer cells with c-erbB-2 resulted in 
resistance to taxol. The increased taxol resistance was not accompanied by changes in 
doubling time and S-phase fraction. The MDA-MB-435 cells expressed very low levels 
of p-glycoprotein and there was no increase of its expression in the c-erbB-2 
overexpressing MDA-MB-435 transfectants. Furthermore, these transfectants were not 
sensitised to taxol treatment by the mdr-1 blocker thioradazine. These data 
demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic taxol resistance 
independent of mdr-1 mechanisms (Yu et al., 1996). This overexpression of c-erbB-2 
in MDA-MB-435 conferred a 5-9-fold increase in Taxol resistance. A panel of human 
breast cancer cell lines established from different patients and expressing c-erbB-2 at 
different levels was examined for their sensitivity to taxol and taxotere. Higher 
expression of c-erbB-2 in these breast cancer cell lines correlated well with resistance to 
taxol and taxotere, and the degree of resistance was about 100-fold that in c-erbB-2 - 
overexpressing MDA-MB-435 transfectants, demonstrating that these breast cancer 
cells are highly resistant to taxol. Higher levels of p-glycoprotein expression were found 
in several of the breast cancer cell lines. They sought to determine the relative 
contribution of c-erbB-2 and p-glycoprotein overexpression to taxol resistance in these 
cell lines. C-erbB-2 was downregulated using anti-c-erbB-2 monoclonal antibodies and 
the sensitivity of cells to taxol was assayed. P-glycoprotein function was inactivated 
using thioridazine or verapamil. Both c-erbB-2 down-regulation and p-glycoprotein 
blockade significantly sensitised the breast cancer cell lines to taxol. These results 
indicated that overexpression of either c-erbB-2 or p-glycoprotein renders human breast 
cancer cells resistant to taxol. Furthermore, c-erbB-2 synergised with p-glycoprotein 
conferring higher degrees of taxol resistance (Yu et al., 1998b).
Studies to elucidate the mechanism of taxol resistance in this model revealed that taxol 
activated expression of p34Cdc2 kinase in MDA-MB-435 leading to cell cycle arrest at 
the G2/M phase and, subsequently, apoptosis. A chemical inhibitor of p34Cdc2 and 
dominant-negative mutant of p34Cdc2 blocked taxol-induced apoptosis in these cells. 
C-erbB-2 overexpression in MDA-MB-435 cells transcriptionally upregulated p21Cipl, 
which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays 
cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. In p21Cipl 
antisense-transfected MDA-MB-435 cells or in p21 -/- MEF cells, c-erbB-2 was unable
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to inhibit Taxol-induced apoptosis. Therefore, p21Cipl participates in the regulation of 
a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in c-erbB- 
2-overexpressing breast cancer cells (Yu et a l, 1998). C-erbB-2 was shown to bind to 
and colocalise with cyclin B-Cdc2 complexes and phosphorylates Cdc2-Y15. The c- 
erbB-2 kinase domain is sufficient to directly phosphorylate Cdc2-Y15. Increased 
Cdc2-Y15-p in c-erbB-2 overexpressing cells corresponds with delayed M phase entry. 
Expressing a nonphosphorylatable mutant of Cdc2 renders cells more sensitive to taxol- 
induced apoptosis. Thus, c-erB-2 can confer resistance to taxol-induced apoptosis by 
directly phosphorylating Cdc2 (Tan et al., 2002).
Chen et al. (2000) selected various NIH 3T3 cell lines that specifically expressed c- 
erbB-1, c-erbB-2, c-erbB-3, c-erbB-l/c-erbB-2, c-erbB-l/c-erbB-3, or c-erbB-2/c-erbB-
3. A cytotoxicity assay showed that expression of c-erbB-2 alone did not significantly 
enhance drug resistance, whereas coexpression of either c-erbB-1 or c-erbB-3 with c- 
erbB-2 significantly enhanced drug resistance. C-erbB-2 was highly phosphorylated in 
NIH 3T3 cells that coexpress c-erbB-2 with either ErbB, but not in NIH 3T3 cells that 
express c-erbB-2 alone. These results suggested that coexpression of c-erbB-1 or c- 
erbB-3 with c-erbB-2 induces high phosphorylation of c-erbB-2 and renders the cells 
more resistant to various anti-cancer drugs (Chen et al., 2000). C-erbB-2 
overexpression in normal human mammary epithelial cells failed to confer resistance or 
sensitivity to chemotherapeutic agents (Orr et al, 2000).
A c-erbB-2-targeted ribozyme was used to abrogate c-erbB-2 expression in human SK- 
OV-3 ovarian cancer cells. SK-OV-3 cells expressing very low residual levels of c- 
erbB-2 protein, were then assessed for their sensitivity to adriamycin, cisplatin and taxol 
and compared to control cells. C-erbB-2 expression had no effect on the cytotoxicity of 
adriamycin or cisplatin in proliferation assays. In contrast, the sensitivity to taxol was 
increased approximately 70-fold in c-erbB-2 depleted cells (Aigner et a l, 2000).
Cell lines transfected with EGFRvIII (activated mutant of c-erbB-1) and c-erbB-2 are 
more resistant to taxol-mediated cytotoxicity, and tubulin polymerization induced by 
taxol is suppressed compared with cells expressing wt-EGFR. Montgomery et al. 
(2000) analysed (3-tubulin isotypes expressed in cell lines transfected EGFRvIII and c- 
erbB-2. EGFRvIII- and c-erbB-2-expressing cells demonstrated equivalent total (3- 
tubulin protein compared with cells transfected with wild type receptor or untransfected
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controls. EGFRvIII-expressing cells demonstrated increases in class IVa (2.5-fold) and 
IVP (3.1-fold) tubulin mRNA, and c-erbB-2-expressing cells showed increases in class 
IVa (2.95-fold) mRNA. Inhibition of EGFRvIII kinase activity using a mutant allele 
with an inactivating mutation in the kinase domain decreased expression of class IVa 
by 50% and partially reversed resistance to taxol.
MCF-10A human mammary epithelial cells transfected with an activated c-Ha-ras gene 
(MCF-10A Ha-ras cells), the c-erbB-2 gene (MCF-10A c-erbB-2 cells) or both genes 
(MCF-10A HE cells) were tested for their sensitivity to different cytotoxic drugs 
(Ciardiello et al., 2000). As compared with parental MCF-10A cells, the transformed 
cells exhibited an increased sensitivity to topoisomerase I- and topoisomerase II- 
inhibitors, and to platinum-derivatives with a 2- to 10-fold reduction in IC(50) values. A 
remarkable difference in sensitivity was observed following treatment with taxanes. 
While MCF-10A Ha-ras cells showed an increased sensitivity, MCF-10A c-erbB-2 and 
MCF-10A HE cells exhibited a relative resistance to taxol and taxotere, with an 
approximately 3.5- to 6.5-fold higher IC(50) as compared with MCF-10A cells 
suggesting that c-erbB-2 overexpression has a dominant effect compared with an 
activated c-Ha-ras gene. Inhibition of the type I cAMP-dependent protein kinase (PKAI) 
by antisense oligonucleotides was able to overcome the effect of c-erbB-2 
overexpression on MCF-10A cell sensitivity to taxol and taxotere, with a 20- to 40-fold 
shift in the IC(50) values for the 2 drugs, indicating a role for PKAI in c-erbB-2 
mediated taxol resistance.
Taxol exposure downregulated the expression of c-erbB-2 protein in MCF-7, MDA- 
MB-435 and MDA-MB-453 (Oldham et al., 2000). 17-allylamino 17- 
demethoxygeldanamycin was found to sensitise NSCLC cells expressing high levels of 
c-erbB-2 to taxol-mediated growth arrest and apoptosis. The combination cytotoxic 
effect was only additive in cells expressing low levels of c-erbB-2. In contrast, 
pretreatment of cells with 17-allylamino 17-demethoxygeldanamycin, before combined 
taxol and 17-allylamino 17-demethoxygeldanamycin exposure actually rendered the 
cells refractory to taxol cytotoxicity (Nguyen et al., 1999). Emodin, a tyrosine kinase 
inhibitor, suppressed tyrosine kinase activity of c-erbB-2-overexpressing breast cancer 
cells and preferentially repressed transformation phenotypes of these cells in vitro. 
Emodin significantly inhibited tumour growth and prolonged survival in mice bearing c- 
erbB-2 overexpressing human breast cancer cells. Furthermore, the combination of
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emodin and taxol synergistically inhibited the anchorage-dependent and anchorage- 
independent growth of c-erbB-2-overexpressing breast cancer cells in vitro and 
synergistically inhibited tumour growth and prolonged survival in athymic mice 
bearing. Xenografts of human tumour cells expressing high levels of c-erbB-2. Both 
immunohistochemical staining and Western blot analysis showed that emodin decreases 
tyrosine phosphorylation of c-erbB-2 in tumour tissue (Zhang el al., 1999).
Using c-erbB-2 transfected MCF-7 cells, Pegram et al (1999) found Herceptin (a c- 
erbB-2 targeting monoclonal antibody, in clinical use) to be synergistic with cisplatin, 
thiotepa and VP-16 in vitro. Effects were additive with adriamycin, taxol, methotrexate 
and vinblastine, while 5-fluorouracil was found to be antagonistic. In vivo, 
combinations of Herceptin plus cyclophosphamide, adriamycin, taxol, methotrexate, 
VP-16, and vinblastine resulted in a significant reduction in xenograft volume compared 
to chemotherapy alone (P<0.05). Xenografts treated with Herceptin plus 5-fluorouracil 
were not significantly different from those that received solely 5-fluorouracil. 
Treatment of well established BT-474 breast cancer xenografts in athymic mice with 
Herceptin resulted in a dose-dependent antitumour activity. In combination studies, 
treatment with taxol and Herceptin, or adriamycin and herceptin, resulted in greater 
inhibition of growth than that observed with any agent alone. The combination of taxol 
and Herceptin resulted in the highest tumour growth inhibition and had a significantly 
superior complete tumour regression rate when compared with either taxol or Herceptin 
alone (Baselga et a l, 1998).
Adriamycin-selected variants of the human small cell lung carcinoma cell line, GLC4, 
displayed increased sensitivity to tumour necrosis factor (TNF). Sensitivity to TNF 
appeared to correlate inversely with the expression and gene copies of topoisomerase 
Ila and decreases in c-erbB-2 gene copies resulting in decreased c-erbB-2 expression, 
probably due to linkage between these 2 genes (Sleijfer et al. 1998).
NRG (3-2 is a naturally occurring ligand that activates c-erbB-2 by inducing its 
heterodimerisation with c-erbB-4. The ability of this ligand to phosphorylate the c-erbB-
2 receptor exogenously allowed Harris et al. (1998) to study the effect of c-erbB-2 
activation on cancer cell behaviour. MCF-7 NRG (3-2 transfected showed markedly 
increased sensitivity to adriamycin and VP-16. Topoisomerase Ila mRNA and protein 
(total protein and enzymatic decatenating activity) were found to be upregulated in the
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NRG p-2 transfected cells. Because up-regulation of Topoisomerase Ila  in vitro and in 
clinical specimens is associated with increased response to adriamycin (presumptively 
by an increase in drug substrate), this may be the mechanism of the increased sensitivity 
to adriamycin seen in NRG P-2 transfected cells. This implies that activation of c-erbB-
2 or one of the other members of the receptor family may increase sensitivity to 
adriamycin by up-regulation of Topoisomerase Ila  (Harris et al., 1998).
Osmak et al. (1997) reported that the selection of SKBR-3 breast cancer cell line with 
adriamycin, did not result in altered expression of c-erbB-1, c-erbB-2, c-erbB-3, c-Myc, 
c-H-ras, cathpsin D, cathepsin L, EGF or TGFa.
Fluorescence in situ hybridisation was used to study copy number aberrations of both 
topoisomerase Ila  and c-erbB-2 in nine breast cancer cell lines and in 97 clinical breast 
tumours, which were selected for the study according to their c-erbB-2 status by 
Southern blotting. Two of the five cell lines with c-erbB-2 gene amplification (SK-BR-
3 and UACC-812) showed amplification of topoisomerase Ila. In MDA-361 cells, 
ErbB-2 amplification (14 copies/cell) was associated with a physical deletion of 
topoisomerase Ila  (four copies of chromosome 17 centromere and two copies of 
topoisomerase Ila). The topoisomerase Ila amplification in UACC-812 cells was 
associated with 5.9-fold-increased topoisomerase Ila  protein expression and 2.5-fold- 
increased sensitivity to the topoisomerase II inhibitor, adriamycin, whereas the deletion 
in MDA-361 leads to decreased protein expression (45% of control) and a 2.4-fold- 
increased chemoresistance in vitro. Of 57 c-erbB-2-amplified primary breast 
carcinomas, 44% showed c-erbB-2/topoisomerase Ila  coamplification and 42% a 
physical deletion of the topoisomerase Ila  gene. No topoisomerase Ila  copy number 
aberrations were found in 40 primary tumours without c-erbB-2 amplification. These 
findings may explain the altered chemosensitivity to topoisomerase II inhibitors 
reported in c-erbB-2-amplified breast cancers (Jarvinen et al., 2000).
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1.5.3 C-erbB-2 as a Predictor of Response to Chemotherapy in the Clinical Setting
1.5.3.1 Taxanes
Studies of patients with advanced breast cancer disease demonstrate that, despite the 
association of c-erbB-2 overexpression with poor prognosis, the odds of c-erbB-2- 
positive patients responding clinically to taxanes were greater than three times those of 
c-erbB-2-negative patients. Further studies in preclinical models used combination 
therapy for breast cancer cells that overexpress c-erbB-2, and the use of agents that 
interfere with c-erbB-2 function plus taxol resulted in significant antitumour effects 
(Baselga et al., 1997). Plasma levels of the extracellular domain of c-erbB-2 was found 
to correlate positively with response to weekly taxol in relapsed cancer patients. 
Weekly taxol treatment was found to be more beneficial to patients with high c-erbB-2 
extracellular domain expression, than those with low expression (Kim el al., 2001).
Van Poznak et al. (2002) found no association between c-erbB-2 status and response to 
single-agent taxane chemotherapy in metastatic breast patients.
Formenti et al. (2002) performed a study, firstly to identify patients with locally 
advanced breast cancer (LABC) who will achieve a pathological response to a pre­
operative regimen of concurrent taxol and radiation; and secondly, to explore 
associations between molecular markers from the original tumours and pathological 
response. A total of 36 patients had pretreatment biopsies and were evaluable for the 
analysis of the association of molecular markers with pathological response. 
Pathological response in the mastectomy specimen was achieved in 12 of these 36 
patients (33%). Tumours with low c-erbB-2 gene expression and negative estrogen 
receptors were more likely to respond to the tested regimen (p = 0.009 and p = 0.006, 
respectively).
A phase II study by Seidman et al. (2001) evaluated weekly Herceptin and taxol therapy
in women with c-erbB-2 normal and overexpressing metastatic breast cancer. Efficacy
was correlated with immunohistochemical and fluorescent in situ hybridisation (FISH)
assay results. Up to three prior chemotherapy regimens, including prior anthracycline
and taxane therapy, were allowed. Herceptin 4 mg/kg and taxol 90 mg/m2 were
administered on week 1, with Herceptin 2 mg/kg and taxol 90 mg/m2 administered on
subsequent weeks. C-erbB-2 status was evaluated using four different
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immunohistochemical assays and FISH. The intent-to-treat response rate for all 95 
patients enrolled was 56.8% (95% confidence interval, 47% to 67%). A response rate of 
61.4% (4.5% complete response, 56.8% partial response) was observed in 88 fully 
assessable patients. In patients with c-erbB-2 overexpressing tumours, overall response 
rates ranged from 67% to 81% compared with 41% to 46% in patients with c-erbB-2 
normal expression (ranges reflect the different assay methods used to assess c-erbB-2 
status), these differences in response rates between patients were statistically significant 
for all assay. Therapy was generally well tolerated, although three patients had serious 
cardiac complications.
Fountzilas et al. (2001) treated 34 patients with c-erbB-2 overexpressing advanced 
breast cancer with weekly taxol immediately followed by Herceptin, for at least 12 
weeks. Expression of c-erbB-2 was determined by immunohistochemical analysis on 
fixed, paraffin-embedded tissues. Eligible patients were required to have > or = 25% 
stained tumour cells. Thirty-three patients completed at least 12 weeks of combined 
treatment. After completion of the 12th week of treatment, four patients (12%) achieved 
complete and 17 (50%) partial response. Median duration of response was 11.6 months. 
Median time to progression was nine months while median survival had not been 
reached. The combination of weekly taxol and Herceptin was a safe and active regimen 
for patients with HER-2/neu overexpressing ABC.
Dieras et al. (2001) reported that the taxanes and herceptin have been shown to possess 
significant clinical activity in metastatic breast cancer. Preclinical testing of 
taxane/Herceptin combinations demonstrated additive and synergistic interactions with 
taxol and taxotere, respectively. In a pivotal clinical trial, combination of taxol (3- 
weekly) and Herceptin was associated with an increased response rate compared with 
taxol monotherapy (41% vs. 17%; p = 0.001). The combination therapy also 
significantly improved time to disease progression (6.9 vs. 2.7 months; p < 0.05). In a 
phase II study of weekly taxol plus Herceptin in patients with normal or increased 
tumour c-erbB-2 levels, a response was observed in 60% of patients and the regimen 
was well tolerated. Responses were more frequent in patients with c-erbB-2- 
overexpressing tumors (83% vs. 45%). Preliminary results from a phase II study of 
Herceptin plus taxotere in patients with c-erbB-2 overexpressing tumours indicate 
significant activity, with a response observed in 7 (44%) of 16 evaluable patients. The
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preliminary results of a trial of weekly taxotere and Herceptin demonstrate a response 
rate of 54% in 13 evaluable patients.
Esteva et al. (2002) evaluated the safety and efficacy of weekly taxotere plus Herceptin 
in women with c-erbB-2 overexpressing metastatic breast cancer. Efficacy was 
correlated with c-erbB-2 extracellular domain (ECD) levels. Thirty women with 
metastatic breast cancer were treated with weekly taxotere and Herceptin as first- or 
second-line therapy. Both taxotere and Herceptin were delivered in 4-week cycles 
consisting of three weekly treatments followed by 1 week of rest. A loading dose of 
Herceptin was administered 1 day before the start of the first cycle. The intent-to-treat 
overall response rate (ORR) was 63% (95% confidence interval [Cl], 44% to 80%). The 
ORR in patients whose tumours were c-erbB-2 positive by FISH was 67% (16 of 24 
patients; 95% Cl, 45% to 84%). In patients with elevated serum c-erbB-2 ECD at 
baseline, the ORR was 76% (95% Cl, 53% to 92%), compared with 33% (95% Cl, 7% 
to 70%) in patients with low c-erbB-2 ECD levels (P = 0.04). Variations in c-erbB-2 
ECD concentrations during treatment correlated with response to treatment.
Hamilton et al. (2000) assessed the potential value of the tumour markers p53, c-erbB-2, 
and Bcl-2 in predicting the clinical response to adriamycin and taxol as single agents in 
the treatment of metastatic breast cancer. The primary tumours of 114 patients in the 
European Organization for Research and Treatment of Cancer 10923 trial were assessed 
by immunohistochemistry using monoclonal antibodies; the results were correlated with 
clinical response to therapy. C-erbB-2 was positive in 24% of patients, p53 was positive 
in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation 
between the expression of any of the markers and the clinical response to either agent. 
This study does not support the use of p53, c-erbB-2, or Bcl-2 to assist the selection of 
anthracycline versus taxane in metastatic breast cancer.
1.5.3.2 Anthracyclines
Recent retrospective analyses have suggested that breast cancer patients whose tumours 
overexpress c-erbB-2 derive preferential benefit from treatment with anthracyclines 
such as adriamycin. Paik et al. (2000) evaluated this recommendation in a retrospective 
study of National Surgical Adjuvant Breast and Bowel Project Protocol B-15, in which 
patients received a combination of adriamycin and cyclophosphamide (AC), CMF, or 
AC followed by CMF. They hypothesised that AC would be superior to CMF only in
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the c-erbB-2 positive patients. Immunohistochemical detection of c-erbB-2 was 
performed on tumour sections from 2034 of 2295 eligible patients. Tumour sections 
from 29% of patients stained positive for c-erbB-2. AC was superior to CMF in c-erbB-
2 positive patients only, although differences in outcomes did not reach statistical 
significance. In the c-erbB-2 positive cohort, relative risks of failure (i.e, after AC 
treatment as compared with CMF treatment) were 0.84 for disease-free survival (DFS) 
(95% confidence interval [Cl] = 0.65—1.07; P =.15), 0.82 for survival (95% Cl = 0.63— 
1.06; P =.14), and 0.80 for recurrence-free survival (RFS) (95% Cl = 0.62—1.04; P 
=.10). Tests for interaction between treatment and c-erbB-2 status were suggestive but 
not statistically significant (P =.19 for DFS, P =.11 for survival, and P =.08 for RFS). 
These results, together with overview results indicating minor overall superiority for 
anthracycline-based regimens relative to CMF, indicate a preference for the AC regimen 
in patients with c-erbB-2 positive tumours. Both AC and CMF regimens may be 
considered for patients with c-erbB-2 negative tumours.
In the National Surgical Adjuvant Breast and Bowel Project protocol B-l l,  patients 
with axillary lymph node-positive, hormone receptor-negative breast cancer were 
randomly assigned to receive either L-phenylalanine mustard plus 5-fluorouracil (PF) or 
a combination of L-phenylalanine mustard, 5-fluorouracil, and adriamycin (PAF). 
Tumour cell expression of c-erbB-2 was determined by immunohistochemistry for 638 
out of 682 eligible patients. Overexpression of c-erbB-2 was observed in 37.5% of the 
tumours studied. Overexpression was associated with tumour size (P=.02), lack of 
estrogen receptors (P=.008), and the number of positive lymph nodes (P=.0001). After a 
mean time on study of 13.5 years, the clinical benefit from adriamycin (PAF versus PF) 
was statistically significant for patients with erbB-2-positive tumours, but it was not 
significant for patients with c-erbB-2 -negative tumours. Interaction between 
adriamycin treatment and c-erbB-2 overexpression was statistically significant for 
disease-free survival (P=.02) and distant disease-free survival (P=.02) but not for 
survival (P= .15) or recurrence-free survival (P=.06). These data support the hypothesis 
of a preferential benefit from adriamycin in patients with c-erbB-2-positive breast 
cancer (Paik et al., 1998).
Jarvinen el al. (1998) looked at predictors of response to topoisomerase II inhibitor 
chemotherapy in advanced breast cancer. Fifty-five patients with advanced breast 
cancer were treated with weekly epirubicin (30 mg/m2 weekly up to 1000 mg/m2), as
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first line cytotoxic chemotherapy. Objective response to treatment was analysed 
according to UICC criteria. The predictive value of topoisomerase Ila, c-erbB-2, p53, 
estrogen (ER) and progesterone receptor (PR), S-phase fraction and DNA ploidy were 
analysed from representative formalin-fixed paraffin-embedded primary tumour 
samples. The proportion of topoisomerase Ila  positive cells failed to predict response to 
epirubicin therapy. Overexpression of c-erbB-2 and hormone receptor negativity were 
significantly associated with poor response. Response rate in patients with c-erbB-2 
overexpressing tumours was 32% compared with 65% in patients with no c-erbB-2 
overexpression (P = 0.0058). Accordingly, the response rate for ER-positive patients 
was 67% compared with 26% in ER-negative patients (P = 0.0021). Histological 
grade, p53, DNA-ploidy, tumour proliferation rate (S-phase fraction), stage of the 
disease at diagnosis, age of the patient, previous anti-oestrogen therapy or site of 
metastasis did not predict the response to epirubicin therapy.
Petit et al. (2001) evaluated the predictive value of a tumour’s c-erbB-2 status for 
chemotherapy response in the neoadjuvant setting and the effect of anthracycline dose 
intensity on this predictive value. C-erbB-2 status was evaluated by immunochemistry 
on microbiopsy before neoadjuvant chemotherapy in 39 patients (group A) treated with 
FEC50 (500 mg/m2 5-fluorouracil, 50 mg/m2 epirubicin, and 500 mg/m2
cyclophosphamide) and 40 patients (group B) treated with FECI00 (500 mg/m2 5-
2 2 « 
fluorouracil, 100 mg/m epirubicin, and 500 mg/m cyclophosphamide). All tumours
were stage II or noninflammatory stage III adenocarcinoma. Patient and tumour
characteristics (age, tumour size, clinical nodal status, SBR grade, hormonal receptor
status, and c-erbB-2 expression) were similar in the two groups. In univariate analyses,
anthracycline dose was the only factor predictive of response (OR = 61.5% with
FEC50; OR = 82.5% with FEC100; P = 0.038). When anthracycline dose was correlated
with c-erbB-2 status, an OR of 73.9% was demonstrated in c-erbB-2 negative tumours,
and an OR of 12.5% was demonstrated in c-erbB-2 positive tumours in group A. In
group B, an OR of 69.5% was demonstrated in c-erbB-2 negative tumours, and an OR
of 100% was demonstrated in c-erbB-2 positive tumours. There was no difference in
OR for c-erbB-2 negative tumours treated with FEC50 or FEC100 (P = 0.74). On the
other hand, c-erbB-2 positive tumours treated with FECI00 had a significantly better
OR than those treated with FEC50 (P = 0.0003). In a multivariate analysis, the most
powerful predictive factor of OR was a conditional variable associating anthracycline
dose with c-erbB-2 status. Low-dose anthracycline and c-erbB-2 positivity predicted a
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poor OR, low- or high-dose anthracycline and c-erbB-2 negativity predicted an 
intermediate OR, and high-dose anthracycline and c-erbB-2 positivity predicted a high 
OR. Vincent-Salomon et al. (2000) reported that c-erbB-2 overexpression was not a 
significant predictive marker of the pathological response to high-dose adriamycin 
based chemotherapy.
1.5.3.3 Other Agents
Sjostrom et al. (2002) assessed whether c-erbB-2 expression is associated with clinical 
sensitivity taxotere or sequential methotrexate and 5-fluorouracil (MF). A total of 283 
patients with metastatic breast cancer were initially enrolled in a randomised 
multicentre trial comparing taxotere with sequential MF in advanced breast cancer. 
Paraffin embedded blocks of the primary tumour were available for 131 patients (46%). 
C-erbB-2 expression was scored immunohistochemically in a semi-quantitative fashion 
using a 0 to 3+ scale. Staining scores 2+ or greater were considered positive. Overall 54 
(42%) patients had c-erbB-2-positive tumours. There was no association between 
treatment outcome and c-erbB-2 overexpression. The overall response rates (n=128) 
among c-erbB-2-negative and -positive patients were 35 and 44%, respectively 
(P=0.359). In the MF arm (n=62), the response rate was somewhat higher in the c-erbB-
2 overexpressors (33% versus 18%, P=0.18). In the taxol arm the response rates were 
very similar, regardless of the c-erbB-2 expression (53% versus 53%).
Konecny et al. (2001) examined the association between c-erbB-2 overexpression and 
the sensitivity to the chemotherapeutic drug combinations of cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF) and 5-fluorouracil, epirubicin and 
cyclophosphamide (FEC) of breast cancer cells derived from 140 chemotherapy-naive 
patients at the time of primary surgery. The data showed that c-erbB-2 overexpression 
was not associated with in vitro drug resistance to CMF or FEC. In contrast, tumours 
with strong c-erbB-2 overexpression demonstrated increased dose-dependent in vitro 
sensitivity to both the FEC and CMF regimens.
Slamon et al. (2001) evaluated the efficacy and safety of Herceptin in women with 
metastatic breast cancer that overexpressed c-erbB-2. They randomly assigned 234 
patients to receive standard chemotherapy alone and 235 patients to receive standard 
chemotherapy plus Herceptin. Patients who had not previously received adjuvant 
(postoperative) therapy with an anthracycline were treated with adriamycin (or
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epirubicin in the case of 36 women) and cyclophosphamide alone (138 women) or with 
Herceptin (143 women). Patients who had previously received adjuvant anthracycline 
were treated with taxol alone (96 women) or taxol with Herceptin (92 women). The 
addition of Herceptin to chemotherapy was associated with a longer time to disease 
progression (median, 7.4 vs. 4.6 months; PO.OOl), a higher rate of objective response 
(50 percent vs. 32 percent, PO.OOl), a longer duration of response (median, 9.1 vs. 6.1 
months; PO.OOl), a lower rate of death at 1 year (22 percent vs. 33 percent, P=0.008), 
longer survival (median survival, 25.1 vs. 20.3 months; P=0.01), and a 20% reduction in 
the risk of death. Herceptin increases the clinical benefit of first-line chemotherapy in 
metastatic breast cancer that overexpresses c-erbB-2.
Vargas-Roig et al. (1999) reported that c-erbB-2 protein expression was associated with 
the development of distant métastasés in breast cancer patients treated with relatively 
high doses of anthracyclines in induction chemotherapy (5-fluorouracil, epirubicin or 
adriamycin, cyclophosphamide).
Bottini et al. (1996) found no significance difference in the expression of c-erbB-2, 
estrogen receptor or progesterone receptor before and after neoadjuvant treatment of 
operable breast cancer. The study included ninety nine patients who received either 
CMF (cyclophosphamide, methotrexate and 5-fluorouracil) or epirubicin.
1.5.4 C-erbB-2 as a Predictor of Response to Hormonal Therapy
Overexpression of c-erbB-2 in oestrogen receptor (ER) positive breast tumours is
associated with resistance to endocrine therapy. Kumar et al. (1996) transfected MCF-7
breast cancer cells, which are strongly ER+ and express low levels of c-erbB-2, with a
full-length c-erbB-2 cDNA. Transfection led to the upregulation of bcl-2 (2.5-6 fold)
compared to the parental or mock-transfected cell lines. Overexpression also led to
enhanced expression o f  bcl-XL, w ith no changes in bcl-Xs. Analysis o f  cell lines which
were ER+, MCF-7 and T47-D and those which are C-erbB-2+, SKBR-3 and MDA-453
showed no difference in bcl-2 expression, the same was also found for bcl-XL.
However analysis of cell lines which overexpress c-erbB-2 and express ER, ZR-75-R
and BT-474, showed a 2-5 fold increase in levels of bcl-2 and a 3 fold increase in bcl-
XL. No significant changes in levels of bax were seen in the transfectants. The
transfection of the MCF-7 cells with c-erbB-2 led to the suppression of tamoxifen-
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induced apoptosis. The result of enhanced bcl-2 expression with c-erbB-2 
overexpression is not consistent with previous reports, which show an inverse 
correlation between c-erbB-2 and bcl-2 expression. These studies however have 
correlated bcl-2 with either c-erbB-2 or ER but never with the two together. Conversely 
Krajewski et al. (1997) found that the percentage of Bax-immunopositive breast tumour 
cells correlated positively with c-erbB-2 immunopositivity. The type of breast cancer 
used in this study was invasive ductal carcinoma.
Giani et al. (1998) found that transfection of MCF-7 cells with c-erbB-2 resulted in 
reduction in the number and size of colonies in a colony formation assay. In hormone- 
deprived media, the transfectants re-acquired growth capacities, indicating that the 
transfectants were now hormone independent. However in the presence of hormone, c- 
erbB-2 overexpression inhibited proliferation by 39-49% and induced differentiation 
shown by the formation of lipid droplets. This suggests that in the presence of 
hormones, the c-erbB-2 signalling pathway is switched towards differentiation. They 
also showed increased MAPK phosphorylation in transfected cells and subsequent 
upregulation of p21WAF1. pRb was found to be hypophosphorylated in the transfected 
cells. Inhibition of c-erbB-2 with a single chain antibody reversed all changes, proving 
that changes were c-erbB-2 specific.
Benz et al. (1992) also transfected MCF-7 cells with c-erbB-2. Those clones isolated 
which overexpressed c-erbB-2 were found to possess increased inositol-1,4,5- 
triphosphate-3’-kinase activity comparable to that of c-erbB-2 overexpressing cell lines 
SKBR-3 and BT474. The transfectants acquired low-level (2-3 fold) resistance to 
cisplatin and were no longer sensitive to tamoxifen. The tumourigenicity of the 
transfectants were found to be estrogen-dependent.
C-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage 
breast cancer without axillary lymph node metastasis. Carlomagno et al. (1996) studied 
the interaction between c-erbB-2 overexpression and adjuvant tamoxifen in node­
negative breast cancer patients. 29.5% of early-stage breast cancer without axillary 
lymph node metastasis were found to overexpress c-erbB-2. C-erbB-2 overexpression 
correlated with a larger tumour size and decreasing levels of ER. In c-erbB-2 positive 
cases, adjuvant tamoxifen did not affect disease-free survival or overall survival, while 
in c-erbB-2 negative cases adjuvant tamoxifen treatment prolonged disease-free survival
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and overall survival duration. C-erbB-2 can be used as a marker for lack of efficacy of 
adjuvant tamoxifen.
A study involving a group of post-menopausal breast carcinoma patients (74) who 
received neoadjuvant tamoxifen therapy found that c-erbB-2 levels showed no 
significant variation uduring treatment. C-erbB-2 levels were not significantly modified 
by hormonal treatment. Those cases that were c-erbB-2 negative initially showed no 
changes after treatment. There was a slight tendency to decrease in c-erbB-2 positive 
cases, but in general c-erbB-2 remained stable (Soubeyran et al., 1996).
In contrast, Elledge et al. (1998) examined 205 paraffin-embedded blocks of tumours 
from patients enrolled on Southwest Oncology Group 8228 for c-erbB-2 expression. 
These patients had metastatic ER positive breast cancer and had not received any prior 
therapy for metastatic disease. All patients were treated with daily tamoxifen. C-erbB-
2 positivity was associated with lower levels of ER and low bcl-2 expression. It was not 
significantly associated with response rate, time to treatment failure or survival. 
Therefore, c-erbB-2 expression in ER positive metastatic breast cancer is not associated 
with poorer response to tamoxifen or a more aggressive clinical outcome, according to 
this study.
Borg et al. (1994) noted a favourable effect of adjuvant tamoxifen on survival for 
patients with c-erbB-2 negative tumours, while patients who were positive did not 
benefit from tamoxifen administration. Giai et al. (1994) observed that node positive 
breast cancer patients co-expressing c-erbB-2 and ras had a worse outcome than those 
patients not co-expressing these oncogenes, when treated with tamoxifen. Wright et al. 
(1992) reported that only 7% of c-erbB-2 positive patients compared to 37% of c-erbB-2 
negative patients responded to tamoxifen treatment. The combination of c-erbB-2 and 
EGFR appears to have an additive effect in reducing the likelihood of response to 
tamoxifen, as 0 out of 8  patients benefited. Nicholson el al. (1993) reported that c- 
erbB-2 expression did not effect response to tamoxifen in an c-erbB-1 negative group of 
patients, while a significant loss of hormone sensitivity was found in the c-erbB-1 
positive group. Archer et al. (1995) found no correlation between c-erbB-2 
overexpression and response to tamoxifen therapy.
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Table 1.6 -  Summary of Effect of C-erbB-2 Overexpression on Response to Therapy
A uthor Therapy Outcome
Baselga et al., 1997 Taxol Predicted favourable response to taxol
Kim et al., 2001 Taxol Predicted favourable response to taxol
Van Poznak et al., 2002 Taxane No association with favourable response to 
therapy
Formend et al., 2002 Taxol & 
Radiation
Predicted lack of response to therapy
Seidman et al., 2001 Taxol & 
Herceptin
Predicted favourable response to therapy
Fountzilas et al., 2001 Taxol & 
Herceptin
Predicted favourable response to therapy
Dieras et al., 2001 Taxol & 
Herceptin; 
Taxotere & 
Herceptin
Predicted favourable response to therapy
Esteva et al., 2002 Taxotere & 
Herceptin
Predicted favourable response to therapy
Paik et al., 2000 AC, CMF, or 
AC & CMF
AC superior to CMF in c-erbB-2 overexpressors 
only
Paik et al., 1998 PF versus PAF PAF superior to PF in c-erbB-2 overexpressors 
only
Jarvinen et al., 1998 Epirubicin Predicted lack of response to therapy
Petit et al., 2001 FEC (dose 
escalation of E)
C-erbB-2 overexpressors benefited from dose 
escalation of epirubcin in FEC therapy
Vincent-Salomon et al., 
2000
Adriamycin 
dose escalation
No prediction of response to therapy
Sjostrom et al., 2002 MF No prediction of response to therapy
Slamon et al., 2001 AC/EC +/- 
Herceptin; 
Taxol +/- 
Herceptin
Addition of herceptin resulted in increased 
response to therapy
Vargas-Roig et al., 
1999
EF or AC Predicted poor response to therapy
Bottini et al., 1996 CMF No prediction of response to therapy
Carlomagno et al., 1996 Tamoxifen Predicted poor response to therapy
Elledge et al., 1998 Tamoxifen No prediction of response to therapy
Borg et al., 1994 Tamoxifen Predicted poor response to therapy
Giai et al., 1994 Tamoxifen Predicted poor response to therapy
Wright et al., 1992 Tamoxifen Predicted poor response to therapy
Nicholson et al., 1993 Tamoxifen No prediction of response to therapy
Archer et al., 1995 Tamoxifen No prediction of response to therapy
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1.6 The Metastatic Process
Metastasis is defined as the escape of tumour cells from their primary site and their re­
establishment at distant secondary locations. The metastatic spread of solid tumours is 
responsible directly or indirectly for most cancer-related deaths. Cancer metastasis 
occurs as a result of a complex series of interactions between the cancer cell and its 
surroundings, known as the metastatic cascade, as depicted in Table 1.6.1.
Table 1.6.1
The Metastatic Cascade
Initial transforming event
4,
Growth of neoplastic cells 
Neovascularisation/angiogenesis of the tumour
4,
Detachment of neoplastic cells from primary tumour
4,
Local invasion of extracellular matrix by tumour cells
I
Intravasation of tumour cells into lymphatics or vasculature 
Survival of tumour cells in circulation and avoidance of immunological attack 
Extravasation of tumour cells from vasculature into secondary organ tissue
4r
Survival and proliferation within organ parenchyma
Following the initial transforming event, neoplastic cells proliferate to form the primary
tumour mass, from which cells can detach. There is increasing evidence that in
epithelial malignancies, loss or down-regulation of expression of the structures
responsible for the maintenance of tissue integrity correlates with an increasing
tendency for metastatic spread. Such de-adhesion acts as a prelude to the cells invading
the extracellular matrix (Ahmad et al., 1997).
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The most common cancers in humans are derived from the epithelial cells. In order to 
metastasise these cells must break contact with their neighbouring cells, traverse the 
basement membrane and migrate through the stroma, in order to reach either blood 
capillaries or lymphatic vessels. Next these cells have to penetrate the vessels 
(intravasation), travel thorough the blood stream or lymph system and then exit the 
vessels at the new site (extravasation), and proliferate. It is worth noting that while 
metastasis is an efficient process in that many primary cancers will generate secondary 
site of metastasis, it is an inefficient process in that the majority of cancer cells do not 
survive this process. Breast tumours can shed up to 1 million cells a day, but only less 
than 0 .1 % are detected in the bloodstream, the rest having destroyed by a combination 
of mechanical stresses, proteolytic degradation and surveillance by the immune system.
1.6.1 The Seven Steps of Metastasis
1.6.1.1 Local Invasion
This refers to the penetration of the host tissue surrounding the neoplasm. This usually 
takes place in the extracellular space, but some carcinomas are thought to be capable of 
intracellular invasion through the cytoplasm of striated muscle fibres, an example of 
emperipolesis. The extent of local invasion is thought to be mainly a result of growth, 
motility and tissue destruction, but differentiation may also play a role (Evans, 1991).
1.6.1.2 Detachment From Primary Site
Only rarely can normal cells achieve growth away from their primary site. Apart from
pregnancy the only common example is endometriosis. One of the first steps involves
the breaking of cell-cell recognition. Breaking of homotypic recognition and changes
in heterotypic recognition are characteristic of invasive and metastatic cancers. A
reduction in the expression of proteins such as E-cadherin is often seen in epithelial
cancers and results in the ability of cancer cell to break apart. E-cadherin expression is
lost early on in breast carcinogenesis. Cell-ECM interactions are also altered in cancer
cells. This involves changes in the patterns of integrin expression. Integrins provide a
major mechanism whereby cells recognise proteins of the extracellular matrix and
basement membrane. Ligands of the integrins include collagen type I, collagen type IV,
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laminin and fibronectin. In general integrins involved in tissue organisation are 
decreased while those involved in migration are not. Some examples of changes in 
integrin expression include the upregulation of a v (33 in melanoma cells, which has a 
broad range specificity. This means that cells expressing this integrin can migrate over 
a broad range of matrices. In contrast a 2 Pi which recognises laminin and collagen is 
decreased in colon and breast cancers. Integrins a 3Pi and « 6Pi (laminin receptors) are 
frequently upregulated in breast and endometrial cancers. An increase in the secretion 
of proteases also facilitates detachment of cells from the primary through the 
degradation of the ECM (Evans, 1991).
1.6.1.3 Intravasation
Cancer cells attach to the stromal face of the blood vessel basement membrane, digest 
the membrane with proteases (discussed below) and migrate between the endothelial 
cells into the bloodstream (Evans, 1991).
1.6.1.4 Transport
Cancer cells commonly use three routes of transport. Firstly, body cavities such as the 
peritoneum facilitates the spread of cancers such as ovary or colon. Cancers invading 
out from the primary site detach from the surface and then are transported by the 
peritoneal fluid to other sites. A similar process occurs in the lungs, whereby lung 
cancers or other cancers invading can colonise the space between the pleural 
membranes surrounding the lungs. This generates a cancer-containing, growth- 
supporting fluid, which must be removed to maintain lung function. Secondly, blood 
vessels such as capillaries which consist of a layer of endotheilial cells plus an external 
basement membrane of glycoproteins. They provide the least difficult barrier to entry 
and exit of cancer cells. Arteries provide a much more difficult barrier in the form of a 
smooth muscle layer, and therefore are rarely ever invaded. Thirdly, lymphatic vessels 
provide even less of a barrier than capillaries as they are not surrounded by a basement 
membrane. They drain into the subclavian veins and thence into the superior vena cava, 
hence reaching the blood stream (Evans, 1991).
Once the tumour cells have gained access to the blood system they may be swept away 
to distant site which they can colonise. Within the bloodstream the tumour cells may
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interact with host components such as lymphocytes, monocytes and platelets, through 
heterotypic adhesion. This may lead to larger clumps incorporating the tumour cells 
lending them protection from mechanical stress and immune attack.
1.6.1.5 Lodgement at a Distant Site
The next step in the metastatic process involves the attachment of the cancer cell to the 
endothelial lining. Most tumour cells appear to be arrested in the first capillary bed they 
encounter, but this does not guarantee growth of a secondary tumour. Tumour cells are 
seen to lodge in capillaries, arterioles, and occasionally venules, but rarely in arteries 
(shear may be too high). It is thought that the walls of arterioles may present effective 
barriers to extravasation, perhaps explaining the low degree of metastasis to tissue such 
as the skeletal muscle. During the process of lodgement within a blood vessel it is 
thought that the tumour cell interacts with either the basement membrane or the 
endothelium. It is thought that there are four possible outcomes from these interactions. 
Firstly, the cells lodge and go on to form metastasis. This lodgement can occur either 
by mechanical means, where the cell literally gets “stuck” as it gets jammed in a vessel 
whose diameter is less than the cell or clump or cells, by specific adhesion in which the 
tumour cell “recognises” the wall of the blood vessel, due to the molecular content of 
the surfaces involved, or lastly by selective adhesion. The second outcome is where 
cells lodge and become dormant. The cells then exist in a dormant state to become 
active at a later date. The third outcome is the cells lodge but do not survive and the 
fourth outcome involves the cells failing to lodge and thus pass through the first organ 
they meet (Evans, 1991).
1.6.1.6 Extravasation
Extravasation is thought to occur due to the retraction of endothelial cells, exposing the 
glycoproteins of the basement membrane. The tumour cell then attaches to the 
basement membrane and digests it with protease and glycosidases, allowing the tumour 
cell to pass through. Different tumours express different integrins, which recognise 
different glycoproteins. Thus it follows that the basement membrane composition plays 
a large role in determining whether tumours are successful at extravasation (Evans, 
1991).
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Extravasation may occur in a number of ways:
(a) The cells may divide and pile up within the lumen of the blood vessel and invade en 
masse by the destruction of the blood vessel.
(b) Single cells may migrate between endothelial cells either destructively or non- 
destructively.
(c) Single cells may leave by passing through the endothelial cells rather than between 
them.
1.6.1.7 Growth
Proliferation of the cancer cells at their new site is initially confined to within 1mm of 
the vessel, until the tumour can form new blood vessels (angiogenesis) to supply 
essential nutrients and oxygen. Tumour growth is dependant on a number of factors 
including the nature of the environment it finds itself in and the nature of the tumour 
itself. These factors include resistance to host defence mechanisms of humoral and 
cellular nature, and response to or requirement for specific growth factors (Evans, 
1991).
1.6.2 Proteases Involved in Metastasis
Matrix degrading proteases play a role in metastasis, as invasive cancer cells must 
degrade the surrounding extracellular matrix, which consists of interstitisal stroma and 
basement membrane. The secretion of such proteases achieves this. Matrix degrading 
proteases can be classified into four major classes,
1. Matrix metalloproteinases (MMPs)
2. Serine proteinases
3. Cysteine proteinases
4. Aspartyl proteinases
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Figure 1.6.2 Interplay of Proteases
1.6.2.1 Matrix Metalloproteases
Matrix metalloproteases (MMPs) are a diverse family of secreted, transmembrane 
proteases. There are 16 known members, which are characterised by a zinc-binding 
domain at their catalytic site. MMPs are secreted as zymogens and activated through 
proteolytic cleavage. Tissue inhibitors of metalloproteases (TIMPs) can inhibit active 
MMPs. In cancer, MMPs contribute to all invasive steps of the metastatic cascade. 
They result in the breakdown of basement membrane and stromal matrices. MMPs are 
not solely produced by the invading cancer cells, but also by host fibroblasts, leukocytes 
and myofibroblasts, and then bind to their specific receptor at the surface of the cancer 
cell. Their association with TIMPs completes the tripartite, establishing a well 
regulated proteolytic complex. During normal physiological events the activity of these 
enzymes is tightly regulated. However in the case of cancer this regulation is disrupted, 
leading to increased invasion. Cancer cells release chemoattractants for leukocytes that 
are recruited to the tumour and contribute to the breakdown of the extracellular matrix. 
MMPs also promote the invasion of endothelial cells, thus promoting tumour growth, 
by aiding tumour angiogenesis (Lauwaet et al., 2000).
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Table 1.6.2.1
Main members of the MMP family
Group Enzyme Name Substrate
Type IV collagenases MMP-2 (Gelatinase A, 72kDA) Type IV collagen 
Gelatin
Collagen types V, VIII, X 
Laminin
MMP-9 (Gelatinase B, 92kDA) Type IV collagen
Gelatin
Elastin
Collagen types I, II, IV
Interstitial collagenases MMP-1 Collagen types I, II, III, VII, X 
Gelatins
MMP-8 Collagen types I, II, III
Stromelysins MMP-3 (Stromelysin-1) Proteoglycan, flbronectin, laminin, 
collagen type III, IV, V, IX
MMP-10 (Stromelysin-2) Proteoglycan, flbronectin, collagen type 
III, IV, V
MMP-11 (Stromelysin-3) a  1-proteinase inhibitor
MMP-7 (Matrilysin) (Pump-1) Gelatin, proteoglycan, flbronectin 
Activates procollagenase
Other MMP-14 (MT-MMP) Activates pro-gelatinase A
MMP-2 and MMP-9 expression has been found to be increased in several tumour types 
when compared to levels in adjacent tissue (Meyer and Hart, 1998). MMP-2 expression 
is associated with breast, colorectal and gastric carcinomas. MMP-11 has been found to 
be expressed specifically in stromal fibroblasts at the tumour-stroma interface, in all 
epithelial carcinomas to date. Levels of MMP-11 have been shown to be an 
independent prognostic marker for relapse-free survival in node-positive breast cancer 
(Ahmad and Hart, 1997). The evidence suggests that tumours can induce the 
production of MMPs in neighbouring stromal fibroblasts, e.g. by secretion of EGF or 
TNFa. The co-culture of MCF-7 with human fibroblasts leads to the induction of MMP 
1, 2 and 3 in the fibroblasts (Ito et al., 1995), whilst co-culture of rat embryo fibroblasts 
results in increased MMP-9 levels (Himelstein et al., 1994). The recently discovered 
MMP-14 is expressed on the cell surface of some tumour cells, where it serves an 
activator of MMP-2 (Curran et al., 2000).
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TIMPs inhibit MMPs by forming tight stoichiometric, non-covalent complexes with 
either the pro-enzyme or the activated MMP, or by controlling their autocatalytic 
activation (Woesner, 1991). Their expression is also influenced by local cytokines and 
growth factors. There are three members of the TIMP family and all have broad range 
activity on all classes of MMPs. TIMP-1 and 2 have been shown to be able to inhibit 
the degradation of the extracellular matrix and invasion of cancer cell lines in vitro.
1.6.2.2 Serine Proteinases
Serine proteases are characterised by a serine residue at their active site and are 
produced in an inactive pro-form. Important members of this family are trypsin, 
thrombin, plasmin, cathepsin G and urokinase type plasminogen activator (uPA). uPA 
converts inactive plasminogen to plasmin, a highly active protease capable of degrading 
a wide variety of ECM components. Plasmin can also activate other proteases including 
several MMPs. uPA is held on the cell surface by a uPA receptor which is also the 
receptor for vitronectin. uPA is expressed selectively at the invasive tumour-stromal 
interface in many experimental and human carcinomas and high levels correlate with 
poor prognosis for breast cancer (Ahmad and Hart, 1997).
1.6.2.3 Cysteine Proteinases
Cathepsin B and cathepsin L are the two cysteine proteases most implicated in cancer 
metastasis (Sloane, 1990). They are characterised by a cysteine residue at their active 
site and are lysosomal proteases that are capable of degrading the ECM. Cathepsin B is 
also capable of activating certain MMPs and receptor bound uPA (Ahmad and Hart, 
1997).
1.6.2.4 Aspartyl Proteinases
Cathepsin D degrades a large variety of endocytosed proteins and has been implicated 
in breast cancer invasion and metastasis, where relapse and metastatic disease correlate 
with high levels of cathepsin D (Ahmad and Hart, 1997).
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1.7 The Role of C-erbB-2 in Cancer Metastasis
1.7.1 Clinical Data Linking C-erbB-2 Overexpression to Metastatic Breast Cancer
C-erbB-2 overexpression is known to be associated with invasion and metastasis in 
human breast cancer. In a study of 163 breast tumours from patients with different 
stages of breast cancer, 33% of invasive ductal carcinomas were positive for c-erbB-2. 
C-erbB-2 protein expression was slightly more common in lymph-node positive (37%) 
than lymph-node negative cancer (30%). However, 50% of patients with three or more 
positive lymph-nodes were c-erbB-2 positive (Marx el al., 1990). In another study 
Quenel et al. (1995) found that 24% of 942 invasive ductal carcinomas had positive 
membrane staining. In this study, multivariate analysis showed that c-erbB-2 was an 
independent prognostic factor, associated with earlier relapse or metastasis in node­
negative patients. In another study, c-erbB-2 plasma levels in 33 patients being treated 
for advanced breast cancer, were determined. 30.3% of the metastatic breast cancer 
were found to be c-erbB-2 positive (Revillion et al., 1996). Therefore, c-erbB-2 gene 
amplification is associated with poor prognosis in non-inflammatory breast carcinoma, 
mainly where axillary nodes are invaded and are associated with increased risk of 
multiple metastases developing simultaneously. In patients with inflammatory breast 
carcinoma, c-erbB-2 overexpression was not found to be associated with a higher risk of 
death, suggesting that c-erbB-2 plays different roles in these two cancers (Prost et al., 
1994). In contrast, a study of 122 primary breast tumours and 62 metastases found that 
the frequency of amplification of c-erbB-2 was less in metastases, although not enough 
to be statistically significant (Driouch et al., 1997).
Breast carcinoma in situ (CIS) is considered to be the earliest form of breast cancer. 
Although 90% of patients with CIS are cured by surgery, the hypothesis that CIS lesions 
are precursors of invasive breast cancer is supported by the reports of a significant rate 
of local reccurrence in patients who are not treated with mastectomy. Liu et al. (1992) 
assessed the amplification and overexpression of c-erbB-2 in paraffin-embedded 
specimens from 27 in situ carcinomas of the breast and 122 stage II breast cancers. 
Gene amplification was detected in 48% of in situ carcinomas and in 21% of stage II 
lesions. C-erbB-2 protein levels corresponded with amplification levels. These results
suggest that the amplification of c-erbB-2 is an early event in human breast cancer.
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P95, a NH2 terminally truncated c-erbB-2 product correlates with its extracellular 
domain and both are shed from the cells under varied conditions. Of 161 breast cancers 
studied, 22.4% expressed p95, 21.7% expressed p i85 and 14.3% expressed both. A 
higher proportion of node positive (23/78) than node negative (9/63) expressed p95. In 
the group that expressed p i85, those that also expressed p95 were associated with node 
positive patients. The authors claim that P95 may distinguish tumours that have 
metastasised to the lymph nodes (Christianson et al., 1998).
O-charoenrat et al. (2002) studied the profile of ErbB receptors in head and neck 
squamous cell carcinomas (HNSCC) to determine whether their expression was 
associated with clinicopathological features and key molecules involved in angiogenesis 
and metastasis. They also assessed the impact of expression on survival. This study 
included 54 cases of primary HNSCC, of which 27 cases showed lymph node 
metastasis. Expression was analysed in the same tissue homogenates by semi- 
quantitative RT-PCR. HNSCC frequently co-expressed multiple ErbB receptors and 
showed significant correlation amongst their levels. High expression of c-erbB-1, c- 
erbB-2 or c-erbB-3 was associated with an infiltrating mode of invasion, nodal 
metastases and advanced pathological stages. C-erbB-1 and c-erbB-2 levels were 
strongly correlated (P=0.0004-0.029) with the expression of MMP-2, MMP-7, MMP-9, 
MMP-10, MMP-11, MMP-13, VEGF-A and VEGF-C whereas the levels of c-erbB-3 
and c-erbB-4 showed a weaker correlation (P=0.049-0.01) with some MMPs and 
VEGF-C. Only nodal metastasis and c-erbB-1 levels were significantly associated with 
poor outcome in uni- and multi-variate analysis.
Expression of the calcium-dependent cell-cell adhesion molecule E-cadherin was 
examined in 187 primary breast carcinomas. A marked difference in expression of E- 
cadherin was observed between infiltrating lobular carcinomas (ILC) and infiltrating 
ductal carcinomas (IDC), the former showing complete loss of membrane staining, 
whereas 93% of IDC retained some level of expression. In IDC, reactivity was not 
related to tumour grade but there was a significant association between reduced 
membrane levels of E-cadherin and the presence of lymph node metastasis, and a highly 
significant correlation between the presence of cytoplasmic E-cadherin and metastasis. 
A significant relationship was also demonstrated between reduced E-cadherin reactivity 
and expression of EGFR (Jones et al., 1996).
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1.7.2 C-erbB-2 Transfection Studies Looking at the Role of C-erbB-2 in 
Metastasis.
Various groups have transfected both transformed and cancer cell lines with c-erbB-2 to 
investigate its effect on their metastatic potential.
MCF-10A was transfected with c-erbB-2 and Ha-ras, both separately (MCF-10A-H and 
MCF-10A-E) and in combination (MCF-10A-HE). In soft agar assays MCF-10A do 
not grow on agar. MCF-10A-H and MCF-10A-E gave rise to a limited number of 
colonies, while MCF-10A-HE showed a 10-fold increase in colony formation. 
Chemotaxis was examined in Boyden chambers. MCF-10A parent cells displayed only 
weak migratory activity. MCF-10A-H, MCF-10A-E and MCF-1 OA-HE were found to 
migrate in response to F-CM (fibroblast conditioned media). They also examined 
degradation of Matrigel as an indicator for the cells’ ability to grow and invade the 
extracellular matrix. All transfectants invaded Matrigel with MCF-10A-H, MCF-10A-E 
and MCF-10A-HE having Invasive Indices of 3-, 4- and 5-fold higher respectively than 
MCF-10A. The MCF10A-HE cells also adopted an invasive stellate growth pattern 
when plated or embedded in Matrigel, in contrast to the spherical colonies formed by 
the single transformants MCF10A-H, MCF10A-E, and the parental cells. Expression of 
MMP-2 was found to be as follows MCF-10A-HE > MCF-10A-E > MCF-10A-H > 
MCF-1OA. TIMP-2 levels were lower in the transfectants. CD44 isoforms were altered 
in MCF-1 OA-HE, and expressed more of the lower molecular weight forms. These 
results indicate that c-erbB-2 and Ha-ras co-expression can induce a more aggressive 
phenotype in vitro, representative of the malignancy of mammary carcinomas 
(Giunciuglio et al., 1995).
Since basement membrane degradation is a prerequisite for tumour progression Gum et 
al. (1995) investigated whether urokinase, a protease which degrades key components 
of the basement membrane/extracellular matrix, was regulated by c-erbB-2. H460 lung 
cancer cells were transfected with c-erbB-2. The transfected cells were found to secrete 
increased amounts of urokinase protein and have enhanced the promoter activity of the 
urokinase gene. Levels of urokinase mRNA were also found to be elevated while 
growth rates were not altered. Urokinase converts inert zymogen plasminogen into the 
widely acting serine protease plasmin, which cleaves a variety of proteins including
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laminin and fibronectin as well as activating type IV collagenase. C-erbB-2-induced 
expression of urokinase may contribute to tumour progression.
Another group transfected MDA-MB-435 with c-erbB-2. Three transfectants, 435.eBl, 
435.eB2 and 435.eB4, were selected expressing 258-, 149- and 165-fold higher levels of 
c-erbB-2 respectively, as compared to the parent cell line. Single cell suspensions of 
MDA-MB-435, MDA-MB-435/neo control cells and 435.eBl, 435.eB2 and 435.eB4 
were injected into the lateral tail veins of 8 -week old female ICR-SCID mice. The size 
of the metastatic nodule found after 90 days were found to be the same, however 
numbers increased significantly in the 435.eBl, 435.eB2 and 435.eB4 injected mice. 
They then created an extravasation model that consisted of Matrigel invasion chambers. 
Significantly higher rates of invasion were observed in the 435.eB transfectants. No 
increase in motility was seen using chemoattractants. Similar adhesion ability to the 
extracellular matrix molecules laminin, fibronectin, collagen IV, vitronectin and 
Matrigel was observed. They observed higher expression of MMP-2 and MMP-9 in the 
cultured media of the transfectants, with the greatest expression of both in the highest 
expression transfectant. C-erbB-2 was not found to effect in vitro growth rate, or in 
vitro transforming ability, as measured in soft agar assays (Tan et al., 1997).
A study by Roetger et al. (1998) analysed disaggregated cells and cell clusters from 
freshly dissected breast cancer tissues. They looked to see whether their capability of 
extravasation is correlated with their expression of c-erbB-2. They found that invasive, 
predominantly clustered cells from 14/23 tumors were positively stained for c-erbB-2 
by immunocytochemistry. In four control breast cancer cell lines (SK-BR-3, MCF-7, 
MDA-MB-468 and MDA-MB-468, the latter transfected with a full-length c-erbB-2 
cDNA vector) producing different levels of the c-erbB-2 receptor, the expression level 
correlated positively with the invasiveness of the cells. They also showed that the 
invasive cell populations express the metastasis-associated proteins, matrix 
metalloproteinase MMP-2, CD44, and integrins ocv(33 and a 6 . Zhang et al. (1998) was 
able to show that c-erbB-2 expression may have a direct effect on the expression of 
gelatinase, Type IV collagenases MMP-2 and MMP-9. NIH 3T3 cells were transfected 
with point mutation activated neu, a mutant analogue of neu, the rat homologue of c- 
erbB-2. These cells were then treated with emodin and DK-V-47 (a derivative of 
emodin) which repress the tyrosine kinase activity of c-erbB-2. A consequence of this 
repression of kinase activity was an inhibition of anchorage and independent growth
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dependant (by 55% and 83% respectively), and a decrease in the expression of MMP-2 
and MMP-9. Both compounds virtually abolished the ability of the cells to perform in 
in vitro invasion assays.
Several transgenic mice carrying the activated rat c-erbB-2 gene under the 
transcriptional control of MMTV have been created. In several strains of 
MMTV/activated c-erbB-2 mice, early onset of transgene expression in the mammary 
epithelium of female mice was associated with the synchronous development of tumors 
involving the entire mammary epithelium. This suggests that c-erbB-2 requires few 
additional genetic events to transform the mammary epithelial cell. This suggests that 
activated c-erbB-2 can act as a potent oncogene in the mammary epithelium. It is 
thought that unactivated c-erbB-2 is the primary mechanism contributing to human 
breast cancer as biopsies have failed to find evidence of activating mutations. Guy et al. 
(1992) derived six MMTV/unactivated c-erbB-2 transgenic mice lines. Overexpression 
of normal c-erbB-2 in the mammary epithelium of 5 of these 6  lines resulted in the 
appearance of focal mammary tumours that metastasised with high frequency. 
Histological examination revealed focal mammary adenocarcinomas surrounded by 
hyperplastic mammary epithelium. These tumours were composed of solid nests of pale 
intermediate cells that were morphologically identical to tumours associated with 
activated c-erbB-2. Transplantation of the tumour cells into the mammary fat pads of 
syngenic recipients resulted in the appearance of tumours, confirming their neoplastic 
potential. Male MMTV/c-erbB-2 carriers did not exhibit any phenotypic abnormalities. 
The tumours were found to express increased levels of c-erbB-2 when compared to 
surrounding normal mammary epithelium. A high percentage of tumours bearing 
MMTV/c-erbB-2 animals developed metastases to the lungs.
Over-expression of c-erbB-2 in MDA-MB-435 cells resulted in increases in mRNA and 
protein levels of the actin bundling protein fascin. Heightened fascin expression has 
been observed in other systems to result in greatly increased cell motility. MDA-MB- 
435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics 
and locomotion, while visualisation of bundled microfilaments within fixed cells 
revealed enhanced formation of dendritic-like processes, microspikes and other dynamic 
actin based structures (Grothey et al., 2000).
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NRG and type I receptor tyrosine kinase (RTK) expression was investigated in the 
highly invasive and metastatic LM3 breast cancer cell line. Although LM3 cells do not 
express NRG, they exhibit high levels of c-rbB-2 and c-erbB-3 as well as moderate 
expression of c-erbB-4. Addition of exogenous NRGpi resulted in inhibition of both 
proliferation and migration of LM3 cells. NRGpi was also able to decrease the activity 
of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase 9 (MMP- 
9), 2 key enzymes in the invasion and metastatic cascade. NRGpi treatment of LM3 
cells induced tyrosine phosphorylation of c-erbB-2, c-erbB-3 and c-erbB-4 as well as 
the formation of c-erbB-2/c-erbB-3 and c-erbB-2/c-erbB-4 heterodimers. Assessment of 
the signalling pathways involved in NRGpi action indicated that the addition of 
NRGpi to LM3 cells resulted in activation of phosphatidylinositol 3- kinase (PI-3K) 
and in strong induction of the association of the p85 subunit of PI-3K with c-erbB-3. 
NRGpi also caused the rapid activation of ERK1/ERK2 and Stat3 and Stat5 (signal 
transducers and activators of transcription [STAT]). This is the first demonstration of 
the ability of NRGpi to activate STATs in mammary tumour cells. Blockage of PI-3K 
activity with its chemical inhibitor wortmannin, or of MEKl/ERKs activity with 
PD98059, resulted in suppression of the ability of NRGpi to inhibit LM3 cell growth. 
Notwithstanding the suppression of these 2 signalling pathways, NRGpi still proved 
capable of inhibiting uPA activity (Puricelli et ah, 2002).
O-charoenrat et ah (1999) examined the effects of ligands with different ErbB receptor 
specificities in terms of their stimulation of HNSCC proliferation, expression of matrix 
metalloproteinases (MMPs) and invasion. NRG-pi (NRG-pi; selective c-erbB-3/B-4 
ligand) was found to stimulate proliferation in the majority of cell lines, whereas 
epidermal growth factor (EGF; c-erbB-1 ligand) and betacellulin (BTC; c-erbB-l/B-4 
ligand) induced variable responses. All three ligands up-regulated multiple MMPs 
including collagenases, stromelysins, matrilysin and gelatinase B (MMP-9) but had 
minimal or no effects on gelatinase A (MMP-2), MT1-MMP and tissue inhibitors of 
MMPs (TIMPs). NRG-pi was less active than EGF and BTC at the optimal 
concentration (relative potency of EGF:BTC:NRG = 3:4:1). In vitro invasion through 
Matrigel was also increased by all three ligands in proportion to their MMP up- 
regulation. A specific anti-EGFR monoclonal antibody (mAb ICR62) inhibited MMP 
up-regulation, migration and invasion induced by all three ligands, whereas an anti-c- 
erbB-2 mAb ICR12 inhibited mitogenic and motogenic responses following ligand
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stimulation but had no effect on MMP expression. These results suggest that ErbB 
ligands may differentially potentiate the invasive phenotype of HNSCC via co-operative 
induction of cell proliferation, migration and proteolysis. The c-erbB-1 signalling 
pathway appears to be the dominant component controlling the proteolytic and invasive 
phenotype in HNSCC, whereas the c-erbB-2 signalling pathway is responsible, in part, 
for the mitogenic and motogenic effects of ligands.
Studies have shown that tumour cells with metastatic propensity secrete more of the 
laminin a 2  chain than non-metastatic tumour cells do, and that laminin-2 , which 
contains the a2 chain, promotes cell adhesion better than laminin-1. Han et al. (1999) 
examined whether a correlation existed between the expression of the laminin- 2  isoform 
and the metastatic phenotype in melanoma cells. They found that expression of the 
laminin-2 isoform was upregulated in the metastatic melanoma cell lines tested. Cell 
attachment studies showed that metastatic melanoma cells attached more efficiently to 
laminin-2 substrates. Studies on integrin expression revealed that the presence of 0.2ft \ 
integrin correlated with expression of the laminin- 2  isoform in metastatic melanoma 
cells; anti-integrin a.2 antibody prevented cell attachment to laminin-2 substrates. This 
interaction, mediated by the « 2Pi integrin, stimulated secretion of the 72 kD type IV 
collagenase and induced a specific 185 kD protein tyrosine phosphorylation, identified 
as the c-erbB-2 by immunoprécipitation. These studies suggest that upregulation of 
expression of the laminin- 2  chain correlates with the metastatic phenotype of melanoma 
cells and provides evidence that specific c-erbB-2 tyrosine phosphorylation may be 
involved in integrin-mediated signalling during tumour cell invasion and metastasis.
C-erbB-2 overexpression in human mammary epithelial cells resulted in acquisition of 
anchorage-independent growth and invasion capabilities. C-erbB-2 induced invasion 
was dependent on fibronectin and correlates with the down-regulation of cell surface a 4 
integrin. In addition c-erbB-2 co-immunoprecipitated with focal adhesion kinase (FAK) 
in these cells. C-erbB-2-induced invasion is dependent on the PI3'-kinase pathway 
(Ignatoski et al., 2000).
Flavopiridol is a flavone that inhibits several cyclin-dependent kinases and exhibits
potent growth-inhibitory activity against a number of human tumour cell lines, both in
vitro and when grown as xenografts in mice. Li el al. (2000) investigated whether
flavopiridol could be an effective agent against a series of isogenic breast-cancer cell
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lines having different levels of c-erbB-2 expression and differential invasion and
metastatic characteristics. Flavopiridol was found to inhibit the growth of MDA-MB-
435 (parental) and 435.eB (stable transfectants) cells that were established by 
transfecting c-erbB-2 cDNA into MDA-MB-435. Induction of apoptosis was also 
observed in these cell lines when treated with flavopiridol. They also found modest up- 
regulation of Bax and down-regulation of Bel-2, but there was a significant down-
regulation of c-erbB-2 in flavopiridol-treated cells. Gelatin zymography showed that
flavopiridol inhibits the secretion of MMPs 2 and 9 in the breast cancer cells and that 
the inhibition of c-erbB-2 and MMPs may be responsible for the inhibition of cell 
invasion observed in flavopiridol-treated cells. Collectively, these molecular effects of 
flavopiridol, however, were found to be independent of c-erbB-2 overexpression, 
suggesting that flavopiridol may be effective in all breast cancer.
Spencer et al. (2000) utilised carcinoma cells depleted of c-erbB-2, but not other ErbB 
receptor members, to specifically examine the role of c-erbB-2 in carcinoma cell 
migration and invasion. Cells stimulated with EGF-related peptides show increased 
invasion of the extracellular matrix, whereas cells devoid of functional c-erbB-2 
receptors do not. C-erbB-2 facilitated cell invasion through extracellular regulated 
kinase (ERK) activation and coupling of the adaptor proteins, pl30CAS and c-Crkll, 
which regulate the actin-myosin cytoskeleton of migratory cells.
Li et al. (1999) investigated the effects of genistein in the breast cancer cell line MDA- 
MB-435 and 435.eB cells that were established by transfecting c-erbB-2 cDNA into 
MDA-MB-435. They also investigated the effect of genistein on matrix 
metalloproteinase (MMP) secretion previously shown to be effected by c-erbB-2 
transfection. Genistein was found to inhibit MDA-MB-435 and 435.eB cell growth. 
Induction of apoptosis was also observed in these cell lines when treated with genistein. 
They also found an up-regulation of Bax and p21W A F 1  expression and down-regulation 
of Bcl-2 and c-erbB-2 in genistein-treated cells. Gelatin zymography showed that 
genistein inhibits the secretion of MMP in the breast cancer cells.
Curcumin, a natural compound present in turmeric, possessing both anti-inflammatory 
and antioxidant effects, has been studied vigorously as a chemopreventative in several 
cancer models. Curcumin dose-dependently inhibited c-erbB-2 autophosphorylation in 
breast cancer cell lines and transphosphorylation in vitro and depleted c-erbB-2 protein
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in vivo. It dissociated the binding of c-erbB-2 with GRP94 (glucose-regulated protein), a 
molecular chaperone, and enhanced the depletion of c-erbB-2. The amount of c-erbB-2 
protein on the cell membrane was drastically decreased after curcumin treatment. The 
growth of several breast cancer cell lines was inhibited; the IC50 ranged from 7 to 18 
microM, which, however, did not correlate with the expression level of pl85neu. 
Colony formation in the soft agar assay, a hallmark of the transformation phenotype, 
was preferentially suppressed in c-erbB-2 overexpressing cell lines by 5 |j,M curcumin 
(% of control, basal level versus overexpression: 59.3 versus 16.7%; P < 0.001 by 
Student's t test) (Hong etl, 1999).
Overexpression of c-erbB-2 in the prostatic epithelial cell line NbE, resulted in 
increased cellular spreading and the expression of integrin ct6Pi. C-erbB-2 transfected 
clones attached significantly better to specific substrates and spread significantly better 
on both specific and non-specific substrates as compared to the control clones. 
Additionally, the expression of integrin otePi, a key receptor enabling attachment and 
spreading on laminin, is upregulated on the metastatic clones NbE-neuT-9 and 10 (Vafa 
et al., 1998). Laminin receptors (integrins otôPi and ctôP-O were found to associate 
directly with c-erbB-2 in carcinoma cell lines and NIH 3T3 transfected with c-erbB-2. 
Carcinoma cells treated with a monoclonal antibody to the a 6 integrin subunit showed a 
ligand-dependent increase of c-erbB-2 phosphorylated molecules coprecipitated with 
integrins and increased DNA synthesis. The interaction between growth factor receptors 
and integrins was also studied in NIH3T3 cells overexpressing 0 ^ 4  receptors and c- 
erbB-2 protein. Cells overexpressing both receptors, showed enhanced proliferation 
rates and invasiveness, further suggesting that 0 ^ 4  integrin and ErbB-2 receptor 
interaction might contribute to generate a more malignant phenotype in carcinoma cells 
(Falcioni etal., 1997).
CD44 is a transmembrane glycoprotein that binds hyaluronic acid (HA). CD44 cell
surface expression was 4.5 times higher in c-erbB-2 overexpressing mouse fibroblasts,
than in the parental cell line. Overexpression of surface CD44s in c-erbB-2 transfected
cells results in a dramatic enhancement of HA-mediated cell adhesion. Scatchard plot
analysis indicates that CD44s in c-erbB-2 transfected cells binds directly and
specifically to ankyrin. The binding affinity between CD44s and ankyrin in c-erbB-2
transfected cells was higher than that found in the untransfected cells. Double
immunofluorescence staining and confocal microscopic analyses indicate that HA
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induces the CD44s to form adhesion plaque-like structures, and causes an accumulation 
of intracellular ankyrin directly underneath CD44s-adhesion plaque-like structures in c- 
erbB-2 transfected cells (but not in untransfected cells). These findings suggest that 
overexpression of CD44s and up-regulation of CD44s-ankyrin interaction by c-erbB-2 
may be one of the pre-requisite steps in regulating tumour cell behavior (Zhu et al., 
1996).
Expression of the activated rat c-erbB-2/neu oncogene in mouse embryo fibroblast 3T3 
cells is sufficient to induce experimental metastases in nude mice. C-erbB-2/neu 
oncogene-transformed 3T3 cells were more adherent to micro vessel endothelial cells 
and had higher gelatinase activities. It had previously been shown that the adenovirus 5 
El A gene product can suppress c-erbB-2/neu-induced transformation of 3T3 cells, and 
was subsequently found to reduce the formation of experimental metastatic tumours and 
inhibited metastasis-associated properties, such as adhesion to microvessel endothelial 
cells, migration through a layer of reconstituted basement membrane (Matrigel) and 
secretion of basement membrane-degradative enzymes. The results indicated that the c- 
erbB-2/neu gene induces higher metastatic potential through the promotion of adhesion 
and invasion steps of the metastatic cascade. The El A gene, which functions by 
inhibiting these steps, is thus a suppressor gene for c-erbB-2/neu-induced experimental 
metastasis (Yu et al., 1992).
Enforced expression of NRG in c-erbB-2 overexpressing SKBr-3 cells induces dramatic 
morphological changes and pronounced inhibition of anchorage-dependent and - 
independent growth. Most SKBr-3/NRG-transfected (SK/NRG) cells exhibited about 
15-fold increase in size and persisted as multinucleated cells with extended flattened 
vacuole-filled cytoplasm with reduced cell attachment. The growth suppression of 
SK/NRG cells was accompanied by a reduction in S phase, the presence of a G2-M cell 
cycle delay, and an increase in DNA aneuploid components. In addition, DNA 
fragmentation assays showed that NRG induced apoptosis of SKBr-3 cells. In contrast, 
while NRG treatment of other erbB-2 overexpressing breast cancer cell lines led to 
growth arrest and cell detachment, it did not induce apoptotic features. Thus, this study 
demonstrates that while growth arrest and cell detachment are general effects of NRG 
towards erbB-2 overexpressing cells, the ability of NRG to induce apoptosis is a 
phenomenon confined to selective cells including SKBr-3 cells (Guerra-Vladusic et al., 
1999).
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The effects of NRG and an anti-c-erbB-2 antibody have been compared in six ovarian 
cancer cell lines. NRG inhibited anchorage-independent growth of SKOv3 cells that 
overexpress c-erbB-2 but stimulated the growth of OVCA420, OVCA429, OVCA432, 
OVCA433, and OVCAR-3 cells that expressed lower levels of the receptor. Thus, cell 
lines with a high level of c-erbB-2 relative to c-erbB-3 or c-erbB-4 were growth 
inhibited, whereas cell lines with lower levels of c-erbB-2 were growth stimulated by 
NRG. Anti- c-erbB-2 antibodies inhibited the growth of SKOv3 cells but failed to 
affect the growth of the other cell lines. In OVCAR-3 cells that had been transfected 
with c-erbB-2 cDNA, NRG inhibited rather than stimulated growth. Conversely, when 
c-erbB-2 expression by SKOv3 cells was downregulated by transfection of the viral 
El A gene, NRG stimulated rather than inhibited growth (Xu el al., 1999). C-erbB-2 
activation by NRG in the c-erbB-2 overexpressing cell line SKBr3, inhibited anchorage- 
independent growth while enhancing tyrosine phosphorylation of c-erbB-2. NRG 
treatment also increased adhesion of SKBr3 cells to plastic and increased invasiveness 
of tumour cells into Matrigel membranes while increasing expression of the CD44 
(HCAM) and CD54 (ICAM-1) adhesion molecules. Tumour cell invasion of Matrigel 
membranes was partially blocked by either anti-CD44 or anti-CD54 antibodies, 
indicating a role for these adhesion molecules in the invasion process. Compatible with 
the increased invasiveness, NRG increased expression of the matrix metalloproteinase 
9. In contrast, the agonistic anti-c-erbB-2 antibody ID5 induced only a subset of the 
responses induced by NRG. ID5 induced tyrosine phosphorylation c-erbB-2, increased 
invasiveness, and increased expression of CD44. The ID5 antibody failed to increase 
adhesion to plastic, expression of CD54, or production of matrix metalloproteinase 9 
(Xu et al., 1997).
Tan et al. (1999) reported that NRG-(31 enhanced aggregation of MCF-7 and SKBR3 
human breast cancer cells. NRG-(31 induced tyrosine phosphorylation of c-erbB-2 and 
c-erbB-3 receptor heterodimers and increased the association of the dimerised receptors 
with the 85-kDa subunit of phosphatidylinositol 3-kinase (PI3K). NRG-(31 also 
increased the kinase activities of extracellular signal-regulated protein kinase (ERK) and 
PI3K in these cells. By using the mitogen-activated protein kinase/ERK 1 (MEK1) 
inhibitor PD98059 and PI3K inhibitors wortmannin and LY294002, they found that 
blocking the MEK1-ERK pathway had no effect on NRG-(31 enhanced cell aggregation;
63
however, blocking the PI3K pathway greatly inhibited NRG-pi mediated cell 
aggregation.
A ligand for the c-erbB-2 receptor has not yet been identified but it can be activated by 
heterodimerization with NRG (NRG)-stimulated erbB3 and erbB4 receptors. The NRGs 
are a family of polypeptide growth factors that have been shown to play a role in 
embryogenesis, tumour formation, growth and differentiation of breast cancer cells. The 
erbB3 and erbB4 receptors are involved in transregulation of erbB2 signalling. The 
work presented here suggests biological roles for NRG including regulation of the actin 
cytoskeleton and induction of motility and invasion in breast cancer cells. NRG- 
expressing breast cancer cell lines are characterised by low erbB receptor levels and a 
high invasive and metastatic index, while those which overexpress erbB2 demonstrate 
minimal invasive potential in vitro and are non-tumorigenic in vivo. Treatment of the 
highly tumorigenic and metastatic NRG-expressing breast cancer cell line MDA-MB- 
231 with an NRG-neutralizing antibody significantly inhibited proliferation in culture 
and motility in the Boyden chamber assay. Addition of exogenous NRG to non-invasive 
erbB2 overexpressing cells (SKBr-3) at low concentrations induced formation of 
pseudopodia, enhanced phagocytic activity and increased chemomigration and invasion 
in the Boyden chamber assay. The specificity of the chemomigration response to NRG 
is demonstrated by inhibition with the anti-NRG neutralising antibody. These results 
suggest that either NRG can act as an autocrine or paracrine ligand to promote the 
invasive behaviour of breast cancer cells in vitro or thus may enhance the metastatic 
process in vivo (Hijazi et al., 2000).
Additional evidence exists which show that c-erbB-2 affects the expression of 
metastatic associated proteins such as E-cadherin and p-catenin. The cadherins are a 
family of transmembrane glycoproteins that mediate cell-cell adhesion. Several 
subclasses of cadherins have been described, E-(epithelial), N-(neural) and P-(placental) 
cadherins. Cadherins appear to function by connecting cells to each other by 
homophilic interactions, in which they bind selectively to identical cadherin types 
(Liang, 1999). The E-cadherin molecule plays a central role in maintaining epithelial 
cell morphology through homotypic Ca2+-dependent interactions. A reduction in E- 
cadherin expression is found in many breast cancers and is associated with increased 
invasiveness (D’Souza and Taylor-Papadimitriou, 1994). Three cytoplasmic proteins, 
a - ,  P~, y- catenin have been found to associate with E-cadherin. Disruption of E-
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cadherin-mediated intercellular adhesion promotes cell dissociation from the primary 
cancer nest and the E-cadherin-catenin complex functions as an invasion suppresser 
system in cancers (Shibata et al., 1996). Overexpression of c-erbB-2 in the human 
mammary epithelial cell line, MTSV1-7, is associated with reduced ability to undergo 
morphogenesis in vitro and with a decreased level of expression of the E-cadherin and 
ot2 integrin genes. Signalling from the c-erbB-2 receptor was blocked using the 4D5 
antibody to c-erbB-2. Transfectants regained the ability to form three-dimensional 
structures in collagen gels and the rates of transcription of E-cadherin and 012 integrin 
genes were returned to normal (D’Souza and Taylor-Papadimitriou, 1994; D’Souza et 
al., 1993). C-erbB-2 phosphorylates (3-catenin. In human gastric cancer TMK-1 cells 
expressing a N-terminally truncated (3-catenin, which binds c-erbB-2 but not E- 
cadherin, the association between endogenous p-catenin and c-erbB-2 protein was 
inhibited, suppressing the phosphorylation of P-catenin. These cells exhibited markedly 
reduced invasiveness in vitro and peritoneal metastasis in vivo and developed an 
epithelial morphology (Shibata et al., 1996).
C-erbB-2 was found to associate with the cadherin-catenin complex through P-catenin 
and plakoglobin, resulting in the phosphorylation of P-catenin causing disruption of the 
cadherin-mediated cell adhesion system in cancer cells (Ochiai et al., 1994).
The human papillomavirus type 16 (HPV-16), the type most often associated with 
cervical cancer, immortalises primary keratinocytes and inhibits serum/calcium- 
stimulated differentiation in culture. An immortalised keratinocyte cell line generated 
by cotransfection with HPV-16 E6  and E7 showed decreased membrane E-cadherin 
expression and redistribution of a-, P-, and y-catenin from the undercoat membrane to 
the cytoplasm. Selection of the immortalised keratinocyte cell line for resistance to 
differentiation generated a more transformed cell line with an invasive phenotype, 
down-regulated E-cadherin and a-catenin, and up-regulated c-erbB-1. Transfection of 
an E-cadherin expression construct into the differentiation-resistant cell line restored 
membrane-bound E-cadherin and catenin expression, down-regulated c-erbB-1, and 
reversed the invasive phenotype. These results indicated that overexpression of the c- 
erbB-1 correlates with perturbation of the E-cadherin/catenin complex seen in the HPV- 
16 E6 - and E7-transfected keratinocytes (Wilding et a l, 1996).
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Geldanamycin depleted c-erbB-2 expression in melanoma cells, resulting in a loss of its 
association with p-catenin without perturbing either LAR receptor or p-catenin levels or 
LAR/p-catenin association. Geldanamycin also stimulated tyrosine dephosphorylation 
of P-catenin and increased P-catenin/E-cadherin association, resulting in substantially 
decreased cell motility. Geldanamycin also decreased the nuclear p-catenin level and 
inhibited p-catenin-driven transcription, as assessed using two different p-catenin- 
sensitive reporters and the endogenous cyclin D1 gene (Bonvini et al., 2001).
66
1.8 Chemotherapeutic Agents
1.8.1 Adriamycin
Adriamycin is an anthracycline isolated from Streptomyces. It has a characteristic four- 
ring structure that is linked via a glycosidic bond to daunosamine, an amino sugar. 
Adriamycin is used to treat a broad range of solid tumours.
Figure 1.8.1 Structure of adriamycin.
Adriamycin binds tightly to DNA by intercalation, resulting in local uncoiling of the 
double helix as a result of the separation of the stacked bases by the intercalated moiety. 
As a result of this the super-coiled double helix is greatly changed by the cumulative 
effects of these local uncoiling events. Adriamycin induces protein-linked double 
stranded DNA breaks, which are introduced by topoisomerase II. The drug somehow 
interferes with the DNA strand breakage reunion of topoisomerase II. There is a direct 
correlation between decreased topoisomerase II activity and adriamycin resistance. 
Another mechanism of action of adriamycin is the formation of active oxygen species 
that form single strand breaks (Pratt et al, 1994).
Adriamycin has a broad range of activity and is used in the treatment of breast, bladder, 
endometrium, lung, ovarian, stomach and thyroid carcinomas. It is also effective 
against sarcomas of the bone and soft tissue, paediatric solid tumours, and lymphoid and 
myelogenous tumours (Hortobagyi, 1997).
Common methods of resistance to adriamycin involve increased drug efflux, due to 
overexpression of P-glycoprotein, MRP family members and LRP (Clynes et a l, 1998; 
Borst et al, 1999; Cui et a l, 1999; Young et al., 1999). Cells selected for resistance to
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adriamycin are usually cross resistant to vinca alkaloids and other antibiotics such as 
actinomycin D. Other cell lines have been found to have altered levels of glutathione 
peroxidase, glutathione or glutathione S-transferase (Cole et al., 1990). Topoisomerase 
II-mediated adriamycin-resistance can be divided into 2 categories. The first involves 
quantitative changes, and usually involves decreased cellular expression of the enzyme. 
The second mechanism involves decreased drug-induced DNA cleavage, differential 
expression of topoisomerase isoforms, altered subcellular distribution of topoisomerase 
II and changes in extrinsic factors modulating topoisomase II activity (Skovsgaard et 
al, 1994).
1.8.2 The Taxanes
Taxol is a natural product isolated from the bark of the Pacefic yew tree, Taxus 
brevifolia. The anti-tumour activity of the yew bark extract was discovered through a 
plant screening program in the 1960s. Taxotere is a semi-synthetic product derived 
from the needles of the European yew, Taxus baccata. Both share the tricyclic taxane 
skeleton but have different substituents at the c-10 and the c-13 side chains. Taxol and 
taxotere share a unique mechanism of cytotoxic action. Both agents promote assembly 
of tubulin into microtubules, and render them resistant to depolymerisation. Treated 
cells are blocked in the G2/M phase of the cell cycle giving rise to mitotic arrest 
(Francis et al., 1995). Both taxoids bind to the (3-subunit of tubulin, but the 
microtubules produced by taxotere are larger than those produced by taxol. This may 
explain why taxotere appears to be two to four times more potent than taxol 
(Vaishampayan et al., 1999).
0
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Figure 1.8.2 The taxanes, taxol and taxotere
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Resistance to taxanes arises through two major mechanisms. Increased expression of p- 
glycoprotein (Bradley and Ling, 1994; Gottesman and Pastan, 1993) and alterations in 
its microtubule binding activity (Cabral and Barlow; 1989; Dumonter et al., 1996; 
Haber et al., 1995).
1.8.3 Carboplatin
Carboplatin (cis-diammine- l , l ’-cyclobutane dicarboxylate platinum II, CBDCA, JM-8 ) 
was developed by Bristol-Myers Squibb in collaboration with the Institute of Cancer 
Research, Sutton, UK and the Johnson-Matthey Company, Reading, UK. It is the only 
cisplatin derivative currently available world-wide for cancer treatment (Lebwohl and 
Canetta, 1998).
Carboplatin is converted to alkylating species in the body forming adducts at the N-7 
position of guanine and adenine. These adducts can interact with adjacent bases on the 
same strand of DNA (intrastrand adducts) or on separate strands (interstrand adducts). 
The order of preference for adduct formation is G:G > A:G > others. Intrastrand 
adducts distort the DNA helix whilst interstrand adducts prevent strand separation so 
that replication is inhibited or abnormal. Carboplatin is effective against ovarian and 
testicular cancer and has minimal effects on the bone marrow. It also has the advantage 
of having greatly reduced side effects in comparison to its analogue (King, 2000).
Resistance to carboplatin can occur by altered cellular transport, enhanced DNA repair, 
increased expression of glutathione and glutathione-S-transferase, and decreased 
apoptosis, in particular increased bcl-2 expression (King, 2000).
1.8.4 Vincristine
Vincristine is a naturally occurring alkaloid. It is found in minute quantities in the 
leaves of the periwinkle plant Catharanthus roseus. It medicinal value has been known 
since the 17 century. Extracts of the plant have been used to stop haemorrhage, heal 
scurvy, relieve toothaches, heal wounds and diabetic ulcers, and to lower blood sugar 
levels. Svoboda showed anti-leukaemic activity against P-1534 lymphocytic leukaemia
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in DBA/2 mice using certain extracts of the plant. Indeed vincristine cured P-1534 
leukemia in mice with an acceptable range of side effects (Gidding et al., 1999).
The molecular structure of vincristine is asymmetrical and dimeric, composed of a 
dihyrdoindole nucleus, vindoline, linked by a carbon-carbon bond to an indole nucleus, 
catharanthine. Vincristine sulphate in the 1:1 sulphate salt from Catharanthus roseus. 
Vincristine is more frequently used in paediatric oncology, than adult oncology. 
Paediatric tumours appear to be more sensitive to vincristine and children are able to 
tolerate higher doses of the drug. It is a key drug in the treatment of acute lymhoblastic 
leukaemia and non-Hodgkin’s lymphoma. In adults response rates are greater in 
malignancies of haematological origin, than in solid malignancies, with the exception 
perhaps of AIDS-associated Kaposi’s sarcoma (Gidding et al., 1999).
Vincristine inhibits tumour growth by its interference with the mitotic spindle 
microtubules resulting in the inhibition of mitosis. In vitro vincristine induces apoptosis 
in tumour cells, while in animal models it induces tumour necrosis. Vincristine binds to 
tubulin or microtubules, which damages the spindle structure in a concentration- 
dependant manner resulting in microtubule disruption. The concentration of vincristine 
used determines the effect it has on the microtubules. Low concentrations of vincristine 
stabilise the spindle apparatus resulting in the failure of chromosomes to segregate, 
leading to metaphase arrest and inhibition of mitosis. Higher concentrations result in 
disruption and total depolymerisation of microtubules (Gidding et al., 1999).
Mechanisms of vincristine resistance include p-glycoprotein, mrpl and lung resistance 
protein (lrp). Verapamil and cyclosporin A may modulate p-glycoprotein-mediated 
vincristine resistance. Decreased binding affinity of tubulin for vincristine also plays a 
role in vincristine resistance. This may be due to changes in tubulin isoforms expressed 
or different tubulin levels. Also altered stability of microtubules may result in changes 
in the equilibrium between free and polymerised tubulin in cells (Gidding et al., 1999).
1.8.5 Etoposide (VP-16)
VP-16 is a semi-synthetic derivative of podophyllotoxin, a microtubule inhibitor found
in extracts of the mandrake plant (Hande, 1998). Podophyllotoxins have been used as
medications by various cultures for over a 1000 years. In the 19th century podophyllin
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was found to be topically effective in the treatment of skin cancer. In the 1950s 
researchers at Sandoz Pharmaceuticals began synthesising a number of derivatives in 
the hope of identifying agents with increased anti-neoplastic activity and reduced 
toxicity. Several derivatives were found to have antitumour activity against L1210 
leukaemia, the most effective being 4’-demethylepipodophyllin benzylidene glucoside 
(DEPBG). Two analogues of DEPBG were subsequently synthesised and named VP-16 
(1966) and teniposide (1967).
VP-16 went into clinical trials before its mechanism of action (inhibition of 
topoisomerase II) was understood. This is in part due to the fact that this enzyme was 
been investigated at the same time and was not understood until 1979. At 
concentrations achieved in vivo, VP-16 causes dose-dependant single strand and double 
strand DNA breaks. Upon its removal, this DNA breakage is swiftly repaired. 
Incubation of VP-16 with purified DNA does not result in DNA breaks, however when 
VP-16 was incubated with isolated nuclei, again DNA breakage was observed. It was 
subsequently discovered that the missing link was topoisomerase II. Topoisomerase II 
enzymes, the target for VP-16, require ATP for overall activity and modulate DNA 
topology by passing an intact helix through the transient double stranded break created 
in the DNA back bone. They therefore regulate over- and under-winding of the double 
helix and resolve nucleic acid knots and tangles. VP-16 poisons topoisomerase II by 
increasing the steady state concentration of their covalent DNA cleavage complexes. 
This action converts the topoisomerases into physiological toxins that introduce high 
levels of transient protein-associated breaks in the genome of the treated cells. 
Replication machinery or helicases attempting to traverse the covalently bound 
topoisomerase roadblock encounter difficulties leading to the disruption of the cleavage 
complex and converts transient DNA breakage into permanent double stranded fractures 
which are no longer held together by the proteinaceous bridges. These breaks then 
become targets for recombination, sister chromatid exchange, the generation of large 
deletions or insertions and the production of chromosomal aberrations ultimately 
leading to apoptosis and cell death (Hande, 1998).
Development of resistance to VP-16 can be due to reduced levels of topoisomerase II 
within the target cells. Increased expression of MDR-1 also confers resistance to VP- 
16. Finally mutations or alterations in drug binding sites on topoisomerase II are 
associated with resistance. VP-16 has demonstrated activity against acute myeloid
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leukaemia, Hodgkin’s disease, non-Hodgkin’s lymphoma, lung cancer, gastric cancer, 
breast cancer, testicular cancer, Kaposi’s sarcoma and ovarian cancer. The major 
toxicities seen with VP-16 are bone marrow depression, nausea, diarrhoea, mucositis 
and hypotension (Hande, 1998).
1.8.6 5-Fluorouracil (5-FU)
5-FU was first synthesised in 1957 and is a member of the antimetabolite group of 
drugs. Its major action is through inhibition of nucleotide synthesis and through 
incorporation into nucleic acids (Pratt et al., 1994). 5-Fluorouracil was one of the first 
rationally designed anti-metabolites. Its activation occurs via the physiologic 
pyrimidine pathway and salvage pathways. 5-FU is activated in analogy to thymine via 
the physiological pyrimidine pathway before incorporation into DNA. 5-FU also 
competes with uracil for uptake into RNA. Thymidylate synthase is responsible for the 
de novo syntheisis of deoxythymidine monophosphatase, which is subsequently 
phosphorylated twice before its incorporation into DNA. This central role of 
thymidylate synthase makes rapidly proliferating cells vulnerable to the biochemical 
modulation of 5-FU by tetrahydrofolates. Activated 5-FU builds a stable complex with 
thymidine synthase abolishing enzyme activity. Elevated levels of thymidylate synthase 
contribute to resistance to 5-FU (Mader et al., 1998).
1.8.7 Methotrexate
Methotrexate is a folate antagonist first developed for the treatment of malignancies and 
subsequently used in non-neoplastic diseases as an anti-inflammatory and/or 
immunosuppressive drug. The transmembrane transport of folate and antifolate 
analogs that share structural similarity with the folate compounds occurs by at least two 
different mechanisms, the low affinity reduced folate transmembrane carrier and a 
membrane associated folate-binding protein. Resistance to methotrexate can be via a 
number of mechanisms. These include decreased uptake, alteration in of its target 
enzyme dihydrofolate reductase (DHFR), overproduction of DHFR, decreased ability 
of cells to convert methotrexate to polyglutamates (Genestier et al., 2000).
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1.8.8 Tamoxifen Hormonal Therapy
Estrogens can both promote and inhibit the growth of breast cancer cells. 
Adenocarcinoma of the breast was the first tumour to be treated by manipulation steroid 
hormone levels. The initial report by Beatson in 1896 describes the clinical courses of 
three breast cancer patients who had their ovaries removed (ablative therapy). 
Lacassagne, who induced the development of breast tumours in male mice by injecting 
them with estrogen, established the first association between estrogens and mammary 
tumourigenesis in 1932. Haddow et al. demonstrated in 1944, that high doses of 
estrogen benefited some breast cancer patients. Subsequently this was shown to be true 
of postmenopausal patients, but not premenopausal patients.
Tamoxifen, the most commonly used drug in breast cancer hormonal therapy, has direct 
anti-estrogenic effects on the tumour cell. It is used in both adjuvant therapy and in 
treatment of metastatic disease. It is structurally similar to estrogen and binds in its 
place. However, it fails to activate the receptor, with the result that estrogen response 
target genes are not activated, thus inhibiting cell proliferation (Pratt et al., 1994).
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Aims of Thesis
The aim of the thesis was to investigate the role of c-erbB-2 in breast cancer, with 
respect to its effects on:-
■ chemotherapeutic drug resistance
■ tamoxifen resistance
■ expression of estrogen receptors and expression of other members of the 
ErbB receptor family
■ cell growth rate
■ adhesion to extracellular matrix proteins
■ cell motility
■ cell invasiveness
An important goal of this thesis was to establish two cell models with altered levels of 
c-erbB-2. BT474A, a c-erbB-2 overexpressing cell line, was transfected with a c-erbB- 
2-targeted ribozyme to reduce levels of c-erbB-2. MCF-7 H3, a c-erbB-2 low-
expressing cell line, was transfected with c-erbB-2 cDNA to increase levels of c-erbB-2.
To further investigate the possible role of c-erbB-2 in the emergence of 
chemotherapeutic drug resistance in breast cancer, two chemotherapeutic drugs, taxol 
and adriamycin, were chosen to establish resistant variants of the breast cell line MDA- 
MB-435S-F, which exhibits very low levels of c-erbB-2 expression. Patterns of cross 
resistance to various chemotherapeutic drugs, ErbB receptor family expression, cell 
growth rate, adhesion to extracellular matrix, motility and invasion properties, and 
expression of resistance-related genes in the drug-resistant variants were examined.
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2.0 Materials & Methods
2.1 Ultrapure water
Ultrapure water (UHP), was used in the preparation of all media and solutions. This 
water was purified to a standard of 12-18 MQ/cm resistance by a reverse osmosis 
system (Millipore Milll-RO 10 Plus, Elgastat UHP).
2.2 Glassware
The solutions used in the various stages of cell culture were stored in sterile glass 
bottles. All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% RBS-25 
(AGB Scientific) for 1 hour. After this time, they were cleansed and washed in an 
industrial dishwasher, using Neodisher detergent and rinsed twice with UHP. The 
resulting materials were sterilised by autoclaving as described in Section 2.3.
2.3 Sterilisation Procedures
All thermostable solutions, water and glassware were sterilised by autoclaving at 121°C 
for 20 minutes at 15 p.s.i.. Thermolabile solutions were filtered through 0.22 (im sterile 
filters (Millipore, Millex-GY SLGV025BS). Larger volumes (up to 10 litres) of 
thermolabile solutions were filter sterilised through a micro-culture bell filter (Gelman, 
12158).
2.4 Preparation of cell culture media
Basal media used during cell culture was prepared as follows: 10X media was added to 
sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-(2- 
ethanesulfonic acid) and NaHCC>3 as required and adjusted to pH 7.5 using sterile 1.5 N 
NaOH or 1.5 N HC1. The media was then filtered through sterile 0.22\xm bell filters 
(Gelman, 12158) and stored in sterile 500ml bottles at 4°C. Sterility checks were 
performed on all bottles of media by inoculation of media samples on to Colombia
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blood agar (Oxoid, CM217), Sabauraud dextrose (Oxoid, CM217) and Thioglycolate 
broths (Oxoid, CM 173). All sterility checks were then incubated at both 25°C and 
37°C. These tests facilitated the detection of bacterial, yeast and fungal contamination.
Basal media were stored at 4°C for up to three months. The HEPES buffer was 
prepared by dissolving 23.8g of HEPES in 80ml UHP water and this solution was then 
sterilised by autoclaving. Then 5ml sterile 5N NaOH was added to give a final volume 
of 100ml. NaHC0 3  was prepared by dissolving 7.5g in 100ml UHP water followed by 
autoclaving. Complete media was then prepared as follows: supplements of 2mM L- 
glutamine (Gibco, 11140-0350) for all basal media and 1ml 100X non-essential amino 
acids (Gibco, 11140-035) and lOOmM sodium pyruvate (Gibco, 11360-035) were added 
to MEM. Other components were added as described in Table 2.4.1. Complete media 
was stored at 4°C for a maximum of one week.
Table 2.4.1 Additional components in media.
Cell Line Basal Media Fetal Calf 
Serum (%)
Additional L- 
Glutamine
Bovine Insulin 
(0.01 mg/mL)
BT474A and 
its variants
RPMI 1640 1 0 2mM +
MDA-MB- 
435S-F and its 
variants
RPMI 1640 1 0 N/A
MCF-7 H3 and 
its variants
ATCC 5 N/A
RPMI 2650 
and its variants
MEM 5 N/A
2.5 Cells and Cell Culture
All cell culture work was carried out in a class II laminar air-flow cabinet (Nuaire 
Biological Laminar Air-Flow Cabinet). All experiments involving cytotoxic compounds 
were conducted in a cytogard laminar air-flow cabinet (Gelman Sciences, CG series). 
Before and after use the laminar air-flow cabinet was cleaned with 70% industrial
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methylated spirits (IMS). Any items brought into the cabinet were also cleaned with 
IMS. At any time, only one cell line was used in the laminar air-flow cabinet and upon 
completion of work with any given cell line the laminar air-flow cabinet was allowed to 
clear for at least 15 minutes so as to eliminate any possibilities of cross-contamination 
between the various cell lines. The cabinet was cleaned weekly with industrial 
disinfectants (Virkon or TEGO) and these disinfectants were alternated every month. 
Details pertaining to the cell lines used for the experiments detailed in this thesis are 
provided in Table 2.5.1. All cells were incubated at 37°C and where required, in an 
atmosphere of 5% CO2 . Cells were fed with fresh media or subcultured (see Section
2.5.1) every 2-3 days in order to maintain active cell growth. All of the cell lines listed 
in Table 2.5.1 are anchorage-dependent cell lines.
2.5.1 Subculturing of cell lines
The waste cell culture medium was removed from the tissue culture flask and discarded 
into a sterile bottle. The flask was then rinsed out with 1ml of trypsin/EDTA solution 
(0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, E9884) solution in PBS 
(Oxoid, BRI4a)) to ensure the removal of any residual media. 5ml of trypsin was then 
added to the flask, which was then incubated at 37°C, for approximately 5 minutes, until 
all of the cells detached from the inside surface of the flask. The trypsin was 
deactivated by adding an equal volume of complete media to the flask. The cell 
suspension was removed from the flask and placed in a sterile universal container 
(Sterilin, 128a) and centrifuged at lOOOrpm for 5 minutes. The supernatant was then 
discarded from the universal and the pellet was suspended in complete medium. A cell 
count was performed and an aliquot of cells was used to re-seed a flask at the required 
density.
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Cell line Basal
Medium*
Cell type Source**
BT474 RPM I1640 Ductal carcinoma of the 
breast
ATCC
BT474A RPMI 1640 Clonal subpopulation of 
BT474
NCTCC
BT474A/ErbB2- 
Rz pool
RPMI 1640 C-erbB-2 ribozyme 
transfected BT474A
NCTCC
BT474A/ErbB2-
Rzl
RPMI 1640 Clonal subpopulation of 
BT474A/ErbB2-Rz pool
NCTCC
BT474A/ErbB2-
Rz3
RPMI 1640 Clonal subpopulation of 
BT474A/ErbB2-Rz pool
NCTCC
BT474A/ErbB2-
Rz4
RPMI 1640 Clonal subpopulation of 
BT474A/ErbB2-Rz pool
NCTCC
BT474A/ErbB2-
Rz5
RPMI 1640 Clonal subpopulation of 
BT474A/ErbB2-Rz pool
NCTCC
MCF-7 H3 ATCC Breast Adenocarcinoma 
Clonal subpopulation of 
MCF-7
NCTCC
MCF-7 H3/ErbB2 
pool
ATCC C-erbB-2 cDNA 
transfected MCF-7 H3
NCTCC
MCF-7 H3/ErbB2- 
A
ATCC Clonal subpopulation of 
MCF-7 H3/ErbB2 pool
NCTCC
MCF-7 H3/ErbB2- 
B
ATCC Clonal subpopulation of 
MCF-7 H3/ErbB2 pool
NCTCC
MCF-7 H3/ErbB2- 
C
ATCC Clonal subpopulation of 
MCF-7 H3/ErbB2 pool
NCTCC
MDA-MB-435S RPMI 1640 Breast Ductal Carcinoma Quintiles1
MDA-MB-435S-F RPMI 1640 Clonal subpopulation of 
MDA-MB-435S
NCTCC
MDA-MB-435S-
F/Taxol-10p
RPMI 1640 Taxol resistant variant of 
MDA-MB-435S-F
NCTCC
MDA-MB-435S-
F/Taxol-10p4p
RPMI 1640 Taxol resistant variant of 
MDA-MB-435S-F
NCTCC
MDA-MB-435S-
F/Adr-10p
RPMI 1640 Adriamycin resistant 
variant of MDA-MB- 
435S-F
NCTCC
MDA-MB-435S-
F/Adr-10pl0p
RPMI 1640 Adriamycin resistant 
variant of MDA-MB- 
435S-F
NCTCC
Table 2.5.1 Source description and media requirements of cell lines used in 
experiments described in this thesis
* ATCC basal media consists of a 1:1 mixture of DMEM and Hams F12.
** ATCC = American Tissue Culture Collection.
*** NCTCC = National Cell and Tissue Culture Centre.
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2.5.2 Assessment of cell number and viability
Cells were trypsinised, pelleted and resuspended in media. An aliquot of the cell 
suspension was then added to trypan blue (Gibco, 525) at a ratio of 5:1. The mixture 
was incubated for 3 minutes at room temperature. A 10|il aliquot of the mixture was 
then applied to the chamber of a glass coverslip enclosed haemocytometer. Cells in the 
16 squares of the four grids of the chamber were counted. The average cell numbers per 
16 squares were multiplied by a factor of 1 0 4 and the relevant dilution factor to 
determine the number of cells per ml in the original cell suspension. Non-viable cells 
stained blue, while viable cells excluded the trypan blue dye as their membrane 
remained intact, and remained unstained. On this basis, % viability could be calculated.
2.5.3 Cryopreservation of cells
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2.5.2. Cell pellets were resuspended in a suitable volume of serum. 
An equal volume of a 10 % DMSO/serum solution was added dropwise to the cell 
suspension. A total volume of 1ml of this suspension (which should contain 
approximately 7xl06 cells) was then placed in cryovials (Greiner, 122278). These vials 
were then placed in the vapour phase of a liquid nitrogen container, which was 
equivalent to a temperature of -80°C. After a period of four hours, vials were removed 
from the vapour phase and transferred to the liquid phase for storage (- 196°C).
2.5.4 Thawing of cryopreserved cells
A volume of 5ml of fresh growth medium was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C. The 
cells were removed from the vials and transferred to the aliquoted media. The resulting 
cell suspension was centrifuged at 1,000 rpm for 5 minutes. The supernatant was 
removed and the pellet resuspended in fresh culture medium. An assessment of cell 
viability on thawing was then carried out (Section 2.5.2). Thawed cells were then added 
to an appropriately sized tissue culture flask with a suitable volume of growth medium 
and allowed to attach overnight. The following day, flasks were refed with fresh media 
to remove any non-viable cells.
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2.5.5 Monitoring of sterility of cell culture solutions
Sterility testing was performed in the case of all cell culture media and cell culture 
related solutions. Samples of prepared basal media were inoculated on to Colombia 
blood agar plates (Oxoid, CM331), Thioglycollate broths (Oxoid, CM173) and 
Sabauraud dextrose (Oxoid, CM217) and incubating the plates at 37°C and 25°C. These 
tests facilitated the detection of bacteria, fungus and yeast contamination. Complete cell 
culture media were sterility tested at least four days prior to use, using Columbia blood 
agar.
2.5.6 Serum Batch Testing
One of the main problems associated with the use of FCS in cell culture is its batch to 
batch variation. In extreme cases this variation may result in a lack of cell growth, 
whereas in more moderate cases growth may be retarded. To avoid the effects of the 
above variation, a range of FCS batches were screened for growth of each cell line. A 
suitable FCS was then purchased in bulk for a block of work with each particular cell 
line in use. Screening involved growing cells in 96 well plates and growth was recorded 
as a percentage of growth of a serum with known acceptable growth rate.
Logarithmically growing cells were seeded into a 96 well plate (Costar; 3599) from a 
single cell suspension at a density of 10 cells/well in 1 0 0 (4.1 of medium without FCS. 
100(j,l volumes of medium containing 10% or 20% FCS was added to respective wells 
on the 96 well plate, resulting in final dilutions of the FCS to 5% or 10%, respectively. 
The first column of each plate was maintained as a control where FCS resulting in a 
known acceptable growth rate was used. Plates were placed at 37°C in 5% CO2 , for 5 
days, after which growth was assessed by acid phosphatase method, see section 2.7.4.
2.5.7 Isolation of Clonal Populations by Clonal Dilution
Clonal populations were isolated by plating cells in 96-well plates at a concentration of 
1 cell per 3 wells. After 2 days, the 96-well plates were monitored for single cells in 
wells. Single cell wells were marked and then allowed to grow until they reached levels 
that would allow them to be subcultured into 24-well plates.
80
2.6 Mycoplasma analysis of cell lines
Cell lines were tested for possible mycoplasma contamination by Dr. Mary Heenan and 
Mr. Michael Henry at the National Cell and Tissue Culture Centre, Glasnevin, Dublin 9. 
The protocol used is detailed in the following Sections 2.6.1 and 2.6.2.
2.6.1 Indirect staining procedure for Mycoplasma analysis
Mycoplasma negative NRK (Normal rat kidney fibroblast) cells were used as an 
indicator cells for this analysis. The cells were incubated with a sample volume of 
supernatant from the cell lines in question and then examined for Mycoplasma 
contamination. A fluorescent Hoechst stain was used in this analysis. The stain binds 
specifically to DNA and so stains the nucleus of the cell in addition to any Mycoplasma 
present. Mycoplasma infection was indicated by fluorescent bodies in the cytoplasm of 
the NRK cells.
2.6.2 Direct staining procedure for Mycoplasma analysis
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403). This was supplemented with 16% serum, 
0.002% DNA (BDH, 42026), 2(ag/ml fungizone (Gibco, 042 05920), 2x103 units 
penicillin (Sigma, Pen-3) and 10ml of a 25% yeast extract solution. Incubation was 
carried out at 37°C for a period of 48 hours. Samples of this broth were then streaked 
onto plates of Mycoplasma agar base (Oxoid, CM401) which had been supplemented as 
described above. The plates were incubated for three weeks at 37°C while exposed to 
CO2 . The plates were examined microscopically every 7 days. The appearance of small 
oval shaped colonies indicated the presence of Mycoplasma infection.
2.7 Miniaturised in vitro toxicity assays
2.7.1 “Long-term” in vitro toxicity assay
Cells in the exponential phase of growth were harvested by trypsinisation as described
in section 2.5.1. Cell suspensions containing lx l0 4 cells/ml were prepared in cell
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culture medium. Volumes of 1 OO^l/well of these cell suspensions were added to 96-well 
plates (Costar, 3599) using a multichannel pipette. Plates were agitated gently in order 
to ensure even dispersion of cells over a given well. Cells were then incubated overnight 
at 37°C in an atmosphere containing 5% CO2 . Cytotoxic drug dilutions were prepared 
at 2X their final concentration in cell culture medium. Volumes of the drug dilutions 
(lOOpl) were then added to each well using a multichannel pipette. Plates were then 
mixed gently as above. Cells were incubated for a further 6-7 days at 37°C and 5% CO2 
until the control wells had reached approximately 80-90% confluency. Assessment of 
cell survival in the presence of drug was determined by the acid phosphatase assay 
(section 2.7.3). The concentration of drug which caused 50% cell kill (IC50 of the drug) 
was determined from a plot of the % survival (relative to the control cells) versus 
cytotoxic drug concentration.
2.7.2 “Short-term” in vitro toxicity assay
Cells in the exponential phase of growth were harvested by trypsinisation as described 
in section 2.5.1. Cell suspensions containing 2xl04 cells/ml were prepared in cell 
culture medium and the 96-well plates were set up and incubated overnight as described 
in 2.7.1. Cytotoxic drug dilutions were prepared at 2X their final concentration in cell 
culture medium. Volumes of the drug dilutions (100^1) were then added to each well 
using a multichannel pipette. Plates were then mixed gently as above and allowed to 
incubate at 37°C and 5% CO2 for 4 hours. After this incubation period the plates were 
removed from the incubator, the drug was removed from the wells and the plates were 
washed out with fresh serum-free media. After washing, the wells were re-fed with 
fresh serum-containing media. Cells were incubated for a further 6-7 days at 37°C and 
5% CO2 , until the control wells had reached approximately 80-90% confluency. 
Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (section 2.7.3). The concentration of drug which caused 50% cell kill 
(IC50 of the drug) was determined from a plot of the % survival (relative to the control 
cells) versus cytotoxic drug concentration.
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2.7.3 Sulindac and Verapamil-mediated drug toxicity enhancement assays (Long­
term assays)
Cells were trypsinised from the flask in the exponential phase of growth as described in 
section 2.5.1. Cell suspensions containing lx l0 4 cells/ml were prepared in cell culture 
medium. Volumes of 100(al/well of this cell suspension were added into 96-well plates 
(Costar, 3599) using a multichannel pipette. Plates were agitated gently in order to 
ensure even dispersion of cells over a given well. Cells were then incubated overnight at 
37°C in an atmosphere containing 5% CO2 . Cytotoxic drug dilutions and NSAID 
dilutions were prepared at 4X their final concentration in media. Volumes of 50jj.l of the 
drug dilution and 50jal of the NSAID dilution were then added to each relevant well so 
that a total final volume of 200(j,l was present in each well. All potential toxicity- 
enhancing agents were dissolved in DMSO, ethanol or media. Stock solutions were 
prepared at approximately 15mg/10ml media, filter sterilised with a 0.22(j,m filter 
(Millex-GV, SLGV025BS) and then used to prepare all subsequent dilutions. Solvent 
control experiments showed that no toxicity enhancement effects were due to the 
presence of DMSO or ethanol. Cells were incubated for a further 6  days at 37°C in an 
atmosphere containing 5% CO2 . At this point the control wells would have reached 
approximately 80-90% confluency. Cell number was assessed using the acid 
phosphatase assay (section 2.7.4).
2.7.4 Assessment of cell number - Acid Phosphatase assay
Following the incubation period of 6-7 days, media was removed from the plates. Each 
well on the plate was washed twice with 100(il PBS. This was then removed and lOOjal 
of freshly prepared phosphatase substrate (lOmM p-nitrophenol phosphate (Sigma 104- 
0) in 0.1M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) 
was added to each well. The plates were then incubated in the dark at 37°C for 2 hours. 
The enzymatic reaction was stopped by the addition of 50|al of IN NaOH. The plate 
was read in a dual beam plate reader at 405nm with a reference wavelength of 620nm.
83
2.8 Safe handling of cytotoxic drugs
Cytotoxic drugs were handled with extreme caution at all times in the laboratory, due to 
the potential risks in handling these drugs. Disposable nitrile gloves (Medical Supply 
Company Ltd) were worn at all times and all work was carried out in cytotoxic cabinets 
(Gelman Sciences, CG series). All drugs were stored in a safety cabinet at room 
temperature or in designated areas at 4°C or -20°C. The storage and means of disposal 
of the cytotoxic drugs used in this work are outlined in Table 2.8.
Cytotoxic Agent Storage Disposal
Adriamycin 4°C in dark Incineration
Taxol Room temperature in dark Incineration
Carboplatin Room temperature in dark Incineration
Vincristine 4°C in dark Incineration
Taxotere 4°C in dark Incineration
VP-16 Room temperature in dark Incineration
Methotrexate Room temperature in dark Incineration
5-fluorouracil Room temperature in dark Incineration
Tamoxifen 4°C in dark Incineration
Table 2.8 Storage and disposal details for chemotherapeutic agents.
2.9 Adaption of MDA-MB-435S-F MDR variants
A number of MDR variants were developed by selecting the sensitive parent cell lines, 
MDA-MB-435S-F with taxol and adriamycin. Clonal populations were chosen to 
ensure that subsequent resistant cells were due to drug exposure and not in fact arising 
from a resistant sub-population already present in the cell line.
2.9.1 IC90 Assay to determine drug concentration for pulse selection
Cells were seeded into twelve 25cm flasks at 1.5 x 10 cells per flask and allowed to 
attach overnight at 37°C. The following day media was removed from the flask and a 
range of concentrations of appropriate drug was added to the flasks in duplicate.
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Complete media was added to two flasks as a 100% survival control. Flasks were 
returned to the 37°C incubator for a 4 hour incubation. Drug was then removed and the 
flasks fed with fresh complete media. The flasks were then incubated for 5-7 days until 
the cells in the control flasks had reached approximately 80% confluency.
Media was then removed from the flasks and cells were rinsed twice with PBS. Cells 
were then fixed for 10 minutes in 10% formalin. Formalin was then removed and the 
flasks allowed to air dry overnight at room temperature. Flasks were then stained for 10 
minutes with 3ml of crystal violet and then rinsed with water and allowed to air dry. 
Crystal violet stains were then eluted with 3 ml of 33% acetic acid, diluted 1:10 with 
UHP and pipetted into a 96-well plate, and then read in a dual beam ELISA plate reader 
at a wavelength of 570nm (reference wavelength 620nm). The first lane was used as a 
blank. The concentration of drug which caused 90% cell kill (IC90 of the drug) was 
determined from a plot of the % survival (relative to the control cells) versus cytotoxic 
drug concentration.
2.9.2 Pulse selection
MDA-MB-435S-F cells were grown to 70-80% confluency in 75cm2 flasks. The cells 
were then exposed to the IC90 concentration of adriamycin, or taxol for 4 hours, after 
which the drug was removed and the flasks re-fed with fresh complete media. The cells 
were then grown in drug-free media for 6  days, refeeding every 2-3 days. This was 
repeated for 10 “pulses”. Invasive potential (see section 2.14) and sensitivity to the 
selecting drug and a variety of cytotoxic drugs was the determined using miniaturised 
toxicity assays (see section 2.7.1 and 2.7.2).
2.10 Western blotting
2.10.1 Whole cell extract preparation
Cells were grown to 80-90% confluency in 75cm2 flasks for western blotting or 175cm2 
flask for immunoprécipitation. Media was removed and cells were trypsinised as 
described in section 2.5.1. Cells were washed twice with ice cold PBS. All procedures
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from this point forward were performed on ice. Cells were resuspended in 100-200jal of 
NP-40 lysis buffer and incubated on ice for 30 minutes.
Table 2.10.1.1 below provides the details of the lysis buffer. Immediately before use, 
1 0 (4.1 of the 100X stocks listed in table 2.10.2 were added to 1ml of lysis buffer.
Addition required per 500ml stock Final concentration
425ml UHP water -
25ml 1M Tris-HCl (pH 7.5) 50mM Tris-HCl (pH 7.5)
15ml 5M NaCl 150 mM NaCl
2.5ml NP-40 0.5% NP-40
Table 2.10.1.1: NP-40 lysis buffer
100X stock Preparation instructions
100mMNa3 V 0 4 1.83g Na3 V 0 4 in 100ml UHP
lOOmMDTT 154mg in 10ml UHP
lOOmM PMSF 174mg in 10ml 100% ethanol
100X Protease inhibitors 2.5 mg/ml leupeptin, 2.5 mg/ml aprotinin, 
15 mg/ml benzamidine and 1 mg/ml 
trypsin inhibitor in UHP water
Table 2.10.1.2: NP-40 lysis buffer 100X stocks
Cells were sonicated with 9 pulses lasting 0.9 seconds at 50% power. Lysed cells were 
transferred to an eppendorf and pelleted at 13,000 r.p.m for 10 minutes. Supernatant 
was removed and protein concentration quantified as detailed in section 2.10.2. Samples 
were then stored in aliquots at -80°C.
2.10.2 Protein Quantification
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad, 5000006) 
as follows. A 2mg/ml bovine serum albumin (BSA) solution (Sigma, A9543) was 
prepared freshly in lysis buffer. A protein standard curve (0, 0.2, 0.4, 0.6, 0.8 and
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l.Omg/ml) was prepared from the BSA stock with dilutions made in lysis buffer. The 
Bio-Rad reagent was diluted 1:5 in UHP water and filtered through Whatman paper 
before use. A 20 .^1 volume of protein standard dilution or sample (diluted 1:20) was 
added to 0.98ml of diluted dye reagent and the mixture vortexed. After 5 minutes 
incubation, absorbance was assessed at 570nm. The concentration of the protein 
samples was determined from the plot of the absorbance at 570nm versus concentration 
of the protein standard.
2.10.3 Immunoprécipitation
Immunoprécipitations were carried out using lmg extracted protein (detailed in section
2.10.1) as estimated using the BioRad assay in section 2.10.2. All steps were performed 
on ice. For biotinylated immunoprécipitations, a cellular labelling and 
immunoprécipitation kit was purchased (Roche, 1647652). 25 (il of biotin-7-NHS stock 
solution was added to lmg of protein extract in 1 ml of lysis buffer for 15 minutes at 
4°C. The biotinylation reaction was stopped by adding 50 |xl of stop solution (1M 
NH4CI) for 15 minutes at 4°C. 50 |il of protein A-agarose or protein G-agarose beads 
were added to biotinylated or non-biotinylated samples and rocked gently for 3 hours at 
4°C to remove any proteins that non-specifically bind to the beads. Beads were pelleted 
at 12,000rpm for 20s, and supernatant removed to a fresh eppendorf. Antibody was 
then added to the supernatant (5 \x\ EGFR Ab-15 (Neomarkers, MS-665-P), 5 |il c- 
erbB-2 Ab-11 (Neomarkers, MS-432-P), 5 |al c-erbB-3 Ab-4 (Neomarkers, MS-262- 
P), 4 |xl c-erbB-4 Ab-1 (Neomarkers, MS-270-P) and rocked gently at 4°C for 6  hours. 
Controls used were an irrelevant antibody and the lysis buffer dilutent. 50 jal of protein 
A-agarose or protein G-agarose beads were added and rocked gently for overnight at 
4°C to immunoprecipitate the protein of interest. Beads were pelleted at 12,000rpm for 
20s, and supernatant discarded. Beads were washed 2X for 20mins with wash buffer A 
(50mM Tris, pH7.5, 150mM NaCl, 0.1% Nonidet P-40), 2X for 20mins with wash 
buffer B (50mM Tris, pH7.5, 500mM NaCl, 0.1% Nonidet P-40) and IX for 20mins 
with wash buffer C (lOmM Tris, pH7.5). All traces of wash buffer were removed from 
beads. Beads were resuspended in a total volume of 15 (il of lysis buffer and 10X 
loading buffer and boiled for three minutes. Samples including beads were loaded onto 
polyacrylamide gels and western blotting carried out as described in section 2.10.4 and 
2.10.5.
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2.10.4 Gel electrophoresis
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). The stacking and resolving gels were prepared as 
illustrated in table 2.10.4.1. The gels were set in clean 10cm x 8 cm gel cassettes, which 
consisted of a glass plate and an ahominium plate. 0.75cm plastic spacers separated 
these plates. The resolving gel was added to the gel cassette and allowed to set while 
covered with 0.1% SDS. Once set, the 0.1% SDS was removed and the stacking gel was 
then added. A comb was placed into the stacking gel after pouring, in order to create 
wells for sample loading (maximum sample loading volume of 15-20(4,1).
Components 7.5% Resolving 
Gel
12% Resolving 
Gel
5% Stacking Gel
Acrylamide stock 3.8ml 6 .0 ml 0 .8 ml
UHP water 8 .0 ml 6 .0 ml 3.6ml
1.875 M Tris-HCl 
pH 8 . 8
3.0ml 3.0ml
1.25 M Tris-HCl 
pH 6 . 8
0.5ml
10% SDS 150|xL 150|4.L 50(xL
10%NH4-
persulfate
60jaL 50(4.L 17|iL
TEMED 9|nL 7.5(j.L 9p.L
Table 2.10.4.1: Preparation protocol for SDS-PAGE gels (2 x 0.75mm gels).
The acrylamide stock in Table 2.10.4.1 consists of a 30% (29:1) ratio of acrylamide:bis- 
acrylamide (Sigma, A2792). In advance of samples being loaded in to the relevant 
sample wells, 25-100fig of protein was diluted in 10X loading buffer. The molecular 
weight markers (Sigma, C3437) and protein samples were heated to 95°C for 3 
minutes. After heating, equal amounts (25-100(j.g in 10X loading buffer in a total 
volume of 1 0 (0.1) of protein were added in to each well. The gels were run at 250V and
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45mA until the bromophenol blue dye front was found to have reached the end of the 
gel, at which time sufficient resolution of the molecular weight markers was achieved.
2.10.5 Western Blotting
Western Blotting was performed by the method of Towbin et al (1979). Once 
electrophoresis had been completed, the SDS-PAGE gel was equilibrated in transfer 
buffer (25mM Tris (Sigma, T8404), 192mM glycine (Sigma, G7126), pH 8 .3-8.5) for 
approximately 30 minutes. Six sheets of Whatman 3mm filter paper were soaked in 
freshly prepared transfer buffer. These were then placed on the cathode plate of a semi­
dry blotting apparatus (Bio-rad). Air pockets were then removed from between the filter 
paper. PYDF membrane (Boehringer Mannheim 1722026) or nitrocellulose membrane 
(Amersham Pharmacia Biotech, RPN 303D), which had been equilibriated in the same 
transfer buffer, was placed over the filter paper on the cathode plate. Air pockets were 
once again removed. The gels were then aligned on to the membrane. Six additional 
sheets of transfer buffer soaked filter paper were placed on top of the gel and all air 
pockets removed. The proteins were transferred from the gel to the membrane at a 
current of 34mA at 15V for 30-40 minutes, until all colour markers had transferred.
Following protein transfer, the membranes were blocked overnight using 5% milk 
powder (Cadburys; Marvel skimmed milk) in PBS at 4°C. The PVDF membranes were 
washed with PBS prior to addition of the primary antibody. Membranes were treated 
with primary antibody for 2-3 hours at room temperature and a negative control where 
the membrane was exposed to antibody diluent was also performed. Primary antibody 
was removed after this period and the membranes rinsed 3 times with PBS containing 
0.5% Tween 20 (Sigma P1379) for a total of 30 minutes. Secondary antibody (1 in
1.000 dilution of anti-mouse IgG peroxidase conjugate (Sigma, A4914) in PBS, 1 in
2.000 dilution of anti-rabbit IgG (Sigma, A4914) in PBS or, 1 in 1,000 dilution of anti­
rat IgG (Dako, P0450) in PBS) was added for 1.5 hour at room temperature. The 
membranes were washed thoroughly in PBS containing 0.5% Tween for 15 minutes.
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Primary Antibody Dilution
EGFR Ab-12 (Neomarkers, MS-400-P) 1 : 2 0 0
C-erbB-2 Ab-10 (Neomarkers, MS-327-P) 1:400
C-erbB-3 Ab-7 (Neomarkers, MS-313-P) 1:500
C-erbB-4 Ab-2 (Neomarkers, RB-284-P) 1 : 2 0 0
B-actin (Sigma, A5441) 1 :1 0 , 0 0 0
Mdr-1 (Alexis, 801-002-el00) 1 :1 , 0 0 0
Mrp-2 (Alexis, MRPrl) 1 : 1 0 0
Anti-phosphotyrosine PY-20 (Affiniti 
Research Products, PY2000)
1 :1 0 , 0 0 0
Estrogen receptor Ab-1 (Oncogene 
Reasearch Products, GR17)
1 : 1 0 0
Estrogen receptor Ab-1 beta (Oncogene 
Reasearch Products, GR39)
1 : 1 0 0 0
Anti-biotin HRP (A0185) 1 :1 0 , 0 0 0
Table 2.10.5 List of Primary antibodies and dilutions.
2.10.6 Enhanced chemiluminescence (ECL) detection
Immunoblots were developed using an Enhanced Chemiluminescence kit (Amersham, 
RPN2109) which facilitated the detection of bound peroxidase-conjugated secondary 
antibody.
Following the final washing PVDF membranes were subjected to ECL. A layer of
parafilm was flattened over a glass plate and the PVDF membrane placed gently upon
the plate. A volume of 3ml of a 50:50 mixture of ECL reagents was used to cover the
membrane. The ECL reagent mixture was completely removed after a period of one
minute and the membrane wrapped in clingfilm. All excess air bubbles were removed.
The membrane was then exposed to autoradiographic film (Kodak, X-OMATS) for
various times (from 10 seconds to 30 minutes depending on the signal). The exposed
autoradiographic film was developed for 3 minutes in developer (Kodak, LX-24). The
film was then washed in water for 15 seconds and transferred to a fixative (Kodak, FX-40)
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for 5 minutes. The film was then washed with water for 5-10 minutes and left to dry at 
room temperature.
2.11 Quantification of adriamycin accumulation in MDA-MB-435S-F 
MDR variants
Cells were seeded into 75cm flasks (Costar, 3375) at 0.5x10 cells per flask (six flasks per 
cell line). Cells were incubated for 48 hours, after which time medium was removed and 
fresh medium containing adriamycin (lOjaM) was added. Flasks were incubated at 37°C 
for a period of two hours. After this two-hour incubation, the media was removed from all 
flasks, and half the flasks were replaced with fresh media and returned to the 37°C 
incubator. The remaining flasks were then trypsinised as described in section 2.5.1 and 
counted as described in section 2.5.2. Pellets were then washed with PBS and frozen at - 
20°C. After a four-hour incubation, the media was removed from the remaining flasks 
and the flasks were washed twice with PBS. Cells were then trypsinised as described in 
section 2.5.1 and counted as described in section 2.5.2. Pellets were then washed with PBS 
and frozen at -20°C.
When required for HPLC analysis, the frozen pellets were thawed, resuspended in 
1 0 0 (0.1 UHP and added to glass tubes (test samples). Untreated cells were resuspended 
in 800(4.1 UHP and 1 0 0 (4,1 aliquots of this were placed in to 8  glass tubes. These were the 
adriamycin control tubes and were labelled as follows: 50(4g/ml, 10(ag/ml, 5(ig/ml, 
2jag/ml, l(4g/ml, 0.5(.ig/ml, 0.25(4g/ml, 0|j,g/ml adriamycin. 1ml of appropriate 
concentration of adriamycin was then added to the adriamycin control tubes. A volume 
of 1 0 0 (1.] 33% aqueous silver nitrate (Sigma, S6506) was then added to the pellets (all 
tubes from 4 and 5), followed by mixing for 5 minutes. A quantity of 300(4.1 of the 
internal standard (6(4g/ml in 50ml methanol) was then added to all tubes.
1.3ml HPLC grade acetonitrile (Labscan) was added to the test sample tubes only. 
300(41 HPLC grade acetonitrile was added to the adriamycin control tubes. All tubes 
were maintained at 4°C for 1 hour. This was followed by centrifugation at 4000rpm for 
15 minutes. 1.1ml of the supernatant was removed and added to HPLC autosampler
vials. All solvent was then removed under a stream of nitrogen gas. The remaining 
solids were resuspended in 50(^ 1 of HPLC mobile phase The HPLC mobile phase was 
prepared as follows: 64ml of 0.1M phosphoric acid (Sigma, P6560) was added to 488ml 
UHP. The pH was then adjusted to 2.3 with IN potassium hydroxide (Sigma P6310). A 
volume of 248 ml acetonitrile was added finally and the completed mobile phase 
allowed to degas at 4°C overnight.
20|j.l of sample for analysis were automatically injected in to the HPLC system 
(Beckman System Gold 507 autosampler, 125 pump and 166 detector). Mobile phase 
flow rate was set at 0.5ml per minute with a total run time of 16 minutes. The column 
used for HPLC analysis of adriamycin in DLKP was a Cl 8  reversed phase Prodigy 5fim 
particle size ODS-3 column (Phenomenex, U.K.). Absorbance was monitored at 253nm. 
A standard curve of adriamycin peak area/daunorubicin internal standard versus 
adriamycin concentration was used to quantify the levels of adriamycin present in the 
samples. Results were finally reported as the content of adriamycin per million cells.
2.12 RT-PCR Analysis
2.12.1 Preparation of materials for RNA analysis.
Due to the labile nature of RNA and the high abundance of RNase enzymes in the 
environment a number of precautionary steps were followed when analysing RNA 
throughout the course of these studies.
• General laboratory glassware and plasticware are often contaminated by RNases. To 
reduce this risk, glassware used in these studies were baked at 180°C (autoclaving at 
121°C does not destroy RNase enzymes) for at least 8 hr. Sterile, disposable 
plasticware is essentially free of RNases and was therefore used for the preparation 
and storage of RNA without pre-treatment. Polyallomer ultracentrifuge tubes, 
eppendorf tubes, pipette tips etc., were all autoclaved before use. All spatulas which 
came in to contact with any of the solution components were baked, chemicals were 
weighed out onto baked aluminium-foil and a stock of chemicals for "RNA analysis 
only" was kept separate from all other laboratory agents.
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• All solutions (which could be autoclaved) that came in to contact with RNA were all 
prepared from sterile ultra-pure water and treated with 0 .1 % diethyl pyrocarbonate 
(DEPC) (Sigma, D5758) before autoclaving (autoclaving inactivates DEPC).
• Disposable gloves were worn at all times to protect both the operator and the 
experiment (hands are an abundant source of RNase enzymes). This prevents the 
introduction of RNases and foreign RNA/DNA in to the reactions. Gloves were 
changed frequently.
• All procedures were carried out under sterile conditions when feasible.
2.12.2 Total RNA extraction from cultured cell lines
•  2 •  •Adherent cells were grown in 75 cm flasks until approximately 80% confluent. Media
was then removed and 1ml per 75cm flasks of TRI reagent (Sigma, T-9424) was added
to the flask for 5 minutes ensuring that all cells are covered with the solution. TRI
reagent is a mixture of guanidine thiocyanate and phenol in a mono-phase solution. It
effectively dissolves DNA, RNA, and protein on lysis of cell culture samples. After
addition of the reagent, the cell lysate should be passed several times through a pipette
to form a homogenous lysate. To ensure complete dissociation of nucleoprotein
complexes, the sample was allowed to stand for 5 minutes at room temperature. 0.2ml
of chloroform (not containing isoamyl alcohol or any other additive) per ml of TRI
reagent was added to the cell lysate. The sample was covered tightly, shaken vigorously
for 15 seconds and allowed to stand for 2-15 minutes at room temperature. The
resulting mixture was centrifuged at 13,000rpm for 15 minutes at 4°C. Centrifugation
separated the mixture into 3 phases: an organic phase (containing protein), an interphase
(containing DNA) and a colourless upper aqueous phase (containing RNA). The
aqueous phase was then transferred to a fresh tube and 0.5ml of isopropanol per ml of
TRI reagent used in sample preparation and mixed. The sample was then allowed to
stand for 5-10 minutes at room temperature. The sample was then centrifuged at
13,000rpm for 10 minutes at 4°C. The RNA precipitate formed a pellet on the side and
the bottom of the tube. The supernatant was removed and the RNA pellet was washed
by adding 1ml (minimum) of 75% ethanol per 1ml of TRI reagent. The sample was
vortexed and centrifuged at 8000rpm for 5 minutes at 4°C. Samples can be stored in
ethanol at 4°C for at least 1 week and up to one year at -20°C. The RNA pellet was air-
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dried briefly. Approximately 50p,l DEPC treated H2O was added to the pellet. The RNA 
was then stored at -80°C until required for PCR analysis.
2.12.3 RNA quantification
RNA was quantified spectrophotometrically at 260nm and 280nm. An optical density of 
1 at 260nm is equivalent to 40mg/ml RNA. An A260/A280 ratio is used to indicate the 
purity of the RNA. Partially solubilised RNA has a ratio of <1.6 (Ausubel et al., 1991). 
The yield of RNA from most lines of cultured cells is 100-200]j,g/90mm plate 
(Sambrook et al., 1989).
2.12.4 Reverse transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for RNA 
isolated from cell lines. l|il oligo (dT)i2-is primers (l|j,g/ml) (Promega, Cl 101), 2 (0,1 of 
total RNA (0.5|j,g/ml), and 2 (0.1 of DEPC-H2O were mixed together and heated at 70°C 
for 10 min and then chilled on ice to remove any RNA secondary structure formation 
and allow oligo (dT) primers to bind to the poly (A)+ tail on the mRNA. 4jol of a 5X 
buffer (consisting of 250mM Tris-HCL, pH 8.3, 375mM KC1 and 15mM MgCb), 2 (0.1 of 
DTT (lOOmM), 1 jol of dNTPs (lOmM each of dATP, dCTP, dGTP and dTTP), 7(il of 
water and 1 jol of Moloney murine leukaemia virus-reverse transcriptase (MMLV-RT) 
(Sigma, M l302) was then added to the heat-denatured RNA complex and the mixture 
was incubated at 37°C for 1 hour to allow the MMLV-RT enzyme catalyse the 
formation of cDNA on the mRNA template. The enzyme was then inactivated and the 
RNA and cDNA strands separated by heating to 95°C for 2 min. The cDNA was used 
immediately in the PCR reaction or stored at -20°C until required for analysis.
2.12.5 Polymerase Chain Reaction (PCR) analysis of cDNA formed from mRNA 
isolated from cell lines
PCR reactions were set up as 50(ol volumes using 5 (ol of cDNA formed during the RT 
reaction (see Section 2.12.4). cDNA was amplified for varying cycle numbers but where
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possible amplification was carried out in the exponential phase of amplification. The 
sequences of all primers used for PCR in this thesis are shown in Figure 2.12.5.
Each PCR reaction tube contained 5(j,l lOXbuffer (lOOmM Tris-HCl, pH 9.0, 50mM 
KC1, 1% Triton X-100), 2 jal 25mM MgCl2 , l(il of first strand target primer* 
(250r|g/jo,l), 1 (0,1 of second strand target primer* (250r|g/(j,l), 0.5(.il of first strand 
endogenous (3-actin control primer* (250r)g/p.l), 0.5 (0,1 of second strand endogenous (3- 
actin control primer* (250r|g/^l) and 3 5 .5 (0,1 UHP. 5jal of cDNA (pre-heated to 95°C for 
3min. to separate strands and remove any secondary structure if the sample had been 
stored at -20°C) was added to the above. The mixture was heated to 94°C for 5min 
(reduces non-specific binding of primers to template). 1 jal of lOmM dNTP (Sigma, 
DNTP-100) and 0.5(ol of Taq DNA Polymerase enzyme (Sigma; D4545) and water to a 
total volume of 8.5fol was then added to the above The cDNA was then amplified by 
PCR (Techne; PHC-3) using the following program:
• 94°C for 3min (denature double stranded DNA)
• 25-35 cycles 94°C for 30sec (denature double stranded DNA);
X°C for 30sec (anneal primers to cDNA);
72°C for 30sec (extension);
• 72°C for 7min (extension).
• Storage at 4°C
* All oligonucleotide primers used throughout the course of this thesis were made to 
order on an “Applied BioSystems 394 DNA/RNA Synthesiser” by Oswel DNA service, 
Lab 5005, Medical and Biological Services Building, University of Southhampton, 
Boldrewood, Basset Cresent East, Southhampton, SO 16 7PX.
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Table 2.12.5 Sequences of primers used for PCR
Gene Length
(bp)
Tm
(°C)
Size
(bp)
Sequence
c-erbB-1 19
19
49 190 CAG GAC CAA GCC ACA GCA G 
ATA TTC TTG CTG GAT GCG T
c-erbB-2 20
20
62 332 AGA CGA AGC ATA CGT GAT GG 
CAT GGT ACT CTG TCT CGT CA
(3-actin
(large)
29
22
55 383 GAA ATC GTG CGT GAC ATT AAG -GAG AAG CT 
TCA GGA GGA GCA ATG ATC TTG A
(3-actin
(small)
23
22
55 142 TGG ACA TCC GCA AAG ACC TGT AC 
TCA GGA GGA GCA ATG ATC TTG A
c-erbB-3 18
20
47 366 GAA CCT TGA GAT TGT GCT 
ACA GCT TCT GCC ATT GTC CT
c-erbB-4 21
21
56 141 CGA TTC TCA GTC AGT GTG TGC 
GTG CTC AAT GCT GGT TAT CTC
mdr-1 20
20
51 157 GTT CAA ACT TCT GCT CCT GA 
CCC ATC ATT GCA ATA GCA GG
mrp-1 21
21
55 202 GTA CAT TAA CAT GAT CTG GTC 
CGT TCA TCA GCT TGA TCC GAT
mrp-2 20
19
53 241 CTG CCT CTT CAG AAT CTT AG 
CCC AAG TTG CAG GCT GGC C
mrp-4 19
18
42 239 CCA TTG AAG ATC TTC CTG G 
GGT GTT CAA TCT GTG TGC
mrp-5 18
20
49 381 GGA TAA CTT CTC AGT GGG 
GGA ATG GCA ATG CTC TAA AG
Topo I 30
27
55 180 AGA CGA ATC ATG CCC GAG GAT ATA ATC ATC 
TCG TGA ACT AGG GTT AAG CAT GAT GTA
Topo Ila 21
26
55 139 ATG CTA GTC CAC CTA AGA CCA
TGT GTA GCA GGA GGG CTT GAA GAC AG
Topo Ila 30
28
55 118 TCC TTC ATA TTC TCA GAA GTC AGA AGA TGA 
ACT TGG AAC TTT ATC TGT CTG TTT CAG A
GSTti 18
24
55 270 ATG CTG CTG GCA GAT CAG
GTA GAT GAG GGA GAT GTA TTT GCA
DHFR 22
20
55 221 GTA GAA GGT AAA CAG AAT CTG G 
CCA ACT ATC CAG ACC ATG TC
TS 20
21
55 350 TCT GCT GAC AAC CAA ACG TG 
GAG GAA GAT CTC TTG GAT TCC
A 10|ol aliquot of tracking buffer, consisting of 0.25% bromophenol blue (Sigma; 
B5525) and 30% glycerol in water, was added to each tube of amplified cDNA 
products. 2 0 (0.1 of cDNA products from each tube were then separated by electrophoresis 
at lOOmV through a 2% agarose (Sigma, A9539) gel containing ethidium bromide 
(Sigma; E8751), using TBE (22.5mM Tris-HCl, 22.5mM boric acid (Sigma; B7901), 
0.5mM EDTA) as running buffer. Molecular weight markers “<j)-X174” Hae III digest 
(Sigma, P0672) were run, simultaneously, as size reference. The resulting product 
bands were visualised as pink bands (due to the intercalation of the cDNA with the 
ethidium bromide) when the gels were placed on a transilluminator (UVP 
Transilluminator). The gels were photographed.
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2.12.6 Densitometrie Analysis
Densitometric analysis was carried out using the MS Windows 3.1 compatible 
Molecular Analyst software/PC image analysis software available for use on the 670 
Imaging Densitometer (Bio-Rad. CA) Version 1.3. Developed negatives of gels were 
scanned using transmission light and the image transferred to the computer. The amount 
of light blocked by the DNA band is in direct proportion to the intensity of the DNA 
present. A standard area was set and scanned and a value was taken for the Optical 
Density (O.D.) of each individual pixel on the screen, The average value of this O.D. 
(within a set area, usually cm ) is normalised for background of an identical set area. 
The normalised reading is taken as the densitometric value used in analysis. As a result, 
these O.D. readings were unitless.
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2.13 Extracellular Matrix Adherence Assays
2.13.1 Reconstitution of ECM Proteins
Adhesion assays were performed using the method of Torimura et al. (1999). Collagen 
type IV (Sigma C-5533), fibronectin (Sigma F-2006) and laminin (Sigma L-2020) were 
reconstituted in PBS to a stack concentration of 500 ng/ml. Stocks were aliquoted into 
sterile eppendorfs. Fibronectin and collagen stocks were stored at -20°C, while laminin 
stocks were stored at -80°C. Matrigel (Sigma E-1270) was aliquoted and stored at -20°C 
until use. Matrigel undergoes thermally activated polymerisation when brought to 20- 
40°C to form a reconstituted basement membrane.
2.13.2 Coating of Plates
Each of the ECM proteins, collagen, fibronectin and laminin, was diluted to 25p,g/ml 
while matrigel was diluted to lmg/ml with PBS. 250(4,1 aliquots were placed into wells 
of a 24-well plate. The plates were gently tapped to ensure that the base of each well 
was completely covered with solution. The plates were then incubated overnight at 
4°C. The ECM solutions were then removed from the wells and the wells rinsed twice 
with sterile PBS. 0.5ml of a sterile 0.1% BSA/PBS solution was dispensed into each 
well to reduce non-specific binding. The plates were incubated at 37°C for 20 minutes 
and then rinsed twice again with PBS.
2.13.3 Adhesion Assay
• 2  *Cells were set up in 75cm flasks and then harvested and resuspended in serum-free
DMEM medium. The cells were then plated at a concentration of 2.5 x 104 cells per
well in triplicate and incubated at 37°C for 60 minutes. Control wells were those which
had been coated but contained no cells. After 60 minutes, the medium was removed
from the wells and rinsed gently with PBS. This was then removed and 200(il of freshly
prepared phosphatase substrate (lOmM p-nitrophenol phosphate (Sigma 104-0) in 0.1M
sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) was added to
each well. The plates were then incubated in the dark at 37°C for 2 hours. The
enzymatic reaction was stopped by the addition of 100(j.l of IN NaOH. 100|_il aliquots
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were transferred to a 96-well plate and read in a dual beam plate reader at 405nm with a 
reference wavelength of 620nm.
2.14 Invasion Assay
Invasion assay was performed using the method of Albini (1998). Matrigel (Sigma E- 
1270) (llmg/ml) was diluted to lmg/ml in serum free DMEM. 1 0 0 (4,1 of 1 mg/ml 
Matrigel was placed into each insert (Falcon 3097) (8 .0 (4m pore size, 24 well format) 
which stands on 24-well plate (Costar). The insert and the plate were incubated 
overnight at 4°C. The following day, cells were harvested and resuspended in DMEM 
containing 5% FCS at the concentration of 1 x 106 cells/ml. The inserts were washed 
with serum-free DMEM, then 100(41 of the suspension cells were added to each insert 
and 250(41 of DMEM containing 5% FCS was added to the well underneath the insert. 
Cells were incubated at 37°C for 48 hours. After this time period, the inner side of the 
insert was wiped with a wet swab while the outer side of the insert was stained with 
0.25% crystal violet for 10 minutes and then rinsed and allowed to dry. The inserts 
were then viewed under the microscope. In some instances crystal violet was eluted 
with 300(41 of 33% glacial acetic acid and 100(41 aliquots were transferred to a 96 well 
plate and the absorbance read on an ELISA reader at 570 and 620nm.
2.15 Motility Assay
Motility assays were carried out in an identical manner to invasion assays, as described 
in section 2.14, with the exception that the inserts were not coated in Matrigel.
2.16 Zymography
Zymography was used to assess the level of proteolytic activity of different proteases in 
cell lines. The choice of substrate incorporated into the resolving gel depended on the 
substrate specificity of the species of enzyme detected. Gelatin is a substrate for matrix 
metalloproteinases (MMPs), serine and cysteine proteases. In the case of stromelysin 1
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and 2 (MMP-3 and MMP-10) and Matrilysin (MMP-7) caesin zymography is more 
suitable.
The gel was prepared by incorporating gelatin within the polymerised acrylamide 
matrix. 10% acrylamide gels were used. The amount for one gel was as follows.
Gel component Resolving Gel (10%) Stacking Gel
30%
Acrylamide/bisacrylamide
3.3ml 0.5ml
3mg/ml Gelatin (Sigma G- 
8150)
2.5ml
Ultrapure Water 1.7ml 2ml
3M Tris-HCl, PH 8.8 2.5ml
2M Tris-HCl, PH 6.8 0.8ml
10% Ammonium 
Persulphate
99|al 99jj,1
TEMED 5jol 5 pi
Table 2.16.1 -  Zymography gel components.
Cells were grown in petri dishes (Greiner) until they reached 80% confluency. They 
were then rinsed twice with sterile PBS and then incubated for 4 hours with serum-free 
media. Media was then replaced with fresh serum-free media and the cells were grown 
for a further 72 hours. After this time had elapsed, the supemantants were collected and 
concentrated. Samples were mixed 3:1 with 4X sample buffer (10% glycerol; 0.25 M 
Tris-HCl, pH 6.8; 0.1% (w/v) bromophenol blue) and loaded onto the gel. The gels 
were run at 30mA per gel in running buffer (0.025 M Tis; 0.19 M glycine; 0.1% SDS) 
until the dye front reached the bottom of the gel. Following electrophoresis, the gels 
were soaked in 2.5% Triton-X-100 with gentle shaking for 30 minutes at room 
temperature. The gels were rinsed in substrate buffer (50mM Tris-HCl, pH.8.0; 5mM 
CaCl2) and then incubated for 24 hours in substrate buffer at 37°C. The gels were then 
stained with Coomassie blue (2.5mg/ml) for 2 hours by shaking and destained in destain 
water (50ml acetic acid; 150ml isopropanol; 300ml UHP) until clear bands were visible. 
The gels were then scanned and analysed.
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Inhibitors or enhancers of proteinases were added to 2.5% Triton-X-100 and substrate 
buffer to identify the different classes of proteins (Table 2.16.2).
Inhibitor/Enhancer Enzyme inhibited/enhanced Concentration
EDTA (Inhibitor) MMPs 30mM
PMSF (Inhibitor) Serine proteases ImM
Cysteine (Enhancer) Cysteine proteases lOmM
DTT Reducing Agent 2mM
Leupeptin (Inhibitor) Serine and cysteine proteases 100|4.M
Table 2.16.2
2.17 Transfection of Mammalian Cells with Exogenous DNA
Throughout the course of this thesis it was found necessary to introduce foreign DNA 
into host cells either to increase the level of expression of a particular gene (by 
transfecting with an expression plasmid) or decrease the level of expression of a 
particular gene (by transfecting with a plasmid containing a ribozyme). Sufficient 
plasmid was produced by transforming JM109 with the plasmid required, growing up a 
large stock of these cells and isolating the plasmid from them; This isolated plasmid 
was then transfected into the chosen cell line.
2.17.1 Plasmids and oligonucleotides used
The c-erbB-2 ribozyme was cloned into pH(3APr-l-neo and was a generous gift from 
Dr. Kevin Scanlon (Suzuki et al, 2000). The c-erbB-2 cDNA constructs were cloned 
into the pCMV4  expression plasmid and were a generous gift from Dr. Dihua Yu (Yu et 
al, 1996).
2.17.2 MgCh / CaCh Transformation of JM109 Cells
10ml of LB broth (Appendix K) was inoculated with a single colony of JM109 bacteria 
from an agar plate and incubated overnight at 37°C at 200rpm The following day 500(4.1 
of this suspension was inoculated into 50ml of LB broth and grown to an ODeoonm of
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0.3. The cells were then pelleted at 3000rpm for lOmin, the supernatant removed and 
the pellet was resuspended in 10ml of lOOmM MgCl2 on ice for 15min. The cells were 
again precipitated at 3000rpm for lOmin and the pellet was resuspended in 10ml of 
lOOmM CaCl2  on ice for a further 15min. The precipitation step was then repeated and 
the pellet was resuspended in l-2ml of lOOmM CaCl2 and left on ice for at least 15min. 
The cells were now competent and ready for transformation with the foreign DNA 
required. 1 OOjal of the competent cell suspension was mixed with 20ng DNA and 
placed on ice for 40min after which the mixture was heat-shocked at 42°C for 90sec and 
then placed on ice for 3min. 1ml of LB broth was added to the competent cell 
suspension and incubated at 37°C for 40min. 400(il of this suspension was spread on a 
selecting agar plate (Ampicillin/AMP (Roche; 835 269)) and incubated overnight at 
37°C. Single colonies which grew on these selecting plates were further colonised on 
another selecting plate and allowed to grow overnight.
2.17.3 Isolation of Plasmid from JM109 cells
A single colony (from 2.17.2) was inoculated into 10ml of LB AMP 50(ig/ml and
grown overnight; 2ml of this suspension was added to 200ml of TB AMP 50|ig/ml and
left to grow overnight at 37°C for large scale isolation of plasmid from JM109 cells.
The following day the cells were pelleted and pZ523 spin columns (5 Prime —» 3 Prime
Inc.; 5-523523) were used to isolate the plasmid according to the manufacturer’s
instructions. This procedure involved lysing the pellet in 20ml of an ice-cold solution
containing 50mM glucose, 25mM Tris-Cl, lOmM EDTA, pH8.0 and 5mg/ml lysozyme
(Sigma; L6876) at room temperature for 10-15min. 40ml of a 0.2N NaOH and 1.0%
SDS solution was gently mixed with the lysate until the suspension became clear and
incubated on ice for lOmin. 30ml of 3M postassium-acetate, pH5.2 was added to the
above and mixed gently until a flocculent precipitate appeared at which stage the
mixture was stored on ice for at least lOmin. The sample was centrifuged at 35,000rpm.
for lh at 4°C after which the supernatant was recovered and added to 0.6 volume of
100% Isopropanol, mixed gently and left at room temperature for 20-3 Omin. The
suspension was then centrifuged at 35,000g. for 30min at 20°C after which the
supernatant was discarded and the pellet washed in ice-cold 70% ethanol and
resuspended in 5ml of TE-HC1, pH 8.0. To remove any contaminating RNA the plasmid
solution was treated with RNase Plus (5 Prime —> 3 Prime Inc.; 5-461036) (to a final
dilution of 1:250) for 30min at 37°C followed by phenol:chloroform:isoamyl alcohol
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extractions. 10M ammonium acetate was added to the aqueous phase to a final 
concentration of 2.0M and 0.6 volume of 100% Isopropanol was added to the sample, 
mixed and stored at room temperature for 20-3 Omin. The sample was centrifuged at 
maximum speed in an microfuge and the DNA pellet was washed in 70% ethanol and 
resuspended in 3.6ml of lOmM Tris-Cl, ImM EDTA, and 1.0M NaCl, pH 8.0. 1.8ml of 
this sample was loaded into one of two pZ523 columns (following the manufacturer’s 
instructions) and the column effluent was precipitated with 0.6 volume 100% 
Isopropanol, as described previously. The DNA was pelleted at maximum speed in an 
microfuge, washed in 70% ethanol and resuspended in TE. The DNA concentration was 
determined by measuring the O D 260nm-
2.17.4 CaPC>4 Transfection of Mammalian Cells
On the day prior to transfection the cells to be transfected with plasmid DNA were 
plated from a single cell suspension (Section 2.5.1) and seeded into a 75cm2 flask at 
5x10s cells per flask. The plasmid DNA was diluted to \\xgl\i\ in TE and 10|j,g DNA 
was stored overnight in 410fj,l H2O at 4°C. On the day of the transfection the diluted 
DNA was incubated at 37°C for lh 60|j,l 2M CaCl2 was added dropwise to the DNA 
with continual mixing. Immediately the DNA-CaCl2 mixture was added dropwise into 
the 2XHBS (Appendix K) solution with continual mixing and left at room temperature 
for 3 Omin to form a DNA-CaP0 4  mixture. The DNA-CaP0 4  mixture was added to the 
flask of cells (containing media) dropwise, swirling constantly to ensure even mixing. 
The cells were then incubated for 4h at 37°C after which time the cells were “shocked” 
with glycerol to aid the entry of the DNA into the cells. Glycerol-shocking was done by 
removing the media from the cells and adding 5ml of 10% glycerol in 1XHBS to the 
cells for 3min. The glycerol was then removed, the cells rinsed twice in 5ml serum-free 
media and then re-fed with 10ml fresh growth media and incubated for 2-3 days at 
37°C.
2.17.5 Selection and Isolation of Colonies
In order to study the true effect of transfection studies, single colonies of stably 
transfected cells were selected and isolated. The selection process was carried out by 
feeding the “transfected” cells with media containing geneticin (Sigma; G9516) - the 
plasmids used had a geneticin-resistant gene, therefore, only those cells containing the
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plasmid will survive treatment with geneticin. 2 days after transfection the flask of cells 
was fed with 200p.g/ml geneticin in complete media. When the cells grew readily in this 
concentration of selecting agent, the concentration was increased step-wise to a final 
concentration of 800|j.g/ml. At this stage the cells were plated at clonal density and 
clonal populations were propagated as described in section 2.5.7. Transfected cells were 
periodically challenged with geneticin to establish stability of transfectants.
2.18 Statistical Analysis
Analysis of the significance of the difference in the mean IC50 value calculated from 
toxicity assays were performed using a paired student t-test, which was run on Sigma 
Plot.
A p value < 0.05 was deemed not significant 
A p value > 0.05 was deemed significant 
A p value > 0.005 was deemed highly significant
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3.0 Results
3.1 The Effect of Upregulation of C-erbB-2 in the Human Breast 
Cancer Cell MCF-7 clone H3 on Resistance to Chemotherapy, 
Tamoxifen Hormonal Therapy, Invasiveness and Expression Patterns 
of the ErbB Receptor Family and a Panel of Drug Resistance 
Asssociated Genes.
An important objective of this thesis was to establish a breast cancer cell model for the 
investigation of the effects of c-erbB-2 expression on resistance to chemotherapeutic 
drugs and tamoxifen hormonal therapy and if any effect were found to, to investigate 
the mechanism(s) involved.
Two breast cancer cell lines were chosen, BT474A and MCF-7 H3 (isolated by Dr. 
Finbar O’Sullivan, NICB). Both are clonal populations isolated from their parental cell 
lines BT-474 and MCF-7. BT474 was derived from a solid, invasive ductal breast 
carcinoma and overexpresses c-erbB-2. MCF-7 was derived from the pleural effusion of 
a metastatic breast adenocarcinoma and express normal levels of c-erbB-2. Both cell 
lines are estrogen receptor positive. BT474A was transfected with a c-erbB-2-targeting 
ribozyme to downregulate expression of c-erbB-2, the results of which are presented in 
section 3.2. MCF-7 H3 was transfected with a c-erbB-2 encoding cDNA plasmid to 
upregulate expression of c-erbB-2.
3.1.1 Transfection of MCF-7 H3 with a cDNA Encoding C-erbB-2 and Isolation of 
Clonal Populations
MCF-7 H3 was co-transfected with a c-erbB-2 expression vector pCMV4/c-erbB-2 
(section 2.18.4) and the hygromycin selection plasmid pTK, in order to up-regulate 
expression of c-erbB-2. Three clones were isolated by clonal dilution from a pooled 
population (section 2.18.5), and were further analysed. This plasmid was a kind gift 
from Dr. Dihua Yu. The clones were designated MCF-7 H3/ErbB2-A, MCF-7 
H3/ErbB2-B and MCF-7 H3/ErbB2-C.
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3.1.2 Effect of C-erbB-2 Upregulation on the Cell Morphology of 
MCF-7H3
Transfection of MCF-7 H3 with a c-erbB-2 encoding cDNA had no effect on the 
morphology of MCF-7 H3. All three clonal populations displayed similar morphology 
to the parental cell line.
Figure 3.1.2a MCF-7 H3 Figure 3.1.2b MCF-7 H3/ErbB2-A
Figure 3.1.2c MCF-7 H3/ErbB2-B Figure 3.1.2d MCF-7 H3/ErbB2-C
3.1.3 Detection of Upregulation of C-erbB-2 in MCF-7 H3 by C-erbB-2 
cDNA Transfection
After transfection of MCF-7 H3 with a c-erbB-2 encoding cDNA, levels of c-erbB-2 
were examined at both the mRNA (RT-PCR) and protein (western blotting and 
immunprecipitation) levels, to determine the success of the transfection.
3.1.3.1 Detection of Levels of C-erbB-2 mRNA in MCF-7 H3 by RT-PCR
Figure 3.1.3.1 shows the expression of c-erbB-2 mRNA by RTPCR in MCF-7 H3 and 
its transfectant clonal populations. Densitometry shows an increase in c-erbB-2, as the 
P-actin levels are low in the clonal populations. It is possible that primer competition is 
playing a role here and that higher levels of c-erbB-2 mRNA are resulting in reduced 
amplification of P-actin. Nevertheless, clearer evidence of upregulation in the 
transfectants would have been hoped for.
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Figure 3.1.3.1 Levels of c-erbB-2 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
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Cell Line Levels of C-erbB-2 mRNA Expression 
(%)
MCF-7 H3 100
MCF-7 H3/ErbB2-A 110
MCF-7 H3/ErbB2-B 130
MCF-7 H3/ErbB2-C 142
Table 3.1.3.1 Levels of c-erbB-2 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
3.1.3.2 Detection of Levels of C-erbB-2 Protein
Expression of c-erbB-2 at the protein level was determined by three separate methods. 
Figure 3.1.3.2a shows that c-erbB-2 protein levels are elevated in all the clonal 
populations, as performed by western blotting. Figures 3.1.3.2b (classic 
immunporecipitation) and 3.1.3.2c (biotinylated immunoprécipitation) also shows 
elevation of c-erbB-2 protein levels. These results confirm that this transfection was a 
success.
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Figure 3.1.3.2a Western Blot of c-erbB-2 protein in MCF-7 H3 c-erbB-2 cDNA 
transfected clones. C-erbB-2 runs as a doublet with the higher molecular weight form 
representing its glycosylated form.
108
< CO u
<N f'l
CÛ CÛ ca
-£ •e -Q
e j m'*■
X X X
r- r-~ r-~ t~-
d U. u. u.
C U O u
s £ s 2
C-erbB-2 (185 kDa)
u *
Figure 3.1.3.2b Classic immunoprécipitation of c-erbB-2 protein in MCF-7 H3 c-erbB-2 
cDNA transfected clones.
< 03 V(N o l
03 ca oaXlu. -s 1
sr
3 X X ac
r~ i~- is r»
d B, & Ù,
O u U
2 £ S £
Figure 3.1.3.2c Biotinylated immunoprécipitation of c-erbB-2 protein in MCF-7 H3 c- 
erbB-2 cDNA transfected clones.
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The effect of c-erbB-2 expression on the chemotherapeutic drug resistance of MCF-7 
H3 was examined. A panel of chemotherapeutic agents was chosen, including 
adriamycin, taxol, carboplatin, taxotere, 5-fluorouracil, vincristine and methotrexate. 
Two methods of toxicity testing were used, entitled long-term and short-term as 
described in sections 2.7.1 and 2.7.2. The purpose of this was to compare the effect of 
c-erbB-2 on the sensitivity of MCF-7 H3 to longer drug exposure at lower levels versus 
shorter exposure at higher levels.
3.1.4.1 Effect of c-erbB-2 Upregulation on Adriamycin Resistance
C-erbB-2 sensitised MCF-7 H3 to adriamycin in two of the clonal populations, MCF-7 
H3/ErbB2-A and MCF-7 H3/ErbB2-B. This was observed in both short and long term 
toxicity assays. There was no significant change in the resistance of MCF-7 H3/ErbB2- 
C to adriamycin in either long or short term assays compared to the parental cell line 
MCF-7 H3.
3.1.4 Effect of c-erbB-2 Upregulation In MCF-7 H3 on
Chemotherapeutic Drug Resistance
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3.1.4.1.1 Long Term Adriamycin IC5 0 Toxicity assay
Cell Line IC50 Adriamycin 
(ng/ml; n=3)
MCF-7 H3 19.83 + 2.3*
MCF-7 H3/ErbB2-A 10.30 ± 1.1
MCF-7 H3/ErbB2-B 11.97 ±0.57
MCF-7 H3/ErbB2-C 27.27 + 2.6
* ± standard deviation
Table 3.1.4.1.1a Results of long term adriamycin toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P = *
MCF-7 H3/ErbB2-A 0.51 0.0415
MCF-7 H3/ErbB2-B 0.60 0.0415
MCF-7 H3/ErbB2-C 1.35 0.1221
*A p level of less than 0.05 is considered significant.
Table 3.1.4.1.1b Fold resistance to adriamycin in long term assays and significance of 
change.
I l l
3.1.4.1.2 Short Term Adriamycin IC50 Toxicity assay
Cell Line IC50 Adriamycin 
(ng/ml; n=3)
MCF-7 H3 348 + 2.8
MCF-7 H3/ErbB2-A 183 ± 15.0
MCF-7 H3/ErbB2-B 290.3 + 15.0
MCF-7 H3/ErbB2-C 369 + 33.8
Table 3.1.4.1.2a Results of short term adriamycin toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.52 0.0037
MCF-7 H3/ErbB2-B 0.83 0.0278
MCF-7 H3/ErbB2-C 1.06 0.3837
Table 3.1.4.1.2b Fold resistance to adriamycin in short term assays and significance of 
change.
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3.1.4.2 Effect of c-erbB-2 Upregulation on Taxol Resistance
C-erbB-2 increased the resistance of MCF-7 H3 to taxol in all three clonal populations, 
MCF-7 H3/ErbB2-A, MCF-7 H3/ErbB2-B and MCF-7 H3/ErbB2-C, in short term 
toxicity assays. Only MCF-7 H3/ErbB2-C displayed a significant increase (p < 0.0147) 
in resistance to taxol in long term assays, compared to the parental cell line MCF-7 H3.
3.1.4.2.1 Long Term Taxol IC50 Toxicity assay
Cell Line IC 50 Taxol 
(ng/ml; n=3)
MCF-7 H3 1.09 + 0.16
MCF-7 H3/ErbB2-A 1.01+0.07
MCF-7 H3/ErbB2-B 1.28 ± 0.09
MCF-7 H3/ErbB2-C 1.62 ± 0.21
Table 3.1.4.2.1 a Results of long term taxol toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.92 0.3391
MCF-7 H3/ErbB2-B 1.27 0.2818
MCF-7 H3/ErbB2-C 1.48 0.0147
Table 3.1.4.2.1b Fold resistance to taxol in long term assays and significance of change.
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3.1.4.2.2 Short Term Taxol IC50 Toxicity assay
Cell Line IC50 Taxol 
(ng/ml; n=3)
MCF-7 H3 9.2 ± 1.0
MCF-7 H3/ErbB2-A 21.7 + 0.64
MCF-7 H3/ErbB2-B 29.5 + 4.8
MCF-7 H3/ErbB2-C 28.8 + 2.4
Table 3.1.4.2.2a Results of short term taxol toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 2.38 0.0018
MCF-7 H3/ErbB2-B 3.20 0.0223
MCF-7 H3/ErbB2-C 3.13 0.0078
Table 3.1.4.2.2b Fold resistance to taxol in short term assays and significance of change.
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3.1.4.3 Effect of c-erbB-2 Upregulation on Carboplatin Resistance
Long term toxicity results for carboplatin showed that their was no change in 
carboplatin resistance, as they showed that c-erbB-2 upregulation decreased resistance 
to carboplatin in two clonal populations, MCF-7 H3/ErbB2-A and MCF-7 H3/ErbB2-C, 
while increasing resistance in MCF-7 H3/ErbB2-B. In short term toxicity assays MCF-
7 H3/ErbB2-B and MCF-7 H3/ErbB2-C displayed increased resistance to carboplatin, 
while the sensitivity of MCF-7 H3/ErbB-A to carboplatin was unchanged, compared to 
the parental cell line.
3.1.4.3.1 Long Term Carboplatin IC50 Toxicity assay
Cell Line IC50 Carboplatin 
(fag/ml; n=3)
MCF-7 H3 1.75 + 0.10
MCF-7 H3/ErbB2-A 1.27 + 0.03
MCF-7 H3/ErbB2-B 2.10 + 0.001
MCF-7 H3/ErbB2-C 1.29 + 0.13
Table 3.1.4.3.1a Results of long term carboplatin toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.72 0.0141
MCF-7 H3/ErbB2-B 1.20 0.0298
MCF-7 H3/ErbB2-C 0.73 0.0346
Table 3.1.4.3.1b Fold resistance to carboplatin in long term assays and significance of 
change.
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3.1.4.3.2 Short Term Carboplatin IC 50 Toxicity assay
Cell Line IC 50 Carboplatin 
(M-g/ml)
MCF-7 H3 42.9 + 3.4
MCF-7 H3/ErbB2-A 40.3 + 3.8
MCF-7 H3/ErbB2-B 58.8 ±3.3
MCF-7 H3/ErbB2-C 73.3 ±4.2
Table 3.1.4.3.2a Results of short term carboplatin toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.93 0.1865
MCF-7 H3/ErbB2-B 1.37 0.0010
MCF-7 H3/ErbB2-C 1.70 0.0170
Table 3.1.4.3.2b Fold resistance to carboplatin in short term assays and significance of 
change.
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3.1.4.4 Effect of c-erbB-2 Upregulation on 5-Fluorouracil Resistance
Both long and short term toxicity results for 5-fluorouracil showed that c-erbB-2 
upregulation decreased resistance to 5-fluorouracil in two clonal populations, MCF-7 
H3/ErbB2-A and MCF-7 H3/ErbB2-C, while increasing resistance in MCF-7 
H3/ErbB2-B. This may indicate that c-erbB-2 overexpression in general leads to 
increased sensitivity to 5-fluorouracil.
3.1.4.4.1 Long Term 5-FUIC50 Toxicity assay
Cell Line IC 50 5-Fluorouracil 
(fog/ml; n=3)
MCF-7 H3 0.17 + 0.005
MCF-7 H3/ErbB2-A 0.12 + 0.000
MCF-7 H3/ErbB2-B 0.26 + 0.005
MCF-7 H3/ErbB2-C 0.14 ±0.005
Table 3.1.4.4.1a Results of long term 5-FU toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.70 0.0034
MCF-7 H3/ErbB2-B 1.52 0.0040
MCF-7 H3/ErbB2-C 0.82 0.0040
Table 3.1.4.4.1b Fold resistance to 5-FU in long term assays and significance of change.
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3.1.4.4.2 Short Term 5-FUIC5 0 Toxicity assay
Cell Line IC50 5-Fluorouracil 
(M-g/ml; n=3)
MCF-7 H3 6.06+ 0.11
MCF-7 H3/ErbB2-A 4.73 + 0.20
MCF-7 H3/ErbB2-B 7.16 + 0.28
MCF-7 H3/ErbB2-C 3.30 ±0.20
Table 3.1.4.4.2a Results of short term 5-FU toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.78 0.0043
MCF-7 H3/ErbB2-B 1.18 0.0198
MCF-7 H3/ErbB2-C 0.54 0.0018
Table 3.1.4.4.2b Fold resistance to 5-FU in short term assays and significance of 
change.
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3.1.4.5 Effect of c-erbB-2 Upregulation on Vincristine Resistance
C-erbB-2 upregulation decreased the resistance of MCF-7 H3/ErbB2-A and MCF-7 
H3/ErbB2-C to vincristine in long term assays. No change was observed in MCF-7 
H3/ErbB2-B. Only MCF-7 H3/ErbB2-C displayed decreased resistance in short term 
assays.
3.1.4.5.1 Long Term Vincristine IC50 Toxicity assay
Cell Line IC 50 Vincristine 
(ng/ml; 11=3)
MCF-7 H3 2.30 + 0.17
MCF-7 H3/ErbB2-A 1.36 + 0.05
MCF-7 H3/ErbB2-B 2.43 + 0.11
MCF-7 H3/ErbB2-C 1.73+0.05
Table 3.1.4.5.1a Results of long term vincristine toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.59 0.0088
MCF-7 H3/ErbB2-B 1.05 0.2697
MCF-7 H3/ErbB2-C 0.75 0.0421
Table 3.1.4.5.1b Fold resistance to vincristine in long term assays and significance of 
change.
119
3.1.4.5.2 Short Term Vincristine IC50 Toxicity assay
Cell Line IC50 Vincristine 
(ng/ml; n=3)
MCF-7 H3 73.3 ±1.52
MCF-7 H3/ErbB2-A 71.3 ±1.15
MCF-7 H3/ErbB2-B 71.6 ±2.30
MCF-7 H3/ErbB2-C 53.0 ±3.46
Table 3.1.4.5.2a Results of short term vincristine toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.97 0.3206
MCF-7 H3/ErbB2-B 0.97 0.1993
MCF-7 H3/ErbB2-C 0.72 0.0095
Table 3.1.4.5.2b Fold resistance to vincristine in short term assays and significance of 
change.
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3.1.4.6 Effect of c-erbB-2 Upregulation on Taxotere Resistance
Long term toxicity results for taxotere showed that their was no change in taxotere 
resistance. C-erbB-2 upregulation resulted in decreased resistance to taxotere in two 
clonal populations, MCF-7 H3/ErbB2-A and MCF-7 H3/ErbB2-B, while increasing 
resistance in MCF-7 H3/ErbB2-C. In short term toxicity assays all clones displayed 
decreased resistance to taxotere, although only MCF-7 H3/ErbB2-B and MCF-7 
H3/ErbB2-C were statistically significant.
3.1.4.6.1 Long Term Taxotere IC50 Toxicity assay
Cell Line IC50 Taxotere 
(ng/ml; n=3)
MCF-7 H3 0.48 ± 0.03
MCF-7 H3/ErbB2-A 0.37 ± 0.02
MCF-7 H3/ErbB2-B 0.42 ± 0.01
MCF-7 H3/ErbB2-C 0.62 ± 0.02
Table 3.1.4.6.1a Results of long term taxotere toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.77 0.0421
MCF-7 H3/ErbB2-B 0.87 0.1037
MCF-7 H3/ErbB2-C 1.29 0.0152
Table 3.1.4.6.1b Fold resistance to taxotere in long term assays and significance of 
change.
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3.1.4.6.2 Short Term Taxotere IC50 Toxicity assay
Cell Line IC50 Taxotere 
(ng/ml; n=3)
MCF-7 H3 6.10 ±0.17
MCF-7 H3/ErbB2-A 5.36 ±0.32
MCF-7 H3/ErbB2-B 5.46 ±0.05
MCF-7 H3/ErbB2-C 5.53 ±0.05
Table 3.1.4.6.2a Results of short term taxotere toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.88 0.0532
MCF-7 H3/ErbB2-B 0.90 0.0188
MCF-7 H3/ErbB2-C 0.91 0.0421
Table 3.1.4.6.2b Fold resistance to taxotere in short term assays and significance of 
change.
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assays
C-erbB-2 transfection of MCF-7 H3 resulted in increased resistance to methotrexate in 
all three clonal populations.
3.1.4.7 Effect of c-erbB-2 Upregulation on Methotrexate Resistance in Long Term
Cell Line IC 50 Methotrexate 
(ng/ml; n=3)
MCF-7 H3 5.16 + 0.47
MCF-7 H3/ErbB2-A 12.36 + 0.87
MCF-7 H3/ErbB2-B 8.03 ± 0.77
MCF-7 H3/ErbB2-C 10.26 + 0.70
Table 3.1.4.7a Results of long term methotrexate toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t-Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 2.39 0.0100
MCF-7 H3/ErbB2-B 1.55 0.0198
MCF-7 H3/ErbB2-C 1.98 0.0156
Table 3.1.4.7b Fold resistance to methotrexate in long term assays and significance of 
change.
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3.1.4.8 Summary of Changes in resistance To Chemotherapeutic Agents in MCF-7 
H3 c-erbB-2 cDNA transfected variants.
The main findings of this section were that c-erbB-2 overexpression conferred 
resistance to taxol in short term assays but not in long term assays, and resistance to 
methotrexate in long term assays. Decreased resistance to vincristine, adriamycin and 
carboplatin was observed in 2 out of 3 clonal populations in long term assays. 
Interestingly drugs of a similar structure and mechanism of action, taxol and taxotere, 
did not correspond in their response to c-erbB-2 overexpression.
Type of Toxicity Assay MCF-7 H3/ MCF-7 H3/ MCF-7 H3/
ErbB2-A ErbB2-B ErbB2-C
Adriamycin Long Term - - 0
Adriamycin Short Term - - 0
Taxol Long Term 0 0 +
Taxol Short Term + + +
Carboplatin Long Term - + -
Carboplatin Short Term 0 + +
Taxotere Long Term - 0 +
Taxotere Short Term 0 - -
Vincristine Long Term “ 0 -
Vincristine Short Term 0 0 -
5-Fluorouracil Long Term - + -
5-Fluorouracil Short Term - + -
Methotrexate Long Term + + +
+ increase in resistance
decrease in resistance 
o no change in resistance
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3.1.5 Investigation of Changes in MDR Associated Gene Expression in C-erbB-2 
cDNA transfected MCF-7 H3 Breast Cancer Cells.
A panel of genes associated with drug resistance were examined at the mRNA level by 
RT-PCR to determine whether the changes in drug resistance observed in Section 3.1.4 
was due to alterations in classical modes of drug resistance.
3.I.5.1 MDR-1
Figure 3.1.5.1 shows that mdr-1 mRNA was not expressed by MCF-7 H3 or any of its 
c-erbB-2 transfected clones.
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Figure 3.1.5.1 Expression of MDR-1 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones. (PCR in Figure 3.3.8.1 was performed with the above at represents a positive 
control for mdr-1 )
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3.1.5.2 MRP-1
Figure 3.1.5.2 shows that mrp-1 mRNA expression levels did not change as a results of
c-erbB-2 transfection of MCF-7 H3.
P-actin (383bp) 
mrp-1 (202bp)
Figure 3.1.5.2 Expression of mrp-1 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of MRP-1 mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 104.3
MCF-7 H3/ErbB2-B 138.8
MCF-7 H3/ErbB2-C 1 2 1 . 1
Table 3.1.5.2 levels of mrp-1 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected clones.
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3.1.5.3 MRP-2
Figure 3.1.5.3 shows that mrp-2 mRNA expression levels did not change as a results of
c-erbB-2 transfection of MCF-7 H3.
p-actin (383 bp) 
mrp-2 (241bp)
Figure 3.1.5.3 Expression of mrp-2 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of MRP-2 mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 99
MCF-7 H3/ErbB2-B 87
MCF-7 H3/ErbB2-C 125
Table 3.1.5.3 levels of mrp-2 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected clones.
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3.1.5.4 MRP-4
Figure 3.1.5.4 shows that mrp-4 mRNA was not expressed by MCF-7 H3 or any of its
c-erbB-2 transfected clones.
Figure 3.1.5.4 Expression of mrp-4 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
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3.1.5.5 MRP-5
Figure 3.1.5.5 shows that mrp-5 mRNA was not expressed by MCF-7 H3 or any of its
c-erbB-2 transfected clones.
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Figure 3.1.5.5 Expression of mrp-5 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
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3.1.5.6 Topoisomerase I
Figure 3.1.5.6 shows that topoisomerase I mRNA levels are unchanged by upregulation 
of c-erbB-2 in MCF-7 H3.
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Figure 3.1.5.6 Expression of topoisomerase I mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
Cell Line Levels of Topo I mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 79
MCF-7 H3/ErbB2-B 1 0 0
MCF-7 H3/ErbB2-C 128
Table 3.1.5.6 levels of topoisomerase I mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
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3.1.5.7 Topoisomerase Ila
Figure 3.1.5.7 shows that topoisomerase Ila  mRNA levels are unchanged by 
upregulation of c-erbB-2 in MCF-7 H3.
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Figure 3.1.5.7 Expression of topoisomerase Ila  mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
Cell Line Levels of Topo I la  mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A Band too diffuse for densitometry
MCF-7 H3/ErbB2-B 74
MCF-7 H3/ErbB2-C 128
Table 3.1.5.7 levels of topoisomerase Ila  mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
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3.1.5.8 Topoisomerase 11 (3
Densitometry of figure 3.1.5.8 shows that topoisomerase 11(3 mRNA levels were 
increased by c-erbB-2 transfection of MCF-7 H3 the clonal transfectant population 
MCF-7 H3/ErbB2-A, but not in the other clonal transfectants.
P-actin (142bp) 
Toponp (118bp)
Figure 3.1.5.8 Expression of topoisomerase 11(3 mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
Cell Line Levels of Topo 11)3 mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 142
MCF-7 H3/ErbB2-B 109
MCF-7 H3/ErbB2-C 83
Table 3.1.5.8 levels of topoisomerase 11(3 mRNA in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
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3.1.5.9 Dihydrofolate reductase
Figure 3.1.5.9 shows that DHFR mRNA was increased by c-erbB-2 transfection of 
MCF-7 H3.
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Figure 3.1.5.9 Expression of DHFR mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of DHFR mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 155
MCF-7 H3/ErbB2-B 131
MCF-7 H3/ErbB2-C 2 2 0
Table 3.1.5.9 levels of DHFR mRNA in MCF-7 H3 c-erbB-2 cDNA transfected clones.
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Figure 3.1.5.10 shows that thymidylate synthase mRNA increased in only MCF-7 
H3/ErbB-C.
3.1.5.10 Thymidylate Synthase
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Figure 3.1.5.10 Expression of TS mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of Thymidylate Synthase 
mRNA Expression (%)
MCF-7 H3 1 0 0 . 0
MCF-7 H3/ErbB2-A 127.2
MCF-7 H3/ErbB2-B 104.4
MCF-7 H3/ErbB2-C 180.5
Table 3.1.5.10 levels of TS mRNA in MCF-7 H3 c-erbB-2 cDNA transfected clones.
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3.1.5.11 GSTti (n=2)
Figure 3.1.5.11 shows that GST n mRNA was not expressed by MCF-7 H3 or any of its 
c-erbB-2 transfected clones. A non specific band was detected, also detectable in 
BT474A but not in MDA-MB-435S-F.
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Figure 3.1.5.11 Expression of GST % mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones. (PCR in Figure 3.3.8.11 was performed with the above and represents a positive 
control for GSTu)
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3.1.5.12 Summary of Results of Gene Expression Studies in MCF-7 H3 c-erbB-2 
cDNA Transfectants
No changes in the expression of drug resistance pumps at the mRNA level, were 
detected by RT-PCR. This suggested that MDR-1, MRP-1, MRP2, MRP4 and MRP5, 
do not play a role in c-erbB-2 associated drug resistance. Also, no significant changes 
in the expression of the different topoisomerase isoforms, thymidylate synthase or 
GST71 were detected. The one alteration seen consistent with changes in drug 
resistance, was an upregulation in the expression of DFHR, which correlated with 
increased resistance to methotrexate.
RT-PCR MCF-7 H3/ 
ErbB2-A
MCF-7 H3/ 
ErbB2-B
MCF-7 H3/ 
ErbB2-C
Mdr-1 neg neg neg
Mrp-1 0 0 0
Mrp-2 0 0 0
Mrp-4 neg neg neg
Mrp-5 neg neg neg
Topo I 0 0 0
Topo Ila 0 0 0
Topo lip 0 0 0
DHFR + + +
TS 0 0 +
GSTtt neg neg neg
C-erbB-1 + + +
C-erbB-4 - - -
+ increase in expression
decrease in expression 
o no change in expression
neg Not expressed
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3.1.6 The Effect of c-erbB-2 Upregulation in MCF-7 H3 on Resistance 
to Tamoxifen
The effects of c-erbB-2 expression on tamoxifen resistance in MCF-7 H3 were varying. 
C-erbB-2 upregulation in MCF-7 H3 had no effect on the sensitivity of MCF-7 
H3/ErbB2-B to tamoxifen. MCF-7 H3/ErbB2-A showed decreased resistance to 
tamoxifen when compared to the parental cell line, MCF-7 H3. MCF-7 H3/ErbB2-C 
was also examined for changes in tamoxifen resistance. Its IC50 was greater than 
50ng/ml, as no cell kill was achieved in these assays.
Cell Line IC50 Tamoxifen 
(ng/ml; n=3; )
MCF-7 H3 24.33 ± 0.57*
MCF-7 H3/ErbB2-A 16.33 ± 1.15
MCF-7 H3/ErbB2-B 22.23 ± 2.08
* ± standard deviation
Table 3.1.6a Results of long term tamoxifen toxicity assay.
Cell Line Fold Change in 
Resistance
Significance - Paired 
Student t -Test
MCF-7 H3 1.00 P =
MCF-7 H3/ErbB2-A 0.67 0.0051
MCF-7 H3/ErbB2-B 0.91 0.1835
Table 3.1.6b Fold resistance to tamoxifen in long term assays and significance of 
change.
137
3.1.7 The Effect of c-erbB-2 Upregulation on Estrogen Receptor Expression
Expression estrogen receptors were examined by western blotting. No changes in the 
expression of estrogen receptor a  expression was detected, while estrogen receptor (3 
was found to be upregulated, particularly isoforms of higher molecular weights. Blots 
were stripped and reprobed for (3-actin
3.1.7.1 Estrogen Receptor a
Figure 3.1.7.1 shows that c-erbB-2 expression in MCF-7 H3 does not affect ERa 
expression. A non specific band was detected in MCF-7 H3/ErbB2-C, reported often 
with this antibody, which is not ERp.
- E R a  (66 kDa) 
Non-specific band 
P-actin (44kDa)
Figure 3.1.7.1 Western blot of estrogen receptor a  expression in MCF-7 H3 c-erbB-2 
cDNA transfected clones.
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Figure 3.1.7.2 shows that c-erbB-2 upregulation in MCF-7 H3 results in an increase in 
the expresión of ERp isoforms.
3.1.7.2 Estrogen Receptor p
- 66 kDa" 
-59 kDa-1
-  50 kDa - 
- 4 4 kDa-
6: 6: f  <*■ f*" EÍ
¡x !x H trr- t- t- r~
■ i i tü n. Ü [1<_ C (_
2 2 2 2
ERP
bands
Swpf* (►
P-actin (44kDa)
Figure 3.1.7.2 Western blot of estrogen receptor P expression in MCF-7 H3 c-erbB-2 
cDNA transfected clones.
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3.1.8 The Effect of C-erbB-2 Upregulation on the Levels of mRNA of C-erbB-1 and 
C-erbB-4 in MCF-7 H3.
In order to determine whether e-erbB-2 had an effect on the expression of other ErbB 
family members, erbB levels were determined at both mRNA and protein levels 
(Section 3.1.9). The effect of c-erbB-2 upregulation in MCF-7 H3, on the expression of 
c-erbB-1 and c-erbB-4 mRNA levels was examined by RT-PCR
3.1.8.1 C-erbB-1
Figure 3.1.8.1 shows that c-erbB-2 upregulation in MCF-7 H3 results in the increase of 
c-erbB-1 mRNA.
P-actin (383 bp) 
c-erbB-1 (190 bp)
Figure 3.1.8.1 Expression of c-erbB-1 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of C-erbB-1 mRNA Expression 
(%)
MCF-7 H3 1 0 0
MCF-7 H3/ErbB2-A 225
MCF-7 H3/ErbB2-B 153
MCF-7 H3/ErbB2-C 209
Table 3.1.8.1 Levels of c-erbB-1 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
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3.1.8.2 C-erbB-4
Figure 3.1.8.2 shows that c-erbB-2 upregulation in MCF-7 H3 results in a decrease of c- 
erbB-4 mRNA.
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P-actin (383 bp) 
C-erbB-4 (141 bp)
Figure 3.1.8.2 Expression of c-erbB-4mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
Cell Line Levels of c-erbB-4 mRNA Expression 
(%)
MCF-7 H3 100
MCF-7 H3/ErbB2-A 52
MCF-7 H3/ErbB2-B 80
MCF-7 H3/ErbB2-C 53
Table 3.1.8.2 Levels of c-erbB-4 mRNA in MCF-7 H3 c-erbB-2 cDNA transfected 
clones.
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3.1.9 Effect of C-erbB-2 Upregulation in MCF-7 H3 on the Expression of 
Remaining ErbB Receptors at the Protein Level
Changes in the mRNA levels of c-erbB-1 and c-erbB-4 were detected in section 3.1.8. 
Protein levels of c-erbB-1, c-erbB-3 and c-erbB-4 were examined to determine if these 
changes were reflected at the protein level.
3.1.9.1 C-erbB-1 western blot
Figure 3.1.9.1 shows that c-erbB-2 upregulation in MCF-7 H3 had no effect on c-erbB-1 
protein expression, despite an increase at mRNA level (section 3.1.8.1)
u c-erbB-1 (170 kDa)
P-actin (44 kDa)
Figure 3.1.9.1a Western blot of c-erbB-1 protein in MCF-7 H3 c-erbB-2 cDNA 
transfected clones. A control gel was run for detection of P-actin protein, as P-actin was 
of too low a molecular weight to detect on ErbB gels.
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Figure 3.1.9.2 shows that c-erbB-2 upregulation in MCF-7 H3 results in an increase in 
c-erbB-3 protein expression, by immunoprécipitation. Immunoprecipiation was 
performed as levels of c-erbB-3 were too low in this cell line to be detected by western 
blot.
3.1.9.2 C-erbB-3 immunoprécipitation
c-erbB-3 (180 kDa)
Figure 3.1.9.2 immunoprécipitation of c-erbB-3 protein in MCF-7 H3 c-erbB-2 cDNA 
transfected clones.
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Figure 3.1.9.3 shows that c-erbB-2 upregulation in MCF-7 H3 results in a decrease in 
full length c-erbB-4 and intracellular domain truncated protein levels.
3.1.9.3 C-erbB-4
* c-erbB-4 (185kDa)
«i
— c-erbB-4 (80kDa) 
intracellular domain
Unidentified 
protein (approx 
50 kDa)
P-actin (44 kDa)
Figure 3.1.9.3a Western blot of c-erbB-4 protein in MCF-7 H3 c-erbB-2 cDNA 
transfected clones. A control gel was run for detection of P-actin protein, as P-actin was 
of too low a molecular weight to detect on ErbB gels.
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3.1.9.4 Immunoprecipitation of Biotinylated Proteins by ErbB Receptors
The following figure shows biotinylated proteins immunoprecipitated by the ErbB 
Receptors. The protein extractions were biotinylated and then subjected to 
immunoprecipitation with the ErbB of interest and then probed with an anti-biotin 
secondary antibody. The transfectant populations show a distinct increase in the 
expression of other proteins co-immunoprecipitated with c-erbB-2 or c-erbB-4, 
suggesting an increase in protein binding to these two receptors, and thus a possible 
activation of signalling pathways. This also coincides with increases in tyrosine 
phosphorylated proteins immunoprecipitated by c-erbB-2, 3 and 4, but not 1, as shown 
in Figure 3.1.9.5
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Figure 3.1.9.4 Expression of biotinylated proteins immunoprecipitated by ErbB 
Receptor Proteins in MCF-7 H3 and its clones A, B and C.
Cell Line C-erbB-1 C-erbB-2 C-erbB-3 C-erbB-4
MCF-7 H3 1.00 1.00 1.00 1.00
MCF-7 H3/ErbB2-A 0.24 2.57 6.73 2.66
MCF-7 H3/ErbB2-B 1.35 2.75 1.33 2.77
MCF-7 H3/ErbB2-C 0.22 2.25 3.75 2.26
Table 3.1.9.4 Fold Increases In Expression of ErbB Proteins in MCF-7 H3 c-erbB-2 
Transfectants.
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3.1.9.5 Effect of C-erbB-2 Upregulation on the Phosphorylation of ErbB proteins
The following figure is the previous figure stripped and reprobed with P-tyrosine and 
shows phosphorylated proteins immunoprecipitated by the ErbB Receptors.
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Figure 3.1.9.5 Reprobing of biotinylation blots (figure 3.1.9.4) with P-Tyr antibody 
post antibody shipping.
Cell Line C-erbB-1
P-Tyr
C-erbB-2
P-Tyr
C-erbB-3
P-Tyr
C-erbB-4
P-Tyr
MCF-7 H3 1.00 1.00 1.00 1.00
MCF-7 H3/ErbB2-A 0.26 3.08 5.43 0.85
MCF-7 H3/ErbB2-B 1.67 2.78 3.69 1.08
MCF-7 H3/ErbB2-C 0.42 1.99 4.41 1.34
Table 3.1.9.5 - Fold expression of P-Tyr phosphorylation relative to MCF-7 H3
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3.1.10 The Effect of C-erbB-2 Upregulation on Growth Rate of MCF-7 
H3.
C-erbB-2 transfection of MCF-7 H3 resulted in increased growth rate in two of the 
clonal populations, MCF-7 II3/ErbB2-B and MCF-7 H3/ErbB2-C, while MCF-7 
H3/ErbB2-A displayed a slower growth rate than MCF-7 H3.
Cell Line Doubling Time (hours)
MCF-7 H3 51
MCF-7 H3/ErbB2-A 55
MCF-7 H3/ErbB2-B 45
MCF-7 H3/ErbB2-C 44
Table 3.1.10 Doubling Times of MCF-7 H3 and it C-erbB-2 Transfected Clones
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3.1.11 The Effect of C-erbB-2 Upregulation on Motility of MCF-7 H3
Motility assays were performed as described in section 2.15 to investigate the effects of 
c-erbB-2 upregulation on the motility of MCF-7 H3. Surprisingly, neither the parental 
cell line nor the clonal populations were motile in this system. A sample photo of the 
parental cell line, figure 3.1.11a shows that the membrane contained few or no cells 
after 48 hours incubation. The clonal populations displayed identical results. The 
Postive (RPMI 2650- Melphalan) and negative (RPMI 2650) controls Figure 3.1.11b 
and 3.1.11c show that this assay was operational (RPMI 2650 displays little or no 
motility, while it Melphalan resistant variants displays high motility (Liang et a l, 
2001)).
Figure 3.1.11 Motility assay for MCF-7 M3
Figure 3.1.1 lb RPMI Figure 3.1.11c RPMI Melphalan
3.1.12 The Effect of C-erbB-2 tlpregulation on Invasion of Matrigel by 
MCF-7 H3
Invasion assays were performed as described in section 2.14 to investigate the effects of 
c-erbB-2 upregulation on the invasiveness of MCF-7 H3. Two of the clonal 
populations, MCF-7 II3/ErbB2-B and MCF-7 II3/ErbB2-C were found to be more 
invasive than the parental cell line, MCF-7 H3. Surprisingly MCF-7 H3/ErbB2-A was 
actually less invasive than MCF-7 H3. Figures 3.1.12.1 to 3.1.12.4 are representative of
3 repeats.
Figure 3.1.12a MCF-7 H3 Figure 3.1.12b MCF-7 H3/ErbB2-A
Figure 3.1.12c MCF-7 H3/ErbB2-B Figure 3.1.12d MCF-7 H3/ErbB2-C
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3.1.13 The Effect of C-erbB-2 Upregulation on Adhesive Properties of 
MCF-7 H3 to Components of the Extracellular Matrix
Cells use various adhesion molecules such as integrins to interact with extracellular 
matrix components such as collagen type IV, laminin and fibronectin. To detect 
changes in the adhesive properties of MCF-7 H3 due to upregulation of c-erbB-2, 
adhesion assay were performed as described in section 2.13.
Figure 3.1.13.1 shows the levels of adhesion of MCF-7 H3 and its c-erbB-2 transfected 
clones to laminin after 1 hour. The clonal populations MCF-7 H3/ErbB2-A and MCF-7 
H3/ErbB2-B show increased adhesion to laminin compared to their parental cell line. 
MCF-7 H3/ErbB2-C on the other hand displays decreased adhesion to laminin.
Figure 3.1.13.2 shows the levels of adhesion of MCF-7 H3 and its c-erbB-2 transfected 
clones to collagen type IV after 1 hour. The clonal populations MCF-7 H3/ErbB2-A 
and MCF-7 H3/ErbB2-B show increased adhesion to collagen type IV compared to their 
parental cell line. MCF-7 H3/ErbB2-C on the other hand displays decreased adhesion to 
collagen type IV. This profile is similar to that seen for laminin in section 3.1.13.1.
Figure 3.1.13.3 shows the levels of adhesion of MCF-7 H3 and its c-erbB-2 transfected 
clones to fibronectin after 1 hour. All three clonal populations, MCF-7 H3/ErbB2-A, 
MCF-7 H3/ErbB2-B and MCF-7 H3/ErbB2-C show decreased adhesion to fibronectin 
compared to their parental cell line.
Figure 3.1.13.4 shows the levels of adhesion of MCF-7 H3 and its c-erbB-2 transfected 
clones to matrigel after 1 hour. Only the clonal populations MCF-7 H3/ErbB2-C show 
any major change in adhesiveness to matrigel (reduction in adhesion).
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3.1.13.1 Adhesion to Laminin.
Adhesion of MCF-7 H3 Variants to Laminin
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Figure 3.1.13.1 Levels of adhesion of MCF-7 H3 and c-erbB-2 transfected clones to 
laminin.
Ceil Line Fold Changes in Cells Attached to 
Laminin After 1 hour
MCF-7 H3 1.00
MCF-7 H3/ErbB2-A 1.35
MCF-7 H3/ErbB2-B 2.07
MCF-7 H3/ErbB2-C 0.77
Table 3.1.13.1 Fold changes in adhesion to laminin relative to the parental cell line 
MCF-7 H3.
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3.1.13.2 Adhesion to Collagen Type IV
Adhesion of MCF-7 H3 Variants to Collagen 
Type IV
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Figure 3.1.13.2 Levels of adhesion of MCF-7 H3 and c-erbB-2 transfected clones to 
collagen type IV.
Cell Line Fold Changes in Cells Attached to 
Collagen Type IV After 1 hour
MCF-7 H3 1.00
MCF-7 H3/ErbB2-A 1.13
MCF-7 H3/ErbB2-B 1.39
MCF-7 H3/ErbB2-C 0.74
Table 3.1.13.2 Fold changes in adhesion to collagen type IV relative to the parental cell 
line MCF-7 H3.
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3.1.13.3 Adhesion to Fibronectin
Adhesion of MCF-7 H3 variants to Fibronectin
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Figure 3.1.13.3 Levels of adhesion of MCF-7 H3 and c-erbB-2 transfected clones to 
fibronectin.
Cell Line Fold Changes in Cells Attached to 
Fibronectin After 1 hour
MCF-7 H3 1.00
MCF-7 H3/ErbB2-A 0.43
MCF-7 H3/ErbB2-B 0.73
MCF-7 H3/ErbB2-C 0.69
Table 3.1.13.3 Fold changes in adhesion to fibronectin relative to the parental cell line 
MCF-7 H3.
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3.1.13.4 Adhesion to Matrigel
Adhesion of MCF-7 H3 Variants to Matrigel
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Figure 3.1.13.4 Levels of adhesion of MCF-7 H3 and c-erbB-2 transfected clones to 
matrigel.
Cell Line Fold Changes in Cells Attached to 
Matrigel After 1 hour
MCF-7 H3 1.00
MCF-7 H3/ErbB2-A 0.92
MCF-7 H3/ErbB2-B 1.18
MCF-7 H3/ErbB2-C 0.58
Table 3.1.13.4 Fold changes in adhesion to matrigel relative to the parental cell line 
MCF-7 H3.
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3.1.13.5 Summary of Adhesion results
Adhesive Values of MCF-7 H3 c-erbB-2 Transfected
Clones
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Figure 3.1.13.5 Adhesion of MCF-7 H3 c-erbB-2 transfectants to ECM proteins.
Laminin Fibronectin Collagen 
Type IV
Matrigel
MCF-7 H3 1.00 1.00 1.00 1.00
MCF-7
II3/ErbB2-A
1.35 0.43 1.13 0.92
MCF-7
H3/ErbB2-B
2.07 0.73 1.39 1.18
MCF-7
H3/ErbB2-C
0.77 0.69 0.74 0.58
Table 3.1.13.5 Fold decrease in adhesion of MCF-7 H3 c-erbB-2 transfected variants to 
ECM proteins relative to parental cell lines MCF-7 H3.
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3.1.14 The Effect of C-erbB-2 Upregulation on Secretion of Proteases 
by MCF-7 H3
Matrix metalloproteinases (MMPs), cysteine proteases and serine protease, which are 
secreted by cells, play an important role in degrading the extracellular matrix. To 
further investigate the mechanisms by which c-erbB-2 exerts an influence of the 
invasiveness of MCF-7 H3, zymography was performed to detect the secretion of 
proteases in these cells, as described in section 2.16.
3.1.14.1 Detection of the Expression of Proteases Secreted by MCF-7 H3 and its C- 
erbB-2 cDNA Transfected Variants
The BHK (baby hamster kidney) cell line, was used as a positive control for the 
secretion of pro-MMP2 (72 kDa), MMP-2 (66kDa), pro-MMP-9 (92kDa) and MMP9 
(86kDa). The MCF-7 H3 parent cell line and its c-erbB-2 cDNA transfected variants 
display secretion bands corresponding to pro-MMP-2, pro-MMP-9 and MMP-9. There 
are also many additional bands expressed by MCF-7 H3 and MCF-7 H3/ErbB2-A, 
which are absent in MCF-7 H3/ErbB2-B and MCF-7 H3/ErbB2-C. These additional 
bands are stronger in MCF-7 H3/ErbB2-A than in the parental cell line MCF-7 H3. It is 
also worth noting that MCF-7 H3/ErbB2-A is not invasive while MCF-7 H3 is slightly 
invasive and both MCF-7 H3/ErbB2-B and MCF-7 H3/ErbB2-C are much more 
invasive.
156
130 kDa 
84 kDa
45 kDa
29 kDa 
22 kDa
la2
"5>
'5
£
J§3oJU
o2
V
CQ
< CQ u
<N <s (N
CQ CQ 03
-e JO
$ $r«->
X X X X
t~- r~~ r~ c~~
uL u. iL u.
o CJ u U
S 2 2 2
i
\ \ p
ta*  ' -«as I— 1 1 -4 ,
• v .
>
J
Figure 3.1.14.1 Zymogram of gelatin proteases secreted by MCF-7 H3
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3.1.14.2 Identification of the Classes of Proteases Secreted by MCF-7 H3 and its C- 
erbB-2 cDNA Transfected Variants
To investigate the identity of the gelatin degrading proteases secreted by MCF-7 H3 and 
its c-erbB-2 transfected variants, protease inhibitors were used.
3.1.14.2.1 The effect of EDTA and PMSF on Protease activity
EDTA is a chelating agent, which can bind zinc and calcium ions, which are needed for 
the activation of MMPs. PMSF is a serine and cysteine protease inhibitor.
Figure 3.1.14.2.1b shows that the addition of EDTA to the substrate buffer eliminates 
expression of all protease bands in BHK, and the majority of those in MCF-7 
H3/ErbB2-B and MCF-7 H3/ErbB2-C, indicating the gelatin degrading proteases 
secreted these cell lines are members of the matrix metalloproteinase family. There are 
still bands present in MCF-7 H3 and MCF-7 H3/ErbB2-A, which are therefore not 
matrix metalloproteinases.
Figure 3.1.14.2.1b also shows the effects of addition of PMSF to the substrate buffer, 
which suppresses slightly the expression of protease bands in the BHKs, but does not 
eliminate them, and has no effect on any of the bands from the four other cell lines, 
suggesting the proteases are not serine or cysteine proteases.
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3.1.14.2.2 The effect of L-Cysteine
Cysteine keeps cysteine proteases in their reduced form, thus making them more active. 
If the extra bands in MCF-7 H3 and MCF-7 H3/ErbB2-A are cysteine proteases then 
their bands should appear stronger. Figure 3.3.14.2.2b showed that addition of cysteine 
to the substrate buffer did not enhance any of the bands in MCF-7 H3 or MCF-7 
H3/ErbB2-A indicating that these bands are not cysteine proteases. Surprisingly it 
eliminates the expression of all bands secreted by BHK, MCF-7 H3/ErbB2-B and MCF- 
7 H3/ErbB2-C. It also eliminates the expression of bands of lower molecular weight in 
MCF-7 H3 and MCF-7 H3/ErbB2-A. This was repeated twice.
130 kDa 
84 kDa
45 kDa 
29 kDa 
22 kD a
Figure 3.1.14.2.2b Effect of cysteine on Protease secretion. Figure 3.1.14.2.2a Protease 
secretion by MCF-7 H3 and its Variants
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3.1.14.3 Investigation of the Findings of the Effects of the Addition of Cysteine on 
the Proteases Secreted by MCF-7 H3 and its C-erbB-2 cDNA Transfected Variants
Previously it was determined that the extra bands detected in MCF-7 H3 and MCF-7 
H3/ErbB2-A were not MMPs, cysteine proteases or serine proteases. Also cysteine had 
the surprise effect of inhibiting various bands secreted by MCF-7 H3 and MCF-7 
H3/ErbB2-A, and also MMP bands. Cysteine is also a reducing agent, and it was 
possible that it was having a reducing affect on the proteases secreted. To further 
clarify this, DTT was chosen, as it is also a reducing agent, to see if this effect could be 
mimicked. Leupeptin another serine and cysteine protease inhibitor was also chosen as 
PMSF has a short half life and it was possible that it was being inactivated before it 
could act on the bands.
Figure 3.1.14.3b demonstrated that the addition DTT to the substrate buffer had the 
same effect as cysteine. This shows that reducing agents have an inhibitory effect on 
the activity of MMPs and also on the unidentified bands.
Addition of PMSF previously had little effect of the band activity in these cell lines 
other than suppressing slightly the activity of the MMPs in the BHKs. Another serine 
and cysteine protease inhibitor, Leupeptin, was used to see whether these definitely 
were not either of these types of proteases. Leupeptin is a serine and cysteine protease 
inhibitor. It inhibits plasmin, trypsin, papain and cathepsin B. It has no effect on 
pepsin, cathepsin A or cathepsin D. Figure 3.1.14.3c shows that leupeptin 
suppressed/eliminated the majority of bands secreted by the 5 cell lines, including BHK 
secreted MMP-2 and MMP-9. It has not inhibited the MMPs in the MCF-7 H3 variants 
however.
These results suggest that the extra bands secreted by MCF-7 H3 and MCF-7 
H3/ErbB2-A are serine proteases as they are not enhanced by cysteine.
161
K> to ■P»
to
s
SO
K
0
CO
öSä öCÙ
M olecular W eieht M arker 
BHK
M CF-7 H3 
M CF-7 H3/ErbB2-A
M CF-7 H3/ErbB2-B 
M CF-7 H3/ErbB2-C
M olecular W eieht M arker 
BHK
MCF-7 H3
MCF-7 H3/ErbB2-A 
M CF-7 H3/ErbB2-B
MCF-7 H3/ErbB2-C
Figure 
3.1.14.3a 
Protease 
secretion 
by 
M
CF-7 
H3 
and 
its V
ariants
SO
5 gP OS g gco
M olecular W eisht M arker 
BHK
M CF-7 m  
M CF-7 H3/ErbB2-A
MCF-7 H3/ErbB2-B 
MCF-7 H3/ErbB2-C
3.2 The Effect of Downregulation of C-erbB-2 in the Human Breast 
Cancer Cell BT474A on Resistance to Chemotherapy, Tamoxifen 
Hormonal Therapy, Invasiveness and Expression Patterns of the ErbB 
Receptor Family and a Panel of Drug Resistance Asssociated Genes.
As mentioned in section 3.1, the first objective of this thesis was to establish a breast 
cancer cell model for the investigation of the effects of c-erbB-2 expression on 
resistance to chemotherapeutic drugs and tamoxifen hormonal therapy. Two breast 
cancer cell lines were chosen, BT474A and MCF-7 H3. BT474A was transfected with a 
c-erbB-2 targeting ribozyme to down regulate expression of c-erbB-2, the results of 
which are presented in section 3.2.
3.2.1 Establishment of BT474A transfected with c-erbB-2 Ribozyme.
BT474A was transfected with a hammerhead ribozyme targeting c-erbB-2 (section 
2.18.4), a generous gift from Dr. Kevin Scanlon. The transfected cell line was then 
selected with G418 (section 2.18.5). Attempts to isolate clones in 96-well plates by 
dilution cloning failed for this cell line, most likely due to their dislike of low cell 
density. 6-well plates were seeded with 5ml of a 20 cells/ml solution, and allowed to
• 9form colonies. Colonies were then upscaled to 12.5 cm hybridoma flasks using cloning 
rings. Four clones were isolated, designated BT474A/ErbB2-Rzl, BT474A/ErbB2- 
Rz3, BT474A/ ErbB2-Rz4 and BT474A/ ErbB2-Rz5.
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3.2.2 Effect of C-erbB-2 Downregulation on the Cell Morphology of 
BT474A
Transfection of BT474A with a c-erbB-2-targeted ribozyme had no effect on the 
morphology of BT474A/ErbB2-Rz pool, BT474A/ErbB2-Rz3 or BT474A/ErbB2-Rz5. 
BT474A/ErbB2 Rzl and BT474A/ErbB2 Rz4 cell morphology appeared to be more 
spread out than the parental cell line BT474A.
Figure 3.2.2a BT474A Figure 3.2.2b BT474A/ErbB2-Rz pool
Figure 3.2.2c BT474A/ErbB2-Rzl Figure 3.2.2d BT474A/ErbB2-Rz3
Figure 3.2.2e BT474A/ErbB2-Rz4 Figure 3.2.2f BT474A/ErbB2-Rz5
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3.2.3 Detection of c-erbB-2 Downregulation by C-erbB-2 Targeting 
Ribozyme Transfection
The effect of the c-erbB-2 targeting ribozyme on the expression of c-erbB-2 in BT474A 
was examined at the mRNA and protein level. Figure 3.2.3.1 shows that c-erbB-2 
mRNA levels were reduced in the clonal populations BT474A/ErbB2-Rz3, 
BT474A/ErbB2-Rz4 and BT474A/ErbB2-Rz5. A reduction was not seen in the pooled 
population or in BT474A/ErbB2-Rzl. It should be noted that while this PCR was 
performed at 25 cycles, the c-erbB-2 bands were still becoming saturated, and the 0- 
actin bands were faint as a result of primer competition. It is therefore possible that no 
reduction in c-erbB-2 was seen in the pooled population or in BT474A/ErbB2-Rzl 
because of c-erbB-2 saturation. Figures 3.2.3.2a and 3.2.3.2b show the level of c-erbB-
2 protein expression by western blotting. All the clonal ribozyme transfectant 
populations displayed decreased c-erbB-2 expression when P-actin was taken into 
account. The pooled population did not show a decrease in c-erbB-2 in this western 
blot. Figure 3.2.3.2b also includes the mutant ribozyme contol transfectant pooled 
population. While the blot is somewhat saturated, it clearly shows that c-erbB-2 levels 
are unchanged in the contol.
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3.2.3.1 Detection of Levels of C-erbB-2 mRNA
Figure 3.2.3.1 Levels of c-erbB-2 expression in BT474A c-erbB-2 ribozyme transfected 
pool and clonal populations.
Cell Line Levels of C-erbB-2 mRNA Expression
(%)
BT474A 100.0
BT474A/ErbB2-Rz pool 100
BT474A/ErbB2-Rzl 123
BT474A/ErbB2-Rz3 71
BT474A/ErbB2-Rz4 68
BT474A/ErbB2-Rz5 77
Table 3.2.3.1 Levels of c-erbB-2 expression.
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The effect of c-erbB-2 expression on the chemotherapeutic drug resistance of BT474A 
was examined. A panel of chemotherapeutic agents was chosen, including adriamycin, 
taxol, carboplatin, taxotere, 5-fluorouracil, and methotrexate. As with the MCF-7 H3 c- 
erbB-2 transfection, as reported in section 3.1.4, two methods of toxicity testing were 
used, entitled long-term and short-term as described in sections 2.7.1 and 2.7.2. The 
purpose of this was to compare the effect of c-erbB-2 on the sensitivity of BT474A to 
longer drug exposure at lower levels versus shorter exposure at higher levels. An 
additional purpose of this section was to see if the opposite of what happened in MCF-7 
H3, would happen in BT474A.
3.2.4 Effect of c-erbB-2 Down regulation in BT474A on
Chemotherapeutic Drug Resistance
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3.2.4.1 Effect of c-erbB-2 Downregulation on Adriamycin Resistance
Long term toxicity assays for adriamycin showed that all four clonal populations and 
the pool population decreased resistance to adriamycin in long term assays. In contrast, 
all four clonal populations and the pool population displayed increased resistance to 
adriamycin in short term assays.
3.2.4.1.1 Long Term Adriamycin IC5o Toxicity assay
Cell Line IC50 Adriamycin 
(ng/ml; n=3)
BT474A 40.3 +/- 4.04 *
BT474A/ErbB2-Rz pool 16.1 +/-1.41
BT474A/ErbB2-Rzl 13.8+/- 0.11
BT474A/ErbB2-Rz3 11.0+/-0.76
BT474A/ErbB2-Rz4 17.3 +/- 0.28
BT474A/ErbB2-Rz5 14.3 +/- 0.75
* +/- standard deviation
Table 3.2.4.1.1a Results of long term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 0.40 0.0167
BT474A/ErbB2-Rzl 0.34 0.0079
BT474A/ErbB2-Rz3 0.27 0.0047
BT474A/ErbB2-Rz4 0.43 0.0094
BT474A/ErbB2-Rz5 0.35 0.0053
Table 3.2.4.1.1b Fold resistance to adriamycin in long term assays and significance of
change.
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3.2.4.1.2 Short Term Adriamycin IC50 Toxicity assay
Cell Line IC50 Adriamycin 
(ng/ml; n=3)
BT474A 104 +/- 4.58
BT474A/ErbB2-Rz pool 212+/-15.94
BT474A/ErbB2-Rzl 156+/-15.27
BT474A/ErbB2-Rz3 179+/- 13.79
BT474A/ErbB2-Rz4 276+/- 25.10
BT474A/ErbB2-Rz5 225 +/- 21 (n=2)
Table 3.2.4.1.2a Results of short term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 2.03 0.0113
BT474A/ErbB2-Rzl 1.50 0.0442
BT474A/ErbB2-Rz3 1.72 0.0190
BT474A/ErbB2-Rz4 2.65 0.0061
BT474A/ErbB2-Rz5 2.16 0.0681
Table 3.2.4.1.2b Fold resistance to adriamycin in short term assays and significance of 
change.
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3.2.4.2 Effect of c-erbB-2 Downregulation on Taxol Resistance
C-erbB-2 ribozyme transfection of BT474A resulted in an increase in resistance to taxol 
in both long and short term assays. Only BT474A/ErbB2-Rzl failed to show any 
increase in resistance in short term assays.
3.2.4.2.1 Long Term Taxol IC50 Toxicity assay
Cell Line IC50 Taxol 
(ng/ml; n=3)
BT474A 1.86+/- 0.05
BT474A/ErbB2-Rz pool 4.16+/- 0.20
BT474A/ErbB2-Rzl 4.13 +/- 0.05
BT474A/ErbB2-Rz3 8.8 +/- 0.70
BT474A/ErbB2-Rz4 5.93 +/- 0.32
BT474A/ErbB2-Rz5 7.10+/- 0.7
Table 3.2.4.2.1a Results of long term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 2.24 0.0014
BT474A/ErbB2-Rzl 2.22 0.0000
BT474A/ErbB2-Rz3 4.73 0.0009
BT474A/ErbB2-Rz4 3.19 0.0013
BT474A/ErbB2-Rz5 3.82 0.0058
Table 3.2.4.2.1b Fold resistance to taxol in long term assays and significance of change.
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3.2.4.2.2 Short Term Taxol IC50 Toxicity assay
Cell Line IC50 Taxol 
(ng/ml; n=3)
BT474A 15.6+/- 1.15
BT474A/ErbB2-Rz pool 21.2+/-3.21
BT474A/ErbB2-Rzl 14.6 +/- 0.57
BT474A/ErbB2-Rz3 24.3 +/- 2.30
BT474A/ErbB2-Rz4 58.6+/- 1.52
BT474A/ErbB2-Rz5 35.3+/- 1.15
Table 3.2.4.2.2a Results of short term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 1.35 0.0421
BT474A/ErbB2-Rzl 0.93 0.4226
BT474A/ErbB2-Rz3 1.55 0.0058
BT474A/ErbB2-Rz4 3.75 0.0001
BT474A/ErbB2-Rz5 2.26 0.0045
Table 3.2.4.2.2b Fold resistance to taxol in short term assays and significance of change.
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3.2.4.3 Effect of c-erbB-2 Downregulation on Carboplatin Resistance
Long term toxicity assays for carboplatin showed that only BT474A/ErbB2-Rz pool and 
BT474A/ErbB2-Rz3 had any statistically significant increased sensitivity to carboplatin 
(figure 3.2.4.3.1a). None of the other clonal populations displayed increased sensitivity 
in comparison to their parental cell line. In contrast, all four clonal populations and the 
pool population displayed increased resistance to carboplatin in short term assays, as 
shown in figure 3.2.4.3.2a.
3.2.4.3.1 Long Term Carboplatin IC50 Toxicity assay
Cell Line IC50 Carboplatin 
(M-g/ml; n=3)
BT474A 2.43+/- 0.20
BT474A/ErbB2-Rz pool 1.38+/- 0.10
BT474A/ErbB2-Rzl 2.20 +/- 0.05
BT474A/ErbB2-Rz3 1.93+/-0.35
BT474A/ErbB2-Rz4 2.13 +/- 0.25
BT474A/ErbB2-Rz5 2.53+/- 0.15
Table 3.2.4.3.1a Results of long term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 0.56 0.0268
BT474A/ErbB2-Rzl 0.90 0.1283
BT474A/ErbB2-Rz3 0.79 0.0377
BT474A/ErbB2-Rz4 0.87 0.1884
BT474A/ErbB2-Rz5 1.04 0.5779
Table 3.2.4.3.1b Fold resistance to carboplatin in long term assays and significance of
change.
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3.2.4.3.2 Short Term Carboplatin IC50 Toxicity assay
Cell Line IC50 Carboplatin 
(fag/ml; n=3)
BT474A 33.0 +/- 3.00
BT474A/ErbB2-Rz pool 78 +/- 4.35
BT474A/ErbB2-Rzl 34.6 +/- 0.57
BT474A/ErbB2-Rz3 58.3 +/-3.51
BT474A/ErbB2-Rz4 80.0+/-5.03
BT474A/ErbB2-Rz5 70 +/- 6.24
Table 3.2.4.3.2a Results of short term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 2.36 0.0050
BT474A/ErbB2-Rzl 1.05 0.4444
BT474A/ErbB2-Rz3 1.77 0.0212
BT474A/ErbB2-Rz4 2.42 0.0075
BT474A/ErbB2-Rz5 2.12 0.0175
Table 3.2.4.3.2b Fold resistance to carboplatin in short term assays and significance of 
change.
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3.2.4.4 Effect of c-erbB-2 Downregulation on 5-FIuorouracil Resistance
Long term toxicity assays for 5-fluorouracil showed that BT474A/ErbB2-Rz pool, 
BT474A/ErbB2-Rzl and BT474A/ErbB2-Rz3 were more resistant to 5-fluororacil in 
long term toxicity assays. In short term toxicity assays for 5-fluorouracil, while 
BT474A/ErbB2-Rz pool and BT474A/ErbB2-Rzl were less resistant to 5-fluorouracil, 
BT474A/ErbB2-Rz3 and BT474A/ErbB2-Rz4 were more resistant. BT474A/ErbB2- 
Rz5 was sensitised to 5-FU in short term assays.
3.2.4.4.1 Long Term 5-FU IC50 Toxicity assay
Cell Line IC50 5-Fluorouracil 
(fig/ml; n=3)
BT474A 0.091+/- 0.012
BT474A/ErbB2-Rz pool 0.123 +/- 0.005
BT474A/ErbB2-Rzl 0.196+/- 0.020
BT474A/ErbB2-Rz3 0.366 +/- 0.007
BT474A/ErbB2-Rz4 0.108+/-0.005
BT474A/ErbB2-Rz5 0.091 +/- 0.007
Table 3.2.4.4.1a Results of long term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 1.35 0.0188
BT474A/ErbB2-Rzl 2.15 0.0052
BT474A/ErbB2-Rz3 4.02 0.0001
BT474A/ErbB2-Rz4 1.19 0.0634
BT474A/ErbB2-Rz5 1.00 1.0000
Table 3.2.4.4.1b Fold resistance to 5-fluorouracil in long term assays and significance of
change.
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3.2.4.4.2 Short Term 5-FUIC50 Toxicity assay
Cell Line IC50 5-Fluorouracil 
(pg/ml; n=3)
BT474A 4.86+/- 0.63
BT474A/ErbB2-Rz pool 4.13 +/- 0.63
BT474A/ErbB2-Rzl 4.50 +/- 0.20 (n=2)
BT474A/ErbB2-Rz3 7.86+/-1.05
BT474A/ErbB2-Rz4 5.6 +/- 0.43
BT474A/ErbB2-Rz5 2.06 +/- 0.32
Table 3.2.4.4.1a Results of short term toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student t-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 0.84 0.1823
BT474A/ErbB2-Rzl 0.92 0.3607
BT474A/ErbB2-Rz3 1.61 0.0102
BT474A/ErbB2-Rz4 1.15 0.0258
BT474A/ErbB2-Rz5 0.42 0.0365
Table 3.2.4.4.1b Fold resistance to 5-fluorouracil in short term assays and significance 
of change.
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3.2.4.5 Effect of c-erbB-2 Downregulation on Methotrexate Resistance in Long
Term Toxicity Assay
Cell Line ICso Methotrexate 
(ng/ml; n=3 )
BT474A 9.66 +/- 1.76
BT474A/ErbB2-Rz pool > 20 (Not fully determined)
BT474A/ErbB2-Rz4 16.8+/- 1.15
BT474A/ErbB2-Rz5 > 20 (Not fully determined)
Table 3.2.4.5a Results of long term toxicity assays
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3.2.4. 6  Summary of Changes in resistance To Chemotherapeutic Agents in 
BT474A c-erbB-2 Ribozyme transfected variants.
The main findings of this section were that c-erbB-2 downregulation in BT474A 
increased resistance to taxol in both short and long term assays. Resistance to 
carboplatin was increased in short term assays only, while adriamycin resistance was 
increased in short term assays, but oppositely decreased in long term assays.
Type of Toxicity Assay BT474A/ BT474A/ BT474A/ BT474A/ BT474A/
Rz pool Rzl Rz3 R/4 Rz5
Adriamycin Long Term - - - - -
Adriamycin Short Term + + + + +
Taxol Long Term + + + + +
Taxol Short Term + 0 + + +
Carboplatin Long Term - 0 - 0 0
Carboplatin Short Term + 0 + + +
5-Fluorouracil Long Term + + + 0 0
5-Fluorouracil Short Term 0 0 + + *
Methotrexate Long Term + npf npf + +
+ increase in resistance
decrease in resistance 
o no change in resistance
npf not performed
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3.2.5 Investigation of Changes in MDR Associated Gene Expression in 
C-erbB-2 Ribozyme Transfected BT474A Breast Cancer Cells.
A panel of genes associated with drug resistance were examined at the mRNA level by 
RT-PCR to determine whether the changes in drug resistance observed in Section 3.2.4 
was due to alterations in classical modes of drug resistance.
3.2.5.1 MDR-1
Figure 3.2.5.1 shows that mdr-1 mRNA is not expressed in BT474A or any of its 
variants.
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Figure 3.2.5.1 Levels of mdr-1 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations. (PCR in Figure 3.3.8.1 was performed with the 
above at represents a positive control for mdr-1)
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3.2.S.2 MRP-1
Figure 3.2.5.2 shows that mrp-1 mRNA levels were not affected by c-erbB-2 expression 
in BT474A.
P-actin (383bp) 
mrp-1 (202bp)
Figure 3.2.5.2 Levels of mrpl mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of MRP-1 mRNA Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 94.8
BT474A/ErbB2-Rzl 113.0
BT474A/ErbB2-Rz3 111.5
BT474A/ErbB2-Rz4 84.7
BT474A/ErbB2-Rz5 99.9
Table 3.2.5.2 Levels o f mrp-1 mRNA expression.
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3.2.5.3 MRP-2
Figure 3.2.5.3 shows that mrp-2 mRNA levels increased in response to a reduction in c-
erbB-2 expression in BT474A.
Figure 3.2.5.3 Levels of mrp-2 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of MRP-2 mRNA Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 91.9
BT474A/ErbB2-Rzl 141.1
BT474A/ErbB2-Rz3 135.5
BT474A/ErbB2-Rz4 107.7
BT474A/ErbB2-Rz5 162.5
Table 3.2.5.3 Levels of mrp-2 mRNA expression.
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Figure 3.2.5.4 shows that mrp-4 mRNA is not expressed in BT474A or any of its 
variants.
3.2.5.4 MRP-4
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Figure 3.2.5.4 Levels of mrp-4 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
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3.2.5.5 MRP-5
Figure 3.2.5.5 shows that mrp-5 mRNA is expressed at very low levels in and was not
affected by c-erbB-2 expression in BT474A.
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Figure 3.2.5.5 Levels of mrp-5 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
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3.2.5.6 Topoisomerase I
Densitometry of figure 3.2.5.6 shows that topoisomerase I mRNA levels increased in
BT474A/ErbB2-Rzl, BT474A/ErbB2-Rz4 and BT474A/ErbB2-Rz5.
Figure 3.2.5.6 Levels of topisomerase I mRNA expression in BT474A c-erbB-2 
ribozyme transfected pool and clonal populations.
Cell Line Levels of Topoisomerase I mRNA 
Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 96
BT474A/ErbB2-Rzl 131
BT474A/ErbB2-Rz3 85
BT474A/ErbB2-Rz4 160
BT474A/ErbB2-Rz5 171
Table 3.2.5.6 Levels of topoisomerase I mRNA expression.
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3.2.5.7 Topoisomerase Hot
Figure 3 2 .5.1 shows that topoisomerase Ila  mRNA levels were reduced in
BT474A/ErbB2-Rz pooled population and in BT474A/ErbB2-Rz4 and BT474A/ErbB2-
Rz5.
P-actin (383 bpO 
Topo Ha (139 bp)
Figure 32.5.1 Levels of topoisomerase Ila  mRNA expression in BT474A c-erbB-2 
ribozyme transfected pool and clonal populations.
Cell Line Levels of Topoisomerase Ila  mRNA 
Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 86
BT474A/ErbB2-Rzl 121
BT474A/ErbB2-Rz3 121
BT474A/ErbB2-Rz4 76
BT474A/ErbB2-Rz5 70
Table 3.2.5.7 Levels of topoisomerase Ila  mRNA expression.
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3.2.5.8 Topoisomerase 11(3
Figure 3.2.5. 8  shows that topoisomerase lip mRNA levels were increased in
BT474A/ErbB2-Rz pooled population, and in BT474A/ErbB2-Rzl and
BT474A/ErbB2-Rz5.
p-actin (142bp) 
Topo Up (118bp)
Figure 3.2.5.8 Levels of topoisomerase II|3 mRNA expression in BT474A c-erbB-2 
ribozyme transfected pool and clonal populations.
Cell Line Levels of Topoisomerase 11 (3 mRNA 
Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 138
BT474A/ErbB2-Rzl 131
BT474A/ErbB2-Rz3 85
BT474A/ErbB2-Rz4 107
BT474A/ErbB2-Rz5 139
Table 3.2.5. 8  Levels of topoisomerase lip mRNA expression.
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3.2.5.9 Dihydrofolate reductase (DHFR)
Figure 3.2.5.9 shows that DHFR mRNA levels increased in response to a reduction in 
c-erbB-2 expression in BT474A in BT474A/ErbB2-Rz pool, BT474A/ErbB2-Rz3 and 
BT474A/ErbB2-Rz5. Levels were not increased in the two remaining clonal 
populations.
DHFR (221 bp) 
P-actin (142 bp)
Figure 3.2.5.9 Levels of DHFR mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of DHFR mRNA Expression (%)
BT474A 100
BT474A/ErbB2-Rz pool 116
BT474A/ErbB2-Rzl 88
BT474A/ErbB2-Rz3 160
BT474A/ErbB2-Rz4 109
BT474A/ErbB2-Rz5 157
Table 3.2.5.9 Levels of DHFR mRNA expression.
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3.2.5.10 Thymidylate Synthase (TS)
Taking into consideration P-actin level, figure 3.2.5.10 showed that TS mRNA levels 
increased in response to a reduction in c-erbB-2 expression in BT474A.
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Figure 3.2.5.10 Levels of TS mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of TS mRNA Expression (%)
BT474A ++
BT474A/ErbB2-Rz pool +++
BT474A/ErbB2-Rzl +++
BT474A/ErbB2-Rz3 +++
BT474A/ErbB2-Rz4 +++
BT474A/ErbB2-Rz5 +++
Table 3.2.5.10 Levels of TS mRNA expression.
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3.2.5.11 GSTrc
Figure 3.2.5.11 shows that GST71 mRNA levels increased in response to a reduction in
c-erbB-2 expression in BT474A.
<
£po
O
£
£
£-P
H
CC
HPO
r:CC
§<
r->
?
CC
C£N
00€i<
t*-
H00
T3Ceir‘:CO*££<
r-
H
CC
c
¡E
- GST 71 (270 bp)
- Non-specific band
- p-actin (142 bp)
Figure 3.2.5.11 Levels of GSTtt mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of GST n mRNA 
Expression (%)
Levels of Extra Band 
Expression (%)
BT474A + +
BT474A/ErbB2-Rz pool ++ +
BT474A/ErbB2-Rzl ++ +++
BT474A/ErbB2-Rz3 ++ ++
BT474A/ErbB2-Rz4 + +++
BT474A/ErbB2-Rz5 ++ ++
Table 3.2.5.11 Levels of GST71 mRNA expression.
190
3.1.5.12 Summary of Results of Gene Expression Studies in BT474A c-erbB-2 
Ribozyme Transfectants
No changes in the expression of drug resistance pumps at the mRNA level, were 
detected by RT-PCR, with the exception of mrp2 mRNA which was increased. This 
suggested that MDR-1, MRP-1, MRP4 and MRP5, do not play a role in c-erbB-2 
associated drug resistance of BT474A, while MRP2 may. The mRNA for 
topoisomerase isoforms I and lib were in general increased in the BT474A c-erbB-2 
ribozyme transfected variants. Thymidylate synthase, GSTtc and DHFR were also 
increased at the mRNA in response to c-erbB-2 downregulation.
RT-PCR BT474A/ 
Rz pool
BT474A/
Rzl
BT474A/
Rz3
BT474A/
Rz4
BT474A/
Rz5
Mdr-1 neg neg neg neg neg
Mrp-1 0 0 0 0 0
Mrp-2 0 + + o +
Mrp-4 neg neg neg neg neg
Mrp-5 o o 0 0 0
Topo I o + - + +
Topo Ila - + + - -
Topo lip + + - 0 +
DHFR + 0 + 0 +
TS + + + + +
GSTtt + + + 0 +
C-erbB-1 0 0 0 + 0
C-erbB-4 o 0 - 0 o
+ increase in expression
decrease in expression 
o no change in expression
neg Not expressed
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3.2.6 The Effect of c-erbB-2 Downregulation in BT474A on Resistance 
to Tamoxifen
C-erbB-2 downregulation in BT474A does not effect any major changes in resistance to 
tamoxifen.
Cell Line IC50 Tamoxifen 
(ng/ml; n=3)
BT474A 498 +/- 7.63
BT474A/ErbB2-Rz pool 433 +/- 20.2
BT474A/ErbB2-Rzl 471 +/-10.4
BT474A/ErbB2-Rz3 656 +/- 30.5
BT474A/ErbB2-Rz4 455 +/- 8.6
BT474A/ErbB2-Rz5 523 +/- 20.8
Table 3.2.6 Results of tamoxifen toxicity assays
Cell Line Fold Change in Resistance Significance -  Paired 
Student T-Test
BT474A 1.00 P =
BT474A/ErbB2-Rz pool 0.87 0.0246
BT474A/ErbB2-Rzl 0.95 0.0038
BT474A/ErbB2-Rz3 1.32 0.0073
BT474A/ErbB2-Rz4 0.91 0.0058
BT474A/ErbB2-Rz5 1.05 0.0820
Table 3.2.6 Fold resistance to tamoxifen in long term assays and significance of change.
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3.2.7 The Effect of c-erbB-2 Downregulation on Estrogen Receptor 
Expression
Expression estrogen receptors were examined by western blotting. No changes in the 
expression of estrogen receptor a  expression was detected, while estrogen receptor (3 
was found to be downregulated. Blots were stripped and reprobed for (3-actin.
3.2.7.1 Estrogen Receptor a
Estrogen receptor a  expression is unaffected by c-erbB-2 expression in BT474A.
"oo
*- ER a  (66 kDa)
*- Non-specific band
P-actin (44kDa)
Figure 3.2.7.la  Estrogen Receptor a  expression in BT474A
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3.2.7.2 Estrogen Receptor p
Estrogen receptor P expression is decreased with decreasing c-erbB-2 expression in 
BT474A. this is very similar to the observations in Section 3.1.7.2 where estrogen 
receptor p expression increased with increasing c-erbB-2 levels. It should also be noted 
that estrogen receptor p levels in the mutant ribozyme population are unaltered, 
indicating that the changes observed in the other populations are specific to the active 
ribozyme.
3
-'d-Hm
m  mr-
ERp bands 
(44-60 kDa)
P-actin (44kDa)
Figure 3.2.7.2 Estrogen Receptor p expression in BT474A
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3.2.8 The Effect of C-erbB-2 Downregulation on the mRNA Expression
c-erbB-1 and c-erbB-4 in BT474A
In order to determine whether c-erbB-2 had an effect on the expression of other ErbB 
family members, erbB levels were determined at both mRNA and protein levels 
(Section 3.2.9). The effect of c-erbB-2 upregulation in BT474A, on the expression of c- 
erbB-1 and c-erbB-4 mRNA levels was examined by RT-PCR
3.2.8.1 C-erbB-1 mRNA
Figure 3.2.8.1 shows that c-erbB-1 mRNA levels were unaffected by c-erbB-2 levels in 
BT474A.
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P-actin (383 bp) 
c-erbB-1 (190 bp)
Figure 3.2.8.1 Levels of c-erbB-1 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of C-erbB-1 mRNA Expression 
(%)
BT474A 100.0
BT474A/ErbB2-Rz pool 106.2
BT474A/ErbB2-Rzl 117.3
BT474A/ErbB2-Rz3 96.8
BT474A/ErbB2-Rz4 125.3
BT474A/ErbB2-Rz5 88.8
Table 3.2.8.1 Levels of c-erbB-1 mRNA expression.
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Figure 3.2.8.2 shows that c-erbB-4 mRNA levels were unaffected by c-erbB-2 levels in 
BT474A.
3.2.S.2 C-erbB-4 mRNA
P-actin (383 bp) 
C-erbB-4 (141 bp)
Figure 3.2.8.2 Levels of c-erbB-4 mRNA expression in BT474A c-erbB-2 ribozyme 
transfected pool and clonal populations.
Cell Line Levels of C-erbB-4mRNA Expression
(%)
BT474A 100
BT474A/ErbB2-Rz pool 94.5
BT474A/ErbB2-Rzl 86.2
BT474A/ErbB2-Rz3 76.6
BT474A/ErbB2-Rz4 109.7
BT474A/ErbB2-Rz5 106.9
Table 3.2.8.2 Levels of c-erbB-4 mRNA expression.
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3.2.9 Effect of C-erbB-2 Down regulation in BT474A on the Expression 
of Remaining ErbB Receptors at the Protein level.
No changes in the mRNA levels of c-erbB-1 or c-erbB-4 were detected in section 3.2.8. 
Protein levels of c-erbB-1, c-erbB-3 and c-erbB-4 were examined to determine whether 
ErbB protein levels had also remained unchanged.
3.2.9.1 C-erbB-1 protein
Figure 3.2.9.1 shows that c-erbB-1 protein expression is unaffected by c-erbB-2 
expression in BT474A. It should also be noted that c-erbB-1 protein levels in the mutant 
ribozyme population are unaltered.
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ß-actin (44 kDa)
Figure 3.2.9.1 C-erbB-1 protein expression in BT474A A control gel was run
for detection of p-actin protein, as p-actin was of too low a molecular weight to detect 
on ErbB gels. This is also the case in section 3.2.9.2
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3.2.9.2 C-erbB-3 protein
Figure 3.2.9.2 shows that c-erbB-3 protein expression decreased in BT474A/ErbB2- 
Rzl, BT474A/ErbB2-Rz4 and BT474A/ErbB2-Rz5 in response to decreasing c-erbB-2 
expression in BT474A. It should also be noted that c-erbB-3 protein levels in the mutant 
ribozyme population are unaltered.
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Figure 3.2.9.2 C-erbB-3 protein expression in BT474A
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3.2.10 The Effect of C-erbB-2 Down regulation on Motility of BT474A
Motility assays were performed as described in section 2.15 to investigate the effects of 
c-erbB-2 downregulation on the motility of BT474A. Surprisingly, similar to results for 
MCF-7 H3, neither the parental cell line nor the clonal populations were motile in this 
system. A sample photo of the parental cell line, figure 3.2.10a shows that the 
membrane contained little or no cells after 48 hours incubation. The clonal populations 
displayed identical results. The Positive (RPMI2650- Melphalan) and negative (RPMI 
2650) controls Figure 3.2.10b and 3.2.10c show that this assay was operational.
Figure 3.2.10a Motility assay for BT474A
Figure 3.2.10b RPMI Figure 3.2.10c RPMI Melphalan
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3.2.11 The Effect of OerbB-2 Down regulation on Invasion of Matrigel 
by BT474A
Invasion assays were performed as described in section 2.14 to investigate the effects of 
c-erbB-2 downregulation on the invasiveness of BT474A. C-erbB-2 downregulation 
was found to decrease the invasiveness of BT474A, with this reduction in invasiveness 
greatest in the four clonal populations. Figures 3.2.11.1 to 3.2.11.6 are representative of
3 repeats.
Figure 3,2.11a BT474A
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Figure 3.2.1 lc BT474A/ErbB2-Rzl
Figure 3.2.1 lb BT474A/ErbB2-Rz pool
Figure 3.2.l id  BT474A/ErbB2-Rz3
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Figure 3.2.1 le BT474A/ErbB2-Rz4 Figure 3.2.I l f  BT474A/ErbB2-Rz5
3.2.12 The Effect of C-erbB-2 Downregulation on Adhesive Properties 
of BT474A to Components of the Extracellular Matrix
Cells use various adhesion molecules such as integrins to interact with extracellular 
matrix components such as collagen type IV, laminin and fibronectin. To detect 
changes in the adhesive properties of BT474A due to downregulation of c-erbB-2, 
adhesion assay were performed as described in section 2.13.
Figure 3.2.12.1 shows the levels of adhesion of BT474A and its c-erbB-2 ribozyme 
transfected clones to laminin after 1 hour. All the clonal populations displayed reduced 
adhesion to laminin in comparison to the parental cell line.
Figure 3.2.12.2 shows the levels of adhesion of BT474A and its c-erbB-2 ribozyme 
transfected clones to collagen type IV after 1 hour. All the clonal populations and the 
pool population displayed decreased adhesion to collagen type IV compared to their 
parental cell line.
Figure 3.2.12.3 shows the levels of adhesion of BT474A and its c-erbB-2 ribozyme 
transfected clones to fibronectin after 1 hour. The pool population and all the clonal 
populations, with the exception of BT474A/ErbB2-Rz4 showed decreased adhesion to 
fibronectin compared to their parental cell line.
Figure 3.2.12.4 shows the levels of adhesion of BT474A and its c-erbB-2 ribozyme 
transfected clones to matrigel after 1 hour. All the clonal populations displayed reduced 
adhesion to matrigel in comparison to the parental cell line.
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3.2.12.1 Adhesion to Laminin.
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Figure 3.2.12.1 Levels of adhesion of BT474A and c-erbB-2 ribozyme transfected 
clones to laminin.
Cell Line Fold Changes in Cells Attached to 
Laminin After 1 hour
BT474A 1.00
BT474A/ErbB2-Rz pool 1.07
BT474A/ErbB2-Rzl 0.27
BT474A/ErbB2-Rz3 0.88
BT474A/ErbB2-Rz4 0.46
BT474A/ErbB2-Rz5 0.55
Table 3.2.12.1 Fold changes in adhesion to laminin relative to the parental cell line 
BT474A.
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3.2.12.2 Adhesion to Collagen Type IV
Adhesion of BT474A Variants to Collagen Type IV
+
I  BT474A Rz pool Rz1 Rz3 Rz4 Rz5
Figure 3.2.12.2 Levels of adhesion of BT474A and c-erbB-2 ribozyme transfected 
clones to collagen type IV.
Cell Line Fold Changes in Cells Attached to 
Collagen Type IV After 1 hour
BT474A 1.00
BT474A/ErbB2-Rz pool 0.55
BT474A/ErbB2-Rzl 0.26
BT474A/ErbB2-Rz3 0.61
BT474A/ErbB2-Rz4 0.55
BT474A/ErbB2-Rz5 0.35
Table 3.2.12.2 Fold changes in adhesion to collagen type IV relative to the parental cell 
line BT474A.
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3.2.12.3 Adhesion to Fibronectin
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Figure 3.2.12.3 Levels of adhesion of BT474A and c-erbB-2 ribozyme transfected 
clones to fibronectin.
Cell Line Fold Changes in Cells Attached to 
Fibronectin After 1 hour
BT474A 1.00
BT474A/ErbB2-Rz pool 0.49
BT474A/ErbB2-Rzl 0.59
BT474A/ErbB2-Rz3 0.65
BT474A/ErbB2-Rz4 1.03
BT474A/ErbB2-Rz5 0.39
Table 3.2.12.3 Fold changes in adhesion to fibronectin relative to the parental cell line 
BT474A.
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3.2.12.4 Adhesion to Matrigel
Adhesion of BT474A Variants to Matrigel
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Figure 3.2.12.4 Levels of adhesion of BT474A and c-erbB-2 ribozyme transfected 
clones to matrigel.
Cell Line Fold Changes in Cells Attached to 
Matrigel After 1 hour
BT474A 1.00
BT474A/ErbB2-Rz pool 0.92
BT474A/ErbB2-Rzl 0.53
BT474A/ErbB2-Rz3 0.73
BT474A/ErbB2-Rz4 0.35
BT474A/ErbB2-Rz5 0.34
Table 3.2.12.4 Fold changes in adhesion to matrigel relative to the parental cell line 
BT474A.
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3.2.12.5 Summary of Adhesion results
Adhesive Values of BT474A c-erbB-2 Ribozyme 
Transfected Clones
BT474A BT474A/RZ
pool
BT474A/Rz1 BT474A/Rz3 BT474A/Rz4 BT474A/Rz5
■  Laminin
■  Fibronectin
□  Collagen IV
□  Matrigel
Figure 3.2.12.5 Adhesion of BT474A c-erbB-2 ribozyme transfectants to ECM proteins.
Laminin Fibronectin Collagen 
Type IV
Matrigel
BT474A 1.00 1.00 1.00 1.00
BT474A/ErbB2-Rz pool 1.07 0.49 0.55 0.92
BT474A/ErbB2-Rzl 0.27 0.59 0.26 0.53
BT474A/ErbB2-Rz3 0.88 0.65 0.61 0.73
BT474A/ErbB2-Rz4 0.46 1.03 0.55 0.35
BT474A/ErbB2-Rz5 0.55 0.39 0.35 0.34
Table 3.1.13.5 Fold decrease in adhesion of BT474A c-erbB-2 ribozyme transfected 
variants to ECM proteins relative to parental cell lines BT474A.
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3.2.13 The Effect of C-erbB-2 Downregulation on Secretion of 
Proteases by BT474A
Matrix metalloproteinases (MMPs), cysteine proteases and serine protease, which are 
secreted by cells, play an important role in degrading the extracellular matrix. To 
further investigate the mechanisms by which c-erbB-2 exerts an influence of the 
invasiveness of BT474A, zymography was performed to detect the secretion of 
proteases in these cells, as described in section 2.16.
3.2.13.1 Detection of the Expression of Proteases Secreted by BT474A and its C- 
erbB-2 Ribozyme Transfected Variants
BHK (baby hamster kidney) cell line, which secretes MMP-2 and MMP-9, was used as 
the positive control in these studies.
130 kDa 
84 kDa
45 kDa
29 kDa 
22 kDa
Figure 3.2.13.1 Zymogram of gelatin proteases secreted by BT474A with BHK 
as a positive control for the secretion of pro-MMP2 (72 kDa), MMP-2 (66kDa), pro- 
MMP-9 (92kDa) and MMP9 (86kDa). The BT474A parent cell line and its c-erbB-2 
ribozyme transfected variants display secretion bands corresponding to pro-MMP-2,
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pro-MMP-9 and MMP-9. There is also an additional band expressed appearing just 
above MMP-9.
3.2.13.2 Identification of the Classes of Proteases Secreted by BT474A and its C- 
erbB-2 Ribozyme Transfected Variants
To investigate the identity of the gelatin degrading proteases secreted by BT474A and 
its c-erbB-2 ribozyme transfected variants, protease inhibitors were used. EDTA is a 
chelating agent, which can bind zinc and calcium ions, which are needed for the 
activation of MMPs. PMSF is a serine and cysteine protease inhibitor.
Figure 3.2.13.2b shows that addition of EDTA to the substrate buffer eliminates 
expression of all protease bands, indicating the gelatin degrading proteases secreted by 
BT474A parent and c-erbB-2 ribozyme transfected variants are members of the 
matrixmetalloproteinase family.
Figure 3.2.13.2b also shows that addition of PMSF to the substrate buffer suppresses 
slightly the expression of all protease bands, but does not eliminate them, suggesting the 
proteases are not serine proteases. Perhaps though there are serine proteases secreted by 
the cells that are involved in MMP action/stabilisation.
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3.3 Establishment of novel MDR variants of the MDA-MB-435S-F cell 
line
MDA-MB-435S is a spindle shaped strain which evolved from the parent line MDA- 
MB-435 isolated by Cailleau et al (1976), from the pleural effusion of a 31 year old 
female with metastatic, ductal adenocarcinoma of the breast. Clonal populations were 
established by clonal dilution, entitled MDA-MB-435S-A, MDA-MB-435S-B, MDA- 
MB-435S-C, MDA-MB-435S-D, MDA-MB-435S-E and MDA-MB-435S-F. It was 
desired to select with a clonal population so that any emergence of drug resistance 
would be due to adaptation of the cells to the selecting drug and not due to selection of a 
resistant subpopulation already present within the cell line. The clonal population 
MDA-MB-435S-F was chosen to establish MDR-variants, due to its low-level c-erbB-2 
mRNA expression (figure 3.3). This would allow us to examine whether c-erbB-2 
induction would play a role in taxol or adriamycin resistance. An attempt was also 
made to transfect MDA-MB-435S-F with c-erbB-2, but was not successful. Hs578T is 
also a breast cancer cell line, and was included in an initial screen of breast cell lines for 
levels of c-erbB-2 expression.
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Figure 3.3 Expression of c-erbB-2 mRNA in Hs578T, BT474, BT474A, MDA-MB- 
435S and MDA-MB-435S-F.
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3.3.1 Establishment of MDA-MB-435S-F taxol resistant variants
The MDA-MB-435S-F cells were exposed to the IC90 value of 15ng/ml taxol for four 
hours, once a week for 10 weeks. The cell line resulting from this exposure was 
designated MDA-MB-435S-F/Taxol-10p. This cell line displayed a 9.15-fold increase 
in resistance to taxol.
It was decided to attempt to further increase the resistance of this cell line to taxol. An 
IC90 assay was carried out to establish the IC90 value of MDA-MB-435S-F/Taxol-10p. 
This value was found to be 125ng/ml. MDA-MB-435S-F/Taxol-10p cells were then 
exposed to 125ng/ml taxol for four hours, once a week for 4 weeks. The cell line 
resulting from this exposure was designated MDA-MB-435S-F/Taxol-10p4p. This cell 
line displayed a 31.8 5-fold increase in resistance to taxol.
3.3.2 Establishment of MDA-MB-435S-F adriamycin resistant variants
The MDA-MB-435S-F cells were exposed to the IC90 value of 120ng/ml adriamycin for 
four hours, once a week for 10 weeks. The cell line resulting from this exposure was 
designated MDA-MB-435S-F/Adr-10p. This cell line displayed a 1.16-fold increase in 
resistance to adriamycin.
It was decided to attempt to further increase the resistance of this cell line to 
adriamycin. An IC90 assay was carried out to establish the IC90 value of MDA-MB- 
435S-F/Adr-10p, which was 200ng/ml. One flask of MDA-MB-435S-F/Adr-10p cells 
was then exposed to 2 0 0 ng/ml adriamycin for four hours, once a week for 1 0  weeks. 
The cell line resulting from this exposure was designated MDA-MB-435S-F/Adr- 
lOplOp. This cell line displayed a 1.40-fold increase in resistance to adriamycin.
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3.3.3 Morphology of MDR variants of the MDA-MB-435S-F
The morphology of MDA-MB-435S-F was found not to have changed dramatically 
during the selection procedure with either adriamycin or taxol. The one observation 
made was that the adriamycin and taxol selected variants appeared not to observe cell­
cell contact inhibition to the same extent as MDA-MB-435S-F. The cells in all four 
variants appeared to have gained the ability to overcome monolayer growth, to grow on 
top of each other. Also if cells floating in the media were removed, and placed in a new 
flask, they would reattach and grow.
Figure 3.3.3b MDA-F/Taxol-10p
Figure 3.3.3d MDA-F/Adr-10p
Figure 3.3.3a MDA-MB-435S-F
Figure 3.3.3c MDA-F/Taxol-10p4p
Figure 3.3.3e MDA-F/Adr-10pl0p
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3.3.4 Cross resistance profiles of MDA-MB-435S-F MDR variants
When cell lines are repeatedly exposed to chemotherapeutic drug, not only do the cells 
develop resistance to the drug in question, but they also can develop a cross-resistance 
to a variety of other chemotherapeutic drugs.
To investigate this phenomenon, the resistance profiles to a variety of drugs were tested 
in the MDA-MB-435S-F MDR variants, by short term toxicity assay. These drugs 
included taxol, adriamycin, carboplatin, VP-16, taxotere, vincristine and 5 -fluorouracil. 
Long term toxicity assays were also performed for adriamycin and taxol.
Table 3.3.4.1a represents the IC50 values of each of the chemotherapeutic agents for the 
parental MDA-MB-435S-F cell line and its taxol selected variant MDA-MB-435S- 
F/Taxol-lOp. MDA-MB-435S-F/Taxol-10p was generated from MDA-MB-435S-F, by 
ten pulses with 15ng/ml taxol. The results demonstrate that the taxol-resistant variant 
exhibited cross resistance to taxol, taxotere, vincristine and carboplatin. Adriamycin 
and VP-16 resistance were unchanged in MDA-MB-435S-F/Taxol-10p, while the cell 
line was sensitised to 5-Fluorouracil.
Table 3.3.4.2a represents the IC50 values of each of the chemotherapeutic agents for the 
parental MDA-MB-435S-F cell line and its taxol selected variant MDA-MB-435S- 
F/Taxol-10p4p. MDA-MB-435S-F/Taxol-10p4p was generated from MDA-MB-435S- 
F/Taxol-lOp, by an additional four pulses with 125ng/ml taxol. The results demonstrate 
that MDA-MB-435S-F/Taxol-10p4p exhibited cross resistance to taxol, taxotere, and 
vincristine as was the case with MDA-MB-435S-F/Taxol-10p, but to a greater extent. 
This pattern of resistance might suggest a microtubule, rather than an efflux pump, 
associated mechanism of resistance. It was, however, no longer resistant to carboplatin 
or sensitised to 5-fluorouracil. Again VP-16 resistance was unchanged in MDA-MB- 
435S-F/Taxol-10p4p, while the cell line was now resistant to adriamycin.
Table 3.3.4.3a represents the IC50 values of each of the chemotherapeutic agents for the 
parental MDA-MB-435S-F cell line and its adriamycin selected variant MDA-MB- 
435S-F/Adr-10p. MDA-MB-435S-F/Adr-10p was generated from MDA-MB-435S-F, 
by ten pulses with 120ng/ml adriamycin. The results demonstrate that adriamycin 
resistance of MDA-MB-435S-F/Adr-10p was not significantly increased in comparison
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to the parental cell line, despite the fact that high cell Mil was observed during selection 
with adriamycin. However MDA-MB-435S-F/Adr-10p was resistance to VP-16 and 
sensitised to 5-fluorouracil, vincristine and taxol. No change in resistance to carboplatin 
or taxotere was observed.
Table 3.3.4.4a represents the IC50 values of each of the chemotherapeutic agents for the 
parental MDA-MB-435S-F cell line and its adriamycin selected variant MDA-MB- 
435S-F/Adr-10pl0p. MDA-MB-435S-F/Adr-10pl0p was generated from MDA-MB- 
435S-F/Adr-10p, by an additional ten pulses with 200ng/ml adriamycin. This additional 
ten pulse did generate an adriamycin resistant variant of MDA-MB-435S-F, although 
the increase was not large. The results demonstrate that MDA-MB-435S-F/Adr-10pl0p 
exhibited cross resistance to taxotere, vincristine and VP-16, was sensitised to taxol, 
carboplatin and 5-fluorouracil.
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3.3.4.1 Cross resistance profile of MDA-MB-435S-F/Taxol-10p in Short Term
Toxicity Assays
IC50
(n=3)
MDA-MB-435S-F MDA-MB-435S-F/
Taxol-lOp
Adriamycin (ng/ml) 271 ±3 242 ±21
Taxol (ng/ml) 28.3 + 1.52 259 ±3**
Carboplatin (|ig/ml) 41.3 ±1.5 54.3 ±5.1*
Taxotere (ng/ml) 3.33 ±0.37 12.23 ±0.37 **
VP-16 (ng/ml) 1844 ±77 2225 ± 152
5-fluorouracil (|ig/ml) 7.43 ± 0.68 3.50 ± 0.17**
Vincristine (ng/ml) 12.9 ± 1.3 74.6 ±0.5**
** p <  0.005 
* p < 0.05
Table 3.3.4.1 .a IC50 values for MDA-MB-435S-F and MDA-MB-435S-F/Taxol- 
lOp.
Drug Fold resistance Student t-test ( p = )
Adriamycin 0.89 0.1320
Taxol 9.15 0.00006
Carboplatin 1.31 0.0301
Taxotere 3.67 0.0015
VP-16 1.20 0.0998
5-fluorouracil 0.47 0.0074
Vincristine 5.78
Table 3.3.4.l.b Fold resistance of MDA-MB-435S-F/Taxol-10p to MDA-MB- 
435S-F.
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3.3.4.2 Cross resistance profile of MDA-MB-435S-F/Taxol-10p4p in Short Term
Toxicity Assays
IC50
(n=3)
MDA-MB-435S-F MDA-MB-435S-F/
Taxol-10p4p
Adriamycin (ng/ml) 271+3 456 + 20**
Taxol (ng/ml) 28.3 + 1.52 900 + 40**
Carboplatin (|j,g/ml) 41.3 + 1.5 33 + 3.4
Taxotere (ng/ml) 3.33 + 0.37 62.4 + 1.3**
VP-16 (ng/ml) 1844 + 77 1740+ 17
5-fluorouracil (|xg/ml) 7.43 + 0.68 6.83 + 0.60
Vincristine (ng/ml) 12.9+1.3 176 + 56**
** p < 0.005
Table 3.3.4.2.a IC50 values for MDA-MB-435S-F and MDA-MB-435S-F/Taxol-
10p4p.
Drug Fold resistance Student t-test ( p = )
Adriamycin 1 . 6 8 0.0039
Taxol 31.80 0.0007
Carboplatin 0.79 0.0544
Taxotere 18.73 . 0 0 0 2
VP-16 0.94 0.1827
5-fluorouracil 0.91 0.1884
Vincristine 13.64
Table 3.3.4.2.b Fold resistance of MDA-MB-435S-F/Taxol-10p4p to MDA-MB- 
435S-F.
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3.3.4.3 Cross resistance profile of MDA-MB-435S-F/Adr-10p in Short Term
Toxicity Assays
IC500
(n=3)
MDA-MB-435S-F MDA-MB-435S-F/
Adr-lOp
Adriamycin 271 ±3 316 ± 15
Taxol 28.3 ± 1.52 20.3 ± 2.1*
Carboplatin 41.3 + 1.5 37.6 ± 1.15
Taxotere 3.33 ±0.37 3.76 ±0.20
VP-16 1844 ±77 2663 ± 148**
5-fluorouracil 7.43 ± 0.68 3.36 ±0.40*
Vincristine 12.9 ± 1.3 6.9 ±0.69**
** p<  0.005 
* p < 0.05
Table 3.3.4.3.a IC50 values for MDA-MB-435S-F and MDA-MB-435S-F/Adr-
Drug Fold resistance Student t-test ( p = )
Adriamycin 1.16 0.0288
Taxol 0.71 0.0056
Carboplatin 0.91 0.0571
Taxotere 1 . 1 2 0.1333
VP-16 1.44 0.0031
5-fluorouracil 0.45 0.0226
Vincristine 0.53
Table 3.3.4.3.b Fold resistance of MDA-MB-435S-F/Adr-10p to MDA-MB- 
435S-F.
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3.3.4.4 Cross resistance profile of MDA-MB-435S-F/Adr-10pl0p in Short Term
Toxicity Assays
IC50
(n=3)
MDA-MB-435S-F MDA-MB-435S-F/
Adr-10pl0p
Adriamycin 271 ±3 381 ± 11.54**
Taxol 28.3 ±1.52 17.6 ±0.2*
Carboplatin 41.3 ±1.5 24.6 ± 1.52*
Taxotere 3.33 ±0.37 4.76 ±0.152*
VP-16 1844 ±77 3785 ±79**
5-fluorouracil 7.43 ± 0.68 3.43 ±0.05*
Vincristine 12.9 ± 1.3 32.1 ±2.5 (n=2)**
* *  p  <  0 . 0 0 5  
*  p < 0 . 0 5
Table 3.3.4.4.a IC50 values for MDA-MB-435S-F and MDA-MB-435S-F/ Adr- 
lOplOp.
Drug Fold resistance Student t-test ( p = )
Adriamycin 1.40 0.0038
Taxol 0.62 0.0079
Carboplatin 0.59 0.0098
Taxotere 1.42 0.0269
VP-16 2.05 0.00002
5-fluorouracil 0.46 0.0106
Vincristine 1.61
Table 3.3.4.4.b Fold resistance of MDA-MB-435S-F/Adr-10pl0p to MDA-MB- 
435S-F.
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3.3.4.5 Summary of Short Term Resistance Profiles of MDA-MB-435S-F MDR
Variants
Table 3.3.4.5 summarises the results of short term toxicity testing of the MDA-MB- 
435S-F taxol and adriamycin selected variants.
Cell Line MDA-MB-
435S-F
MDA-MB-
435S-F/
Taxol-lOp
MDA-MB-
435S-F/
Taxol-
10p4p
MDA-MB-
435S-F/
Adr-lOp
MDA-MB-
435S-F/
Adr-
lOplOp
Adriamycin 1.00 0.89 1.68 1.16 1.40
Taxol 1.00 9.15 31.80 0.71 0.62
Carboplatin 1.00 1.31 0.79 0.91 0.59
Taxotere 1.00 3.67 18.73 1.12 1.42
VP-16 1.00 1.20 0.94 1.44 2.05
5-fluorouracil 1.00 0.47 0.91 0.45 0.46
Vincristine 1.00 5.78 13.64 0.53 1.61
Table 3.3.4.5 Summary of fold changes in resistance of MDA-MB-435S-F MDR 
variants
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3.3.4.6 Long Term Toxicity Profiles for Adriamycin and Taxol
Long term toxicity assays also show that MDA-MB-435S-F failed to develop resistance 
to adriamycin, while developing resistance to taxol in long term assays.
Cell Line IC50 Taxol Long Term 
(ng/ml; n=3)
IC50 Adriamycin Long Term 
(ng/ml; n=3)
MDA-MB-435S-F 2.12 ± 0.057 26.6 ± 1.95
MDA-MB-435S-F/ 
Taxol-1 Op
5.76 ±0.251 30.6 ±3.21
MDA-MB-435S-F/ 
Taxol-10p4p
9.63 ± 0.152 37.0 ± 2.64
MDA-MB-435S-F/
Adr-10p
3.16 ±0.057 22.6 ± 1.52
MDA-MB-435S-F
/Adr-10pl0p
2.16 ± 0.208 20.2 ± 0.91
Table 3.3.4.6 IC50 values for MDA-MB-435S-F taxol and adriamycin selected variants 
in long term toxicity assays.
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3.3.5 Adriamycin Accumulation in MDA-MB-435S-F MDR Variants
Adriamycin accumulation and efflux was examined in MDA-MB-435S-F and its taxol 
and adriamycin selected variants. In brief, as described in Section 2.11, cells were grown 
for 48 hours, after which time medium was removed and fresh medium containing 
adriamycin (10|uM) was added. After a two-hour incubation, the media was removed from 
all flasks, and half the flasks were replaced with fresh media and returned to the 37°C 
incubator. Cells were collected from the remaining flasks by trypsinisation and adriamycin 
accumulation quantified. After a four-hour incubation, media was removed and cells 
collected by trypsinisation and adriamycin remaining in cells quantified. Efflux was 
calculated as the % of adriamycin effluxed during the four hour incubation.
Adriamycin Accumulation in MDA-MB-435S-F 
MDR Variants
2500
MDA-MB- MDA-MB- MDA-MB- MDA-MB- MDA-MB-
435S-F 435S-F/Taxol- 435S-F/Taxol- 435S-F/Adr- 435S-F/Adr-
lOp 10p4p lOp lOplOp
Figure 3.3.5 Adriamycin Accumulation in MDA-MB-435S-F MDR variants.
Table 3.3.5a describes the amount of adriamycin accumulated by MDA-MB-435S- 
F/Taxol-lOp, MDA-MB-435S-F/Taxol-10p4p, MDA-MB-435S-F/Adr-10p and MDA- 
MB-435S-F/Adr-10pl0p, as a % of that accumulated by the parental cell line MDA- 
MB-435S-F. Adriamycin uptake in MDA-MB-435S-F/Taxol-10p was less than that of 
the parent, while MDA-MB-435S-F/Taxol-10p4p and MDA-MB-435S-F/Adr-10p
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accumulated more adriamycin than MDA-MB-435S-F. MDA-MB-435S-F/Adr-10pl0p 
was similar to the parent.
Cell Line % Adriamycin Influx relative to Parent
MDA-MB-435S-F 100.00
MDA-MB-435S-F/T axol-1 Op 81.45
MDA-MB-43 5 S-F/Taxol-10p4p 110.78
MDA-MB-435S-F/Adr-10p 128.41
MDA-MB-43 5 S-F/Adr-1 Opl Op 97.06
Table 3.3.5a % Adriamycin accumulated after 2 hour adriamycin exposure.
Table 3.3.5b describes the amount of adriamycin effluxed by MDA-MB-435S-F, MDA- 
MB-435S-F/Taxol-1 Op, MDA-MB-435S-F/Taxol-10p4p, MDA-MB-43 5S-F/Adr-1 Op 
and MDA-MB-43 5 S-F/Adr-1 Op 1 Op. All the selected variants exhibited greater efflux 
than the parent cell line. Adriamycin efflux was greater in MDA-MB-435S-F/Taxol- 
10p4p than in MDA-MB-435S-F/Taxol-10p, which corresponds to their adriamycin 
resistance profiles, as described in Section 3.3.4.5. Adriamycin efflux was similar in 
MD A-MB -43 5 S -F / Adr-1 Op and MDA-MB-435S-F/Adr-10pl0p.
Cell Line % Adriamycin Effluxed after 4 hours
MD A-MB -43 5 S -F 11.0
MDA-MB-43 5 S-F/Taxol-1 Op 23.1
MDA-MB-43 5 S -F/T axol-10p4p 55.4
MDA-MB-435S-F/Adr-1 Op 40.6
MDA-MB-43 5 S-F/Adr-1 Op 1 Op 38.6
Table 3.3.5b % Adriamycin effluxed 4 hours post adriamycin removal from media.
Figure 3.3.5 shows that that the final adriamycin content is least in MDA-MB-435S- 
F/Taxol-10p4p followed by MDA-MB-43 5 S-F/Adr-1 Op 1 Op, which corresponds 
somewhat to their adriamycin resistance profiles, as described in Section 3.3.4.5.
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3.3.6 Circumvention of Adriamycin Resistance by Verapamil and
Sulindac in MDA-MB-435S-F MDR Variants
As described in section 3.3.5 all the MDR variants of MDA-MB-435S-F display 
increased adriamycin efflux. Despite this increase in adriamycin efflux, which one 
would assume would confer resistance to adriamycin, Table 3.3.4.5 shows that only 
MDA-MB-435S-F/Taxol-10p4p and MDA-MB-435S-F/Adr-10pl0p display any 
increase in adriamycin resistance. To further investigate mechanisms of increased 
adriamycin efflux, combination assays were performed with adriamycin and either 
sulindac or verapamil. Sulindac circumvents MRP mediated adriamycin drug 
resistance, while verapamil is a modulator of MDR-1 mediated drug resistance, and to a 
lesser extent MRP. It was desired to see whether verapamil or sulindac could 
circumvent adriamycin resistance in MDA-MB-435S-F and its MDR variants.
Verapamil and sulindac were found to enhance adriamycin resistance in MDA-MB- 
435S-F and all its MDR variants. Sulindac was more potent than verapamil in the 
parental cell line MDA-MB-435S-F. The reverse was true for MDA-MB-435S- 
F/Taxol-lOp, MDA-MB-435S-F/Taxol-10p4p, MDA-MB-435S-F/Adr-10p and MDA- 
MB-435S-F/Adr-10pl0p. This would suggest that the role of MRP in the adriamycin 
resistance of MD A-MB-43 5 S-F is declining while MDR-1 is emerging to play a greater 
role.
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3.3.6.1 Adriamycin and Verapamil in MDA-MB-435S-F
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 98.49 1.204
V erapam i 1 ( 10(.ig/m 1 ) 100.98 0.370
Adriamycin ( 1 Ong/ml) + 
Verapamil (10|u,g/ml)
45.37 4.769
Verapamil (20^g/ml) 99.86 0.540
Adriamycin (1 Ong/ml) + 
Verapamil (20p,g/ml)
20.08 3.760
Verapamil (30|j.g/ml) 99.20 2.875
Adriamycin (1 Ong/ml) + 
Verapamil (30|iig/ml)
9.45 0.995
Table 3.3.6.1 Adriamycin and verapamil combination assays in MDA-MB-435S-F
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3.3.6.2 Adriamycin and Sulindac m MPA-MB-435S-F
Average % Cell Survival 
(n=3)
Standard Déviation
Control 100.00 0.000
Adriamycin (1 Ong/ml) 96.22 4.205
Sulindac (3fj.g/ml) 99.81 2.110
Adriamycin (1 Ong/ml) + 
Sulindac (3|ag/ml)
39.87 4.492
Sulindac (6p,g/ml) 98.08 2.214
Adriamycin (1 Ong/ml) + 
Sulindac (ô^ig/ml)
7.51 0.685
Sulindac (12|a.g/ml) 99.59 3.129
Adriamycin (1 Ong/ml) + 
Sulindac (12|j.g/ml)
3.11 0.358
Table 3.3.6.2 Adriamycin and sulindac combination assays in MDA-MB-435S-F
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3.3.6.3 Adriamycin and Verapamil in MDA-MB-435S-F/Taxol-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 100.49 2.642
Verapamil (10jj.g/ml) 99.01 0.416
Adriamycin (10ng/ml) + 
Verapamil (10ng/ml)
90.50 2.266
Verapamil (20|ig/ml) 98.78 2.091
Adriamycin (10ng/ml) + 
Verapamil (20|4.g/ml)
61.06 3.258
Verapamil (30jj.g/ml) 98.01 0.815
Adriamycin (10ng/ml) + 
Verapamil (30|ig/ml)
36.48 3.910
Table 3.3.6.3 Adriamycin and verapamil combination assays in MDA-MB-435S- 
F/Taxol-10p
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3.3.6.4 Adriamycin and Sulindac in MDA-MB-435S-F/Taxol-10p
Average % Cell Survival 
(n=3)
Standard Déviation
Control 100.00 0.000
Adriamycin (1 Ong/ml) 98.27 0.822
Sulindac (3|ag/ml) 98.34 1.282
Adriamycin (1 Ong/ml) + 
Sulindac (3|ig/ml)
98.00 1.367
Sulindac (6|ig/ml) 97.44 3.021
Adriamycin (1 Ong/ml) + 
Sulindac (6)a.g/ml)
90.67 2.078
Sulindac (12|ag/ml) 98.82 3.233
Adriamycin (1 Ong/ml) + 
Sulindac (12[ig/ml)
74.35 1.864
Table 3.3.6.4 Adriamycin and sulindac combination assays in MDA-MB-435S-F/Taxol-
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3.3.6.5 Adriamycin and Verapamil in MDA-MB-435S-F/Taxol-10p4p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 99.50 2.244
Verapamil ( 10(o,g/ml) 99.73 1.846
Adriamycin (10ng/ml) + 
Verapamil (lOfig/ml)
14.35 2.352
Verapamil (20fig/ml) 98.77 4.124
Adriamycin (10ng/ml) + 
Verapamil (20|ig/ml)
4.50 2.313
Verapamil (30|ig/ml) 99.98 0.363
Adriamycin (10ng/ml) + 
Verapamil (30|o.g/ml)
2.72 2.165
Table 3.3.6.5 Adriamycin and verapamil combination assays in MDA-MB-435S- 
F/Taxol-10p4p
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3.3.6.6 Adriamycin and Sulindac in MDA-MB-435S-F/TaxoI-10p4p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 91.31 3.596
Sulindac (3ja,g/ml) 98.98 1.842
Adriamycin (10ng/ml) + 
Sulindac (3|_ig/ml)
46.30 2.272
Sulindac (6|j,g/ml) 98.97 1.609
Adriamycin (10ng/ml) + 
Sulindac (6|ig/ml)
18.11 3.310
Sulindac (12|ig/ml) 99.93 2.112
Adriamycin (10ng/ml) + 
Sulindac (12|o,g/ml)
13.26 1.602
Table 3.3.6.6 Adriamycin and sulindac combination assays in MDA-MB-435S-F/Taxol- 
10p4p
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3.3.6.7 Adriamycin and Verapamil in MDA-MB-435S-F/Adr-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 78.38 4.616
Verapamil (10fxg/ml) 102.00 4.668
Adriamycin (10ng/ml) + 
Verapamil (10|J.g/ml)
16.54 1.313
Verapamil (20f.ig/ml) 101.45 5.689
Adriamycin (10ng/ml) + 
Verapamil (20|j,g/ml)
6.55 1.273
Verapamil (30|j,g/ml) 102.51 5.337
Adriamycin (10ng/ml) + 
Verapamil (30}.ig/ml)
4.41 0.468
Table 3.3.6.7 Adriamycin and verapamil combination assays in MDA-MB-435S-F/Adr-
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3.3.6.8 Adriamycin and Sulindac in MDA-MB-435S-F/Adr-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 81.14 7.074
Sulindac (3|o.g/ml) 96.50 2.731
Adriamycin (10ng/ml) + 
Sulindac (3|ig/ml)
33.59 12.181
Sulindac (6[ig/ml) 98.86 2.203
Adriamycin (10ng/ml) + 
Sulindac (6(a,g/ml)
13.48 3.816
Sulindac (12jxg/ml) 96.89 2.030
Adriamycin (10ng/ml) + 
Sulindac (12|xg/ml)
3.42 1.261
Table 3.3.6.8 Adriamycin and sulindac combination assays in MDA-MB-435S-F/Adr- 
lOp
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3.3.6.9 Adriamycin and Verapamil in MDA-MB-435S-F/Adr-10pl0p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 100.63 1.000
Verapamil (10|j,g/ml) 101.51 2.469
Adriamycin (10ng/ml) + 
Verapamil ( 10|u,g/ml)
82.57 7.926
Verapamil (20|j,g/ml) 98.07 8.143
Adriamycin (10ng/ml) + 
Verapamil (20fxg/ml)
38.41 8.165
Verapamil (30jj,g/ml) 100.39 1.822
Adriamycin (10ng/ml) + 
Verapamil (30|ng/ml)
21.16 2.147
Table 3.3.6.9 Adriamycin and verapamil combination assays in MDA-MB-435S-F/Adr- 
lOplOp
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3.3.6.10 Adriamycin and Sulindac in MDA-MB-435S-F/Adr-10pl0p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.000
Adriamycin (10ng/ml) 99.48 2.295
Sulindac (3|j,g/ml) 98.27 1.413
Adriamycin (10ng/ml) + 
Sulindac (3|j,g/ml)
99.10 3.304
Sulindac (6p,g/ml) 99.39 1.300
Adriamycin (10ng/ml) + 
Sulindac (6|ag/ml)
82.54 3.857
Sulindac (12|_ig/ml) 99.89 0.181
Adriamycin (10ng/ml) + 
Sulindac (12fj.g/ml)
27.67 4.594
Table 3.3.6.10 Adriamycin and sulindac combination assays in MDA-MB-435S-F/Adr- 
lOplOp
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3.3.7 Circumvention of Taxol Resistance by Verapamil and Sulindac in
MDA-MB-435S-F MDR Variants
It was reported in section 3.3.6 that verapamil and sulindac were found to enhance 
adriamycin resistance in MDA-MB-435S-F and all its MDR variants. Sulindac was 
more potent than verapamil in the parental cell line MDA-MB-435S-F. The reverse was 
found for MDA-MB-435S-F/Taxol-10p, MDA-MB-435S-F/Taxol-10p4p, MDA-MB- 
435S-F/Adr-10p and MDA-MB-435S-F/Adr-10pl0p. This suggested that the role of 
mrp in the adriamycin resistance of MDA-MB-435S-F is declining while MDR-1 is 
emerging to play a greater role.
Sulindac was not found to circumvent taxol resistance, indicating that taxol is not 
transported by MRP. Interestingly taxol was circumvented by verapamil only in MDA- 
MB-435S-F/Taxol-10p and MDA-MB-435S-F/Taxol-10p4p. It had no effect on taxol 
resistance in the parental cell line or either of the adriamycin selected variants. It is 
possible that the verapamil circumvention of adriamycin observed in section 3.3.6 was 
as a result of inhibition of MRP transport of adriamycin, and not by MDR-1 transport. 
However if this were the case then sulindac circumvention would be stronger than 
verapamil. However a discrepancy remains, if taxol is transported by MDR-1 in MDA- 
MB-435S-F/Taxol-10p and MDA-MB-435S-F/Taxol-10p4p, why is enhanced 
circumvention by verapamil of adriamycin resistance or larger increases in adriamycin 
resistance, not observed in this cell line? Perhaps verapamil is inhibiting the transport 
of taxol through some novel transporter protein.
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3.3.7.1 Taxol and Verapamil in MDA-MB-435S-F
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (2ng/ml) 31.75 5.23
Verapamil (10|.ig/ml) 100.10 1.59
Taxol (2ng/ml) + 
Verapamil (lO^g/ml)
29.91 4.73
Verapamil (20|_ig/ml) 99.46 2.46
Taxol (2ng/ml)+ 
Verapamil (20|ag/ml)
28.62 7.32
Verapamil (30[j.g/ml) 99.58 1.82
Taxol (2ng/ml)+ 
Verapamil (30j.tg/ml)
28.03 6.00
Table 3.3.7.1 Taxol and verapamil combination assays in MDA-MB-435S-F
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3.3.7.2 Taxol and Sulindac in MDA-MB-435S-F
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (2ng/ml) 35.67 1.60
Sulindac (3|j.g/ml) 97.90 2.23
Taxol (2ng/ml)+ 
Sulindac (3^g/ml)
33.61 1.71
Sulindac (6|.ig/ml) 97.73 0.89
Taxol (2ng/ml)+ 
Sulindac (6jig/ml)
32.14 1.56
Sulindac ( 12fj.g/ml) 98.28 1.32
Taxol (2ng/ml)+ 
Sulindac (12^ig/ml)
29.25 1.49
Table 3.3.7.2 Taxol and sulindac combination assays in MDA-MB-435S-F
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3.3.7.3 Taxol and Verapamil in MDA-MU-435S-F/Taxol-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (5ng/ml) 58.16 1.62
Verapamil (10/xg/ml) 99.05 1.82
Taxol (5ng/ml) + 
Verapamil (10f.ig/ml)
15.58 0.62
Verapamil (20|a.g/ml) 98.63 0.27
Taxol (5ng/ml)+ 
Verapamil (20jxg/ml)
15.14 0.37
Verapamil (30|o,g/ml) 97.19 1.92
Taxol (5ng/ml)+ 
Verapamil (30^,g/ml)
16.33 1.05
Table 3.3.7.3 Taxol and verapamil combination assays in MDA-MB-435S-F/Taxol-10p
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3.3.7.4 Taxol and Sulindac in MDA-MB-435S-F/Taxol-10p
Average % Celi Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (5ng/ml) 62.35 1.20
Sulindac (3(j,g/ml) 99.53 2.06
Taxol (5ng/ml)+ 
Sulindac (3[ig/ml)
60.29 0.41
Sulindac (6|a.g/ml) 94.78 7.39
Taxol (5ng/ml)+ 
Sulindac (6(j,g/ml)
60.21 1.07
Sulindac (12p,g/ml) 98.45 3.11
Taxol (5ng/ml)+ 
Sulindac (12|og/ml)
59.69 3.11
Table 3.3.7.4 Taxol and sulindac combination assays in MDA-MB-435S-F/Taxol-10p
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3.3.7.5 Taxol and Verapamil in MDA-MB-435S-F/Taxol-10p4p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (10ng/ml) 48.71 2.43
Verapamil (lO^ig/ml) 100.08 1.62
Taxol (10ng/ml) + 
Verapamil (lO^g/ml)
5.25 4.55
Verapamil (20|j,g/ml) 98.46 1.30
Taxol (10ng/ml)+ 
Verapamil (20|ig/ml)
8.18 0.86
Verapamil (30(j,g/ml) 98.04 1.61
Taxol (10ng/ml)+ 
Verapamil (30|ig/ml)
8.02 0.61
Table 3.3.7.5 Taxol and verapamil combination assays in MDA-MB-435S-F/Taxol- 
10p4p
239
3.3.7.6 Taxol and Sulindac in MDA-MB-435S-F/TaxoI-10p4p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (lOng/ml) 46.71 4.34
Sulindac (3(j.g/ml) 99.43 3.12
Taxol (10ng/ml)+ 
Sulindac (3(J,g/ml)
44.44 4.56
Sulindac (6|j.g/ml) 99.50 3.08
Taxol (10ng/ml)+ 
Sulindac (6|xg/ml)
43.78 4.55
Sulindac (12|j,g/ml) 96.61 3.14
Taxol (10ng/ml)+ 
Sulindac (12(j,g/ml)
40.63 3.40
Table 3.3.7.6 Taxol and sulindac combination assays in MDA-MB-435S-F/Taxol-10p4p
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3.3.7.7 Taxol and Verapamil in MDA-MB-435S-F/Adr-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (3ng/ml) 22.27 1.76
Verapamil (10|ig/ml) 99.90 5.84
Taxol (3ng/ml) + 
Verapamil (10|ug/ml)
21.33 0.54
Verapamil (20jo,g/ml) 98.71 2.47
Taxol (3ng/ml)+ 
Verapamil (20|.ig/inl)
26.39 5.95
Verapamil (30j.ig/ml) 101.20 8.90
Taxol (3ng/ml)+ 
Verapamil (30j.ig/ml)
22.26 0.77
Table 3.3.7.7 Taxol and verapamil combination assays in MDA-MB-435S-F/Adr-10p
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3.3.7.8 Taxol and Sulindac in MDA-MB-435S-F/Adr-10p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (3ng/ml) 22.56 2.86
Sulindac (3|j,g/ml) 98.57 5.61
Taxol (3ng/ml)+ 
Sulindac (3jag/ml)
23.89 1.23
Sulindac (6j.ig/ml) 96.89 7.58
Taxol (3ng/ml)+ 
Sulindac (6|ag/ml)
22.06 2.68
Sulindac (12jig/ml) 98.44 6.44
Taxol (3ng/ml)+ 
Sulindac (12jig/ml)
20.62 1.55
Table 3.3.7.8 Taxol and sulindac combination assays in MDA-MB-435S-F/Adr-10p
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3.3.7.9 Taxol and Verapamil in MDA-MB-435S-F/Adr-10pl0p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (3ng/ml) 22.46 1.86
Verapamil (10|xg/ml) 81.54 8.68
Taxol (3ng/ml) + 
Verapamil (lOjxg/ml)
17.72 2.62
Verapamil (20|j,g/ml) 68.38 7.41
Taxol (3ng/ml)+ 
Verapamil (20|a.g/ml)
18.65 1.63
Verapamil (30|j.g/ml) 65.37 1.33
Taxol (3ng/ml)+ 
Verapamil (30j^g/ml)
16.92 1.57
Table 33.1.9 Taxol and verapamil combination assays in MDA-MB-435S-F/Adr- 
lOplOp
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3.3.7.10 Taxol and Sulindac in MDA-MB-435S-F/Adr-10pl0p
Average % Cell Survival 
(n=3)
Standard Deviation
Control 100.00 0.00
Taxol (3ng/ml) 18.76 1.45
Sulindac (3 fig/ml) 102.62 2.33
Taxol (3ng/ml)+ 
Sulindac (3j^g/ml)
17.25 1.27
Sulindac (6jxg/ml) 103.86 5.60
Taxol (3ng/ml)+ 
Sulindac (6|j,g/ml)
16.88 1.85
Sulindac (12jj,g/ml) 109.86 4.13
Taxol (3ng/ml)+ 
Sulindac (12p.g/ml)
17.82 1.21
Table 3.3.7.10 Taxol and sulindac combination assays in MDA-MB-435S-F/Adr- 
lOplOp
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3.3.8 Expression of Drug Resistance Associated Genes in MDA-MB-
435S-F MDR variants
A panel of genes associated with drug resistance were examined at the mRNA level by 
RT-PCR to determine whether their expression was affected by taxol and adriamycin 
selection.
3.3.8.1 MDR1
Figure 3.3.8.1 shows that MDR-1 mRNA expression was induced by taxol but not 
adriamycin in MDA-MB-435S-F.
mdr-l (157bp)
Figure 3.3.8.1 Expression of MDR-1 mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.2 MRP-1
Figure 3.3.8.2 shows that mrp-1 mRNA expression was induced slightly by taxol and
adriamycin in MDA-MB-435S-F.
Figure 3.3.8.2 Expression of mrp-1 mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of mrpl mRNA Expression (%)
MDA-MB-435S-F 100
MDA-MB -435S -F/T axol-1 Op 115.1
MDA-MB-435S -F/T axol-10p4p 141.5
MDA-MB-435S-F/Adr-1 Op 131.6
MDA-MB-435S-F/Adr-10pl0p 117.8
Table 3.3.8.2 Levels of MRP-1 mRNA in MDA-MB-435S-F MDR variants.
246
3.3.8.3 MRP-2
Figure 3.3.8.3 shows that mrp-2 mRNA expression was reduced by taxol and 
adriamycin in MDA-MB-435S-F. This result is dependent on P-actin levels, being 
lower in MDA-MB-435S-F.
p-actin (383 bp) 
mrp-2 (241 bp)
Figure 3.3.8.3 Expression of mrp-2 mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of mrp2 mRNA Expression (%)
MDA-MB-435S-F 100
MDA-MB -435S -F/T axol-1 Op 77.8
MDA-MB -435S -F/T axol-10p4p 47.1
MDA-MB-435S-F/Adr-1 Op 47.7
MDA-MB-43 5 S-F/Adr-1 Op 1 Op 56.4
Table 3.3.8.3 Levels of mrp-2 mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.4 MRP-4
Figure 3.3.8.4 shows that neither MDA-MB-435S-F nor any of it adriamycin or taxol 
selected variants expressed mrp-4 mRNA.
Figure 3.3.8.4 Expression of mrp-4 mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.5 MRP-5
Figure 3.3.8.5 shows that neither MDA-MB-435S-F nor any of it adriamycin or taxol 
selected variants expressed mrp-5 mRNA.
Figure 3.3.8.5 Expression of mrp-5 mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.6 Dihydrofolate Reductase (DHFR)
Figure 3.3.8.6 shows no change in the expression of DHFR mRNA in response to
adriamycin or taxol selection.
DHFR (221 bp) 
P-actin (142 bp)
Figure 3.3.8.6 Expression of DHFR mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of DHFR mRNA Expression (%)
MDA-MB-435S-F 100
MDA-MB-435S -F/T axol-1 Op 72
MDA-MB-435S-F/T axol-10p4p 101
MDA-MB-435S-F/Adr-10p 84
MDA-MB-43 5S-F/Adr-1 Op 1 Op 128
Table 3.3.8.6 Levels of DHFR mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.7 Glutathione-S-Transferase n (GSTtd)
Figure 3.3.8.7 shows reduced expression of GSTu mRNA in both taxol and adriamycin 
selected variants of MDA-MB-435S-F. This is dependent on P-actin levels being lower 
in MDA-MB-435S-F. By eye, there appears to be no change in expression.
<- GST 7t (270 bp) 
*- P-actin (142 bp)
Figure 3.3.8.7 Expression of GSTrc mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of GST71 mRNA Expression (%)
MDA-MB-435S-F 100
MD A-MB-435S -F/T axol-1 Op 62.1
MDA-MB-43 5S-F/T axol-10p4p 62.4
MD A-MB-43 5S-F/Adr-1 Op 52.0
MDA-MB-43 5 S-F/Adr-1 Op 1 Op 70.3
Table 3.3.8.7 Levels of GSTtc mRNA in MDA-MB-435S-F MDR variants.
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3.8.8.8 Thymidylate Synthase (TS)
Densitometry of figure 3.3.8.8 shows a slight reduction in expression of TS mRNA in 
MDA-MB-435S-F/Taxol-10p, which increases in MDA-MB-435S-F/Taxol-10p4p after 
further taxol selection, to levels greater than the parental cell line. Reduced expression 
of TS mRNA was detected in both MDA-MB-435S-F/Adr-10p and MDA-MB-435S- 
F/Adr-lOplOp.
Thymidylate 
Synthase (350 bp) 
(3-actin (142bp)
Figure 3.3.8.8 Expression of TS mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of TS mRNA Expression (%)
MDA-MB-435S-F 100
MDA-MB-435S-F/T axol-1 Op 79.3
MDA-MB-435S -F/T axol-10p4p 121.5
MDA-MB-43 5 S -F/Adr-1 Op 75.9
MDA-MB-435S-F/Adr-1 Op 1 Op 84.1
Table 3.3.8.8 Levels of TS mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.9 Topoisomerase I (Topo I)
Figure 3.3.8.9 shows that expression of Topo I mRNA decreased in later stage Taxol 
selection, as it is not decreased in MDA-MB-435S-F/Taxol-10p, but does decrease in 
MDA-MB-435S-F/Taxol-10p4p. Topo I levels decreased with increasing adriamycin 
resistance as shown in MDA-MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10pl0p.
P-actin (383 bp) 
Topo I (180bp)
Figure 3.3.8.9 Expression of Topo I mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of Topo I mRNA Expression 
(%)
MDA-MB-435S-F 100
MDA-MB-435S-F/T axol-1 Op 102
MDA-MB-435S -F/T axol-10p4p 63
MDA-MB-435S -F/Adr-1 Op 81
MDA-MB-435S-F/Adr-1 Op 1 Op 52
Table 3.3.8.9 Levels of Topo I mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.10 Topoisomerase Ila
Figure 3.3.8.10 shows that expression of Topo Ila  mRNA was not detectable in the 
parental cell line MDA-MB-435S-F. Its expression was induced by taxol and 
adriamycin selection. Expression was not detectable in MDA-MB-435S-F/Adr-10pl0p, 
but this is most likely a reflection on the low levels of P-actin in this cell line, in this 
PCR prep. Densitometry could not be performed to compare expression of Topo Ila  as 
it was not detectable in the parental cell line.
P-actin (383 bp)
Topo Hoc (139 bp)
Figure 3.3.8.10 Expression of Topo Ila  mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of Topo Ila  mRNA Expression 
(%)
MDA-MB-435S-F -
MDA-MB-435S-F/Taxol-10p +
MD A-MB -435S -F/Taxol-10p4p +++
MDA-MB-435S-F/Adr-10p ++
MDA-MB-435S-F/Adr-1 Opl Op -
Table 3.3.8.9 Levels of Topo Ila  mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.11 Topoisomerase 11(3
Densitometry of figure 3.3.8.11 showed that expression of Topo lip mRNA is increased 
by taxol selection. In contrast levels of expression were reduced by adriamycin 
selection. Visually there appears to be no change in the expression of Topo lip mRNA.
P-actin (142bp) 
Topo np (118bp)
Figure 3.3.8.11 Expression of Topo lip mRNA in MDA-MB-435S-F MDR variants.
Cell Line Levels of Topo lip  mRNA Expression 
(%)
MDA-MB-435S-F 100
MDA-MB-435S-F/T axol-1 Op 151
MDA-MB-435S-F/Taxol-l 0p4p 134
MDA-MB-435S-F/Adr-1 Op 71
MDA-MB-435S-F/Adr-10pl0p 90
Table 3.3.8.11 Levels of Topo lip mRNA in MDA-MB-435S-F MDR variants.
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3.3.8.11 Summary of Changes in Gene Expression
Table 3.3.8.11 give an overview of the changes in drug resistance associated gene 
expression. Taxol selection of MDA-MB-435S-F resulted in upregulation of MDR-1, 
mrp-1, topo I and topo Hoc mRNA expression and downregulation of mrp-2 mRNA 
expression. TS mRNA decreased in MDA-MB-435S-F/Taxol-10p, while TS mRNA 
increased in MDA-MB-435S-F/Taxol-104p. Adriamycin selection of MDA-MB-435S-F 
resulted in upregulation of mrp-1, topo I and topo Hoc mRNA expression, 
downregulation of mrp-2 and TS mRNA expression. Mrp-4 and mrp-5 mRNA were 
undetectable in these cell lines.
RT-PCR MDA-F MDA-F/
Taxol-lOp
MDA-F/
Taxol-10p4p
MDA-F/
Adr-10p
MDA-F/
Adr-10pl0p
Mdr-1 neg + + neg neg
Mrp-1 exp 0 + + 0
Mrp-2 exp “ - - -
Mrp-4 neg neg neg neg neg
Mrp-5 neg neg neg neg neg
Topo I exp 0 - - -
Topo l ia neg + + + inconclusive
Topo lip exp 0 - - -
DHFR exp - 0 - +
TS exp - - - -
GSTti exp - + - -
C-erbB-1 exp - - - -
C-erbB-2 exp - - - -
C-erbB-4 exp - - - -
Table 3.3.8.11 Summary of changes in expression of drug resistance related genes. 
+ increase in expression
decrease in expression 
o no change in expression
neg Not expressed
exp expressed by parental cell line
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3.3.9 Levels of pl70MDR"1 and MRP-1 protein expression in MDA-MB-
435S-F MDR variants
Western blots were performed to examine the expression of MDR-1 and MRP-1 at the 
protein level, to determine whether changes in their expression detected at the mRNA 
level were reflected at the protein level.
Figure 3.3.9.1 shows the expression of MDR-1 protein in MDA-MB-435S-F MDR 
variants. Taking P-actin into account, there only appears to be a slight increase in 
MDR-1 expression in the MDA-MB-435S-F MDR variants. Figure 3.3.9.2 shows the 
expression of MRP-1 protein in MDA-MB-435S-F MDR variants. Taking P-actin into 
account, MRP-1 expression is increased in all of the MDA-MB-435S-F MDR variants.
3.3.9.1 plTO1'108"1 protein expression
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MDR-1 (170 kDa)
P-actin (44 kDa)
Figure 3.3.9.1 Expression of pHO1^ 11'1 protein in MDA-MB-435S-F MDR variants.
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3.3.9.2 MRP-1 protein expression
Figure 3.3.9.2 Expression of MRP-1 protein in MDA-MB-435S-F MDR variants.
Note - A control gel was run for the detection of P-actin levels in the protein preps, due 
to the P-actin being of too low a molecular weight to detect on the same gel as MDR-1 
and MRP-1.
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3.3.10 Expression of Members of the ErbB Receptor Family in MDA-MB-435S-F 
MDR variants.
In order to determine the effects of taxol and adriamycin selection on the expression of 
ErbB receptors, RT-PCR was performed to determine the expression of ErbB receptors 
at the mRNA level in these drug selected variants. Western blotting and 
immunoprecipitation were then performed to determine whether any changes were also 
reflected at the protein level.
3.3.10.1 Expression of ErbB Receptor mRNA
Figure 3.3.10.1.1 shows the expression of c-erbB-1 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. C-erbB-1 mRNA levels were unaffected by taxol or 
adriamycin selection.
Figure 3.3.10.1.2 shows the expression of c-erbB-2 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. C-erbB-2 mRNA expression decreased with 
increasing taxol and adriamycin resistance. This decrease was greater in the adriamycin 
selected variants than the taxol selected variants.
Figure 3.3.10.1.3 shows the expression of c-erbB-4 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. C-erbB-4 mRNA expression was not induced in the 
initial selection with taxol, which generated the cell line MDA-MB-435S-F/Taxol-10p. 
It was induced though following four further pulses, generating the cell line MDA-MB- 
435S-F/Taxol-10p4p. C-erbB-4 mRNA expression was initially induced in the first 
selection with adriamycin, which generated the cell line MDA-MB-435S-F/Adr-10p. 
Levels then reverted back similar to the parent in the subsequent additional pulses 
resulting in MDA-MB-435S-F/Adr-10pl0p.
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3.3.10.1.1 C-erbB-1 mRNA expression
Figure 3.3.10.1.1 shows the expression of c-erbB-1 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. No c-erbB-1 signal difference was apparent between 
the parental cell line or the taxol or adriamycin selected variants.
p-actin (383 bp) 
c-erbB-1 (190 bp)
Figure 3.3.10.1.1 Expression of c-erbB-1 mRNA in MDA-MB-435S-F Taxol and 
adriamycin selected variants.
Cell Line Levels of C-erbB-1 mRNA Expression 
(%)
MDA-MB-435 S-F 100
MDA-MB-435 S-F/T axol-1 Op 93
MDA-MB-435S-F/T axol-10p4p 70
MDA-MB-435 S-F/Adr-1 Op 64
MDA-MB-435 S-F/Adr-1 Op 1 Op 60
Table 3.3.10.1.1 Levels of C-erbB-1 mRNA expression in MDA-MB-435S-F variants.
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3.3.10.1.2 C-erbB-2 mRNA expression
Figure 3.3.10.1.2 shows the expression of c-erbB-2 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. C-erbB-2 mRNA expression decreased with 
increasing taxol and adriamycin resistance.
C-erbB-2 (332bp) 
P-actin (142bp)
Figure 3.3.10.1.2 Expression of c-erbB-2 mRNA in MDA-MB-435S-F Taxol and 
adriamycin selected variants (unidentified bands are also present and may be due to 
primer dimer formation).
Cell Line Levels of C-erbB-2 mRNA Expression 
(%)
MDA-MB-435S-F 100
MDA-MB-435S-F/Taxol-10p 66.6
MDA-MB-435 S-F/T axol-10p4p 51.3
MD A-MB-435S-F/Adr-1 Op 58.4
MDA-MB-435S-F/Adr-10p(200-1 Op) 29.6
Table 3.3.10.1.2 Levels of C-erbB-2 mRNA expression inMDA-MB-435S-F variants.
3.3.10.1.3 C-erbB-4 mRNA expression
Figure 3.3.10.1.3 shows the expression of c-erbB-4 mRNA in MDA-MB-435S-F Taxol 
and adriamycin selected variants. C-erbB-4 mRNA expression was unchanged in 
MDA-MB-435S-F/Taxol-10p, and then increased in MDA-MB-435S-F/Taxol-10p4p. 
C-erbB-4 mRNA expression increased in MDA-MB-435S-F/Adr-10p, returned to 
parental levels in MDA-MB-435S-F/Adr-10pl0p.
Figure 3.3.10.1.3 Expression of c-erbB-4 mRNA in MDA-MB-435S-F Taxol and 
adriamycin selected variants.
Cell Line Levels of C-erbB-4 mRNA Expression 
(%)
MDA-MB-435 S-F 100
MDA-MB-435S-F/Taxol-10p 103
MD A-MB-435 S -F/T axol-10p4p 167
MDA-MB-435S-F/Adr-10p 143
MDA-MB-435S-F/Adr-10pl0p 90
Table 3.3.10.1.3 Levels of C-erbB-4 mRNA expression in MDA-MB-435S-F variants.
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3.3.10.2 Expression of ErbB Receptor protein
Figure 3.3.10.1.1 showed that the expression of c-erbB-1 mRNA in MDA-MB-435S-F 
Taxol and adriamycin selected variants was unchanged. C-erbB-1 protein expression 
was found to have increased with increasing taxol and adriamycin resistance, as shown 
in figure 3.3.10.2.1.
Figure 3.3.10.1.2 showed that the expression of c-erbB-2 mRNA in MDA-MB-435S-F 
Taxol and adriamycin selected variants decreased with increasing taxol and adriamycin 
resistance. This decrease was greater in the adriamycin selected variants than the taxol 
selected variants. Figure 3.3.10.2.2 showed that the expression of c-erbB-2 protein was 
in fact unchanged in the MDA-MB-435S-F MDR variants. It should be noted that the 
lane containing BT474A protein is not evenly loaded and therefore does not reflect the 
levels of c-erbB-2 expressed compared to MDA-MB-435S-F, but rather was included as 
a positive control in this immunoprécipitation.
Figure 3.3.10.2.3 showed that c-erbB-3 protein expression decreased with increasing 
taxol resistance and also with adriamycin selection
Figure 3.3.10.1.3 showed while the expression of c-erbB-4 mRNA in MDA-MB-435S- 
F was increased in MDA-MB-435S-F/taxol-10p4p and MDA-MB-435S-F/Adr-10p, 
levels were similar to the parental cell line in the other two variants. C-erbB-4 protein 
expression was virtually undetectable in any of the MDA-MB-435S-F variants (figure 
3.3.10.2.4).
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3.3.10.2.1 C-erbB-1 protein expression
Figure 3.1.10.2.1a Immunoprécipitation of c-erbB-1 protein expression in MDA-MB- 
435S-F MDR variants
Expressionof ErbB-1 in MDR variants
2.5 
2
1.5
0.5 
0
MDA-F TaxoMOp Taxol-10p4p Adr-10p 200-1 Op
2.12
1.94
T./U
1.52
1.00
Figure 3.1.10.2.1b C-erbB-1 Expression in MDA-MB-435S-F MDR variants
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3.3.10.2.2 C-erbB-2 protein expression
Figure 3.3.10.2.2a Immunoprécipitation of c-erbB-2 protein expression in MDA-MB- 
435S-F MDR variants
Expression of C-erbB-2 In MDR variants
1.2 
1
0.8 
0.6 
0.4
0.2
MDA-F Taxol-10p Taxol-10p4p Adr-10p 200-1 Op
Figure 3.3.10.2.2b C-erbB-2 Expression in MDA-MB-435S-F MDR variants
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3.3.10.2.3 C-erbB-3 protein expression
Figure 3.1.10.2.3 shows that c-erbB-3 protein expression is decreased in both taxol and
adriamycin selected variants.
c-erbB-3 
(180 kDa)
*■ P-actin  
(44 kD a)
Figure 3.1.10.2.3 C-erbB-3 Expression in MDA-MB-435S-F MDR variants. A control 
gel was run for the detection of P-actin.
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3.3.10.2.4 C-erbB-4 protein expression
Figure 3.1.10.2.4 shows that c-erbB-4 protein expression is virtually undetectable in all
variants of MDA-MB-435S-F.
P-actin
(44kDa)
Figure 3.1.10.2.4 C-erbB-4 Expression in MDA-MB-435S-F MDR variants
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3.3.11 Doubling Times of MDA-MB-435S-F MDR Variants
Table 3.3.11 shows the doubling times for MDA-MB-435S-F and each of its MDR 
variants. With increased taxol resistance, decreased growth rate was observed. MDA- 
MB-435S-F/Adr-10p has a much slower grower than MDA-MB-435S-F, however 
further selection with adriamycin saw return of growth rate almost to that of MDA-MB- 
435S-F.
Cell Line Doubling Time (Hours)
MDA-MB-435S-F 33 ±2.7
MDA-MB-435S-F/Taxol-10p 35 ± 1.5
MD A-MB-435S-F/T axol-10p4p 44 ± 3.7
MD A-MB -435S -F/Adr-1 Op 44 ± 3.4
MD A-MB -435 S -F/Adr-1 Op 1 Op 37 ± 1.2
Table 3.3.11 Doubling Times of MDA-MB-435S-F MDR variants.
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3.3.12 Motility Assays
Motility assays were performed, as described in Section 2.15, to access the locomotive 
ability of MDA-MB-435S-F and its MDR variants. The procedure used to demonstrate 
cell motility was similar to that used for invasion assays, with exception of the non­
inclusion of matrigel prior to the addition of cells.
3.3.12.1 Motility of Taxol selected MDA-MB-435S-F variants.
Figure 3.3.12.1a shows the MDA-MB-435S-F cells which have moved through the 
membrane in a 48-hour assay. This cell line is highly motile. Figures 3.3.12.1b and 
3.3.12.1c show the motility of the taxol sleeted variants MDA-MB-435S-F/Taxol-10p 
and MDA-MB-435S-F/Taxol-10p4p in the 48-hour assay. While these cell lines were 
highly motile, decreased motility was observed with increasing taxol resistance.
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Again Figure 3.3.12.2a shows the motility of MDA-MB-435S-F in a 48-hour assay. 
Figures 3.3.12.2b shows no significant change in the motility of the adriamycin selected 
variant MDA-MB-435S-F/Adr-10p. Figure 3.3.12.2c show that further selection with 
adriamycin resulted in a reduction in the motility of MDA-MB-435S-F/Adr-10pl0p.
3.3.12.2 Motility of Adriamycin selected MDA-MB-435S-F variants.
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Figure 3.3.12.2b MDA-F/Adr-lOp Figure 3.3.12.2c MDA-F/Adr-lOplOp
It can be concluded from this that the adriamycin and taxol selection of MDA-MB- 
435S-F results in reduced motility.
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3.3.13 Invasive Properties of MDA-MB-435S-F MDR variants: 
Discovery of a New In Vitro Model for Studying Different Phases of 
Invasion
Adhesion of cells to the extracellular matrix or basement membrane is the first step of 
cell invasion. The cell will then utilise various mechanisms to degrade the extracellular 
matrix, thereby facilitating its movement through it. Invasion assays were performed, as 
described in Section 2.14, to access the invasiveness of MDA-MB-435S-F and its MDR 
variants. Cell culture inserts, which stand in medium containing 24-well plates, were 
coated with matrigel prior to cell addition. Cells were allowed to migrate through the 
matrigel and subsequently through the 8 jjM  of the membrane of the insert to the 
underside of the insert.
3.3.13.1 Invasion of MDA-MB-435S-F MDR variants into matrigel
3.3.13.1.1 Invasion of Taxol selected MDA-MB-435S-F variants.
The ability of MDA-MB-435-F and its taxol-selected variants to invade through 
matrigel was assessed.
Figure 3.3.13.1.1a displays invasion of matrigel by MDA-MB-435S-F in a 48-hour 
assay. This cell line is highly invasive. Figure 3.3.13.1.1b displays invasion of matrigel 
by MDA-MB-435S-F/Taxol-10p. This cell line is highly invasive, although there 
appears to be very slightly fewer cells attached to the underside of the membrane. 
Figure 3.3.13.1.1c displays invasion of matrigel by MDA-MB-435S-F/Taxol-10p4p. 
Again this cell line is also highly invasive. Similar to MDA-MB-4345S-F/Taxol-10p, 
there are fewer cells attached to the underside of the membrane, compared to the 
parental cell line. Selection of MDA-MB-435S-F with taxol would appear at first glance 
to have made the cells less invasive. This is not the case however, as will be described 
in section 3.3.13.2.
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Figure 3.3.13.1.1a
Figure 3.3.13.1.1b
Figure 3.3.13.1.1c
MDA-MB-535S-F
MD A-MB-435S-F/T axol-1 Op
MDA-MB-435 S-F/Taxol-10p4p
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3.3.13.1.2 Invasion of Adriamycin selected MDA-MB-435S-F variants.
The ability of MDA-MB-435-F and its adriamycin-selected variants to invade through 
matrigel was assessed.
Figure 3.3.13.1.2a displays invasion of matrigel by MDA-MB-435S-F in a 48-hour 
assay. As noted before, this cell line is highly invasive. Figure 3.3.13.1.2b displays 
invasion of matrigel by MDA-MB-435S-F/Adr-10p. This cell line is considerably less 
invasive than the parental cell line MDA-MB-435S-F. Figure 3.3.13.1.2c displays 
invasion of matrigel by MDA-MB-435S-F/Adr-10pl0p. This cell line is considerably 
less invasive than the parental cell line MDA-MB-435S-F/Adr-10p. These results would 
initially indicate that increasing adriamycin resistance in Mda-MB-435S-F coincides 
with decreased invasiveness. This is not the case though as is shown the following 
section 3.3.13.2.
Figure 3.3.13.1.2a MDA-MB-535S-F
Figure 3.3.13.1.2b MDA-F/Adr-lOp Figure 3.3.13.1.2c MDA-F/Adr-lOplOp
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3.3.13.2 Discovery of An In Vitro Model For Two-Stage Invasiveness
An unexpected observation was made in the invasion assays of MDA-MB-435S-F and 
its MDR variants. When the invasion inserts removed for crystal violet staining, it was 
observed that a portion of cells had detached from the bottom of the insert and 
reattached to the bottom of the 24-well plate, in the adriamycin and taxol selected 
variants. This did not occur with the parental cell line MDA-MB-435S-F. It is thought 
that this could indicate a more invasive phenotype, pertaining to the “seed and soil” 
model of cancer cell invasion as described in the introduction.
Figure 3.3.13.2a shows that no cells were attached to the bottom surface of the 24-well 
plate in invasion assays of MDA-MB-435S-F. Figures 3.3.13.2b and 3.3.13.2c show 
that a large number of cells had detached from the bottom of the insert and reattached to 
the bottom surface of the 24-well plate in invasion assays of MDA-MB-435S-F/Taxol- 
lOp and MDA-MB-435S-F/Taxol-10p4p. This indicates that the taxol selection of 
MDA-MB-435S-F results in highly aggressive invasive behaviour. Figures 3.3.13.2d 
and 3.3.13.2e show that a number of cells had detached from the bottom of the insert 
and reattached to the bottom surface of the 24-well plate in invasion assays of MDA- 
MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10pl0p. The aggressive invasive 
behaviour of the adrimycin selected variants was not as great as that observed in the 
taxol selected variants. Also the number of cell invading in the adrimaycin selected 
variants is less than that of the parental cell line. This may however be an indication of 
a more aggressive phenotype, which could convey a greater chance of the survival of 
the invasive cell in a foreign environment.
274
Figure 3.3.13.2a MDA-MB-535S-F, Figure 3.3.13.2b MDA-F/Taxol-10p
'7  C  \  V '
Figure 3.3.13.2c MDA-F/Taxol-10p4p Figure 3.3.13.2d MDA-F/Adr-lOp
Figure 3.3.13.2e MDA-F/Adr-lOplOp
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3.3.14 The Adhesive Properties of the MDA-MB-435S-F MDR variants
Cells use various adhesion molecules such as integrins to interact with the extracellular 
components such as collagen type IV, laminin and fibronectin. To detect the 
adhesiveness of MDA-MB-435S-F parental cell line and its MDR variants to as 
collagen type IV, laminin, fibronectin and matrigel, adhesion assays were carried out as 
described in section 2.13.
Figure 3.3.14.1 shows the levels of adhesion of MDA-MB-435S-F and its MDR 
variants to laminin after 1 hour. MDA-MB-435S-F is more adhesive to laminin than 
either the taxol- or the adriamycin-selected variants. Loss of adhesion to laminin is 
greater in taxol-selected variants than in adriamycin-selected variants.
Figure 3.3.14.2 shows the levels of adhesion of MDA-MB-435S-F and its MDR 
variants to collagen type IV after 1 hour. MDA-MB-435S-F is more adhesive to 
collagen type IV than either the taxol or the adriamycin selected variants. Loss of 
adhesion to collagen type IV is greater in taxol selected variants than in MDA-MB- 
435S-F/Adr-10p. No great reduction in adhesion to collagen type IV was observed in 
MD A-MB-43 5 S-F/Adr-1 Op 1 Op.
Figure 3.3.14.3 shows the levels of adhesion of MDA-MB-435S-F and its MDR 
variants to fibronectin after 1 hour. MDA-MB-435S-F is more adhesive to fibronectin 
than either the taxol or the adriamycin selected variants. Loss of adhesion to fibronectin 
is greater in taxol selected variants than in adriamycin selected variants.
Figure 3.3.14.4 shows the levels of adhesion of MDA-MB-435S-F and its MDR 
variants to matrigel after 1 hour. MDA-MB-435S-F is more adhesive to matrigel than 
either the taxol or the adriamycin selected variants. While the loss of adhesion to 
matrigel was large in the taxol selected variants, it was only slight in the adriamycin 
selected variants.
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3.3.14.1 Adhesion to Laminin.
Adhesion of MDA-MB-435S-F MDR Variants
to Laminin
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Figure 3.3.14.1 Levels of MDA-MB-435S-F and MDR variant cell adhesion to laminin.
Cell Line Fold Changes in Cells Attached 
to Laminin After 1 hour
MD A-MB-43 5 S-F 1.00
MD A-MB-435 S-F/T axol-1 Op 0.14
MDA-MB-435S-F/Taxol-10p4p 0.20
MDA-MB-435 S-F/Adr-1 Op 0.71
MDA-MB-435S-F/Adr-10pl0p 0.62
Table 3.3.14.1 Fold change in adhesion to laminin relative to the parental cell line 
MDA-MB-435S-F.
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3.3.14.2 Adhesion to Collagen Type IV
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Figure 3.3.14.2 Levels of MDA-MB-435S-F and MDR variant cell adhesion to collagen 
type IV.
Cell Line Fold Changes in Cells Attached to 
Collagen Type IV After 1 hour
MDA-MB-435S-F 1.00
MD A-MB-435S-F/T axol-1 Op 0.09
MD A-MB-435S-F/T axol-10p4p 0.17
MD A-MB-435 S-F/Adr-1 Op 0.56
MD A-MB -435 S-F/Adr-1 Op 1 Op 0.93
Table 3.3.14.2 Fold change in adhesion to collagen type IV relative to the parental cell 
line MDA-MB-435S-F.
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3.3.14.3 Adhesion to Fibronectin
Adhesion of MDA-MB-435S-F MDR Variants 
to Fibronectin
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Figure 3.3.14.3 Levels of MDA-MB-435S-F and MDR variant cell adhesion 
fibronectin.
Cell Line Fold Changes in Cells Attached to 
Fibronectin After 1 hour
MDA-MB-435S-F 1.00
MDA-MB-435 S-F/Taxol-1 Op 0.13
MDA-MB-435S-F/Taxol-10p4p 0.15
MDA-MB-435 S-F/Adr-1 Op 0.51
MDA-MB-435S-F/Adr-1 Op 1 Op 0.54
Table 3.3.14.3 Fold change in adhesion to fibronectin relative to the parental cell line 
MDA-MB-435S-F.
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3.3.14.4 Adhesion to Matrigel
Adhesion of MDA-MB-435S-F MDR Variants 
to Matrigel
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Figure 3.3.14.4 Levels of MDA-MB-435S-F and MDR variant cell adhesion matrigel.
Cell Line Fold Changes in Cells Attached to 
Matrigel After 1 hour
MD A-MB-435S-F 1.00
MDA-MB-435 S-F/Taxol-1 Op 0.35
MDA-MB-435S-F/Taxol-10p4p 0.26
MDA-MB-435S-F/Adr- lOp 0.73
MDA-MB-435S-F/Adr-1 Opl Op 0.81
Table 3.3.14.4 Fold change in adhesion to matrigel relative to the parental cell line 
MDA-MB-435S-F.
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3.3.14.5 Summary of Adhesion results
Adhesion of MDA-MB-435S-F Drug Selected Variants to 
Me ECM Proteins
□  Laminin
□  Fibronectin
□  Collagen Typo IV
□  Matrige!
MDA-F TaxoMOp Taxol-10p4p Adr-10p Adr-10p10p
Figure 3.3.14.5.1 Adhesion of MDA-MB-435S-F Drug Selectant Variants to ECM 
Proteins
Laminin Fibronectin Collagen 
Type IV
Matrigel
MDA-MB-435S-F 1.00 1.00 1.00 1.00
MDA-MB-435S-
F/TaxoI-lOp
0.14 0.13 0.09 0.35
MDA-MB-435S-
F/Taxol-10p4p
0.20 0.15 0.17 0.26
MDA-MB-435S-
F/Adr-lOp
0.71 0.51 0.56 0.73
MDA-MB-435S-
F/Adr-lOplOp
0.62 0.54 0.93 0.81
Table 3.3.14.5 Fold decrease in adhesion of MDA-MB-435-S-F MDR variants to ECM 
proteins relative to parental cell line MDA-MB-435S-F.
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The following figures display the results presented in sections 3.3.14.1, 3.3.14.2,
3.3.14.3 and 3.3.14.4 in a different manner. The purpose of this is to show the 
preference of each cell line for particular ECM substrates, and how this is altered by 
taxol and adriamycin selection. MDA-MB-435S-F and all its variants are adherent to 
laminin, fibronectin, collagen type IV and matrigel.
MDA-MB-435S-F is most adhesive to fibronectin, followed by matrigel and laminin 
and least adhesive to collagen type IV. Figure 3.3.14.5.3 demonstrates the adhesive 
properties of the taxol selected cell line MDA-MB-435S-F/Taxol-10p. The graph 
demonstrates that the cell line is now most adhesive to matrigel, followed by 
fibronectin, laminin and lastly least adhesive to collagen type IV. In comparison to the 
parent cell line, MDA-MB-435S-F/Taxol-10p shows greatly reduced adhesion 
properties, with adhesion to laminin at 0.14, fibronectin at 0.13, collagen type IV at 0.09 
and matrigel at 0.35 of the parent cell line.
The second taxol selected cell line, MDA-MB-435S-F/Taxol-10p4p also shows changes 
in adhesive properties. Figure 3.3.14.5.4 shows that the MDA-MB-435S-F/Taxol- 
10p4p is most adhesive to matrigel, followed by fibronectin, laminin and lastly collagen 
type IV. Interestingly adhesion to laminin, fibronectin and collagen type IV is slightly 
greater than for MDA-MB-435S-F/Taxol-10p, with adhesion to laminin at 0.20, 
fibronectin at 0.15, collagen type IV at 0.17. The cell line is however less adhesive to 
matrigel at 0.26 of the parent.
The adriamycin selected cell lines also show reduced adhesion, although not to the same 
extent as the taxol selected cell lines. Again as with the Taxol selected cell lines, MDA- 
MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10pl0p are most adhesive to matrigel, 
followed by fibronectin, laminin and least adhesive to collagen type IV. The loss of 
adhesion in these cell lines is not as great as in the taxol selected cell lines but is still 
significant. Adr-lOp has adhesive values to laminin at 0.71, fibronectin at 0.51, collagen 
type IV at 0.56 and matrigel at 0.73 of the parent, while Adr-lOplOp has values of 
adhesion to laminin at 0.62, fibronectin at 0.54, collagen type IV at 0.93 and matrigel at
0.81 of the parent.
282
Adhesion Porperties of MDA-MB-435S-F to ECM 
Proteins
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Figure 3.3.14.5.2 -  Adhesion properties of parent cell line MDA-MB-435S-F.
Adhesion Properties of MDA-MB-435S-F/TaxoM0p 
to ECM Proteins
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Figure 3.3.14.5.3 - Adhesion properties of taxol selected cell line MDA-MB-435S- 
F/Taxol-lOp.
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Figure 3.3.14.5.4 - Adhesion properties of taxol selected cell line MDA-MB-435S-
F/Taxol-10p4p.
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Adhesion Properties of MDA-MB-435S-F/Adr-10p 
to ECM Proteins
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Figure 3.3.14.5.5 - Adhesion properties of adriamycin selected cell line MDA-MB- 
435S-F/Adr-10p.
Adhesion Properties of MDA-MB-435S-F/Adr- 
10p10p to ECM Proteins
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Figure 3.3.14.5.6 - Adhesion properties of adriamycin selected cell line MDA-MB- 
435S-F/Adr-1 Op 1 Op
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3.3.15 Protease secretion by MDA-MB-435S-F MDR variants.
Matrix metalloproteinases (MMPS), cysteine proteinases and serine proteineases, which 
are secreted by cells, play an important role in degrading the extracellular matrix. To 
investigate the mechanism underlying the invasive phenotype of the MDA-MB-435S-F 
parental cell line and its MDR variants, studies of MMPs were carried out as described 
in section 2.16.
3.3.15.1 Expression of Gelatin Degrading Proteases by MDA-MB-435S-F and Its 
MDR variants
BHK (baby hamster kidney) cell line, which secretes MMP-2 and MMP-9, was used as 
the positive control in these studies.
130kDa 
84kDa
45kDa
29kDa 
22kDa
Figure 3.3.15.1 Zymogram of gelatin proteases secreted by MDA-MB-435S-F
with BHK as a positive control for the secretion of pro-MMP2 (72 kDa), MMP-2
(66kDa), pro-MMP-9 (92kDa) and MMP9 (86kDa). The MDA-MB-435S-F parent cell
line and its MDR variants display secretion bands corresponding to pro-MMP-2 and
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pro-MMP-9. There are also double bands expressed at approximately 50-60kDa. A 
candidate for this is MMP-1, which runs as a doublet at 52 and 57 kDa in their 
unglycosylated and glycosylated forms of the proenzyme.
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To confirm that the bands detected in MDA-MB-435S-F and its MDR variants were 
MMPs, proteinase inhibitors were added.
3.3.15.2 Invastigation of Type of Class of Gelatin Degrading Proteases by MDA-
MB-435S-F and Its MDR variants
3.3.15.2.1 The effect of EDTA
EDTA is a chelating agent which can bind the zinc and calcium which are needed for 
the activation of MMPs.
130kDa
84kDa
45kDa
29kDa
22kDa
Figure 3.3.15.2.1 Addition of EDTA to the substrate buffer eliminates expression 
of all protease bands, indicating the gelatin degrading proteases secreted by MDA-MB- 
435S-F parent and MDR variants are probably members of the matrix metalloproteinase 
family.
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PMSF is a serine and cysteine proteinase inhibitor.
3.3.15.2.2 The effect of PMSF
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Figure 3.3.15.2.2 Addition of PMSF to the substrate buffer suppresses slightly 
expression of all protease bands, but does not eliminate them, suggesting the proteases 
are not serine or cysteine proteases.
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3.3.16 Analysis of Populations Isolated from Invasion Assays
Three populations of cells were isolated from MDA-MB-435S-F and its MDR variants. 
Invasion assays were set up as described in section 2.14. After allowing cells to invade 
for 48 hours, the three populations were isolated as follows. Firstly cells which had not 
invaded were isolated from the inside of the invasion chamber (Non-Invasive), by 
pipetting up remaining cells and transferring to a well containing fresh media. A second 
population was isolated from the bottom side of the insert by trypsinisation (Invasive) of 
cells into a well containing fresh media. The third population was isolated from those 
cells, which had invaded, detached from the bottom of the insert and reattached to the 
bottom of the 24-well plate (Superinvasive). These populations were allowed to grow 
until they reached levels for further subculturing.
wan rfive.si.V6 Invasion
pt'fjuffSton Chamber
Invasive
population
“ “ “ “  Superinvasive
population Well
Figure 3.3.16 Diagram of isolation of populations from invasion chamber
3.3.16.1 Morphology of Isolated Populations
No changes were observed in the morphology of the three invasive populations isolated, 
except for an increased tendency of Invasive and Superinvasive cells to lack of cell 
contact growth inhibition.
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3.3.16.1.1 Morphology of Non-Invasive Populations
Figure 3.3.16.1.1a MDA-MB-535S-F Figure 3.3.16.1.1b MDA-F/Taxol-10
Figure 3.3.16.1.1c MDA- F/Taxol-10p4p Figure 3.3.16.1. Id MDA-F/Adr-10p
Figure 3.3.16.1.1 e MDA-F/Adr-1 Op 1 Op
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3.3.16.1.2 Morphology of Invasive Populations
Figure 3.3.16.1.2 c MDA- F/Taxol-10p4p Figure 3.3.16.1.2d MDA-F/Adr-lOp
Figure 3.3.16.1.2e MDA-F/Adr-lOplOp
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3.3.16.1.3 Morphology of Superinvasive Populations
Figure 3.3.16.1.3a MDA-F/TaxoI-10p Figure 3.3.16.1.3b MDA-F/Taxol-10p4p
Figure 3.3.16.1.3c MDA-F/Adr-10p Figure 3.3.16.1.3d MDA-F/Adr-10pl0p
292
3.3.16.2 Motility of Isolated Populations
Motility assays were performed to compare the motility of the three populations isolated 
from MDA-MB-435S-F and its MDR variants. Motility assays were performed as 
described in section 2.15. Post-motility assay, the bottom side of the motility chambers 
and also the bottom of the 24 well plate were stained with crystal violet. The crystal 
violet was then eluted with 33% acetic acid and transferred to a 96-well plate and the 
absorbance read at 570nm.
These results show that the superinvasive populations were far more motile than either 
the non-invasive or invasive populations. Total cell motility showed that the MDA- 
MB-435S-F/Taxol-10p4p invasive populations were far more motile than the parental 
cell line. Unexpectedly, within this cell line, the invasive population was more motile 
than the superinvasive population.
Motility Assay - Cells Attached to Underside of 
Motility Chamber
0.3
g 0.25(N
Ee
□ Non Invasive
□ Invasive
□ Superinvasive
I  °-,s
o
MDA-F TaxoHOp Taxol- 
10p4p
Adr-10p Adr- 
10p10p
Figure 3.3.16.2a Comparison of levels of locomotion to underside of motility chamber
by Non-Invasive, Invasive and Superinvasive populations, isolated from MDA-MB-
435S-F and its MDR variants.
Motility assay - Cells Attached to Surface of 24- 
Well Plate
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Figure 3.3.16.2b Comparison of levels of cells attached to bottom of 24 well plate after 
motility assay of Non-Invasive, Invasive and Superinvasive populations, isolated from 
MDA-MB-435S-F and its MDR variants.
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Figure 3.3.16.2c Comparison of total cell motility by Non-Invasive, Invasive and
Superinvasive populations, isolated from MDA-MB-435S-F and its MDR variants.
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3.3.16.3 Invasiveness of Isolated Populations
Invasion assays were performed to compare the invasiveness of the three populations 
isolated from MDA-MB-435S-F and its MDR variants. Invasion assays were 
performed as described in section 2.14. After invasion the bottom side of the invasion 
chambers and also the bottom of the 24 well plate were stained with crystal violet. The 
crystal violet was then eluted with 33% acetic acid and transferred to a 96-well plate 
and the absorbance read at 570nm.
Figure 3.3.16.3.c shows that there was a general trend towards increased invasiveness in 
the adriamycin and taxol selected variants compared to their parental cell line MDA- 
MB-435S-F. It was also observed that the superinvasive populations were more 
invasive than the other supopulations. Again similar to the motility assays in section 
3.3.16.2, the invasive subpopulation of MDA-MB-435S-F/Taxol-10p4p was more 
invasive than its superinvasive subpopulation. All subpopulations were capable of 
invading regardless of their point of isolation, but they did show different rates of 
invasion.
Invasion Assay - Cells Attached to 
Underside of Invasion Chamber
□ Non Invasive
□ Invasive
□ Superinvasive
MDA-F TaxoMOp Taxol- 
10p4p
Adr-10p Adr- 
10p10p
Figure 3.3.16.3a Comparison of levels of invasion to underside of invasion chamber by 
Non-Invasive, Invasive and Superinvasive populations, isolated from MDA-MB-435S-F 
and its MDR variants.
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Invasion assay - Cells Attached to Surface of 24- 
Well Plate
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Figure 3.3.16.3b Comparison of levels of cells attached to bottom of 24 well plate after 
invasion by Non-Invasive, Invasive and Superinvasive populations, isolated from 
MDA-MB-435S-F and its MDR variants.
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Figure 3.3.16.3c Comparison of total cell by Non-Invasive, Invasive and Superinvasive
populations, isolated from MDA-MB-435S-F and its MDR variants.
296
3.3.16.4 Adhesion of Superinvasive Populations to ECM Components in 
Comparison to Parental Populations
Adhesion assays were performed as described in section 2.13 to compare the 
adhesiveness of the superinvasive populations in comparison to the parental populations 
from which they were isolated.
Results showed that all of the superinvasive populations with the exception of MDA- 
MB-435S-F/Taxol-10p were more adhesive to laminin, fibronectin, collagen type IV 
and matrigel. On the other hand MDA-MB-435S-F/Taxol-10p is less adhesive to these 
ECM proteins.
Adhesion of MDA-MB-435S-F/Taxol-10p 
Superinvasive Population to ECM Proteins
0.700 t-------------------------------------------------------
+
Laminin Fibronectin Collagen IV Matrigel
Figure 3.3.16.4.1 Comparison of adhesion of MDA-MB-435S-F/Taxol-10p 
superinvasive population to ECM proteins compared to its parental cell line MDA-MB- 
435S-F/Taxol-10p
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Adhesion of MDA-MB-435S-F/Taxol-10p4p
Superinvasive Population to ECM Proteins
Laminin Fibronectin Collagen IV Matrigel
Figure 3.3.16.4.2 Comparison of adhesion of MDA-MB-435S-F/Taxol-10p4p 
superinvasive population to ECM proteins compared to its parental cell line MDA-MB- 
435S-F/T axol-10p4p
Adhesion of MDA-MB-435S-F/Adr-10p Superinvasive 
Population to ECM Proteins
1.600
+
Laminin Fibronectin Collagen IV Matrigel
Figure 3.3.16.4.3 Comparison of adhesion of MDA-MB-435S-F/Adr-10p superinvasive 
population to ECM proteins compared to its parental cell line MDA-MB-435S-F/Adr-
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Adhesion of MDA-MB-435S-F/Adr-10p10p
Superinvasive Population to ECM Proteins
1.400
+
Laminin Fibronectin Collagen IV Matrigel
Figure 3.3.16.4.4 Comparison of adhesion of MDA-MB-435S-F/Adr-10pl0p 
superinvasive population to ECM proteins compared to its parental cell line MDA-MB- 
435S-F/Adr-1 Op 1 Op
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4.0 Discussion
4.1 Characterisation of BT474A, MCF-7 H3 and MDA-MB-435S-F cell 
lines
The purpose of the thesis was to study the effects of c-erbB-2 levels on 
chemotherapeutic drug and tamoxifen resistance, expression of drug resistance related 
genes and on cell invasiveness. Previous studies had indicated that c-erbB-2 
overexpression was associated with poor prognosis, increased metastatic potential and 
resistance to chemotherapy and hormonal therapy (see sections 1.4; 1.5; 1.7).
This was approached from three directions.
1. To study the effect of c-erbB-2 upregulation on the processes described 
above. This was achieved by the transfection of MCF-7 H3 with c-erbB-2 
cDNA
2. To study the effect of c-erbB-2 downregulation on the processes described 
above and to see if the reverse of that seen in the previous point could be 
detected. This was achieved by the transfection of BT474A with a c-erbB-2- 
targeted ribozyme.
3. As c-erbB-2 overexpression was associated with increased drug resistance, a 
low level c-erbB-2 expressing cell line, MDA-MB-435S-F was chosen for 
selection with adriamycin and taxol to determine whether c-erbB-2 would 
play a role in emerging drug resistance.
MCF-7 H3 is a clonal population isolated by Dr. Finbar O’Sullivan (NCTCC, Dublin 
City University) from the human breast carcinoma cell line MCF-7. MCF-7 H3 
expresses normal levels of c-erbB-2 expression and is also estrogen receptor positive 
(both a  and P). BT474A is a clonal population isolated during the course of this thesis 
from the human breast carcinoma cell line BT474A. BT474A expresses high levels of c- 
erbB-2 and is also estrogen receptor positive (both a  and P). MDA-MB-435S-F is a 
clonal populations isolated during the course of this thesis from the human breast 
carcinoma cell line MDA-MB-435S. MDA-MB-435S-F expresses normal levels of c- 
erbB-2 expression and is estrogen receptor negative.
None of the three cell lines overexpress p-glycoprotein, and their drug resistance 
profiles are very similar as is shown in Table 4.1. MCF-7 H3 and BT474A express very
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low levels of GST n mRNA compared to MDA-MB-435S-F. MDA-MB-435S-F 
expresses much lower levels of topoisomerase Ila  compared to MCF-7 H3 and 
BT474A. MCF-7 H3 expresses high levels of c-erbB-4 at both the mRNA and protein 
level.
Drug BT474A MCF-7 H3 MDA-MB-435S-F
IC50 Taxol LT 1.86 ±0.05 1.09 ±0.16 2.12 ±0.057
IC50 Taxol ST 15.6 ± 1.15 9.2 ± 1.0 28.3 ± 1.52
IC50 Adriamycin LT 40.3 ± 4.04 19.83 ±2.3 26.6 ± 1.97
IC50 Adriamycin ST 104 ±4.58 348 ± 2.8 271 ±3
IC50 Carboplatin LT 2.43 ± 0.20 1.75 ±0.10
IC50 Carboplatin ST 33.0 ±3.00 42.9 ± 3.4 41.3 ± 1.5
IC50 Taxotere ST 6.10 ± 0.17 3.33 ± 0.37
IC50 5-FU LT 0.09 ± 0.012 0.17 ± 0.005
I C 50 5-FU ST 4.86 ± 0.63 6.06 ±0.11 7.43 ± 0.68
IC50 Vincristine ST 73.3 ± 1.52 12.9 ± 1.3
Table 4.1 IC50 values for BT474A, MCF-7 H3 and MDA-MB-435S-F.
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4.2 The Role of C-erbB-2 in Resistance to Chemotherapy
Overexpression due to gene amplification has been found in 10-40% of breast cancers, 
although some carcinomas overexpress in the absence of gene amplification (Suo et al., 
1998). High levels of c-erbB-2 expression have been shown to correlate strongly with 
poor prognosis in breast cancer (Verbeek et al., 1998).
An objective of this thesis was to establish a breast cancer cell model for the 
investigation of the effects of c-erbB-2 expression on resistance to chemotherapeutic 
drugs and the expression of genes associated with drug resistance. Two breast cancer 
cell lines were chosen, BT474A and MCF-7 H3. BT474A overexpresses c-erbB-2, 
while MCF-7 H3 expresses normal levels of c-erbB-2. MCF-7 H3 was transfected with 
a c-erbB-2 encoding plasmid to upregulate expression of c-erbB-2 (section 3.1). C- 
erbB-2 expression was not elevated to a great extent at the mRNA level, but was 
increased at the protein level as shown in section 3.1.3. BT474A was transfected with a 
c-erbB-2 targeting ribozyme to downregulate expression of c-erbB-2 (section 3.2). The 
transfection was found to be successful as c-erbB-2 levels were decreased at both the 
mRNA level and protein level (section 3.2.3). The mutant ribozyme control 
transfection exhibited no reduction in the expression of c-erbB-2, indicating that the 
transfection was successful.
Tables 4.2a and 4.2b show the findings of alteration of c-erbB-2 levels of expression in 
BT474A and MCF-7 H3. The effect of c-erbB-2 expression on drug resistance appears 
to be cell line dependent. This finding is very similar to Slamon et al. (1997) who 
found that the chemosensitivity profiles resulting from c-erbB-2 transfection observed 
in vitro were cell line specific. There were only two consistent changes in drug 
resistance exerted by c-erbB-2 expression, the first was a decrease in resistance to 
adriamycin in short term assays as a result of upregulation of c-erbB-2 in MCF-7 H3, 
which was mirrored by an increase in resistance to adriamycin in BT474A when c- 
erbB-2 was downregulated in short term assays (section 3.1.4.1.2; 3.2.4.1.2). Secondly, 
a decrease in resistance to 5-fluorouracil was observed in long and short term assays as 
a result of upregulation of c-erbB-2 in MCF-7 H3, which again was mirrored by a 
increase in resistance to 5-fluorouracil in BT474A when c-erbB-2 was downregulated 
(section 3.1.4.4.1; 3.1.4.4.2; 3.2.4.4.1; 3.2.4.4.2).
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Main Findings in the MCF-7 H3 C-erbB-2 cDNA Transfectants Methods used
Decreased resistance to adriamycin in long and short term assays Toxicity assay
Increased resistance to taxol in short term assays only Toxicity assay
No consistent changes in resistance to carboplatin in long term assays 
Increased resistance to carboplatin in short term assays
Toxicity assay
Increased resistance to methotrexate in long term assays Toxicity assay
No significant changes in vincristine, taxotere or 5-fluorouracil 
ressitance
Toxicity assay
DHFR and topoisomerase lip mRNA levels increased RT-PCR
MDR-1, mrp-4, mrp-5 and GSTtc mRNA expression not detected RT-PCR
Mrp-1, mrp-2, TS, topoisomerase I and topoisomerase Ila  mRNA 
expression unchanged
RT-PCR
Table 4.2a Summary of findings of the effects of c-erbB-2 upregulation in MCF-7 H3 
on chemotherapeutic drug patterns of resistance and expression of a panel of resistance 
associated genes.
Findings in the BT474A C-erbB-2 Ribozyme Transfectants Methods used
Decreased resistance to adriamycin in long term assays 
Increased resistance to adriamycin in short term assays)
Toxicity assay
Increased resistance to taxol in long and short term assays Toxicity assay
No consistent changes in resistance to carboplatin in long term assays 
Increased resistance to carboplatin in short term assays
Toxicity assay
Increased resistance to 5-fluorouracil in long and short term assays Toxicity assay
Increased resistance to methotrexate in long term assays Toxicity assay
Mrp-2, DHFR, TS, GSTti topoisomerase I and topoisomerase 11(3 
mRNA levels increased
RT-PCR
Topoisomerase Ila  mRNA levels decreased RT-PCR
MDR-1 and mrp-4 mRNA expression not detected RT-PCR
Mrp-1 and mrp-5 mRNA expression unchanged RT-PCR
Table 4.2b Summary of findings of the effects of c-erbB-2 downregulation in BT474A 
on chemotherapeutic drug patterns of resistance and expression of a panel of resistance 
associated genes.
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An important observation was the variation in response of the transfectants to a 
particular drug, depending on whether the toxicity testing assay used was long or short 
term. Long term toxicity assays involved the determination of the IC50 for a particular 
drug after 7 days drug exposure in 96 well plates. Short term toxicity assays involved 
the determination of the IC50 for a particular drug after 4 hour exposure to the drug, 
followed by growth in drug-free media for another 7 days in 96 well plates. One might 
say that the two assays differ in that long term assays reflect the ability of the cells to 
withstand lengthier exposure to drug, while short term assays reflect the ability of the 
cells to recover from an acute shock with a high concentration of the drug in question. 
It should be noted that the half-life of chemotherapy drugs is quite short (approximate 
range 6-16 hours) in culture medium. It is likely that short term assays reflect what is 
seen in the clinical setting. The majority of chemotherapy regimes involve a series of 
exposures to the chemotherapy agent/agents, over a number of weeks, rather than 
continuous exposure to drug. Downregulation of c-erbB-2 in BT474A resulted in 
decreased resistance to adriamycin in long term assays, while resistance was increased 
to adriamycin in short term assays (section 3.2.4.1.1; 3.2.4.1.2). No consistent changes 
in resistance to carboplatin in long term assays was observed in the BT474A ribozyme 
transfectants, while increased resistance to carboplatin was observed in short term 
assays (section 3.2.4.3.1; 3.2.4.3.2). These results suggest that c-erbB-2 is beneficial to 
BT474A where adriamycin exposure is continuous, but it is not beneficial to BT474A if 
it receives a high dose of adriamycin. This may explain the findings whereby c-erbB-2 
overexpression is linked to better response to high dose adriamycin chemotherapy (Petit 
et al., 2001). The carboplatin results suggest that c-erbB-2 has no effect on BT474A 
response to carboplatin where exposure is continuous, and it is not beneficial to 
BT474A if it receives a high dose of carboplatin. MCF-7 H3 results suggest that c- 
erbB-2 has no effect on the resistance of MCF-7 H3 to continuous taxol or carboplatin 
exposure, while c-erbB-2 expression is beneficial to MCF-7 H3 in the case of high 
doses of taxol or carboplatin (section 3.2.4.2.1; 3.2.4.2.2; 3.2.4.3.1; 3.2.4.3.2). Due to 
the conflicting effects of c-erbB-2 on resistance to chemotherapeutic agents, it would 
not be advisable to recommend a particular type of chemotherapeutic drug on the basis 
of c-erbB-2 status. It is highly likely that c-erbB-2 is one of many proteins in a much 
larger picture. Until these pathways and receptor combinations are completely 
elucidated, the role of c-erbb-2 in chemo-resistance, will remain extremly complicated, 
and difficult to determine.
There are numerous conflicting studies on the effects of c-erbB-2 overexpression on 
resistance to chemotherapy. In general, these reportes suggest that c-erbB-2 confers 
ressitance to durugs such as taxol. Transfection of MDA-MB435 human breast cancer 
cells with c-erbB-2 confers a 5-9-fold increase in taxol resistance (Yu et al., 1996), not 
linked to p-glycoprotein function (Yu et al., 1998b), due to upregulation of p21Cipl, 
blocking taxol-induced apoptosis in these cells (Yu et al., 1998). In contrast c-erbB-2 
overexpression in normal human mammary epithelial cells failed to confer resistance or 
sensitivity to chemotherapeutic agents (Orr et al., 2000). Transfection of SKOV-3 
ovarian cancer cells with an anti-c-erbB-2-targeted ribozyme had no effect on resistance 
to adriamycin or cisplatin in proliferation assays. In contrast, the sensitivity to taxol was 
increased approximately 70-fold (Aigner et al., 2000). Ciardiello et al. (2000) found 
that c-erbB-2 transfection of MCF-10A normal human mammary epithelial cells 
resulted in an increased sensitivity to topoisomerase I- and topoisomerase II-inhibitors, 
and to platinum-derivatives. The cells were however more resistant to taxol and 
taxotere.
Harris et al. (2001) that Herceptin inhibited the cytotoxicity of adriamycin in c-erbB-2 
overexpressing breast cancer cells. This was accompanied by a decrease in 
topoisomerase Ila  protein and activity, suggesting that this is at least one of the 
mechanisms of change in adriamycin response.
A number of genes involved in drug resistance were examined at the mRNA levels, to 
determine whether their expression was altered by c-erbb-2 expression, and whether 
they could explain any of the changes in drug resistance observed in MCF-7 H3 and 
BT474A. In this thesis, the effect of c-erbB-2 expression on topoisomerase mRNA 
expression was determined by RT-PCR. C-erbB-2 upregulation in MCF-7 H3 had no 
effect on the expression of topoisomerase I or topoisomerase Ila  mRNA in MCF-7 H3, 
while topoisomerase IIP mRNA levels were increased in one of the clonal populations 
(section 3.1.5.6; 3.1.5.8). This was not consistent with findings for BT474A, as c-erbB- 
2 downregulation resulted in increased topoisomerase I and topoisomerase II p mRNA, 
while topoisomerase Ila  mRNA levels were decreased (section 3.2.5.6; 3.2.5.8). These 
results are limiting however, as protein expression or enzyme activity were not 
examined
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C-erbB-2 expression appears to have no effect on the regulation of MDR-1, mrp-1, mrp-
4, mrp-5 mRNA expression in either cell line as determined by RT-PCR. There is 
however nothing in the literature to link c-erbB-2 with any of these genes. Mrp-2 
mRNA levels increased as a result of c-erbB-2 downregulation in BT474A (section
3.2.5.3). This is a very interesting finding as there are no links in the literature between 
c-erbB-2 and mrp-2. This may also explain increases in resistance to adriamycin and 
carboplatin in these cell lines, as shown by short term toxicity assays. Adriamycin is 
transported by mrp-2 as is cisplatin, an analogue of carboplatin. Therefore it is possible 
that mrp-2 also transports carboplatin. A next step will be to determine the expression 
of mrp-2 protein in these cell lines at the protein level, and examine its activity by 
circumvention assays.
There is no literature linking c-erbB-2 with thymidylate synthase or dihydrofolate 
reductase. DHFR mRNA levels increased as a result of upregulation of c-erbB-2 in 
MCF-7 H3 (section 3.1.5.9). However, they also increased in three of the transfectant 
populations of BT474A as a result of c-erbB-2 downregulation (section 3.2.5.9). TS 
mRNA levels increased in the c-erbB-2 transfected MCF-7 H3 clones (section 3.1.5.10). 
Again, TS mRNA levels also increased in BT474A as a result of c-erbB-2 
downregulation (section 3.2.5.10).
In this thesis, GST n mRNA was undetectable in MCF-7 H3 (section 3.1.5.11), while it 
increased in BT474A as a result of c-erbB-2 downregulation (section 3.2.5.11). GST n 
did not correlate with c-erbB-2 overexpression in intraduct breast carcinomas (Bellamy 
et al., 1994). There was no association between expression GST n, GST a  or GST [i 
and expression of c-erbB-2 in a series of 74 primary human breast carcinomas (Cairns et 
al., 1992). In contrast a correlation was found between GST 7t expression and c-erbB-1 
and c-erbB-2 in renal carcinoma cells (Volm et al. 1993).
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4.3 The Role of C-erbB-2 in Cell Motility, Adhesion, Invasion and 
Protease Secretion
C-erbB-2 overexpression is known to be associated with invasion and metastasis in 
human breast cancer (Marx et al., 1990; Quenel et al., 1995; Revillion et al., 1996; 
Prost et al., 1994; Driouch et al., 1997). A second objective of the establishment of a 
breast cancer cell model for altering c-erbB-2 expression, was to investigate the role of 
c-erbB-2 in cell motility, adhesion, invasion and protease secretion.
Findings in the MCF-7 H3 C-erbB-2 cDNA Transfectants Methods used
Lack of cell motility in parental cell line and c-erbB-2 transfectants Motility assay
Increased invasion in 2 of 3 clonal transfected populations 
Decreased invasion in 1 clonal transfected population
Invasion assay
No consistent changes in adhesion to laminin, collagen type IV or 
matrigel
Adhesion
assay
Decreased adhesion of all transfected clonal populations to fibronectin Adhesion
assay
Matrix metalloproteinases secreted by MCF-7 H3 and transfectants Zymography
Inhibition of MMP and serine proteases activity of BHK, MCF-7 H3 
and clonal transfected populations by cysteine and DTT
Zymography
Secretion of serine/cysteine proteases correlate with lack of 
invasiveness
Zymography
Table 4.3a Summary of findings of the effects of c-erbB-2 upregulation in MCF-7 H3 
on cell motility, adhesion, invasion and protease secretion.
C-erbB-2 expression appears to have no effect on cell motility in these cell lines, 
although it is not possible to be absolutely conclusive on this, as these cell lines do not 
exhibit motility in the first place (section 3.1.11; 3.2.11). It is very unusual that the 
cells are invasive but not motile. There is a distinct possibility that motility might be 
triggered in these cell lines only in the presence of substrates such as the extracellular 
matrix, when the cell is about to become invasive.
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Findings in the BT474A C-erbB-2 Ribozyme Transfectants Methods used
Lack of cell motility in parental cell line and c-erbB-2 ribozyme 
transfectants
Motility assay
Decreased invasion in all transfectant populations Invasion assay
Decreased adhesion of clonal populations to laminin and matrigel Adhesion
assay
Decreased adhesion of pool and clonal populations to collagen type IV Adhesion
assay
Decreased adhesion of pool and three clonal populations to fibronectin Adhesion
assay
Secretion of matrix metalloproteinase by BT474A and ribozyme 
transfectant, levels of which were reduced in several clonal transfected 
populations
Zymography
Table 4.3b Summary of findings of the effects of c-erbB-2 downregulation in BT474A 
on cell motility, adhesion, invasion and protease secretion.
Several studies have shown that c-erbB-2 overexpression results in increased cell 
motility. Smith et al. (2002) reported that the transfection of an ovarian cancer cell line 
with c-erbB-2, resulted in increased motility, while geldanamycin depletion of c-erbB-2 
expression in melanoma cells resulted in decreased motility, accompanied by a loss of 
c-erbB-2 association with p-catenin. Geldanamycin also stimulated tyrosine 
dephosphorylation of P-catenin and increased P-catenin/E-cadherin association, 
resulting in substantially decreased cell motility (Bonvini et al., 2001). Over­
expression of c-erbB-2 in MDA-MB-435 cells resulted in increases in mRNA and 
protein levels of the actin bundling protein fascin. Heightened fascin expression has 
been observed in other systems to result in greatly increased cell motility. MDA-MB- 
435 cells over-expressing c-erbB-2 exhibit significantly heightened cellular dynamics 
and locomotion, while visualization of bundled microfilaments within fixed cells 
revealed enhanced formation of dendritic-like processes, microspikes and other dynamic 
actin based structures (Grothey et al., 2000).
C-erbB-2 levels had a profound affect on the invasiveness of BT474A and MCF-7 H3. 
C-erbB-2 downregulation in BT474A (section 3.2.12) resulted in decreased
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invasiveness. This decreased invasiveness was greater in the clonal populations than 
the pooled population. In MCF-7 H3 c-erbB-2 upregulation resulted in increased 
invasion in two of the clonal populations, MCF-7 H3/ErbB2-B and MCF-7 H3/ErbB2- 
C. MCF-7 H3, the parental cell line was only very slightly invasive, while MCF-7 
H3/ErbB2-A was not in any way invasive.
Results in the literature suggest that c-erbB-2 overexpression is associated with 
increased invasiveness. Various groups have transfected both transformed and cancer 
cell lines with c-erbB-2 to investigate its effect on their metastatic potential. MCF-10A 
was transfected with c-erbB-2 and Ha-ras, both separately (MCF-10A-H and MCF- 
10A-E) and in combination (MCF-10A-HE) (Giunciuglio et al., 1995), resulting in the 
ability to grow in soft agar, increased migration in response to FCM (fibroblast 
conditioned media) and increased invasion of Matrigel. The MCF10A-HE cells also 
adopted an invasive stellate growth pattern when plated or embedded in Matrigel, in 
contrast to the spherical colonies formed by the single transformants MCF10A-H, 
MCF10A-E, and the parental cells. Expression of MMP-2 was found to elevated while 
TIMP-2 levels were lower in the transfectants. These results indicate that c-erbB-2 and 
Ha-ras co-expression can induce a more aggressive phenotype in vitro, representative of 
the malignancy of mammary carcinomas (Giunciuglio et al., 1995).
Transfection of MDA-MB-435 with c-erbB-2 resulted in increased formation of 
metastatic nodules when injected into the lateral tail veins of 8-week old female ICR- 
SCID mice, although not larger in size than those formed by the parental cell line. 
Significantly higher rates of matrigel invasion were also observed. Interestingly, similar 
to the findings for both the c-erbB-2 cDNA and ribozyme transfectants in this thesis, no 
increase in motility was seen, in this case using chemoattractants. Similar adhesion 
ability to the extracellular matrix molecules laminin, fibronectin, collagen IV, 
vitronectin and Matrigel was observed. They observed higher expression of MMP-2 and 
MMP-9 in the cultured media of the transfectants, with the greatest expression of both 
in the highest expression transfectant. C-erbB-2 was not found to effect in vitro growth 
rate, or in vitro transforming ability, as measured in soft agar assays (Tan et al., 1997). 
These findings are very similar to the findings in this thesis.
A study by Roetger et al. (1998) analysed disaggregated cells and cell clusters from 
freshly dissected breast cancer tissues and found that invasive, predominantly clustered
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cells from 14 of 23 tumors were positively stained for c-erbB-2 by 
immunocytochemistry. In four control breast cancer cell lines (SK-BR-3, MCF-7, 
MDA-MB-468, and MDA-MB-468, the latter transfected with a full-length c-erbB-2 
cDNA vector) producing different levels of the c-erbB-2 receptor, the expression level 
correlated positively with the invasiveness of the cells. They also showed that the 
invasive cell populations express the metastasis-associated proteins, matrix 
metalloproteinase MMP-2, CD44, and integrins a vp3 and a6. Zhang et al. (1998) was 
able to show that c-erbB-2 expression may have a direct effect on the expression of 
Type IV collagenases (MMP-2 and MMP-9). NIH 3T3 cells were transfected with 
point mutation activated neu, a mutant analogue of neu, the rat homologue of c-erbB-2. 
These cells were then treated with emodin and DK-V-47 (a derivative of emodin) which 
repress the tyrosine kinase activity of c-erbB-2. A consequence of this repression of 
kinase activity was an inhibition of anchorage dependant (by 55% and 83% 
respectively) and independent growth, and a decrease in the expression of MMP-2 and 
MMP-9. Both compounds virtually abolished the ability of the cells to perform in in 
vitro invasion assays.
C-erbB-2 overexpression in human mammary epithelial cells resulted in acquisition of 
anchorage-independent growth and invasion capabilities, dependent on fibronectin and 
correlated with the down-regulation of cell surface a4 integrin (Ignatoski et al., 2000). 
Spencer et al. (2000) utilised carcinoma cells depleted of c-erbB-2, but not other ErbB 
receptor members, to specifically examine the role of c-erbB-2 in carcinoma cell 
migration and invasion. Cells stimulated with EGF-related peptides show increased 
invasion of the extracellular matrix, whereas cells devoid of functional c-erbB-2 
receptors do not. Expression of the activated rat c-erbB-2/neu oncogene in mouse 
embryo fibroblast 3T3 cells is sufficient to induce experimental metastases in nude mice 
(Yu et al., 1992).
The effects of c-erbB-2 upregulation on MCF-7 H3 adhesion were described in section 
3.1.13. C-erbB-2 expression had no profound effect of the adhesive properties of MCF- 
7 H3, with the exception of a reduction in adhesion to fibronectin. However, figure
3.2.13.3 shows that adhesion to fibronectin was also reduced in BT474A after 
transfection with the c-erbB-2 ribozyme. Therefore this effect is likely to be cell line 
specific rather than as a result of c-erbB-2 regulation of adhesion. As mentioned c- 
erbB-2 downregulation in BT474A resulted in decreased adhesion to fibronectin.
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Figures 3.2.13.1; 3.2.13.2; 3.2.13.4 shows that c-erbB-2 downregulation resulted in 
decreased adhesion to laminin, collagen type IV and matrigel. These findings do 
support the reports in the literature, to the effect that c-erbB-2 overexpression is 
associated with increased adhesion.
Tumour cells with metastatic propensity secrete more of the laminin 0C2 chain than non­
metastatic tumour cells do, and laminin-2, which contains the 0C2 chain, promotes cell 
adhesion better than laminin-1. Han et al. (1999) found a correlation between the 
expression of the laminin-2 isoform and the metastatic phenotype in melanoma cells. 
Cell attachment studies showed that metastatic melanoma cells attached more efficiently 
to laminin-2 substrates. Studies on integrin expression revealed that the presence of 
CH2 P1 integrin correlated with expression of the laminin-2 isoform in metastatic 
melanoma cells, inducing a specific 185 kD protein tyrosine phosphorylation, identified 
as c-erbB-2 by immunoprécipitation. These studies suggest that upregulation of 
expression of the laminin-2 chain correlates with the metastatic phenotype of melanoma 
cells and provides evidence that specific c-erbB-2 tyrosine phosphorylation may be 
involved in integrin-mediated signalling during tumour cell invasion and metastasis. 
Laminin receptors (integrins cxôPi and OC6P4) were found to associate directly with c- 
erbB-2 in carcinoma cell lines and NIH 3T3 transfected with c-erbB-2. Carcinoma cells 
treated with a monoclonal antibody to the a 6 integrin subunit showed a ligand- 
dependent increase of c-erbB-2 phosphorylated molecules coprecipitated with integrins 
and increased DNA synthesis. The interaction between growth factor receptors and 
integrins was also studied in NIH3T3 cells overexpressing receptors and c-erbB-2 
protein. Cells overexpressing both receptors, showed enhanced proliferation rates and 
invasiveness, further suggesting that 0 ^ 4  integrin and ErbB-2 receptor interaction 
might contribute to generate a more malignant phenotype in carcinoma cells (Falcioni et 
al., 1997).
Evidence exists, that c-erbB-2 effects the expression of metastasis associated proteins
such as E-cadherin and P-catenin. The cadherins are a family of transmembrane
glycoproteins that mediate cell-cell adhesion, by connecting cells to each other by
homophilic interations, in which they bind selectively to identical cadherin types
(Liang, 1999). A reduction in E-cadherin expression is found in many breast cancers
and is associated with increased invasiveness (D’Souza and Taylor-Papadimitriou,
1994). Disruption of E-cadherin-mediated intercellular adhesion promotes cell
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dissociation from the primary cancer nest and the E-cadherin-catenin complex functions 
as an invasion suppresser system in cancers (Shibata et al., 1996). Overexpression of c- 
erbB-2 in the human mammary epithelial cell line, MTSV1-7, is associated with 
reduced ability to undergo morphogenesis in vitro and with a decreased level of 
expression of the E-cadherin and ci2 integrin genes (D’Souza and Taylor-Papadimitriou, 
1994; D’Souza et al., 1993). In human gastric cancer TMK-1 cells expressing a N- 
terminally truncated P-catenin, which binds c-erbB-2 but not E-cadherin, the association 
between endogenous p-catenin and c-erbB-2 protein was inhibited, suppressing the 
phosphorylation of p-catenin. These cells exhibited markedly reduced invasiveness in 
vitro and peritoneal metastasis in vivo and developed an epithelial morphology (Shibata 
et al., 1996).
CD44 is a transmembrane glycoprotein that binds hyaluronic acid (HA). CD44 cell 
surface expression was 4.5 times higher in c-erbB-2 overexpressing mouse fibroblasts, 
than in the parental cell line. Overexpression of surface CD44s in c-erbB-2 transfected 
cells results in a dramatic enhancement of HA-mediated cell adhesion. These findings 
suggest that overexpression of CD44s and up-regulation of CD44s-ankyrin interaction 
by c-erbB-2 may be one of the pre-requisite steps in regulating tumour cell behavior 
(Zhuetal., 1996).
Zymography of conditioned media from BT474A shows that this cell line secretes 
matrix metalloproteinases (MMPs). These MMPs appear to be MMP-2 and MMP-9. 
C-erbB-2 downregulation in BT474A resulted in decreased secretion of these MMPs. 
This is similar to the finding of Zhang et al. (1998) reported above, as emodin depletion 
of c-erbB-2 also resulted in decreased expression of MMP-2 and MMP-9. Genistein 
induced several specific molecular changes in head and neck cancer cells, such as 
down-regulation of c-erbB-2 expression, down-regulation of MMP-2 and MMP-9 
secretion, inhibition of tumour cell invasion and down-regulation of nuclear factor- 
kappaB DNA binding activity (Alhasan et al., 2001).
O-charoenrat et al. (2002) studied the profile of ErbB receptors in head and neck 
squamous cell carcinomas (HNSCC) to determine whether their expression was 
associated with clinicopathological features and key molecules involved in angiogenesis 
and metastasis. They also assessed the impact of expression on survival. This study 
included 54 cases of primary HNSCC, of which 27 cases showed lymph node
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metastasis. HNSCC frequently co-expressed multiple ErbB receptors and showed 
significant correlations amongst their levels. High expression of c-erbB-1, c-erbB-2 or 
c-erbB-3 was associated with an infiltrating mode of invasion, nodal metastases and 
advanced pathological stages. C-erbB-1 and c-erbB-2 levels were strongly correlated 
(P=0.0004-0.029) with the expression of MMP-2, MMP-7, MMP-9, MMP-10, MMP-
11, MMP-13, VEGF-A and VEGF-C whereas the levels of c-erbB-3 and c-erbB-4 
showed a weaker correlation (P=0.049-0.01) with some MMPs and VEGF-C. Only 
nodal metastasis and c-erbB-1 levels were significantly associated with poor outcome in 
uni- and multi-variate analysis.
Zymography of conditioned media from MCF-7 H3 shows that this cell line secretes, in 
addition to MMPs, some additional proteases. These proteases not yet identified appear 
to be serine proteases of approximately, 22, 35, 45, 84 and 130kDa. They are only 
expressed in MCF-7 H3 and MCF-7 H3/ErbB2-A, with expression greatest in MCF-7 
H3/ErbB2-A. It is interesting to note that MCF-7 H3/ErbB2-A is less invasive than 
MCF-7 H3, and also these bands were not detected in the invasive BT474A and MDA- 
MB-435S-F. These results were unexpected as previous transfections with c-erbB-2 
had resulted in increased secretion of MMPs, especially MMP-2 and MMP-9., in 
association with increased invasiveness.
Sections 3.1.9.4 and 3.1.9.5 shows that transfection of MCF-7 H3 with c-erbB-2 leads 
to an increase in the expression of other proteins co-immunoprecipitated with c-erbB-2 
or c-erbB-4, suggesting an increase in protein binding to these two receptors, and thus a 
possible activation of signalling pathways. This also coincides with increases in 
tyrosine phosphorylated proteins immunoprecipitated by c-erbB-2, 3 and 4, but not 1, as 
shown in Figure 3.1.9.5. It is possible that some of these proteins upstream of the 
signalling pathways which exert the effects seen in this thesis. Of special interest would 
be the isolation of these proteins and their identification, which could lead to a greater 
understanding of the mechanisms involved in c-erbB-2 receptor signalling. Future work 
would also include investigation of these phenomenon in the BT474A c-erbB-2 
ribozyme transfected cells to determine whether the same proteins are downregulated.
313
4.4 The Role of c-erbB-2 in Tamoxifen Resistance
The evidence in the literature is conflicting as to whether c-erbB-2 overexpression plays 
a role in resistance to tamoxifen hormonal therapy. No evidence was found in this 
thesis for a role for c-erbB-2 in tamoxifen resistance. This may be due to the small 
changes in expression of c-erbb-2. It is possible that greater alteration in c-erbB-2 
expresión may be necessary to have an effect on tamoxifen resistance. C-erbB-2 levels 
had no effect on the expression of estrogen receptor a  protein, while c-erbB-2 
overexpression in MCF-7 H3 resulted in increased estrogen receptor (3, which was also 
accompanied by a decrease of estrogen receptor p in c-erbB-2 downregulated BT474A. 
Estrogen receptor p expression was shown to be significantly up-regulated in a 
tamoxifen-resistant group of breast cancer patients as compared with a tamoxifen- 
sensitive group (P = 0.001 by Fisher's exact test) (Speirs et al., 1999). This is 
interesting as this may indicate a starting point for the development of resistance to 
tamoxifen as is seen in c-erbB-2 overexpressing patients.
Tsutsui et al. (2002) found that c-erbB-2 overexpression in patients with primary breast 
cancer was associated with reduced disease-free survival and overall survival in patients 
receiving tamoxifen. It was also associated with decreased estrogen receptor 
expression. Dowsett et al. (2001) evaluated the antiproliferative effects of endocrine 
therapy in c-erbB-2 positive/ER-positive primary human breast cancer. ER-positive/c- 
erbB-2 positive primary breast carcinomas show an impeded antiproliferative response 
to endocrine therapy that nonetheless may vary between individual treatments.
Bieche et al. (2001) examined the relation between c-erbB-2 gene expression and the 
response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ERa positive 
postmenopausal patients with breast cancer. C-erbB-2 did not persist as an independent 
prognostic factor in multivariate analysis. Nevertheless, when c-erbB-2 mRNA level 
was analysed as a continuous variable, the higher the c-erbB-2 mRNA level, the poorer 
the outcome (P=0.00036). Ellis et al. (2001) reported that the aromatase inhibitor 
letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for c-erbB-1 
and/or c-erbB-2 positive, estrogen receptor-positive primary breast cancer (Spigel et al., 
2002).
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Knoop et al. (2001) investigated interactions between adjuvant treatment with 
tamoxifen and the content of c-erbB-1, c-erbB-2, and p53 in steroid receptor-positive 
patients. Patients with steroid receptor-positive tumors and positive 
immunohistochemical staining for c-erbB-1, c-erbB-2 or p53 benefited from treatment 
with tamoxifen for 1 year. This study did not support the hypothesis that c-erbB-1, c- 
erbB-2 or p53 status predicts benefit from tamoxifen treatment in estrogen receptor- 
positive patients with early-stage breast cancer. Stal et al. (2000) studied the 
importance of c-erbB-2 status in early stage postmenopausal breast cancer for patients 
who participated in a trial of five vs. two years of adjuvant tamoxifen. Overall, c-erbB- 
2-positive patients had a significantly lower recurrence-free probability than others, 
62% at five years as compared to 83%, and showed a significantly decreased breast 
cancer survival rate (P =0.0007).
Kumar el al. (1996) transfected MCF-7 breast cancer cells with a full-length c-erbB-2 
cDNA, gaining high expression of c-erbB-2. Transfection led to the upregulation of 
bcl-2 (2.5-6 fold) compared to the parental or mock-transfected cell lines. 
Overexpression also led to enhanced expression of bcl-X L , with no changes in bcl-Xs. 
No significant changes in levels of bax were seen in the transfectants. The transfection 
of the MCF-7 cells with c-erbB-2 led to the suppression of tamoxifen induced 
apoptosis. Benz et al. (1992) also transfected MCF-7 cells with c-erbB-2, which were 
no longer sensitive to tamoxifen. In this thesis transfection of MCF-7 H3 with c-erbB- 
2 had no effect on tamoxifen sensitivity.
Carlomagno et al. (1996) reported that c-erbB-2 positive node-negative patients did not 
benefit from tamoxifen treatments while those patients that were c-erbB-2 negative did. 
C-erbB-2 expression was not found to be significantly modified by tamoxifen treatment 
(Soubeyran et al., 1996). Borg et al. (1994) noted a favourable effect of adjuvant 
tamoxifen on survival for patients with c-erbB-2 negative tumours, while patients who 
were positive did not benefit from tamoxifen administration. Giai et al. (1994) 
observed that node positive breast cancer patients co-expressing c-erbB-2 and ras had a 
worse outcome than those patients not co-expressing these oncogenes, when treated 
with tamoxifen. Wright et al. (1992) reported that only 7% of c-erbB-2 positive patients 
compared to 37% of c-erbB-2 negative patients responded to tamoxifen treatment. The 
combination of c-erbB-2 and c-erbB-1 appears to have an additive effect in reducing the 
likelihood of response to tamoxifen, as 0 out of 8 patients benefited. Nicholson et al
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(1993) reported that c-erbB-2 expression did not effect response to tamoxifen in a c- 
erbB-1 negative group of patients, while a significant loss of hormone sensitivity was 
found in the c-erbB-1 positive group. In contrast Archer el al. (1995) found no 
correlation between c-erbB-2 overexpression and response to tamoxifen therapy.
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4.5 Taxol Resistance
For ease of discussion MDA-MB-435S-F shall from here on be referred to as MDA-F, 
MDA-MB-435S-F/Taxol-10p as Taxol-lOp, MDA-MB-435S-F/Taxol-10p4p as Taxol- 
10p4p, MDA-MB-435S-F/Adr-1 Op as Adr-lOp and MDA-MB-435S-F/Adr-10pl0p as 
Adr-lOplOp.
Taxol has demonstrated remarkable antineoplastic effects against a wide range of 
human tumours, including ovarian, breast, head and neck, small-cell and non-small-cell 
lung cancers, as well as metastatic melanomas. Studies of taxol-resistant tumour cell 
lines, have shown that the cellular transport of taxol and its microtubule-binding activity 
play a major role in the development of resistance to taxol (Pratt et ah, 1994).
Findings in the MDA-MB-435S-F taxol resistant variants Methods used
Overexpression of mdr-1 at the RNA but not the protein level RT-PCR 
Western Blot
Overexpression of mrp-1 at the RNA and protein level RT-PCR 
Western Blot
Decreased expression of mrp-2, topo I, topo 11(3 and GST % 
mRNA, increased expression of TS, topo Hoc mRNA.
RT-PCR
Cross resistance to vincristine, taxotere and adriamycin, but not 
significantly resistant to carboplatin, VP-16 or 5-fluorouracil
Toxicity assay
Increased adriamycin efflux Adriamycin 
accumulation assay
Circumvention of adriamycin toxicity by sulindac or verapamil 
and circumvention of taxol toxicity by verapamil but not sulindac.
Combination
assays
Table 4.5 Summary of findings in MDA-MB-435S-F Taxol selected variants
There are numerous studies indicating that pl70MUR"’ (but not mrp-1 to a significant 
extent), plays a role in taxol resistance (Reinecke et a l, 2000; Mechetner et a l, 1998; 
Parekh et a l, 1997; Masenek et ah, 1997; Lehnert et ah, 1993, Kamazawa et ah, 2002). 
In an attempt to identify the mechanisms of resistance in Taxol-1 Op and Taxol- 10p4p, 
alterations in the levels of a number of MDR markers were studied in this thesis.
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Overexpression of mdr-1 mRNA in the taxol selected variants, Taxol-1 Op and Taxol- 
10p4p, was detected by RT-PCR compared to their parental cell line MDA-F (section
3.3.8.1), however western blotting did not reveal an increase at the protein level (section
3.3.9.1). Western blotting and RT-PCR revealed that mrp-1 levels were increased at 
both the mRNA and protein levels (section 3.3.8.2; 3.3.9.2). Mrp2 mRNA levels were 
shown by RT-PCR to have decreased with increasing Taxol resistance (section 3.3.8.3). 
Expression of mrp4 and mrp5 was undetectable by RT-PCR in MDA-F, Taxol-1 Op and 
/Taxol-10p4p (section 3.3.8.4; 3.3.8.5). These finding do not correlate with the general 
observations made in the literature with repsect to taxol resistance, that mdr-1 
overexpression plays a role in resistance, while mrp-1 does not. Bhalla et al. (1994) 
described taxol resistant sublines of HL-60 myeloid leukaemia cells (HL-60/Taxl00 and 
HL-60/Taxl000). HL-60/Taxl00 and HL-60/Taxl000 displayed crossresistance to 
taxotere, vincristine and adriamycin, accompanied by increased mdr-1 mRNA and 
protein expression, circumventable by cyclosporin or verapamil. Decreased 
accumulation of taxol and daunomycin was also observed. Reinecke et al. (2000) 
compared the effects of taxol in human renal cell carcinoma of different histological 
types. Mrp-1 was not found to be related to taxol sensitivity, while expression of mdr-1 
correlated positively with lack of response to taxol.
Mrp-1 expression was shown by Kamazawa et al. (2000) to increase in both KF human 
ovarian adenocarcinoma cell line and its taxol-resistant variant after exposure to taxol. 
Vanhoefer et al. (1996) investigated the modulatory activity of the novel pyridine 
analogue PAK-104P, an MRP specific inhibitor, on MRP-mediated resistance to 
adriamycin in two adriamycin-selected human tumour cell lines, HT1080/DR4 
(sarcoma) and HL60/ADR (leukaemia). In cell lines HT1080/DR4 (MRP/1LRP 
phenotype) and HL60/ADR (MRP phenotype), adriamycin resistance was significantly 
higher (250-fold and 180-fold, respectively) than that to taxol (6-fold and 9-fold, 
respectively). With noncytotoxic concentrations of PAK-104P, the reversal of 
adriamycin resistance was significant but partial in HT1080/DR4 and HL60/ADR cells, 
whereas complete reversal of taxol resistance was achieved in HL60/ADR cells. This is 
opposite to the finding of this thesis as sulindac failed to circumvent taxol resistance in 
MDA-F or any of its taxol and adriamycin variants. The findings of Breuninger et al
(1995) were opposite to those of Kamazama et al. (2000) and Vanhoefer et al. (1996). 
NIH 3T3 transfection with Mrp-1 conferred resistance to adriamycin, daunorubicin, VP- 
16, actinomycin D, vincristine and vinblastine, but not taxol.
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Adriamycin accumulation assays were performed on these cell lines to determine 
whether taxol resistance was associated with decreased adriamycin accumulation and 
increased drug efflux. Section 3.3.5 shows that adriamycin accumulation in Taxol-1 Op 
was less than that of the parental cell line), while Taxol- 10p4p accumulated more 
adriamycin. Adriamycin efflux was higher in both cell lines than in MDA-F, with 
Taxol-10p4p efflux greater than Taxol-lOp. These results indicate that increased drug 
efflux may play a role in adriamycin resistance in these cell lines. By extension efflux 
may also play a role in taxol resistance in these cell lines, but a taxol accumulation 
assay was not available for use.
Combination assays were performed to further elucidate mechanisms of resistance to 
adriamycin and taxol in the MDA-F variants. Verapamil inhibits both MDR-1 function 
and MRP-1 function. Sulindac inhibits MRP-1 function only. Sulindac and verapamil 
sensitised MDA-F, Taxol-1 Op and Taxol- 10p4p to adriamycin, with sulindac having the 
greatest effect in the parental MDA-F cells (section 3.3.6.1; 3.3.6.2), and verapamil in 
the taxol selected variants (section 3.3.6.3; 3.3.6.4; 3.3.6.5; 3.3.6.6). These results 
suggest that MRP-1 and MDR-1 play a role in adriamycin resistance in these cell lines, 
although MDR-1 may have a greater role to play in the MDA-F taxol selected variants. 
Sulindac failed to circumvent taxol resistance in any of these cell lines (section 3.3.7.2; 
3.3.7.4; 3.3.7.6), suggesting that MRP-1 may not transport taxol in these cell lines, 
while verapamil sensitised Taxol-lOp (section 3.3.7.3) and Taxol-10p4p (section
3.3.7.5) to taxol, but had no effect on taxol sensitivity in parental MDA-F cells (section
3.3.7.1).
These results pose a question, why does verapamil circumvent adriamycin resistance in 
MDA-F, Taxol-lOp and Taxol-10p4p, while circumventing taxol resistance in Taxol- 
lOp and Taxol-10p4p, but not in the parental cells? Also if verapamil affects taxol only 
in taxol-selected cell lines, this would indicate that mdr-1 plays a role in taxol resistance 
in these cell lines. If this were the case, one would also expect to see large increase in 
resistance to adriamycin and a large increase in the effect of verapamil on adriamycin 
sensitivity in the taxol selected cell lines, which is not the case (section 3.3.4.1; 3.3.4.2; 
3.3.6.1; 3.3.6.3; 3.3.6.5). It should be noted that, while Mdr-1 mRNA is overexpressed 
in Taxol-lOp and Taxol-10p4p (section 3.3.8.1), it is not overexpressed at the protein 
level (section 3.3.9.1).
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The cross-resistance profile of the MDA-F taxol resistant variants (section 3.3.4.1;
3.3.4.2) illustrates that Taxol-lOp and Taxol-10p4p are both cross-resistant to taxotere 
and vincristine, while only Taxol- 10p4p is cross-resistant to adriamycin. They are not 
resistant to 5-fluorouracil, VP-16 or carboplatin. Taxol resistant cell lines that 
overexpress mdr-1 are normally cross-resistant to adriamycin, vincristine, vinblastine, 
VP-16 and show little or no cross resistance to alkylating agents, platinum drugs and 
antimetabolites. Therefore these taxol-resistant variants do not display a MDR profile 
consistent with classic mdr-1 conferred drug resistance. As noted in the previous 
paragraph, mdr-1 overexpression in the taxol-resistant variants appears to be at mRNA 
level rather than at the protein level.
Neither dihydrofolate reductase mRNA (section 3.3.8.6), glutathine-S-transferase n 
mRNA (section 3.3.8.7) nor thymidylate synthase mRNA (section 3.3.8.8) levels were 
found to be significantly altered in MDA-F taxol selected variants. Dihydrofolate 
reductase does not play any known role in taxol resistance consistent with the findings 
in this thesis. Longley et al. (2001) transfected MDA-MB-435 with thymidylate 
synthase but found it had no effect on CPT-11, cisplatin, oxaliplatin or Taxol resistance. 
GST 7i was downregulated in human colon cancer cell line M7609 and in a M7609 
Adriamycin selected variant, by antisense cDNA. The changes in the sensitivity of 
these transfectants to various anticancer drugs were investigated. Sensitivities to 
adriamycin, cisplatin, melphalan, and etoposide were increased while, the sensitivities 
to Taxol, vincristine, 5-fluorouracil, and mitomycin C were not significantly changed. 
Thus, GST 7i does not play a role in taxol resistance (Ban et al., 1996).
Levels of topoisomerase I and IIJ3 mRNA decreased, while topoisomerase Hoc mRNA 
increased with increasing taxol resistance in MDA-F/MDR variants (section 3.3.8.9;
3.3.8.10). This may explain the emergence of increased adriamycin resistance in Taxol- 
10p4p (section 3.3.4.2), but is unlikely to play a direct role in taxol resistance.
Apart from mdr-1 overexpression, reports have suggested that other mechanisms may 
be involved in taxol resistance. This includes development of altered a- or (3- tubulin 
isotypes. Taxol is also metabolised by the cytochrome P-450 system and its metabolism 
may be altered by other drugs affected by this system (Rahman et al., 1994; Martinez C 
et al., 2002). Consequently, this system may be involved in the mechanism of
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resistance to taxol. The sister gene of P-glycoprotein (Spgp) is a liver-specific ATP- 
binding cassette protein highly related to the P-glycoprotein (Pgp). Spgp is an 
approximately 170kDa glycosylated plasma membrane protein localised to the 
canalicular surface of hepatocytes in the rat liver. The expression of Spgp correlates 
with the differentiation of hepatocytes and is seen only in late liver development. It is 
not observed in hepatoma cell lines. The physiological function of Spgp in liver is 
unknown, but it maps to 2q31 in humans, in the vicinity of liver transport disorders for 
bile acids and cholesterol. Spgp may therefore be involved in some aspect of bile acid or 
cholesterol metabolism. Spgp transfectants have a low level resistance to Taxol but not 
to other drugs that form part of the multidrug resistance phenotype. This resistance is 
reversible by the mdr-1-reversing agents cyclosporin A, PSC833, and verapamil, 
suggesting a conservation in some functions of Pgps across large evolutionary distance. 
It is not known whether Spgp plays a role in taxol resistance in cancer cells (Childs et 
al., 1998). Roy and Horwitz (1985) described a correlation between the presence of a 
135kDa phosphoglycoprotein and resistance to taxol. The 135kDa phosphoglycoprotein 
was isolated from a taxol resistant subline of the macrophage-like cell line J744.2
A taxol-resistant subline, derived from the human ovarian cancer cell line SKOV-3, was 
established through selection by culture in incrementally increasing taxol 
concentrations. Comparison of SKOV-3 to SKOV-3TR by differential display identifed 
a new gene, TRAG-3 (Taxol Resistance Associated Gene- 3). TRAG-3 mRNA was 
overexpressed in the taxol-resistant cell line SKOV-3 TR. DNA and protein analysis 
revealed that TRAG-3 has no homology to any known cDNAs or proteins. Northern 
analysis demonstrated that TRAG-3 is overexpressed in the taxol-resistant breast cancer 
cell line MDA 435TR as well as the adriamycin-resistant multiple myeloma cell lines 
8226/DOX40 and 8226/MDR10V. A survey of normal tissue showed minimal or absent 
TRAG-3 mRNA expression. Screening of a wide variety of cancer cell lines 
demonstrated TRAG-3 expression in many cell lines derived from different tissue types. 
In summary, TRAG-3 is a novel gene whose expression is associated with the 
chemotherapy-resistant and neoplastic phenotype (Duan et al., 1999). Early studies of 
TRAG-3 revealed overexpression in many carcinoma cell lines including several 
melanoma lines. Expression of TRAG-3 was present in normal testis but absent in all 
other tissues. RT-PCR evaluation of TRAG-3 reveals two transcripts in many carcinoma 
cell lines with sequencing of these products demonstrating the 799 bp TRAG-3
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transcript and a second alternatively spliced transcript, TRAG-3 long TRAG-3 maps to 
band Xq28. TRAG-3 appears to be a novel cancer/testis antigen (Feller et a l, 2000).
Apoptotic factors have been implicated in the development of resistance to taxol in 
carcinoma cell lines. Stable transfection of human ovarian carcinoma cells with survivin 
cDNA caused a four- to six-fold increase in cell resistance to taxotere and taxol with a 
concomitant reduction in the apoptotic response to taxol, but did not affect cell 
sensitivity to cisplatin or oxaliplatin. High levels of survivin protein expression, 
detected by immunohistochemistry in advanced ovarian carcinomas, were significantly 
associated with clinical resistance to a taxol/platinum-based regimen but unrelated to 
tumour shrinkage following cisplatin-including combinations (non-taxol based) 
(Zaffaroni et al., 2002).
Haider et al. (1996) reported that the treatment of prostate cancer cell lines expressing 
bcl-2 with taxol induced bcl-2 phosphorylation and programmed cell death, whereas 
treatment of bcl-2-negative prostate cancer cells with taxol did not induce apoptosis. 
They suggested that these findings supported the use of taxol for the treatment of bcl-2- 
positive prostate cancers and other bcl-2-positive malignancies, such as follicular 
lymphoma. Ibrado et al. (1996) reported on the effect of bcl-XL overexpression on 
resistance to taxol-induced apoptosis. Intracellularly, taxol induces tubulin 
polymerization and mitotic arrest, followed by apoptosis. High Bcl-xL levels did not 
affect the microtubular bundling or mitotic arrest due to taxol but significantly inhibited 
the morphological, flow cytometric, and DNA fragmentation features associated with 
taxol-induced apoptosis. This resulted in a significant improvement in the survival of 
taxol-treated cells that possess high Bcl-xL levels.
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4.6 Adriamycin Resistance
The most common method of resistance to adriamycin is increased drug efflux due to 
overexpression of P-glycoprotein. Cells selected for resistance to adriamycin are 
usually cross resistant to vinca alkaloids and other antibiotics such as actinomycin D. 
Other cell lines have been found to have increased glutathione peroxidase, glutathione 
or glutathione S-transferase.
Findings in the MDA-MB-435S-F adriamycin selected
variants
Methods used
Failure of MDA-MB-435S-F to develop high resistance to 
adriamycin despite ability to develop resistance to taxol
Toxicity assay
No change in expression of MDR at RNA or protein level RT-PCR 
Western Blot
Overexpression of MRP-1 at RNA and protein level RT-PCR 
Western Blot
Decreased expression of mrp-2, GST n, TS and topo I mRNA, 
increased expression of topo Ila mRNA
RT-PCR
Cross resistance to VP-16, vincristine and taxotere, while 
sensitised to carboplatin, taxol and 5-fluorouracil
Toxicity assay
Increased adriamycin efflux Adriamycin 
accumulation assay
Circumvention of adriamycin resistance by sulindac and 
verapamil, while no circumvention of taxol resistance by 
verapamil or sulindac detected.
Combination
assays
Table 4.6 Summary of findings in MDA-MB-435S-F adriamycin selected variants
Numerous studies have indicated a role for mdr-1, mrp-1, GST n and topoisomerases in 
adriamycin resistance (Uchiyama-kokubu, el al., 2001; Bader el al., 1998; Yoo et al., 
1998; Lee et al., 1996; Kuriyama et al., 1997). In an attempt to identify the 
mechanisms of resistance in Adr-lOp and Adr-lOplOp, mRNA expression of a number 
of MDR markers were studied in this thesis.
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MDA-F failed to select for resistance to adriamycin. Adr-lOp failed to achieve a 
significant increase in adriamycin resistance (section 3.3.4.3), although it was 
significantly resistant to VP-16. Adr-lOplOp did have a statistically significant increase 
in adriamycin resistance (section 3.3.4.4), although it was only a 1.4 fold increase. This 
cell line was also cross resistant to vincristine (1.61X), VP-16 (2.05X) and Taxotere 
(1.42X). Both variants were significantly sensitised to taxol and 5-fluorouracil, while 
only Adr-lOplOp was sensitised to carboplatin. It can be concluded that this breast 
cancer cell line is resistant to selection by adriamycin, but not by taxol. Interestingly, 
previous work in this lab showed that the breast cell line BT-20 was not selectable for 
resistance to adriamycin, while MCF-7 was (NicAmhlaoibh, 1997). It may also be of 
interest that there is a trend here in p53 status in breast cell lines and development of 
resistance to adriamycin. MCF-7 contains wild type p53, while BT-20 and MDA-MB- 
435 (the grandparental cell line of MDA-F) both express mutant p53.
A large number of factors play a role in adriamycin resistance. This includes the 
overexpression of drug pumps such as mdr-1, mrp-1, mrp-2, mrp-3 and LRP (Clynes et 
al., 1998; Borst et al., 1999; Cui et al., 1999; Young et al., 1999). The cross resistance 
profiles of Adr-lOp and Adr-lOplOp, do not indicate a role for mdr-1 in the drug 
resistance of these cell lines. This confirmed by the lack of detection of any increase in 
mdr-1 expression at either the mRNA (section 3.3.8.1) or protein level (3.3.9.1) in either 
of these adriamycin selected variants. Mrp-1 overexpression has been shown to confer 
resistance to anthracyclines, epipodophyllotoxins and some vinca alkaloids (Clynes et 
al., 1998). Breuninger et al. (1995) transfected NIH 3T3 with Mrp-1 and studied its 
affect on drug resistance. Mrp-1 overexpression in NIH 3T3 conferred resistance to 
adriamycin, daunorubicin, etoposide, actinomycin D, vincristine and vinblastine, but not 
taxol. The increased resistance to adriamycin, VP-16 and vincristine in Adr-lOplOp is 
consistent with an mrp-1 drug resistant phenotype. Western blotting and RT-PCR 
revealed that mrp-1 levels were increased at both the mRNA and protein level (section 
3.3.8.2; 3.3.9.2). As described in section 4.2 adriamycin selected cell lines expressed 
high levels of mrp-1 (Vanhoefer et al., 1996; Beck et al., 2001). Mrp-2 mRNA 
expression was reduced in Adr-lOp and Adr-lOplOp, relative to their parental cell 
(section 3.3.8.3). This was unexpected as mrp2 is known to confer resistance to 
adriamycin (Koike et al., 1997; Cui et al., 1999). This may go some way in explaining 
why MDA-F did not develop adriamycin resistance, as a reduction in mrp-2 expression 
may have cancelled out any benefits seen by increased mrp-1 expression.
324
Adriamycin accumulation assays were performed to determine whether the adriamycin 
selected variants showed changes in adriamycin accumulation or adriamycin efflux. 
Section 3.3.5 shows that adriamycin accumulation in Adr-lOp was greater than the 
parental cell line (28% more), while Adr-lOplOp accumulated the same amount of 
adriamycin as the parental cell line. Adriamycin efflux was higher in both cell lines 
than in MDA-F, with almost a 4-fold increase in efflux. These results indicate that the 
adriamycin selected cell lines have gained increased adriamycin efflux. However the 
fact still remains that they failed to become highly resistant to adriamycin. It is possible 
that the increased accumulation of adriamycin in Adr-lOp, counteracts the increased 
efflux in this cell line, and may explain why no increase in adriamycin resistance is 
observed.
Combination assays performed on these cell line, showed that sulindac and verapamil 
sensitised MDA-F, Adr-lOp and Adr-lOplOp to adriamycin. While sulindac had a 
greater effect on adriamycin sensitivity than verapamil in MDA-F (section 3.3.6.1;
3.3.6.2), the reverse was observed in Adr-lOp (section 3.3.6.7; 3.3.6.8) and Adr-lOplOp 
(section 3.3.6.9; 3.3.6.10). This was similar to findings for Taxol-1 Op (section 3.3.6.3;
3.3.6.4) and Taxol-10p4p (section 3.3.6.5; 3.3.6.6). These results suggest that MRP-1 
and mdr-1 play a role in adriamycin sensitivity in these cell lines. No large changes in 
potency of verapamil or sulindac were observed in Adr-lOp (section 3.3.6.7; 3.3.6.8) 
and Adr-lOplOp (section 3.3.6.9; 3.3.6.10). Neither sulindac nor verapamil were 
capable of circumventing taxol resistance in either the parental (section 3.3.7.2) or any 
of the adriamycin-resistant variants (section 3.3.7.8; 3.3.7.10). This that the verapamil 
circumvention of adriamycin toxicity observed was through inhibition of MRP-1 and 
not MDR-1, as if MDR-1 were present verapamil would also circumvent taxol 
resistance. Adriamycin-resistant cell lines that express mrp-1 are normally cross- 
resistant to adriamycin, daunorubicin, VP-16, actinomycin D and vincristine, but not 
taxol or vinblastine. Mrp-2 resistance profiles are similar to mrp-1 with exception that 
it also transports cisplatin and vinblastine.
No significant changes in dihydrofolate reductase mRNA levels were observed (section
3.3.8.6), consistent with findings in the literature (Mandelbaum-Shavit and Ramu, 
1987;. NicAmhlaoibh et al., 1999). Thymidylate synthase mRNA levels decreased in 
both Adr-lOp and Adr-lOplOp (section 3.3.8.8). This correlates well with a decrease in
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5-Fluorouracil resistance in these cell lines (section 3.3.4.3; 3.3.4.4). It is unlikely that 
(section 3.3.4.3; 3.3.4.4) has a direct effect on adriamycin resistance, although 
correlations have been made between thymidylate synthase expression and failure to 
respond to adriamycin therapy in human squamous cell lung carcinomas patients (Yolm 
andMattem, 1992).
No changes in glutathione-S-transferase n mRNA levels were observed in these 
adriamycin selected variants (section 3.3.8.7). These results differ from those found in 
the literature. Increased GST n expression is linked to increased adriamycin resistance 
and is often induced during adriamycin selection. As mentioned in section 4.2, GST n 
antisense sensitised human colon cancer cell line M7609 to adriamycin, cisplatin, 
melphalan, and VP-16, but not taxol, vincristine, 5-fluorouracil, or mitomycin C (Ban et 
ah, 1996). Masanek et ah (1997) showed that adriamycin selected OAW-42 displayed 
overexpression of mdr-1, GST n, thymidylate synthase , glutathione peroxidase and c-
Kiura et ah (1993) selected the human small cell lung cancer cell line SBC-3 with 
resulting adriamycin resistance was accompanied by slower growth rate, increased 
MDR-1 expression, a decrease in intracellular accumulation of Adriamycin, elevation of 
the intracellular GSH content coupled with GST n levels and a decrease in 
topoisomerase II activity.
Two types of topoisomerases (Topo I and Topo II) have been distinguished and 
characterised. Topoisomerase I catalyses the conversion of of the DNA topology by 
introdicing single strand breaks into the DNA molecule. Topoisomerase II (of which 
there are two isoforms (Ila of pl70 kDa and lip of 180 kDa) are able to cleave double 
stranded DNA and can support more complex interconversions of the DNA topoology 
by an ATP-dependant strand passage process (Parchment & Pessina, 1998). Levels of 
topoisomerase I mRNA decreased in response to adriamycin selection (section 3.3.8.9;
3.3.8.11), while levels of topoisomerase Ila mRNA increased as compared to the 
parental cell line. These results are surprising as increased adriamycin resistance is 
usually associated with decreased topoisomerase Ila expression (Cole et ah, 1991) or 
activity (De Jong et al., 1990; Deffie et ah, 1989), or mutation of topoisomerase 
Ila  (Deffie et ah, 1989).
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4.7 The Effects of Taxol Selection on Cell Adhesion, Motility and 
Invasion.
4.7.1 Effects of Taxol Selection on Cell Adhesion
Findings in the MDA-MB-435S-F taxol resistant variants Methods used
Reduced adherence to laminin Adhesion Assay
Reduced adherence to fibronectin Adhesion Assay
Reduced adherence to collagen type IV Adhesion Assay
Reduced adherence to matrigel Adhesion Assay
Reduced adherence of Taxol-1 Op superinvasive population to 
laminin, fibronectin, collagen type IV and matrigel
Adhesion Assay
Increased adherence of Taxol- 10p4p superinvasive population to 
laminin, fibronectin, collagen type IV and matrigel
Adhesion Assay
Table 4.7.1 Summary of adhesive properties of taxol selected variants of MDA-MB- 
435S-F.
Taxoids exert a direct effect on cell adhesion by stabilisation of microtubules. Cell 
adhesion is important in the regulation of cell proliferation, migration, survival, and 
apoptosis. The major components of cell adhesion are the cadherin family of proteins, 
a-, p~ and y-catenins, and cytoskeletons. In addition, P-catenin, when associated with 
adenomatous polyposis coli (APC) protein, an oncosuppressor, is implicated in the 
regulation of P-catenin/APC-related signaling pathways. To examine the correlation 
between impairment of cell adhesion events and apoptosis, Ling et al. (2001) used 
human non-small-cell lung cancer H460 and H520 cell lines as models to determine 
whether taxol-induced apoptosis was associated with disruption of the components of 
cell adhesion and their functions. Taxol treatment resulted in cells rounding up and 
losing contact with their neighboring cells, suggesting that the drug does indeed affect 
cell adhesion and related events. Western blot analysis revealed that taxol caused a 
time- and concentration-dependent cleavage of P-catenin, y-catenin, and APC protein, 
but not a-catenin or E-cadherin. Taxol treatment led to the proteolysis and activation of 
caspase-3 and -7, but not caspase-1. Furthermore, taxol-induced apoptosis and cleavage
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of (3-catenin and y-catenin were inhibited by the pan-caspase inhibitor Z-VAD-FMK 
and partially inhibited by the caspase-3 inhibitor Z-DEVD-FMK but were not affected 
by the caspase-1 inhibitor AC-YVAD-CMK. Interestingly, the taxol-induced (3-catenin 
fragment lost its ability to bind to E-cadherin, a-catenin, or APC protein and to serve as 
a substrate for tyrosine kinase. All their data demonstrate that the caspase-mediated 
cleavage of (3-catenin, y-catenin, and APC protein might contribute to taxol-induced 
apoptosis.
These observations suggest that taxol-mediated stabilisation of microtubules and 
subsequent cell death may be more effective if the tumour is adherent to the 
extracellular matrix. It may be advantageous to a tumour or cell line to become less 
adhesive to extracellular matrix components, in order to lessen the effects of taxol on 
microtubules. In the case of the taxol-selected variants of MDA-F, they are 
considerably less adhesive to laminin, fibronectin, collagen type IV and matrigel 
(sections 3.3.14.1; 3.3.14.2; 3.3.14.3; 3.3.14.4). If the cell is less adherent, then taxol 
will be unable to induce events such as observed by Ling et al. (2001). Bershadsky et 
al. (1996) also studied the disruption of microtubules by nocodazole or vinblastine, 
without the addition of external growth factors in serum-starved Swiss 3T3 cells. In 
matrix-adherent, serum-starved Swiss 3T3 cells, the system of focal adhesions and actin 
bundles is poorly developed, and the level of tyrosine phosphorylation of FAK and 
paxillin is low. A number of growth factors rapidly stimulate tyrosine phosphorylation 
of these proteins and the assembly of focal adhesions and actin bundles. Growth factors 
and adhesion to the ECM are both necessary for the subsequent transition of cells to the 
S-phase of the cell cycle. Vinblastine and nocodazole induced the rapid assembly of 
focal adhesions and microfilament bundles, tyrosine phosphorylation of FAK and 
paxillin, and subsequent enhancement of DNA synthesis. All these effects required cell 
adhesion to the ECM and do not occur when cells are plated on substrates coated with 
poly-L-lysine or concanavalin A. Inhibitors of tyrosine phosphorylation and cell 
contractility also eliminate the effects of microtubule disruption on adhesion-dependent 
signal transduction. In ECM-attached cells, microtubule disruption activates the 
integrin-dependent signalling cascade, which leads to the assembly of matrix adhesions 
and the induction of DNA synthesis. The increase in cell contractility is an 
indispensable intermediate step in this signalling process.
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The effectiveness of chemotherapeutic drug is severely limited by expression of 
intrinsic resistance in some patients and by acquired resistance in others. Kerbel el al.
(1996) hypothesised that the resistance of solid tumors, including breast cancer, can be 
expressed at the prototissue/multicellular level, and that this "multicellular resistance" 
can be minimized or reversed by the appropriate use of so-called "anti-adhesive" agents. 
It is well known that monolayer cultures of tumour cells including murine breast cancer 
are generally much more intrinsically chemosensitive than the same cells grown as solid 
tumors in vivo. However, the relative resistance of solid tumors can often be 
recapitulated in tissue culture simply by growth of the tumour cells as three dimensional 
multicellular spheroids. There are cases where this is also true with respect to acquired 
drug resistance. This "multicellular resistance" could be due to such factors as 
insufficient drug penetration, a reduced growth fraction, or a decreased sensitivity to 
drug induced apoptosis mediated by cell-cell interaction survival signals. The relative 
intrinsic resistance of intact murine EMT-6 mouse mammary carcinoma spheroids can 
be significantly reversed by the anti-adhesive (disaggregating) effects of hyaluronidase. 
Moreover, this novel method of chemosensitization appears to depend on increased 
recruitment of disaggregated cells into the cycling pool, thus rendering them more 
sensitive to a cell cycle dependent drug such as cyclophosphamide. The reduced growth 
fraction observed in spheroids appears to be due to a marked cell contact-dependent 
upregulation of the cyclin dependent kinase inhibitor, p27Kipl.
If one of the mechanisms of action of taxol is to reduce the adhesiveness of tumour cells 
to their tumour mass there by increasing the surface area available to the drug, and 
reducing cell-cell interactions which might be advantageous to the tumour cells, it is 
possible that tumour cells may develop resistance to taxol, through loss of adhesiveness, 
thereby eliminating one of the mechanisms of taxol action.
4.7.2 Effects of Taxol Selection on Cell Motility
Findings in the MDA-MB-435S-F taxol resistant variants Methods used
Decreased motility of Taxol-1 Op compared to parental cell line Motility Assay
Decreased motility of Taxol-10p4p compared to parental cell line Motility Assay
Table 4.7.2 Summary of motility properties of taxol selected variants of MDA-MB- 
435S-F.
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Taxol treatment at non-lethal levels in general leads to decreased cell motility (Stracke 
et al., 1993; Liao et al., 1995; Belotti et al., 1996). Motility assays for MDA-F and its 
taxol resistant variants showed that Taxol-1 Op and Taxol-10p4p were considerably less 
motile then their parental cell line (section 3.12.1). This may be as a direct result of 
exposure to taxol which inhibits motility, after which the subsequent cell population did 
not recover, or due to the development of reduced motility so that taxol is no longer able 
to target components involved in motility.
Taxol, which stabilises microtubules, decreases stimulated-motility of the human 
tumour cell line, A2058. Taxol had an inhibitory effect on adherence, with adhesion to 
gelatin being greater affected than adhesion to tissue culture plastic or laminin. This 
suggests that, in these tumour cells, taxol stabilisation of microfilaments inhibits both 
motility and adherence (Stracke et al., 1993).
The effect of taxol on the morphological changes induced by hepatocyte growth 
factor/scatter factor (HGF/SF) in MDCK cells were studied. The results suggest that 
there are two components in the response to HGF/SF: (a) activation of the extension of 
lamellae leading to cell spreading; and (b) reorganisation of microtubules leading to 
polarisation of cell shape. The latter response is highly sensitive to taxol. HGF/SF 
induced spreading in taxol-treated MDCK cells but these cells retained a non-polarized 
discoid shape and a pattern of actin microfilament bundles characteristic of the 
untreated cells. Taxol did not prevent HGF/SF-induced migration of cells in Boyden 
chambers but completely inhibited the outgrowth of multicellular strands and tubules 
from cell aggregates in collagen gels. These results show that enhanced lamella 
formation in response to HGF/SF without polarisation of cell shape is sufficient to 
induce cell motility. In contrast, microtubule-dependent polarisation is essential for 
complex morphogenetic responses such as tubulogenesis in collagen gels (Dugina et al.,
1995). These results again suggest that taxol action is enhanced when cells are adhered 
to an extracellular type substrate.
Liao et al. (1995) measured the rate of locomotion of NRK fibroblasts migrating into an 
in vitro wound, before and after treatment with different concentrations of nocodazole 
to generate cells with different levels of microtubules. A comparison of the locomotion 
rate measurements with the microtubule level measurements indicated that over half of
the cell locomotion rate could be blocked by nocodazole without significantly affecting 
microtubule levels in the cell; the remaining locomotion rate was reduced proportionally 
to microtubule levels. This suggests that low concentrations of nocodazole interfere 
with microtubule dynamics and thus, microtubule dynamics are critical for the maximal 
speed of cell locomotion. Analogous effects of taxol and vinblastine on cell locomotion 
further supported this notion: at concentrations that reportedly cause little change in the 
level of microtubules, taxol and vinblastine also dramatically decreased the rate of 
locomotion of NRK cells.
Belotti el al. (1996) studied the effect of taxol on the adhesive and motility properties of 
human ovarian carcinoma cell lines. Taxol significantly inhibited the motility of 
OVCAR 5, SK-OV-3, and HOC-IOTC ovarian carcinoma cell but did not affect the 
adhesion of these cells to the subendothelial matrix. The association between inhibition 
of motility and cytotoxic activity was investigated using an A2780 subclone (1A9) and 
three taxol-resistant variants (designated 1A9/PTX22, 1A9/PTX10, and 1A9/PTX18). 
Although taxol did not significantly affect the adhesion to subendothelial matrix of the 
sublines, it completely inhibited their migration. Inhibition of migration was similar in 
1A9 cells and the resistant sublines. Taxol inhibited motility induced by soluble 
attractant (chemotaxis) and immobilised attractant (haptotaxis). Inhibition of cell 
motility occurred in the absence of an antiproliferative effect, because higher 
concentrations of taxol were required to inhibit tumour cell. These data show that taxol 
is a potent inhibitor of ovarian carcinoma cell motility and that this activity is 
independent of its cytotoxic activity.
The effect of taxol on endothelial cell functions and on angiogenesis was studied by 
Belotti et al. (1996). In vivo, non-lethal concentrations of taxol significantly inhibited 
the angiogenic response induced by tumour cell supernatant embedded in a pellet of 
reconstituted basement membrane (Matrigel) injected s.c. into C57BL/6N mice. In vitro, 
it inhibited endothelial cell proliferation, motility, invasiveness, and cord formation on 
Matrigel in a dose-dependent manner. This data indicates that taxol has a strong anti- 
angiogenic activity, a property that might contribute to its antineoplastic activity in vivo.
Migrating cells are polarised with a protrusive lamella at the cell front followed by the 
main cell body and a retractable tail at the rear of the cell. The lamella terminates in 
ruffling lamellipodia that face the direction of migration. Ballestrem et al. (2000)
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studied the contribution of microtubules to cell motility by time-lapse video microscopy 
on green fluorescence protein-actin- and tubulin-green fluorescence protein-transfected 
melanoma cells. Treatment of cells with either the microtubule-disrupting agent 
nocodazole or with the stabilising agent taxol showed decreased reversible ruffling and 
lamellipodium formation. Although ruffling and lamellipodia were formed without 
microtubules, the microtubular network was needed for advancement of the cell body 
and the subsequent retraction of the tail. The formation of lamellipodia occurs via actin 
polymerisation independently of microtubules, but microtubules are required for cell 
migration, tail retraction, and modulation of cell adhesion.
4.7.3 Affects of Taxol Selection on Cell Invasion
Findings in the MDA-MB-435S-F taxol resistant variants Methods used
Novel finding of thesis - Development of a two tiered invasive 
phenotype not present in the parental cell line
(1) Invasion of matrigel to underside of invasion chamber
(2) Detachment of cells from underside of invasion chamber 
and reattachment to bottom of 24-well plate (only in taxol 
selected and adriamycin selected variants -  see section 
4.5)
Invasion Assay
No changes observed secretion of MMP-2 or MMP9 in Taxol-1 Op 
or Taxol-10p4p compared to parental cell line
Zymography
Table 4.7.3 Summary of invasion properties of taxol selected variants of MDA-MB- 
435S-F.
Initially invasion assays indicated no major changes in the invasiveness of Taxol-lOp or 
Taxol- 10p4p compared to MDA-F (section 3.3.13.1). It actually appeared that the cell 
lines were less invasive which would have been similar to reports of the effects of taxol 
on cell invasion as seen in the literature (Steams and Wang, 1992; Terzis et ah, 1997; 
Westerlund et ah, 1997; Sgadari et ah, 2000; Liu et ah, 1998). It was then observed that 
the taxol selected variants had developed the ability to invade to the underside of the 
invasion chamber and then detach from the bottom and reattach to the bottom of the 24
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well plate. It was thought that this phenomenon might be linked to the vastly reduced 
adhesiveness of these cells to components of the extracellular matrix (section 3.3.14). 
This could be an indication that taxol selects for a more aggressive invasive phenotype, 
which may appear to be overall less invasive, but selects for cells capable of invading 
further, and perhaps with a greater survival rate. No changes in the secretion of MMP-2 
or MMP-9 were observed in these cell lines (section 3.3.15), however it has not yet been 
investigated whether there is a reduction in the tissue inhibitors of matrix 
metalloproteinases in these variants.
While some reports indicate that taxol increases motility and invasion, they are very few 
(Silbergeld et al., 1995; Welch et al., 1989), the majority of reports indicate that that 
taxol exposure has an inhibitory effect on invasion and metastasis. Steams and Wang 
(1992) reported that taxol blocked processes essential for prostate tumour cell (PC-3 
ML) invasion and metastases. Abnormal bundling of microtubules in a dosage- 
dependent manner, was observed upon treatment with taxol, accompanied by inhibition 
of secretion of the 72kDa and 92 kDa type IV collagenases and 57kDa gelatinase, and 
inhibition of invasion of Matrigel in Boyden chamber chemotactic studies. More 
importantly, studies in SCID mice demonstrated that taxol (50 to 250 mg/m2/day) 
blocked the establishment, growth, and long-term survival of PC-3 ML cells. 
Verschueren et al. (1994) also reported on the inhibition by taxol of BW-O-Lil, a T- 
lymphoma cell line that forms metastases in various organs after injection into 
syngeneic mice, motility and invasion.
In contrast Silbergeld et al. (1995) evaluated in vitro chemosensitivity of glioblastoma 
to Taxol and the affect of Taxol on glioblastoma cell locomotion. Five human 
glioblastomas and the C6  rat glioma, were exposed to taxol (0-250 nM) and suspended 
in agar in capillary tubes. All six cell lines demonstrated sensitivity to Taxol (LD50 1 
nM to > 250 nM). Increasing Taxol concentration caused increased locomotion in all 
six cell lines (p < 0.0001). These findings suggested that the clinical use of Taxol for 
glioblastoma may slow the growth of bulk disease, but may also lead to increased 
tumour invasion. Terzis et al. (1997) tested taxol for its anti-migrational, anti-invasive 
and anti-proliferative effect on two human glioma cell lines (GaMg and D-54Mg) 
grown as multicellular tumour spheroids. Both cell lines showed a dose-dependent 
growth and migratory response to taxol. Taxol also proved to be remarkably effective in
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preventing invasion in a co-culture system in which tumour spheroids were confronted 
with fetal rat brain cell aggregates.
Westerlund et al. (1997) studied the effect of the taxol on a human ovarian cancer cell 
line (Ovcar-3). Ovcar-3 cell attachment, migration and in vitro invasion were 
significantly decreased after taxol treatment (P = 0.02, P < 0.01 and P = 0.001, 
respectively) whereas no alteration in the secretion of latent MMP-2 was noted. 
However, the intracellular localisation of the immunoreactive protein for MMP-2 was 
altered in response to taxol treatment. Interestingly, taxol increased the appearance of 
TIMP-2 protein in culture medium (P = 0.002) but did not change the expression of 
mRNA for TIMP-2 in Ovcar-3 cells. These data show that taxol is an effective 
suppressor of Ovcar-3 cell invasion. It inhibits attachment and migratory activities of 
the cells and also causes a release of TIMP-2 protein into the tissue culture medium.
Sgadari et al. (2000) investigated the mechanisms of taxol activity in Kaposi's sarcoma 
(KS), an angioproliferative disease. Using a model of experimental KS induced by the 
inoculation of KS-derived spindle cells in nude mice and primary cultures of KS spindle 
cells, they found that taxol promoted regression of KS lesions in vivo and that it blocked 
the growth, migration, and invasion of KS cells in vitro. Furthermore, taxol treatment 
promoted apoptosis and down-regulated Bcl-2 protein expression in KS cells in vitro 
and in KS-like lesions in mice. These results suggest that taxol interferes with KS by 
down regulating Bcl-2 antiapoptotic effect. Liang et al. (2001) reported that the 
selection of RPMI 2650 with taxol had no effect on the invasiveness of the cell line, 
while selection with melphalan resulted in a cell line with increased invasiveness.
Myoung el al. (2001) investigated the inhibitory effects of taxol and thalidomide on the 
growth of oral squamous cell carcinoma (OSCC) xenotransplanted into nude mice. 
Taxol showed an inhibitory effect on the growth of transplanted human OSCC and 
reduced the immunohistochemical expression of VEGF and CD31 and VEGF mRNA 
(PO.Ol). Thalidomide also lowered remarkably VEGF expression (PO.Ol) and CD31 
(P<0.01) as well as VEGF mRNA (P<0.05), but it did not show statistically significant 
inhibitory effect on the tumour growth. These results suggest that the growth of human 
OSCC is not simply dependent on VEGF-induced angiogenesis and that anti-angiogenic 
therapy alone is not likely to be effective for the treatment of OSCC, but might be 
regarded as an adjuvant chemotherapeutic strategy.
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Liu et al. (1998) reported on the antitumour and anti-invasion activities of taxol, 
harringtonine, homoharringtonine (harringtonine and its derivative homoharringtonine 
are ester-containing anti-leukemic alkaloids isolated from the tree Cephalotaxus 
harringtonia) and camptothecin on highly metastatic melanoma B16-BL6 and human 
fibrosarcoma HT-1080 cells. Results demonstrated that taxol, harringtonine, 
homoharringtonine and camptothecin exhibited significant inhibition of cell growth of 
B16-BL6 and HT-1080 cells. Taxol, harringtonine and homoharringtonine were also 
found to be effective for the inhibition of cell invasion and migration of B16-BL6 cells, 
but camptothecin showed basically no effect at the indicated concentration. Welch et 
al. (1989) studied the effects of chemotherapeutic drug pre-treatment on the 
invasiveness of cell lines demonstrating low and high invasive and metastatic potentials. 
Cells were treated with drug for 48 hours prior to invasion assays, at non-cytotoxic 
levels. Of these, vincristine, colcemid and colchicine inhibited invasion but taxol did
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4.8 The Effects of Adriamycin Selection on Cell Adhesion, Motility and 
Invasion.
4.8.1 Affects of Adriamycin Selection on Cell Adhesion
Findings in the MDA-MB-435S-F adriamycin selected
variants
Methods used
Reduced adherence to laminin Adhesion Assay
Reduced adherence to fibronectin Adhesion Assay
Reduced adherence to collagen type IV Adhesion Assay
Reduced adherence to matrigel Adhesion Assay
Increased adherence of/Adr-lOp superinvasive population to 
laminin, fibronectin, collagen type IV and matrigel
Adhesion Assay
Increased adherence of Adr-lOplOp superinvasive population to 
laminin, fibronectin, collagen type IV and matrigel
Adhesion Assay
Table 4.8.1 Summary of adhesive properties of adriamycin-selected variants of MDA- 
MB-435S-F.
Similar to the taxol-selected variants, the adriamycin-selected variants of Adr-lOp and 
Adr-lOplOp exhibited decreased adhesion to laminin (section 3.3.14.1), collagen type 
IV (section 3.3.14.2), fibronectin (section 3.3.14.3) and matrigel (section 3.3.14.1). The 
reduction in adhesion was greatest for fibronectin and laminin). These reductions in 
adhesion to ECM proteins were not as great as for the taxol-selected variants.
Tumour cell adhesion to the extracellular matrix (ECM) is closely linked with tumour 
cell invasion and metastasis. Repesh et al. (1993) demonstrated that low levels of 
adriamycin can inhibit the invasion of highly metastatic K173 5-M2 mouse melanoma 
cells in vitro through a reconstituted basement membrane extract. Adriamycin-induced 
inhibition of melanoma cell invasion occurred at levels of the drug (i.e. 1 ng/ml) that did 
not inhibit tumour cell growth, suggesting that the observed inhibition in tumour cell 
invasion was not due to the well-documented ability of adriamycin to interfere with 
DNA and/or RNA synthesis. Rather, these studies indicated that adriamycin-induced
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inhibition of melanoma cell invasion was accompanied by a corresponding decrease in 
the ability of adriamycin-treated tumour cells to migrate in response to several isolated 
ECM components including fibronectin, laminin and basement membrane (type IV) 
collagen. The decreased migration of adriamycin-treated tumour cells was not 
accompanied by a decrease in the adhesion or spreading of the adriamycin-treated cells 
on substrata coated with these ECM components. Instead, adriamycin-treated cells 
actually exhibited a slightly increased propensity (compared to untreated control cells) 
to adhere on fibronectin-, laminin-, and type IV collagen-coated substrata. Additionally, 
adriamycin treatment caused a dramatic increase in focal contact formation by these 
melanoma cells, as assessed by fluorescent microscopy of actin and vinculin. The 
findings of Repesh et al. (1993) suggest that decreased invasion is accompanied by 
decreased motility and increased adhesion.
4.8.2 Effects of Adriamycin Selection on Cell Motility
Findings in the MDA-MB-435S-F adriamycin selected
variants
Methods used
Increased motility of Adr-lOp compared to parental cell line Motility Assay
Decreased motility of Adr-lOplOp compared to Adr-lOp, but 
levels similar to grandparental cell line MDA-F
Motility Assay
Table 4.8.2 Summary of motility of adriamycin selected variants of MDA-MB-435S-F.
From these results there does not appear to be a direct link in our system to the motility 
of Adr-lOp and Adr-lOplOp and their adhesion to ECM proteins.
Drug-resistance is critical in treating malignant tumours. Little study has been done on 
the biological changes in tumour cell activity in the course of acquiring drug-resistance. 
Hikawa et al. (2000) used a glioma cell line to study changes in cell adhesion and 
invasion on acquiring drug-resistance. Human glioma culture cell line IN 157 was used 
to establish the cell lines resistant to VP-16, vincristine and adriamycin. Expressions of 
integrin ot2 , 0C3 , as, and Pi, neuronal cell adhesion molecule (NCAM) and MMPs were 
examined by flow cytometry. In drug-resistant cells, integrin expression was enhanced 
and NCAM expression was reduced. Adhesions to the extracellular matrix (ECM)
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proteins (laminin, fibronectin or type IV collagen) were studied. The adhesive ability of 
all cell lines increased in a concentration-dependent manner. Adhesion of drug-resistant 
cells was significantly stronger than that of INI 57. The cell invasion of drug-resistant 
cell lines to the basal membrane was significantly lower than that of INI57. The cell 
invasion of INI 57 was significantly suppressed by adding anti-NCAM antibody. In the 
case of INI 57 with the acquisition of drug-resistance, an increase in the expression of 
integrins may have enhanced the adhesion to ECM proteins. This finding may be 
concerned with the decreased activity of drug-resistant cell lines in invading the 
basement membrane. NCAM expression in drug-resistant cell lines was reduced and 
anti-NCAM antibody abated invasion of INI57, suggesting that NCAM is involved in 
INI 57 invasion.
4.8.3 Affects of Adriamycin Selection on Cell Invasion
Findings in the MDA-MB-435S-F adriamycin resistant
variants
Methods used
Development of a two tiered invasive phenotype not present in the 
parental cell line
(1) Invasion of matrigel to underside of invasion chamber
(2) Detachment of cells from underside of invasion chamber 
and reattachment to bottom of 24-well plate (only in taxol 
selected and adriamycin selected variants — see section 4.4)
Invasion Assay
No changes observed in the secretion of MMP-2 or MMP9 in 
Adr-lOp or Adr-lOplOp compared to parental cell line
Zymography
Table 4.8.3 Summary of invasion of adriamycin selected variants of MDA-MB-435S-F.
Similar to results for the taxol selected variants of MDA-F, initially invasion assays 
indicated no major changes in the invasiveness of Adr-lOp or Adr-lOplOp compared to 
MDA-F (section 3.3.13.1). Again it appeared that the cell lines were less invasive than 
the parental MDA-F, and even less invasive than the taxol-selected variants. It was 
again observed that similar to the taxol selected variants, Adr-lOp and Adr-lOplOp had 
developed the ability to invade to the underside of the invasion chamber and then detach 
from the bottom and reattach to the bottom of the 24 well plate. Again this
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phenomenon coincided with vastly reduced adhesiveness of these cells to components 
of the extracellular matrix (section 3.3.14). This could be an indication that adriamycin 
and taxol selection, selects for more aggressive invasive phenotypes, which appear 
overall to be less invasive, but selects for cells capable of invading further, and perhaps 
with a greater survival rate. Again no changes in the secretion of MMP-2 or MMP-9 
were observed in these cell lines (section 3.3.15), however it has not yet been 
investigated whether there is a reduction in the tissue inhibitors of matrix 
metalloproteinases in these variants.
As mentioned in the previous paragraph, selection of MDA-F with adriamycin or taxol 
appears to generate a more invasive phenotype in this cell line, characterised by the 
ability of the cells to detach from the bottom of the invasion chamber and relocate to the 
bottom of the 24-well plate. In order to investigate this further it was decided to isolate 
three populations from invasion assays of MDA-F and its selected variants. The three 
populations were those cells that had not invaded, those that had and those that had also 
relocated to the bottom of the 24-well plate. The purpose of this study was to see if 
there were variations in the morphology, motility, invasiveness and adhesiveness of 
these populations, and to determine if particular cell populations were in a particular 
stage of invasiveness, due to their inability to proceed further, or just because the other 
cells had “got there first” or had been in a different physiolgical state, for example in a 
different phase of the cell cycle. The results of these experiments are presented in 
section 3.3.16.
Analysis of these populations revealed no major difference in their morphology. An 
observation was made that they displayed decreased cell contact inhibition. The 
superinvasive populations displayed increased motility in comparison to both the 
invasive and non-invasive subpopulations, in all cases except for Taxol-10p4p 
subpopulations. In Adr-lOp-SI and Adr-lOplOp-SI this increase was most apparent, 
these are very motile populations. Invasion showed with the exception of Taxol-10p4p 
that non-invasive populations were less invasive than invasive populations, while the 
superinvasive populations were the most invasive. The most invasive populations 
proved to be Adr-lOp-SI and Adr-lOplOp-SI. There appears to be a link in these cell 
lines between motility and invasion. The Taxol-lOp-SI population is less adhesive than 
its parental cell line Taxol-1 Op which in turn is less adhesive than the grandparental cell 
line MDA-F to laminin, fibronectin, collagen type IV and matrigel Taxol-10p4p-SI,
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Adr-lOp-SI and Adr-lOplOp-SI superinvasive populations are more adhesive than their 
individual parental cell lines, which in turn are less adhesive than the parental cell line 
MDA-F to laminin, fibronectin, collagen tyoe IV and matrigel. The superinvasive 
populations of Adriamycin selected origin are more adhesive to ECM proteins than 
those of taxol selected origin. This is also similar to their ability to perform in motility 
assays and invasion assays, but is dissimilar to the link between invasion and adhesion 
in their parental populations.
The findings of this thesis are opposite to those of Hikawa et al. (2000) in that increased 
resistance to adriamycin and taxol lead to a more aggressive invasive pheonotype 
(section 3.3.13.2). However these findings are similar in that Hikawa et al. (2000) 
found that decreased invasion was accompanied by increased adhesion to laminin, 
fibronectin or type IV collagen. The findings of this thesis were that more aggressive 
invasiveness was accompanied by decreased adhesion to laminin, fibronectin, collagen 
type IV and matrigel (section 3.3.13.2; 3.3.14).
Rintoul et al. (2002) studied the role of extracellular matrix in regulation of drug 
resistance in small-cell lung cancer (SCLC). They hypothesised that factors within the 
local environment of SCLC cells could provide a survival signal or block a death signal, 
thereby accounting for the protection of SCLC cells from chemotherapy-induced 
apoptosis. They showed that, in vivo, SCLC cells are surrounded by an extensive stroma 
of extracellular matrix (ECM) at both primary and metastatic sites which contain, 
among other proteins, fibronectin, laminin and collagen IV. Furthermore, adhesion of 
SCLC cells to fibronectin, laminin and collagen IV through pi integrins enhanced 
tumorigenicity and conferred resistance to apoptosis induced by standard 
chemotherapeutic agents, including VP-16, cisplatin and adriamycin. Adhesion to ECM 
proteins stimulated protein tyrosine kinase (PTK) activity in both untreated and 
etoposide-treated cells. This effect could be completely blocked by a selective PTK 
inhibitor or by a function-blocking pi integrin antibody. PTK activation was found to 
block chemotherapy-induced activation of the death protease caspase-3 and, hence, 
apoptosis. Adhesion to ECM or treatment with a PTK inhibitor did not affect etoposide 
inhibition of topoisomerase II. Thus adhesion to ECM through pi integrins protects 
SCLC cells from chemotherapy-induced caspase-3 activation and apoptosis by 
activating PTK signalling downstream of DNA damage. Survival of tumour cells
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attached to ECM within this microenvironment could explain the local recurrence of 
SCLC and other tumours that is often seen clinically after chemotherapy.
Adhesion of U937 human histiocytic lymphoma cells to fibronectin provided a survival 
advantage with respect to damage induced by the topoisomerase II inhibitors 
mitoxantrone, adriamycin and VP-16. Cellular adhesion by means of pi integrins 
resulted in a 40% to 60% reduction in mitoxantrone- and etoposide-induced DNA 
double-strand breaks. When the mechanisms regulating the initial drug-induced DNA 
damage were examined, a p 1 integrin-mediated reduction in drug-induced DNA double­
strand breaks was found to correlate with reduced topoisomerase II activity and 
decreased salt-extractable nuclear topoisomerase lip protein levels. Confocal studies 
showed changes in the nuclear localisation of topoisomerase Up; however, alterations in 
the nuclear-to-cytoplasmic ratio of topoisomerase IIP in fibronectin-adhered cells were 
not significantly different. Higher levels of topoisomerase lip-associated DNA binding 
were observed in fibronectin-adhered cells than in cells in suspension. Together, these 
data suggest that topoisomerase lip is more tightly bound to the nucleus of fibronectin- 
adhered cells. Thus, fibronectin adhesion by means of pi integrins appears to protect 
U937 cells from initial drug-induced DNA damage by reducing topoisomerase II 
activity secondarily to alterations in the nuclear distribution of topoisomerase lip. 
(Hazlehurst et al., 2001). Similar findings were also reported by Damiano et al. (1999).
These results do not correlate with the findings of this thesis, as the taxol and 
adriamycin selected variants are less adhesive to the ECM proteins tested, but exhibit 
increased resistance (section 3.3.14). Of further interest would be the examination of 
the drug resistance of MDA-F, MDA-F/Taxol-lOp, MDA-F/Taxol-10p4p, MDA-F/Adr- 
lOp and MDA-F/Adr-lOplOp, while in the presence of various extracellular matrix 
components. Does adhesion to, for example laminin, increase the resistance of the cells 
to taxol or adriamycin. This is a potential avenue for future work.
Another mechanism whereby tumour cells may become increasingly invasive, is by the 
alteration in the expression of proteins regulating cell-cell adhesion. In a study by 
Molinari et al. (2002) the phenotypic alterations that are associated with the acquisition 
of the multidrug-resistant phenotype in tumour cells, together with drug transporter 
overexpression, were investigated in human melanoma cells. The expression of cell
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adhesion molecules was analysed in a panel of multidrug-resistant melanoma cell lines 
(M14Dx) showing different degrees of resistance to adriamycin and different levels of 
the expression of the drug transporter P-glycoprotein. In particular, expression of 
intercellular adhesion molecule-1, CD44, very late activation antigen OC5P1 and 012(31 was 
determined by flow cytometry in the different resistant cell lines. A progressive 
downregulation of all the adhesion molecules examined was revealed in M14Dx cells, 
in parallel with an increasing level of expression of the drug transporter P-glycoprotein. 
These results also raise a question about the role of P-glycoprotein in the invasive and 
metastatic behaviour of tumour cells.
E-cadherin-mediated cell-cell adhesion plays a crucial role in intercellular 
com m unication, which is related to the regulation of cell proliferation, differentiation, 
and apoptosis. Decreased expression of MUC1 can induce E-cadherin-mediated cell­
cell adhesion in human breast cancer cell lines proliferating in suspension without 
aggregation. Using such a cell line (YMB-S) Yang et al. (1999) observed the effects of 
adriamycin on cell-cell adhesion and expression of E-cadherin-catenin complex and 
MUC1. The cells showed E-cadherin-mediated cell-cell adhesion after 48 h exposure to
0.4 (o.M/1 adriamycin, accompanied by increases in E-cadherin and P-catenin and a 
decrease in MUC1 mRNA and protein levels. In immunohistochemical analysis, p- 
catenin protein in untreated cells showed diffuse cytoplasmic localization, whereas p- 
catenin in treated cells was present in cytoplasm with a clear submembranous 
localisation, indicating that increased p-catenin mainly bound with E-cadherin, 
participating in cell-cell adhesion.
A number of questions arise from the findings of this thesis and those of other 
investigators. Is P-glycoprotein directly involved in the downregulation of these cell 
adhesion molecules? It should be noted that the taxol selected variants display the 
lowest levels of adhesion (section 3.3.14) and also overexpress mdr-1 mRNA (section 
3.3.8.1). It would be beneficial in future work following this thesis to look at the 
expression of cell adhesion molecules also including the cadherin, catenin and actin 
families in the adriamycin and taxol selected variants of MDA-F. Finally it would be 
interesting to see whether adhesion of MDA-F and its variants to ECM proteins, would 
result in increased resistance to chemotherapeutic drugs.
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4.9 Long and Short Term Toxicity Assays
In this thesis both long and short term assays were performed for a number of different 
chemotherapeutic drugs. In the MDA-F MDR selectants it was found that the increase 
in resistance to taxol was greater in short term than in long term assays (section 3.3.4.5; 
3.3.4.6). This was similar to the findings of (Tuohey, et al. 2000). Transfection of the 
cell line 2008 with MRP1, MRP2 and MRP3 resulted in greater resistance in short term 
than long term assays for adriamycin, methotrexate, taxol and taxotere. Kool el al.
(1999) and Hooijberg et al. (1999) reported that transfected 2008 MRP1, 2008 MRP2 
and 2008 MRP3 showed a marked level of resistance to the polyglutamatable antifolate, 
methotrexate. These results were obtained by short term assays, but not in long term 
assays. They suggested that this was due to fact that methotrexate is polyglutamated 
after entering the cell, a form which is very effective at inhibiting dihydrofolate 
reductase. Polyglutamatation is slow and after short term exposure, cells with good 
efflux pumps can pump out monoglutamate methotrexate efficiently, thereby 
accumulating less methotrexate, rendering the cells more resistant.
In the MCF-7 H3 c-erbB-2 transfected variants, resistance to taxol was also greater in 
short than in long term assays (section 3.1.4.2). This trend was also observed for 
carboplatin in these cell lines (3.1.4.3). No such trend was observed for adriamycin, 
taxotere, 5-fluorouracil or vincristine. The BT474A c-erbB-2-ribozyme transfected cell 
lines yielded very unexpected results. In adriamycin toxicity assays, the ribozyme- 
transfected variants, were sensitised to adriamycin in long term assays, but were 
actually resistant in short term assays. A similar trend was observed for carboplatin in 
that the ribozyme variants displayed no changes in resistance in long term assays but 
were resistant in short term assays. The reason behind these results has yet to be 
determined.
As mentioned in section 4.2 these two assays differ in that long term assays reflect the 
ability of the cells to withstand lengthier exposure to drug, while short term assays 
reflect the ability of the cells to recover from an acute shock with a high concentration 
of the drug in question. It is therefore possible that different mechanism of resistance 
to drug exposure come into play in these two assays, such as detoxification systems and 
apoptosis resistance factors. This is an area for future study.
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4.10 Conclusions
The establishment of a model to investigate the effects of upregulation of c-erbB-2 by 
cDNA transfection and the downregulation by ribozyme transfection on 
chemotherapeutic drug sensitivity, in vitro invasion, and expression of a range of 
mRNA and proteins was a major part of this thesis.
Conclusions with Respect to the Effect of C-erbB-2 on Drug Resistance and Expression 
of a Panel of Resistance Associated Genes
1. C-erbB-2 upregulation in MCF-7 H3 c-erbB-2 cDNA transfectants resulted in 
decreased resistance to adriamycin in long and short term assays, while c-erbB-2 
downregulation in BT474A- ribozyme transfectants resulted in decreased resistance 
in long term assay, but increased resistance in short term assays.
2. C-erbB-2 upregulation in MCF-7 H3 c-erbB-2 cDNA transfectants resulted in 
increased resistance to taxol in short term assays only, while c-erbB-2 
downregulation in BT474A- ribozyme transfectants resulted in increased resistance 
in long and short term assays. These apparently contradictory results indicate the 
importance of different cell backgrounds in determining the phenotypic effects of a 
single gene.
3. C-erbB-2 upregulation in MCF-7 H3 c-erbB-2 cDNA transfectants resulted in 
decreased resistance to carboplatin in long term assays, but increased resistance in 
short term assays, while c-erbB-2 downregulation in BT474A ribozyme 
transfectants also resulted in decreased resistance to carboplatin in long term assays, 
but increased resistance in short term assays.
4. C-erbB-2 upregulation in MCF-7 H3 c-erbB-2 cDNA transfectants resulted in 
decreased resistance to 5-Fluorouracil in long and short term assays for two clonal 
transfectants, but increased resistance in the remaining transfectant, while c-erbB-2 
downregulation in BT474A- ribozyme transfectants resulted in increased resistance 
in long and short term assays for several of the clonal transfectants.
5. C-erbB-2 upregulation in MCF-7 H3 c-erbB-2 cDNA transfectants resulted in 
increased resistance to methotrexate in long term assays, while c-erbB-2 
downregulation in BT474A ribozyme transfectants also resulted in increased 
resistance long term assays.
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6. No significant changes in vincristine or taxotere were observed in MCF-7 H3 c- 
erbB-2 cDNA
7. MDR-1, mrp-1, mrp-4 and mrp-5 mRNA were not not affected by c-erbB-2 
expression.
8. Mrp-2 mRNA levels was inversely associated with c-erbB-2 expression.
9. Topoisomerase I and topoisomerase Ila  mRNA expression were unaltered in MCF- 
7 H3 transfectants, while topoisomerase lip mRNA expression decreased. 
Topoisomerase Ila and topoisomerase lip mRNA expression were unaltered in 
BT474A transfectants, while topoisomerase I mRNA expression increased. These 
changes in topoisomerases were inconsistent between the two cell systems and 
therefore are unlikely to play a role in c-erbB-2 mediated resistance.
10. DHFR, TS and GST71; mRNA levels were not found to play an obvious role in c- 
erbB-2 mediated drug resistance.
Conclusions With Respect to the Effects of C-erbB-2 Expression on Other ErbB
Receptors
1. C-erbB-1 expression was unaltered by c-erbB-2 downregulation at both the mRNA 
and protein levels in BT474A ribozyme transfectants, while c-erbB-1 increased at 
the mRNA level, but not the protein in MCF-7 H3 cDNA transfectants.
2. C-erbB-3 protein expression was increased by c-erbB-2 upregulation and decreased 
by c-erbB-2 down regulation. C-erbB-3 levels appear to be linked to c-erbB-2 
levels.
3. C-erbB-4 expression was unaltered by c-erbB-2 downregulation at the mRNA level, 
while c-erbB-4 was decreased at both the mRNA and protein levels in MCF-7 H3 
cDNA transfectants.
Conclusions With Respect to the Effects of C-erbB-2 Expression on Tamoxifen
resistance and Estrogen Receptor Expression
1. C-erbB-2 was not found to influence tamoxifen resistance or estrogen receptor a  
expression. Interestingly, though, it did regulate estrogen receptor p expression. 
The effect of this is not known.
Conclusions With Respect to the Effects of C-erbB-2 Expression on Cell Growth,
Motility, Invasiveness and Adhesiveness
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1. C-erbB-2 upregulation resulted in increased invasion, while its downregulation had 
the opposite effect. It is interesting to note that while these cell lines are invasive 
they do not display any motility.
2. C-erbB-2 upregulation in MCF-7 H3 had no effect on adhesion to laminin, collagen 
type IV or matrigel, but did result in decreased adhesion to fibronectin. C-erbB-2 
downregulation BT474A resulted in decreased adhesion to fibronectin laminin, 
collagen type IV and matrigel.
3. MCF-7 H3 secretes a serine proteases which seems to be associated with a lack of 
invasion, since it is expressed in MCF-7 H3 and MCF-7 H3/ErbB2-A, but not in the 
invasive MCF-7 H3/ErbB2-B, MCF-7 H3/ErbB2-C, MDA-MB-435S-F or BT474A. 
C-erbB-2 upregulation in this cell line abolishes its expression. The ell line also 
secretes MMPs. BT474A also secretes MMPs, which appear to decrease with 
decreasing c-erbB-2 levels.
The establishment and characterisation of novel taxol- and adriamycin-resistant variants 
of MDA-MB-435S-F with interesting cross-resistance patterns and invasion related 
properties is a major achievement of this thesis. Of particular interest was the novel 
finding that the taxol- and adriamycin-selected variants had developed a two step 
invasive phenotype. This later achievement was a major novel achievement of this 
thesis. For ease of discussion MDA-MB-435S-F shall from here on be referred to as 
MDA-F, MDA-MB-435S-F/Taxol-1 Op as Taxol-lOp, MDA-MB-435S-F/Taxol-10p4p 
as Taxol-10p4p, MDA-MB-435S-F/Adr-10p as Adr-lOp and MDA-MB-435S-F/Adr- 
lOplOp as Adr-lOplOp.
Conclusions with Respect to Drug Resistance and ErbB Receptor Status
1. Taxol resistant variants of the human breast cancer cell line MDA-F are readily 
selectable on treatment with taxol, but selection with adriamycin in slower and more 
difficult.
2. Taxol selection of MDA-F yields a cross-resistance pattern whereby the cells 
become resistant to taxol, taxotere and vincristine, and to a lesser extent to 
adriamycin.
3. This cross-resistance pattern suggests the involvement of microtubule alteration in 
the development of taxol resistance.
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4. Taxol selection does not alter sensitivity of MDA-F to VP-16, 5-fluorouracil or 
carboplatin. This may indicate that taxol in combination with 5-fluorouracil, 
carboplatin or VP-16 may be an effective combination in the treatment of breast 
cancer. Also patients who develop resistance to taxol chemotherapy may benefit 
from one of these drugs.
5. Adriamycin resistance in MDA-F is slow to develop and even then developed to 
only a low level. Adriamycin selection results in cross-resistance to VP-16, 
vincristine and taxotere.
6. Adriamycin selection sensitises the cells to taxol, 5-fluorouracil and carboplatin. 
Again this may indicate that adriamcyin in combination with these drugs may be an 
effective combination in the treatment of breast cancer, or a means to treat 
adriamycin resistant cancer.
7. The MRP family does not appear to play a significant role in taxol resistance our 
system, while it does play a role in adriamycin resistance. Mrp-1 is induced by taxol 
and adriamycin selection, but is not involved in taxol resistance, as sulindac does 
not circumvent taxol resistance. Sulindac is capable of circumventing adriamycin 
resistance in the parental, taxol-selected and adriamycin-selected variants. There is 
no significant difference in its ability to circumvent adriamycin in any of the cell 
lines and therefore it is unlikely that mrp-1 plays a major role in the development of 
resistance to adriamycin in MDA-F. Rather it is likely that mrp-1 is a part of its 
intrinsic resistance. Mrp-2 mRNA appears to be reduced by adriamycin and taxol 
selection, this may explain to some extent why there is no major change in 
adriamycin circumvention by sulindac, as mrp-2 transports adriamycin. Mrp-4 and 
mrp-5 are not expressed by MDA-F, or any of its taxol selected or adriamycin 
selected variants.
8. MDR-1 mRNA expression was increased in response to taxol but not to adriamcyin 
selection.
9. MDR-1 protein levels were unchanged in either the taxol- or the adriamycin- 
selected variants.
10. Verapamil circumvention of taxol and adriamycin does not follow expectedpattems 
in the taxol-selected variants of MDA-F. Verapamil circumvents adriamycin 
resistance equally in the parental and taxol-selected variants, while only 
circumventing taxol resistance in the taxol-selected variants, but not in the parental 
cells. This may suggest involvement of a mdr-1 like pump.
11. All the resistant variants display increased adriamycin accumulation
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12. As expected dihydrofolate reductase, and thymidylate synthase do not appear to play 
any major role in the development of resistance to taxol or adriamycin. One side 
effect of adriamycin selection is a reduction in the expression of thymidylate 
synthase mRNA perhaps resulting in the sensitisation of Adr-10pl0p to 5-FU. 
Interestingly unlike what is generally reported in the literature levels of GST 71 
decreased with both adriamycin and taxol selection.
13. Taxol and adriamycin selection have a definite effect on the expression of ErbB 
receptors in MDA-F. C-erbB-1 is induced at the protein, but not at mRNA level by 
both taxol and adriamycin selection. C-erbB-2 expression at the protein level is not 
induced by taxol or adriamycin selection, although its expression is reduced at the 
mRNA level. C-erbB-3 protein expression is downregulated hugely in response to 
adriamycin and taxol selection, while c-erbB-4 mRNA is increased in the more taxol 
resistant variant and is increased by adriamycin selection. C-erbB-4 protein 
expression was undetectable in these cell lines.
14. Topoisomerase I and Ilß were induced by taxol and adriamycin selection.
Conclusions With Respect to Cell Growth, Motility, Invasiveness and Adhesiveness
1. Selection of MDA-F with taxol and adriamycin leads to reduced growth rates.
2. Selection of MDA-F with taxol and adriamycin leads to reduced motility for taxol 
selected variants while the motility of MDA-F is unaffected by adriamycin 
selection.
3. Taxol and adriamycin selection of MDA-F results in a two staged invasive 
phenotype. In vitro invasion is generally measured as the ability of cells to travel 
through a layer of matrigel and then through 8|j,M pores in a multi well plate insert -  
Cell invasiveness is proportional to the number of cells on the underside of the 
insert. It was discovered in this thesis a more aggressive phenotype whereby the 
cells are able to detach after invasion of the matrigel and movemnet through the 
pores and to then reattach to the bottom of the 24 well plate in which the invasion 
chamber sits. This is not accompanied by a change in MMP secretion, but is 
accompanied by reduced adhesion to laminin, and matrigel, and especially 
fibronectin and collagen type IV. Interestingly while MDA-F was most adhesive to 
fibronectin, all the MDR variants of MDA-F are most adherent to matrigel.
As a result of the two stage invasive phenotype observed in the MDA-F adriamycin and
taxol selected variants, nine cell populations were isolated from invasion assays. They
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were entitled non-invasive, invasive and superinvasive depending on the area of 
isolation. The non-invasive populations (NI) referred to cells that had not invaded 
through the matrigel (5 lines isolated from parental, adriamycin selected and taxol 
selected cell lines). The invasive populations (I) referred to cells that had invaded 
through the matrigel and were attached to the bottom of the insert (5 lines isolated from 
parental, adriamycin selected and taxol selected cell lines). The superinvasive 
populations (SI) referred to cells that had invaded through the matrigel and relocated to 
the bottom of the 24-well plate (4 lines isolated from the adriamycin selected and taxol 
selected cell lines). The member of cell lines is 4 in the final group because the parental 
cell lines were incapable of the 2-step invasion.
Conclusions for the Morphology, Motility, Invasiveness and Adhesiveness of the Non- 
invasive, invasive, and Superinvasive Populations Were
1. No changes in morphology were observed.
2. The SI populations displayed increased motility in comparison to both the I and NI 
subpopulations, in all cases except for Taxol- 10p4p subpopulations. In Adr-lOp-SI 
and Adr-lOplOp-SI this increase was most apparent, these are very motile 
populations.
3. Invasion showed with the exception of Taxol- 10p4p that NI populations were less 
invasive than I populations, while the SI populations were the most invasive. The 
most invasive populations proved to be Adr-lOp-SI and Adr-lOplOp-SI. There 
appears to be a link in these cell lines between motility and invasion.
4. The Taxol-lOp-SI population is less adhesive than its parental cell line Taxol-lOp 
which in turn is less adhesive than the grandparental cell line MDA-F to laminin, 
fibronectin, collagen tyoe IV and matrigel
5. Taxol- 10p4p-SI, Adr-lOp-SI and Adr-lOplOp-SI superinvasive populations are 
more adhesive than their individual parental cell lines, which in turn are less 
adhesive than the parental cell line MDA-F to laminin, fibronectin, collagen type IV 
and matrigel.
6. The superinvasive populations of Adriamycin selected origin are more adhesive to 
ECM proteins than those of taxol selected origin. This is also similar to their ability 
to perform in motility assays and invasion assays, but is dissimilar to the link 
between invasion and adhesion in their parental populations.
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4.11 Future Work
1. Investigation of the role of other ErbB family members (alone and in combination) 
in drug resistance and invasion by stable or transient transfection of ErbB cDNAs 
and ribozymes
2. Application of DNA arrays and proteomic approaches to determine genes under the 
control of ErbB receptors.
3. Further investigation of the lack of motility displayed by BT474A and MCF-7 H3 is 
necessary. Despite the fact that these cell lines are invasive, they failed to perform 
in motility assays. This raises the following question, do these cell lines only 
exhibit motility in the presence of ECM proteins, but not when attached to plastic, as 
is the case for most cells in culture. Assays could be designed to observe the 
motility of these cell lines on plastic, membranes and ECM proteins.
4. The role of estrogen receptor (3 also needs to be further investigated in these cell 
lines, involving cDNA transfection and its effect on estrogen response, tamoxifen 
and ErbB expression.
5. Investigation of mechanism involved in taxol transport in MDA-MB-435S-F/Taxol- 
lOp and MDA-MB-435S-F/Taxol-10p4p. Clearly taxol resistance in circumvented 
by verapamil in the taxol selected variants, but not in the parental cells or the 
adriamycin selected variants, despite the fact that adriamycin resistance is 
circumvented by verapamil in all five variants of MDA-MB-435S-F. This raises the 
question as to why are these cell lines not also resistant to Adriamycin and VP-16 
(also substrates of P-glycoprotein). Indeed is there a novel transporter protein 
expressed here specific for vincristine, taxol and taxotere? Would the same effect 
be seen with verapamil and taxotere or vincristine? Future work would involve 
combination assays of verapamil with taxotere and vincristine and epirubicin, to 
determine if their resistance can be circumvented by verapamil. If so, are they also 
circumvented by other specific p-glycoprotein inhibitors? If not, what particular 
part of p-glycoprotein do these inhibitors work on? This may give an insight into 
structural differences between p-glycoprotein and any novel mdr-type protein.
6. DNA arrays and proteomics are a possible avenue to begin to search for any 
novwlgenes/proteins involved in taxol resistance. Gene profiling and 2-D 
electrophoresis/MS of possible novel proteins isolated may help to yield a clue as to 
the type or identity of proteins involved.
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7. Judging by the cross-resistance profiles of MDA-MB-435S-F/Taxol-10p and MDA- 
MB-435S-F/Taxol-10p4p, the expression and taxol-binding profiles of a-tubulins 
and P-tubulins need to be studied.
8. Investigation of the inability of MDA-MB-435S-F to develop resistance to 
adriamycin, while being able to develop resistance to taxol. Does this also apply to 
other members of the anthracycline family? Is there an X factor that prevents 
development of resistance? Comparison of gene arrays of other adriamycin selected 
cell lines with these selectants, and MDA-MB-435S-F selected with other 
anthracyclines could be a place to start.
9. Despite decreased accumulation of adriamycin in MDA-MB-435S-F/Taxol-10p, 
MDA-MB-435S-F/Taxol-10p4p, MDA-MB-435S-F/Adr-10p and MDA-MB-435S- 
F/Adr-lOplOp, they display little or no increase in resistance to adriamycin. It is 
necessary to investigate further whether other mechansims of adriamycin resistance 
are downregulated thus reversing any advantage increased efflux may have on the 
cells. GST activity and topoisomerase protein expression/activity would be a place 
to begin.
10. Identification of specific MMPs and TIMPs expressed by the MDA-MB-435S-F 
variants.
11. Further investigation of subpopulations with different invasive potential of MDA- 
MB-435S-F and its variants isolated from invasion assays.
• Protease secretion
• ErbB receptor profiles
• Expression of integrins, cadherins, catenins and a-actin
12. As c-erbB-3 protein levels are drastically reduced in taxol- and adriamycin- selected 
variants, c-erbB-3 cDNA transfection into MDA-MB-435S-F may show whether c- 
erbB-3 plays a role in the observations made in these variants. C-erbB-1 and 4 are 
other candidates for this also, while c-erbB-2 levels were unchanged by taxol or 
adriamycin selection, and therefore may not be as interesting.
13. Finally its is desirable to pulse select a panel of breast cancer cell lines to determine 
whether these observations are common to breast cell lines or unique to MDA-MB- 
435S-F.
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Appendix A -  Molecular Weights of Chemotherapeutic Agents Used in 
This Thesis
Drug Molecular Weight
Adriamycin 543
Taxol 853
Taxotere 808
Methotrexate 454
Carboplatin 371
5-Fluorouracil 130
VP-16 588
Vincristine 824
1
Appendix B - Abbreviations
Ab - Antibody
ABC - ATP Binding Cassette
AMP - Adenosine Monophosphate
ATP - Adenosine-triphosphate
ATCC - American Tissue Culture Collection
BSA - Bovine Serum Albumin
cDNA - Complementary DNA
Da - Daltons
DEPC - Diethyl Pyrocarbonate
DHFR - Dihydrofolate reductase
DMEM - Dulbecco’s Minimum Essential Medium
DMSO - Dimethyl sulfoxide
DNase - Deoxyribonuclease
DNA - Deoxyribonucleic Acid
dNTP - Deoxynucleotide triphosphate (N= A, C, T, G or U)
DTT - Dithiothreitol
ECM - Extracellular matrix
EDTA - Ethylene diamine tetracetic acid
FCS - Fetal Calf Serum
GSH - Glutathione
GST - Glutathione-S-Transferase
GS-X Pump - GSH-conjugate export carrier
HEPES - N-[2-Hydroxyethyl]piperazine-N’-[2-ethanesulphonic acid]
H-SFM - Ham’s F12 Serum Free Medium
IC50 - Inhibitory Concentration 50%
Ig - Immunoglobulin
IMS - Industrial Methylated Spirits
LRP - Lung Resistance-related Protein
MAb - Monoclonal Antibody
MDR - Multiple Drug Resistance
MRP - Multidrug Resistance-associated Protein
MEM - Minimum Essential Medium
min - Minute(s)
2
MMLV-RT - Moloney Murine Leukemia Virus-Reverse Transcriptase
mRNA - Messenger RNA
Mr marker - Molecular Weight Marker
NCTCC - National Cell & Tissue Culture Centre
NSCLC - Non-Small Cell Lung Carcinoma
OD - Optical Density
Oligos - Oligonucleotides
P - Passage
PBS A - Phosphate Buffered Saline A
PEG - Polyethylene Glycol
PCR - Polymerase Chain Reaction
P-gp - P-glycoprotein
PKA - cAMP-dependant protein kinase
RNA - Ribonucleic Acid
RNase - Ribonuclease
RPA - RNase protection assay
RNasin - Ribonuclease Inhibitor
rpm - Revolution(s) Per Minute
RT-PCR - Reverse Transcriptase-PCR
Rz - Ribozyme
SCLC - Small Cell Lung Carcinoma
SDS - Sodium Doedecyl Sulphate
sec(s) - Second(s)
TBE - Tris-boric acid-EDTA buffer
TBS - Tris Buffered Saline
TE - Tris-EDTA
Topo I - Topoisomerase I
Topo Ila  - Topoisomerase Ila
Topo lip - Topoisomerase IIp
TEMED - N, N, N’, N ’ -T etramethyl-Ethylenediamine
Tris - Tris(hydroxymethyl)aminomethane
TS -■ Thymidylate Synthase
UHP - Ultra high pure water
v/v - volume/volume
w/v - weight per volume
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